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Abstract 
Dr. Fred Stephen Sarfo, The long-term effectiveness of efavirenz-based combination 
antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction 
of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV-
infected patients. PhD dissertation, Durham University, January 2013. 
Introduction: In sub-Saharan Africa, HIV treatment is initiated with combination of 
antiretroviral medications comprising of a backbone of either stavudine or zidovudine plus 
lamivudine with a non-nucleoside reverse transcriptase inhibitor of either efavirenz or 
nevirapine. Efavirenz is highly efficacious, durable and well tolerated. The risk for toxicity of 
efavirenz is determined by several factors including single nucleotide polymorphisms in the 
hepatic enzymes responsible for its metabolism and concurrently administered medications such 
as antimalarials, which share common metabolic pathways. The aims of this dissertation are to 
assess the long-term effectiveness of efavirenz-based antiretroviral therapy and the impact of 
pharmogenomics and pharmacokinetic interactions of artemisinin-based antimalarial therapy on 
efavirenz exposure among Ghanaian HIV-infected patients. 
Methods: The effectiveness of efavirenz- compared with nevirapine-based antiretroviral 
therapy was assessed retrospectively in nearly 4000 patients starting treatment between 2004 
and 2010. The main outcome measure was a composite of toxicity, disease progression and 
attrition, and CD4 count changes. A prospective pharmacokinetic study of artesunate and 
efavirenz was conducted among 22 HIV-infected and 21 controls. Plasma efavirenz and 
artesunate/ dihydroartemisinin concentrations were measured using validated and standardised 
methods. Genotyping for single nucleotide polymorphisms in CYP2B6 G516T, T983C; 
CYP2A6*9B, UGT2B7*735 and *802 as well as CAR rs2307424 were performed for 800 
patients with real-time polymerase chain reaction with allelic discrimination.  
Results: Antiretroviral therapy was associated with robust CD4 increases. Efavirenz was 
comparable with nevirapine in composite outcomes but better tolerated. Artesunate was well 
tolerated when administered to HIV-infected patients on efavirenz. Single nucleotide 
polymorphisms in the CYP2B6 G516T and T983C were associated with increased plasma 
efavirenz concentrations.  
Conclusions/Recommendation: Among this Ghanaian cohort, both efavirenz and nevirapine-
based antiretroviral therapy were effective. The better tolerability of efavirenz compared with 
nevirapine means it can be safely used as the preferred first line non-nucleoside reverse 
transcriptase inhibitor in sub-Saharan Africa.  
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CHAPTER ONE 
Rationale of this dissertation and literature review 
1.1 Rationale for this study 
1.1.1 Research questions 
The research questions that are answered in this dissertation are as follows: 
1. How effective is efavirenz compared with nevirapine as the base of a dual NRTI 
cART among Ghanaian HIV-infected patients over the long-term? 
2. What are the frequencies of selected single nucleotide polymorphisms of cytochrome 
P450 2B6, 2A6, UGT2B7 and constitutive androstane receptor (CAR) genes which 
have been predicted to impact on plasma efavirenz exposure? Are there any associations 
between pharmacogenomics of efavirenz and pharmacodynamics such as risk of 
toxicity and treatment failure among Ghanaian HIV-infected patients? 
3. Is it safe to co-administer artesunate for treatment of malaria in patients on efavirenz 
without compromising the effectiveness and kinetics of either medications? 
1.1.2 Why is this study important? 
Nearly 10% of the world population reside in Sub-Saharan Africa but this continent is at 
the epicentre of the HIV/AIDS epidemic with more than 65% of all people living with 
HIV resident here
1
. The continent therefore has the highest rates of HIV-related 
mortality due predominantly to opportunistic infections particularly from tuberculosis. 
The overall impact of the HIV epidemic has been the reduction of life-expectancy by 
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approximately 15 years in some regions in SSA
2
. This prompted a global response in 
2001 with a commitment to increase access to life-saving antiretrovirals across the 
continent. This unprecedented roll-out of cART across SSA since 2002, has began 
showing beneficial results with reports of decreasing incidence of HIV-related mortality 
and morbidity within the first few months of therapy
1
. These benefits have been 
achieved with a very limited repertoire of first line cART comprising until recently of a 
dual NRTI backbone of either zidovudine plus lamivudine or stavudine plus lamivudine 
with an NNRTI-base of either efavirenz or nevirapine. Thus the advent of cART has 
made a once fatal disease into one of a chronic infection requiring life-long treatment 
with antiretrovirals. But only 37% of eligible patients were on cART in the African sub-
continent by end of 2009, hence there is an urgent need to accelerate access to effective 
and well tolerated life-saving medications in the coming years
1
. As many more patients 
stay on these antiretrovirals, it has also become important to determine how effective 
NNRTI-based cART among HIV-infected patients over the long-term is.  
Efavirenz has not yet been surmounted in its efficacy and safety across several studies 
as a third component of the triple cART compared with other classes of antiretrovirals
3
. 
In one large randomised controlled trial, nevirapine has been found to be non-inferior to 
efavirenz
4
. However, EFV has the advantage of superior outcome data to NVP in a 
number of observational studies
5-20
, whilst also being less likely to cause serious 
adverse events such as rashes
4,21-23
 or hepatotoxicity
24-28
. Furthermore EFV (unlike 
NVP) can be used with rifampicin in patients with TB co-infection. However, there 
remains concern regarding the teratogenicity of EFV in pregnant women, despite the 
lack of clear evidence of excess risk in pregnancy risk registers, such that it is still not 
recommended in women of child-bearing age who are not using effective 
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contraception
29,30
. None-the-less a WHO-led survey has shown that around of two thirds 
of developing countries use NVP as the main first-line NNRTI in preference to EFV, 
largely due to lower cost and its availability as a generic fixed dose combination tablet.   
A number of randomised controlled trials, one metanalysis and observational studies
5-
20,31
 have compared EFV and NVP as first-line therapies. There was little evidence 
favouring either in terms of virological outcomes, however more observational studies 
conducted in developing countries favoured EFV in terms of virological 
outcomes
7,8,14,15
. Few studies comparing these NNRTIs have been conducted in sub-
Saharan Africa, and these have followed up patients for relatively short periods of time. 
Moreover few comparisons of NNRTIs have been conducted in settings with patients 
presenting with late HIV infection and starting ART at low CD4 counts, as is often the 
case in Africa. In Ghana, first-line ART consists of two nucleoside reverse transcriptase 
inhibitors (NRTI) and either EFV or NVP, if female with reproductive potential. Like 
many developing countries there is a high rate of tuberculosis and 17% of the HIV-
infected population is co-infected with hepatitis B virus (HBV)
32
, leading to further 
challenges with NNRTI-based ART in terms of drug toxicities and interactions. One 
aim of this study was to determine the long-term effectiveness and tolerability of first 
line ART, particularly comparing NVP and EFV, in a large cohort of patients attending 
a government HIV clinic in central Ghana. This was an ‘effectiveness’ not an ‘efficacy’ 
analysis because by definition efficacy relates to the extent to which a drug has the 
ability to bring about its intended effect under ideal circumstances, such as in a 
randomised clinical trial whereas effectiveness deals with the extent to which a drug 
achieves its intended effect in the usual clinical setting. 
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It is well known that the risk for toxicity to some ART is influenced significantly by the 
level of plasma exposure to the components of antiretrovirals. Specifically efavirenz has 
been shown to demonstrate a well-defined pharmacokinetic-pharmacodynamic 
relationship with supra-therapeutic exposure predisposing to higher risk of toxicity
33,34
. 
Single nucleotide polymorphisms (SNPs) in the enzymes responsible for the hepatic 
metabolism of efavirenz or nevirapine particularly the cytochrome P450 2B6 (CYP2B6) 
play major contributory roles in determining systemic exposure. A number of 
mutations, particularly the G516T and T983C in CYP2B6, have been found to be 
relatively common in Ghanaians
35,36
, with the latter mutation having a gene frequency 
of around 7.3%. It is has also been postulated that in settings where polymorphisms in 
the CYP2B6 are common, the presence of other loss-of-function SNPs in the alternative 
oxidative metabolic pathway of efavirenz, namely the CYP2A6 enzymes, become 
important in predicting supra-therapeutic exposure. Given that supra-therapeutic 
exposure to efavirenz predicts risk of CNS toxicity with the potential for poor 
adherence, it is important to determine the prevalence of SNPs in the CYP2B6 and 
CYP2A6 enzymes involved in the oxidative metabolism of efavirenz as well as CAR 
and UGT2B7 involved induction of CYP2B6 expression and glucuronidation of 
oxidized efavirenz metabolites respectively and to assess their impact on efavirenz 
exposure in a Ghanaian HIV-infected population.  
Other concurrently administered medications may also significantly influence exposure; 
for instance when treating patients with anti-tuberculous medications concurrently with 
cART, the induction of hepatic enzymes by rifampicin has been shown to lead to sub-
therapeutic exposure to nevirapine hence increasing the risk of treatment failure, thus 
efavirenz is indicated for HIV-patients receiving TB treatment along with cART. Also 
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the commonly used artemisinin-based antimalarial shares the CYP2B6 utilized in the 
metabolism of the NNRTIs and thus it has been predicted that potential 
pharmacokinetic and pharmacodynamic interactions between artemisinins and efavirenz 
may be of clinical interest in the African context. Thus it is important to conduct 
pharmacogenomic and pharmacokinetic studies to explore these questions especially as 
it is foreseen that efavirenz may become cheaper and more widely available within SSA 
in the coming years. This is within the strategic framework of the WHO towards 
providing effective anti-retrovirals that are minimally toxic for the treatment of HIV in 
developing countries
1
. 
1.1.3. Motivation for the study 
The author has worked at the Department of Internal Medicine of the Komfo Anokye 
Teaching Hospital in Kumasi, Ghana for the past 9 years as a house-officer, a medical 
resident and as a specialist physician. When I started my training as a house-officer in 
2004 the HIV clinic had just been commissioned and although I was not working in that 
clinic, I was involved in the management of several patients with advanced HIV disease 
referred from the HIV clinic for emergency admissions to the Medical block with 
various AIDS defining illnesses and ART-related toxicities. The most dramatic 
experiences in my mind were the severe and life-threatening skin rash from the 
NNRTIs. Unfortunately, a significant proportion of these patients with AIDS who came 
for admission died from various etiologies, predominantly from opportunistic infections 
due to late presentation at the clinic. An interest in HIV medicine was sparked by these 
experiences and in 2005, I had the opportunity to work at the clinic as resident in 
training. Over the years my encounter with patients on cART has shown that although 
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most patients improved clinically and immunologically on treatment, different patients 
responded differently to treatment especially in the predisposition for developing 
adverse side effects and treatment failure. The extent to which the NNRTI chosen 
influences these outcomes is what has motivated this study.  
To answer these questions, the author over the past 2 years had to collect retrospective 
data on ARV treatment outcomes in a busy outpatient clinic in Kumasi, Ghana where 
anti-retroviral therapy has been administered over the past 9 years at the time of writing 
this brief, but data presented in this dissertation involved follow up to 7.5 years. Data 
collected focused on clinical and immunological outcomes as well as toxicity of cART. 
Clinical outcome measures collected included deaths, loss-to-follow up, new AIDS 
defining conditions indicative of disease progression, non-AIDS defining events 
(NADEs) and infectious diseases neither fulfilling the criteria of AIDS-defining nor 
NADEs which nonetheless contributed to significant morbidity such as malaria. 
Immunological outcomes were assessed using the changes in the CD4+ T-cell counts 
over the course of treatment and risk for immunological failure as defined using the 
WHO criteria. Because patients are not routinely monitored with viral loads, virological 
outcomes were not available. 
The risk for developing toxicity from efavirenz has been shown to be predicted by 
steady plasma concentrations which in turn is determined by its clearance 
predominantly via hepatic metabolism. To examine the impact of genetic 
polymorphisms in the metabolic pathways of efavirenz among Ghanaians and thus its 
systemic exposure, samples from nearly 800 patients were genotyped using real-time 
PCR with allelic discrimination for selected SNPs in CYP2B6, CYP2A6, UGT2B7 and 
 26 
CAR and plasma efavirenz concentrations measured to explore the predictive 
associations between these SNPs and efavirenz exposure in the Ghanaian population of 
HIV patients. This was followed by a retrospective analysis of risk for efavirenz-
associated toxicity and clinical outcomes for a subset of patients with complete data to 
evaluate the relationships between pharmacogenomic, pharmacokinetic and 
pharmacodynamic parameters. 
This study was conducted with the future of ART in Sub-Saharan Africa in mind. If 
efavirenz should become cheaper and available as a fixed dose combination ART, 
would it be safe to administer to the vast majority of African patients who frequently 
harbour genetic polymorphisms which could potentially exposed them to supra-
therapeutic levels of this potent NNRTI? Secondly, at its current cost compared with 
nevirapine, would there be an extra benefit of using a predominantly efavirenz-based 
first line over nevirapine in terms of effectiveness as governments, policy makers and 
donor agencies spread scant resources to increase access to life-saving antiretrovirals 
across Sub-Saharan Africa? Thirdly, can we safely use artemisinin-based anti-malarial 
combination therapy in patients on efavirenz? 
1.1.4. The structure of the thesis 
Data on long-term effectiveness of first line cART among four thousand and thirty-nine 
(4,039) Ghanaian HIV patients who initiated treatment between 2004 to 2010, together 
with pharmacogenomic data of eight hundred (800) patients of whom five hundred and 
thirty-one (531) were on efavirenz and twenty two (22) HIV-infected patients on 
efavirenz-based cART who were treated for malaria with artesunate to study the safety 
and pharmacokinetics of both anti-malarial and efavirenz are presented in this 
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dissertation. Thus scope of this thesis spans from epidemiology through population 
pharmacogenomics and pharmacokinetics. The challenge was how to write a coherent 
piece that inculcated the multi-faceted and complicated management issues associated 
with long-term HIV treatment and to blend this with the pharmacology studies and to 
reduce the vast wealth of data into reasonably sized chapters.   
In chapter one, the author states the rationale for this study and reviews relevant 
literature to capture themes on HIV epidemiology in Sub-Saharan Africa, factors 
influencing efficacy of antiretroviral therapy, the efficacy of efavirenz-based cART 
compared with other classes of antiretrovirals and concludes by reviewing the 
pharmacology of efavirenz by focussing on pharmacogenomics of efavirenz 
highlighting the cytochrome P450 2B6 as a highly polymorphic enzyme exhibiting 
profound inter-individual variability.  
It became obvious during the write up of the methods sections of the main chapters of 
the thesis that, some statistical methods were reiterations (the effectiveness chapters) 
while others had labyrinthine methodology (pharmacogenomic chapter) which 
obstructed the flow of the story from the introduction to the results and discussion 
sections. This led to the creation of chapter 2 which is a compilation of methodology for 
chapters 3 through to chapter 8.  
The main results of the body of work in this dissertation begins in chapter 3. Here the 
author presents an analytical description of the baseline characteristics of 4,039 patients 
at initiation of cART focusing on demographic, clinical and laboratory parameters of 
these patients and went in-depth to assess the risk factors and prevalence of HIV-related 
renal impairment as assessed by estimated glomerular filtration rates from serum 
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creatinine measurements. This was followed by a longitudinal analysis of the clinical 
and immunological outcomes of first line cART emphasising the robust and sustained 
CD4 increases over the long-term from baseline values among patients who remained 
on treatment and also the decline in the incidence rates of deaths, loss-to-follow-up, 
AIDS-defining and NADEs over the course of time among patients who remained on 
treatment (chapter 4). Given the importance of toxicity on the durability of any cART, 
chapter 5 is presented to highlight the incidence rates and risk factors of five common 
ART-associated toxicity namely anaemia, skin rash, neuro-psychiatric toxicity, severe 
hepatic toxicity and mitochondrial toxicity. The preceding chapters (3 to 5) culminates 
in chapter 6 where the effectiveness of efavirenz-based cART is compared with 
nevirapine-based cART using a composite end-point of deaths, disease progression and 
all-cause discontinuation of therapy with sensitivity analysis included to evaluate the 
impact of the NRTI-backbone on these outcomes. The studies on the pharmacology of 
efavirenz among Ghanaian HIV-infected patients begins with a prospective 
pharmacokinetic study of artesunate monotherapy for treatment of clinically suspected 
malaria among HIV-infected patients on efavirenz with a control group of patients with 
symptoms of malaria whose HIV-status was not known (chapter 7). Chapter 8 focuses 
on the impact of single nucleotide polymorphisms in the CYP 2B6, CYP 2A6, UGT 
2B7 and CAR on mid-dose exposure to efavirenz by assessing the frequency of these 
polymorphisms, the pharmacokinetics of efavirenz and the pharmacodynamic impact of 
these polymorphisms on the risk of developing CNS toxicity on efavirenz and also on 
the risk of immunological failure. To conclude, chapter 9 summarises the major 
findings, limitations and recommendations for further studies to improve our 
knowledge.  
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1.1.5. About the Author. 
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Technology with BSc Human Biology in 2000 and MBChB degree in 2003. He did his 
house jobs at the Department of Medicine and Obstetrics and Gynaecology in 2004 and 
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respectively. Over the past 7 years, Dr. Sarfo has been working at the HIV Clinic in 
Kumasi where he has been involved in patient management since early 2005. His major 
research interests have been on infectious diseases such as HIV, HIV-HBV co-infection, 
HIV-TB co-infections and has also been involved in pinioneering work on the 
immunopathogenesis and antimicrobial therapy for a neglected tropical disease called 
Mycobacterium ulcerans disease. Prior to this dissertation the research experience 
accrued by the author has ranged from laboratory methods in DNA and RNA extraction 
techniques for real-time PCRs and microarrays, ELISAs for proteomics and lipid 
extraction for mycobacterial lipids. The author therefore had a novel challenge of 
collecting data and performing statistical analysis from an epidemiological perspective 
with a large database to assess outcomes of effectiveness of cART. The work on 
pharmacology of efavirenz and artesunate was also a new experience for which the 
author is very grateful to staff at both the department of Pharmacology and Therapeutics 
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of the University of Liverpool and the Liverpool School of Tropical Medicine. Most of 
this study was conducted in Kumasi, Ghana with short-term academic visits to the UK 
for analysis and meetings with supervisors to discuss progress with supervisors. The 
journey has been very exciting with lots of opportunities for learning. All these 
experiences have helped shape my thought processes and deepened my appreciation of 
statistical modelling, pharmacogenomics and pharmacokinetics as it pertains to patients 
whom I will encounter either in consulting rooms at the HIV clinics or on the wards and 
has better placed me to launch a career as research clinician.  
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1.2.0. REVIEW OF LITERATURE 
1.2.1 Human Immunodeficiency Virus (HIV) 
1.2.1.1 Epidemiology of HIV/AIDS 
Acquired Immune Deficiency Syndrome (AIDS) has claimed the lives of more than 25 
million people worldwide since the clinical syndrome was first described in 1981 
(UNAIDS/WHO 2007). The Human Immunodeficiency Virus (HIV), initially referred 
to as either the Lymphadenopathy-associated Virus (LAV) or the Human T-cell 
Lymphotropic Virus type III (HTLV-III) was first identified as the causative agent of 
AIDS in 1983 
37,38
. The predominant route of transmission of HIV is through 
unprotected sexual intercourse (>75%), followed by vertical transmission from mother 
to baby, during pregnancy, at birth or through breast feeding (5-10%) and to a lesser 
extent via the parenteral route (<2%) (through injection drug use and/or 
injection/transfusion of contaminated blood products). Certain sexual activities carry a 
higher risk of infection than others; for example, unprotected anal sex carries a greater 
risk of infection than either vaginal 
39, 40
 or oral sex
41
. It is also apparent that the 
presence of other sexually transmitted diseases (STDs) significantly increases the risk of 
becoming infected with HIV. 
HIV is a global pandemic with an estimated 33.3 million (31.4 million-35.3 million) 
persons  living with the virus worldwide at the end of 2009 compared to 26.2 million in 
1999 according to epidemiological data from UNAIDS/WHO
1
. In spite of intensive 
research efforts and the massive roll-out of treatment interventions, HIV/AIDS 
continues to pose the most serious infectious disease challenge to public health. This is 
particularly true in Sub-Saharan Africa where over 22.5 million (20.9 million-24.2 
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million) people are HIV infected (approximately two-thirds or 68% of the global HIV 
infected population). 61% and 90% of all HIV infections in women and children 
respectively occur in Sub-Saharan Africa. Indeed in SSA ~ 1.3 million (1.1 - 1.5 
million) of the global total of 1.8 million (1.6 – 2.0 million) deaths in 2009 were 
attributable to HIV/AIDS accounting for 72% of all HIV/AIDS related mortality 
worldwide (UNAIDS/WHO 2010). 
Within the Sub-Sahara African region the Eastern and Southern African countries are 
the most devastated with an average national prevalence ranging from 15 -35% of 
populations affected (Figure 1.1). However like the trend globally, the prevalence of 
HIV infection (percentage of persons infected with HIV) is stabilising, although the 
number of persons living with HIV continues to increase mainly due to an increasing 
number of newly acquired and diagnosed infections (albeit, at a reduced rate), longer 
survival times which is a corollary of the introduction of antiretroviral therapy (ART) 
and the unprecedented expansion of ART in Africa and other developing countries. For 
instance, the number of new infections in 2009 in Sub-Saharan Africa was 1.8 million 
compared with 2.2 million in 2001. An estimated 5.2 million people in low- and 
middle-income countries were receiving life-saving antiretroviral therapy by end of 
2009 representing an increase of 1.2 million people or 30% over the number receiving 
such treatment 12 months earlier. In Sub-Saharan Africa nearly 37% (34-40%) of 
people eligible for treatment were accessing ARV by December 2009 and this 
unprecedented roll-out of ARV has translated into an estimated 320,000 (or 20%) fewer 
AIDS-related deaths in 2009 than in 2004. Clearly, the current data demonstrate that 
investments in the HIV response has started to yield fruitful dividends in reducing 
discrimination and stigmata, helping people access information and services to reduce 
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their risk of HIV infection and delivering the treatment, care and support that will 
extend and improve the lives of people living with HIV. 
Ghana, a West African developing country with a population of 24.5 million, is in the 
stable phase of the HIV pandemic with an estimated adult (aged 15-49) HIV national 
prevalence of 1.8% in 2009
1
 from the estimated 3.1% estimated prevalence at the end of 
2003. It is estimated that 260,000 (low estimate of 230,000; high estimate of 300,000) 
people of all ages in Ghana are living with HIV/AIDS and the age group predominantly 
affected are within their reproductive years. The highest prevalence is found in 
metropolitan cities and big towns where there is a lot of commercial activities. The 
Ghana AIDS Commission is the coordinating body for all HIV/AIDS-related activities 
in the country and through the National strategic programme has set targets for reducing 
new infections, addressing service delivery issues and individual and societal 
vulnerability, and promote the establishment of a multisectoral, multidisciplinary 
approach to HIV/AIDS programmes. Substantial funding for HIV/AIDS activities from 
multilateral and bilateral partnerships for activities such as the Global Fund to Fight 
AIDS, Tuberculosis and Malaria and the World Bank-funded treatment acceleration 
program for public-private partnership in HIV/AIDS management and several others. 
These initiatives have been rewarded by a downward trend in HIV prevalence observed 
in national surveys since 2006 and this has been attributed to the increased awareness of 
the disease and increased uptake of protected sexual practises public health messages. 
An estimated 30,265 patients were on antiretroviral medications representing 25% ART 
coverage at the end of 2009 in Ghana, an indication of a need to improve access to ART 
in the country 
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Figure 1.1. National HIV prevalence map of percent of men and women aged 15 to 49 
years with HIV infection at 2010. Source: Blake Zachary ICF Macro at 
http://www.hivspatialdata.net 
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1.2.1.2 HIV Structure 
HIV is a retrovirus, meaning its genetic information is stored in the form of ribonucleic 
acid (RNA) instead of deoxyribonucleic acid (DNA) and the virus therefore requires 
reverse transcription in order to replicate. HIV belongs to a sub-family of lentiviruses, 
which include the simian immunodeficiency virus (SIV) in monkeys, feline 
immunodeficiency virus (FIV) in cats and related viruses in sheep, goats and horses; 
these retroviruses are characterised by the lengthy time period between infection of the 
host and clinical manifestation of symptoms. Two strains of HIV have been identified 
(HIV-1 and HIV-2), the latter was identified 2 years later after HIV-1
42
. HIV-1 is 
derived from the SIV of chimpanzees called Pan troglodyte troglodytes while HIV-2 
which is quite dissimilar is genetically closer to the sooty mangabey (called Cercocebus 
atyps) virus. HIV-2 is associated with a slower and more benign disease course, is more 
difficult to transmit via sexual and parenteral routes than HIV-1 and is endemic in West 
Africa. However HIV-1 is the major cause of AIDS worldwide and even in West 
Africa. 
HIV-1 is further divided into three groups, group M (main group, >98%), group O 
(outlier, <1%), and group N (new, <1%). Group M is responsible for the majority of 
infections worldwide and is further subcategorised into recognised phylogenetic 
subtypes or clades namely clades  A (23%), B (8%), C (56%), D (5%), E (5%) and 
subtypes F-K (3%). There are also recombinants, which contain a mix of these 
subtypes. 
HIV-1 viral particles are spherical in shape and 100nm in diameter. A double layer of 
lipoprotein membrane, also known as the viral envelope, surrounds the virus. Integrated 
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within the lipid membrane are 72 glycoprotein spikes, each composed of trimers of 
gp41, a transmembrane protein, and an external glycoprotein gp120. The HIV matrix 
proteins consisting of the p17 protein, lie anchored to the viral envelope and 
encompasses the viral core. The viral core or capsid, contains the viral protein p24 
which surrounds two single strands of HIV-1 RNA and the enzymes required for viral 
replication, including reverse transcriptase p66, integrase p32 and protease p11. The 
HIV-1 RNA is a protein-nucleic acid complex, composed of the nucleoprotein p7 and 
the reverse transcriptase.  
The viral genome consists of 9 genes. Structural proteins such as glycoprotein 160, 
which is subsequently cleaved to form the gp120 surface molecule and the gp41 
transmembrane molecule is encoded by the env gene whiles the gag gene encodes the 
precursor to the capsid molecules p24, p17, p9 and p6; the latter enabling budding of the 
virus. Viral enzymes including reverse transcriptase, protease and integrase are encoded 
for by pol. There are also regulatory genes- tat, which regulates transcription, rev, 
which aids translation and nef, which down-regulates expression of CD4, major 
histocompatibility complex (MHC) class 1 proteins and interleukin-2, and recruits 
lymphocytes to infected macrophages to aid spread. Other accessory genes include vif 
and vpr. The strands of RNA are flanked by repeated sequences known as long terminal 
repeats (LTR), which do not encode any viral proteins but play a role in regulating gene 
expression
43
. 
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1.2.1.3 HIV Replication Cycle 
The CD4 surface receptor, a 58kDa monomeric glycoprotein, is the primary target for 
HIV entry into the host cell. CD4 is present in ~60% of T-cell helper lymphocytes, T- 
cell precursors, monocytes and macrophages, eosinophils, dendritic cells and microglial 
cells of the central nervous system (CNS). However, in addition to CD4, human co-
receptors (CCR5 and CXCR4) also located on the host cell surface are necessary for 
viral entry. HIV-1 tropism refers to the cell type that HIV preferentially infects and 
replicates in, such that T-tropic (X4) HIV-1 isolates mainly infect activated CD4 T-cells 
using the CXCR4 co-receptor; M- tropic (R5) isolates are able to infect CD4 bearing 
macrophages, monocytes and T-cells; whereas the dual-tropic virus can use either 
CCR5 or CXCR4. During the early course of HIV-1 infection, M-tropic isolates 
predominate. In fact, M-tropic HIV-1 isolates are preferentially transmitted even if the 
donor predominantly harbours T-tropic isolates. It has been postulated that preferential 
transmission may be due to selective transportation of M-tropic isolates by sub-
mucosally located dendritic cells or because local cytokine/ chemokine elaboration 
favours the replication of the M-tropic viruses. In contrast, the more virulent X4 or 
dually tropic viruses, which are probably able to infect a wider spectrum of cell types, 
evolve during the more advanced stages of infection. 
The replication of HIV can be divided into 6 stages: attachment/ uncoating, reverse 
transcription, integration, transcription, translation and assembly/release; as 
schematically illustrated in Figure 1.2 and described below. 
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Figure 1.2. The life cycle of HIV-1. 
Attachment/ uncoating: Binding of gp120 protein of the HIV to the CD4 surface 
receptor on the host cell induces a conformational change in gp 120, which facilitates a 
more efficient interaction with co-receptors CCR5 and/or CXCR4. Following binding to 
these co-receptors another conformational change in gp41 ensues enabling the fusion of 
the viral and host cell membrane. Subsequent to membrane fusion, the capsomere is 
uncoated and the contents of the viral particle are released into the host cell cytoplasm. 
Reverse transcription: The genetic information stored in the RNA of HIV must be 
reverse transcribed into proviral HIV DNA in order for the virus to replicate. This 
process is mediated by the viral reverse transcriptase enzyme, which utilises host 
deoxynucleotide triphosphates (dNTPs) in the cytoplasm of the host target cell.  
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Integration: Once formed, proviral DNA is transported into the host cell nucleus where 
cellular activation causes integration of the proviral HIV DNA into the host cell 
genome, catalysed by the viral integrase enzyme. This newly incorporated viral DNA is 
known as a provirus. This provirus will remain inside the host cell awaiting stimuli 
from cellular transcription factors, such as NF-B, to initiate transcription44. However 
without cellular stimuli the provirus may remain dormant within the target cell; for 
example, as proviral non-integrated HIV DNA in quiescent CD4 T-cells and in 
monocytes, macrophages and microglial cells and represent an important source of 
cellular reservoirs of HIV
45
, which is one of the principal reasons why complete 
eradication of HIV is unattainable at the moment. 
Transcription: following a cellular stimulus, transcription of host cell DNA occurs, 
which now includes the provirus. Transcription is mediated by host RNA polymerase 
and using endogenous dNTPs of the host. 
Translation: the messenger RNA (mRNA) is transported out of the cell nucleus and 
translated into viral polyproteins using host amino acids and ribosomes forming large 
precursor molecules. 
Assembly/release: new viral core proteins, enzymes and viral RNA migrate towards the 
cell surface where the large precursor viral proteins are cleaved by the HIV-1 protease, 
resulting in the formation of infectious viral particles, which bud through the host cell 
membrane into the extracellular space
46,47
. During the budding process, virus lipid 
membranes can incorporate various host cell proteins and become enriched with certain 
phospholipids and cholesterol
48,49
. 
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1.2.1.4 Natural History of HIV Infection 
The ‘ natural history’ of HIV infection refers to disease progression in the absence of 
antiretroviral treatment and can be described in 3 phases namely primary or acute 
infection, latent or asymptomatic infection and symptomatic infection. 
Primary infection is defined as the time period from initial infection with HIV to the 
development of an antibody response (seroconversion) and typically lasts between 1 to 
3 months. It is characterised by a surge in plasma viremia due to unrestrained viral 
replication, with plasma viral loads (pVL) reaching over 100 million copies/ml in the 
absence of any detectable adaptive immune response
50,51
. Following seroconversion 
there is a marked decline in the number of CD4 T-lymphocytes as a result of both 
destruction by HIV and migration to peripheral lymph tissue
52,53
. During the period 
patients may develop a generalised rash, sore throat and lymph gland swellings, which 
is frequently misdiagnosed as flu by clinicians particularly because no HIV specific 
antibodies are detectable during this early phase of infection. Although higher pVL 
during primary infection are not directly indicative of disease progression, they are 
linked to the severity of these initial symptoms. Certainly, it has been observed that 
individuals presenting with more severe symptoms during acute infection tend to have 
poorer long-term clinical outcomes and progress more rapidly to AIDS
54-56
. 
An immune response capable of controlling viral replication develops over the 
following weeks, which is evidenced by a diminution of the high pVL. This coincides 
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with a concurrent increase in the CD4 count, although levels rarely re-establish to pre-
infection values in the absence of antiretroviral therapy. The high plasma viremia during 
the primary infection stage makes patients highly infectious hence accurate early 
diagnosis of acute HIV infection is important, as infection of sexual partners can be 
potentially prevented. 
Latent infection refers to the time period in which equilibrium is established between 
rate of viral replication and the host immune response. This is often referred to as the 
viral ‘set point’ where the level of viral RNA remains constant at approximately 103-105 
copies/ml
57, 58
 and is a strong predictor of the speed of HIV disease progression 
following infection
59
. In the absence of antiretroviral treatment, this period of clinical 
‘latency’ can last for 8-10 years or more52, 60, 61, and during this period many infected 
individuals do not present with any clinical symptoms of the disease. However, the term 
latency is misleading, giving the high turnover of virus (up to 10
10 
new virions per day) 
and the relentless daily destruction of CD4 cells
62
. 
A number of host factors have been identified to influence the time spent in clinical 
‘latency’, including gender63, age64, viral fitness and genetic predisposition65, 66 
(CCR532 deletion). The most important of these is a deletion in the CCR5 coreceptor. 
Homozygotes for this 32 base pair deletion (CCR532) do not express the coreceptor at 
the cell-surface and therefore can only be infected with T-tropic HIV strains that are 
able to use other coreceptors, such as CXCR4. Heterozygotes for the deletion exhibit 
significantly lower viral set points and a slower progression to AIDS; these individuals 
belong to the group of, so called, long-term non-progressors; representing  5% of all 
HIV –infected patients. 
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Symptomatic infection eventually occurs in the presence of high viral replication and 
consequent destruction of the immune system. Although the immune system has the 
capacity to regenerate it is not unlimited and HIV finally overcomes the immune 
response. Indeed, once CD4 counts fall to below 200cells/ l the immune system is 
sufficiently compromised and patients are at significant risk of contracting many AIDS-
defining illnesses, including a number of opportunistic infections (e.g. tuberculosis) and 
certain neoplasms (e.g. Kaposi’s Sarcoma). Above 200cells/ l, most AIDS-defining 
illnesses are rare events. Without antiretroviral treatment most patients with 
symptomatic infection will eventually succumb within 2-3 years. 
1.2.1.5 HIV Testing 
The laboratory diagnosis of an HIV infection is normally made indirectly by 
measurement of virus-specific antibodies
67
 with most screening tests based on the 
ELISA principle (enzyme linked immunosorbent assay). HIV infection may also be 
diagnosed through detection of the virus using branch chain DNA PCR and GenProbe, 
detecting either intracellular proviral cDNA (complementary DNA) in leucocytes or 
extracellular HIV-1 RNA in the cell-free compartment. However this approach to viral 
detection is only relevant in certain situations, such as suspected primary infection or to 
test babies born to HIV-infected mothers in resource endowed settings. 
In all cases, HIV infection can only be confirmed/diagnosed by a reactive (positive) 
result followed by at least one confirmatory test result. HIV infection should never be 
diagnosed (or reported to the patient) on the basis of a single reactive screening assay 
alone. Whereas qualitative testing for viral genome/ virus-specific antibodies serves as a 
marker of infection, the quantitative detection of HIV RNA in plasma; in copies per 
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millilitre of plasma and the CD4 T-lymphocyte count (number of cells per microlitre of 
blood) are key prognostic indicators of a patient’s viral burden/infectivity status and 
immunological function, and are routinely used to guide clinical and therapeutic 
management of HIV-infected patients. HIV RNA is commonly measured by a 
commercially available RT-PCR kit by Roche, which has a detection limit of 50 
copies/ml; hence, in current practice, patients with a pVL below or equal to this value 
are referred to as ‘undetectable’ and described as being virologically suppressed. 
1.2.1.6 Clinical and laboratory staging of HIV disease 
In developing countries like Ghana, the WHO staging system that include clinical, 
laboratory and a combined clinical /laboratory classifications is used to stage HIV/AIDS 
in adults and adolescents as shown on Table 1.1A and 1.1B. The clinical markers fall 
into four stages of prognostic significance and this forms the basis of the WHO clinical 
staging. In resource limited settings this staging system, which has proven reliable in 
predicting morbidity and mortality is used to classify clients according their level of 
immunosuppression, to help prompt clinicians to look out for other disease features 
when one is present in a stage and to decide when to start cART. 
 
 
 
 
 
 
 
 
 44 
 
 
 
Table 1.1A. The revised WHO clinical staging of HIV/AIDS for adults and adolescents. 
Clinical 
Stage 
 
                                                      Clinical conditions 
1
0
 HIV 
Infection 
  
 Acute retroviral syndrome  
1   
 Asymptomatic  
 Persistent generalised lymphadenopathy  
2   
 Moderate unexplained weight loss <10% of presumed 
or measured body weight 
Recurrent oral ulcerations 
 Recurrent upper respiratory tract infections Papular pruritic eruptions 
 Herpes zoster Seborrhoeic dermatitis 
 Angular cheilitis Fungal nail infections of fingers 
3   
 *a presumptive diagnosis can be made on the basis 
of clinical signs or simple investigation 
** a diagnostic confirmatory test is necessary 
 Severe weight loss >10% of presumed or measured 
body weight 
Unexplained anaemia (< 8g/dl), and or neutropenia 
(<500/mm3) 
 Unexplained diarrhoea for > 1 month Unexplained thrombocytopaenia  
(<50 000/mm3) for > 1month 
 Unexplained persistent fever (intermittent or 
constant) 
 
 Oral candidiasis  
 Oral hairy leukoplakia  
 Pulmonary tuberculosis diagnosed within the last 2 
years 
 
 Severe presumed bacterial infections e.g. pneumonia, 
empyema, meningitis, bone and joint infection 
 
 Acute necrotising ulcerative stomatitis, gingivitis, or 
periodontitis 
 
4  ** a diagnostic confirmatory test is necessary 
 HIV wasting syndrome Extrapulmonary cryptococcosis 
 Pneumocystis pneumonia Disseminated non-TB mycobacterial infection 
 Recurrent severe or radiological bacterial pneumonia Progressive multifocal leukoencephalopathy (PML) 
 Chronic herpes simplex infection (orolabial, genital 
or anorectal) >1month 
Candida of trachea, bronchi or lungs 
 Oesophageal candidiasis Cryptosporidiosis 
 Extrapulmonary tuberculosis Isosporidiosis 
 Kaposi sarcoma Visceral herpes simplex infection 
 CNS toxoplasmosis Visceral leishmaniasis 
 HIV encephalopathy Invasive cervical carcinoma 
  Lymphoma (cerebral or B cell non-Hodgkin) 
  Recurrent non-typhoidal salmonella sepsis 
  Any disseminated mycosis such as histoplasmosis, 
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coccidiomycosis, penicilliosis 
  Cytomegalovirus (CMV) infection (retinitis or of any 
organ other than liver, spleen or lymph nodes) 
 
 
 
Table 1.1B. Improved WHO Clinical staging. 
             Laboratory axis                                      Clinical axis 
Lymphocyte count CD4 
counts 
Stage 1 
Asymptomatic 
PGL 
Stage 2 
Early 
HIV 
Stage 3 
Intermediate 
(ARC)* 
Stage 4 
Late 
AIDS 
A > 2000 >500 1A 2A 3A 4A 
B 1000- 2000 200-500 1B 2B 3B 4B 
C < 1000 <200 1C 2C 3C 4C 
 
 
1.2.2 Combination Antiretroviral Therapy (cART) 
Combination antiretroviral therapy (cART) involves the simultaneous administration of 
three or more antiretroviral drugs. Currently there are more than 20 antiretroviral 
medications from six different mechanistic classes including: the nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PI), entry/ fusion inhibitors (FIs), CCR5 antagonists and 
integrase strand transfer inhibitors (INSTIs). These drugs target different stages in the 
HIV life cycle. In addition there are several novel and experimental antiretroviral drugs 
including maturation inhibitors, uncoating inhibitors, transcription inhibitors and 
translation inhibitors at various stages of development.  
1.2.2.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) 
Blockade of the viral reverse transcriptase enzyme was the first attempt to inhibit the 
HIV life cycle, and in 1987 the first antiretroviral, zidovudine (AZT) was licensed for 
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treatment of HIV infection. The NRTI act as competitive inhibitors of reverse 
transcriptase. The drugs in this class enter the host cells via endocytosis and require 
intracellular phosphorylation in order to produce an active triphosphate form. The 
triphosphate derivatives then act as alternative substrates for the viral reverse 
transcriptase and compete with physiological nucleosides, since their structure differs 
by only a minor modification in the ribose molecule. The incorporation of nucleoside 
analogues ultimately terminates viral DNA replication, as phosphodiester bridges can 
no longer be built to stabilise the DNA double strand.  
The overall tolerability of NRTI is fairly good, with initial side effects being easy to 
manage. The pill burden is low compared with other drug classes [once daily (q.d.) 
dosing is sufficient for most NRTI], which reduces the potential for non-adherence
68, 69
. 
There is also a reduced risk of drug interactions, as NRTI predominantly undergo renal 
excretion and are less likely to interact with drugs metabolised by the hepatic/intestinal 
cytochrome P450 (CYP450) system. Despite these potential advantages, the NRTI are 
associated with long-term safety problems, including mitochondrial toxicity caused by 
their inhibition of mitochondrial DNA polymerase-70. 
Two NRTIs remain an integral part of cART and are combined with either an NNRTI or 
a ritonavir-boosted PI. There are currently seven NRTI available, namely, zidovudine 
(AZT), didanosine (ddI), stavudine (d4T), lamividine (3TC), tenofovir (TDF), abacavir 
(ABC) and emtricitabine (FTC). Extensive data support the inclusion of 3TC and/or 
FTC as one of the two NRTI
71-73
. Single-pill formulations containing two or more NRTI 
are also licensed to further simplify treatment regimens. Combinations include AZT + 
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3TC (Combivir), ABC + 3TC (Kivexa), TDF + FTC (Truvada) and 3TC + AZT + ABC 
(Trizivir).  
 
 
1.2.2.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
The NNRTIs, which include efavirenz (EFV), nevirapine (NVP) and delavirdine (DLV) 
also possess a high affinity for the enzyme reverse transcriptase. However, unlike the 
NRTI they do not act as false substrates or require transformation within the cell to form 
an active metabolite. Instead, the parent form binds non-competitively to the viral 
enzyme at a specific region known as the NNRTI pocket, located close to the substrate 
binding site. The resulting complex blocks the active site by allosteric interactions, so 
that fewer nucleosides can bind, thereby slowing the polymerase reaction significantly. 
EFV can cause mild CNS manifestations, including dizziness, somnolence, impaired 
concentration and nightmares, and is best taken at night. However, these effects are 
usually transient, only occurring during the initial two to four weeks of therapy, 
although they can persist in approximately one fifth of patients
74, 75
. NVP can provide 
an alternative to EFV in pregnant women or patients with baseline mental health 
disorders
76
. However, NVP is known to cause elevation of liver enzymes in up to 16% 
of patients which can result in severe hepatotoxicity, and must be administered under 
specific CD4 criteria. Women with good immune status particularly those with CD4 
>350/mm
3
 appear to be more prone to this effect. DLV is rarely prescribed due to its 
high pill burden and is not licensed in Europe and in Africa. 
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Overall, the NNRTIs are well tolerated and have relatively long half-lives permitting 
simple dosing. Their one major drawback however is the low genetic barrier to 
resistance, in which single amino acid substitutions (K103N and Y188C) are sufficient 
to confer NNRTI cross-resistance
77
 necessitating a swift but decisive change in 
treatment regimens. In addition, a risk of drug-drug interactions with NNRTI is high as 
both EFV and NVP are metabolised by the CYP450 system and cause induction (NVP) 
or both induction and inhibition (EFV) of CYP3A4 and CYP2B6 and can therefore 
impact the metabolism of concurrent drugs
78
 which will later be discussed under 
Section 1.2.7.3.ii. of this literature review. 
Second generation NNRTI: due to the genetic frailty and potential for cross-resistance, a 
second generation of NNRTIs, including etravirine (ETV) and rilpivrine (RPV), has 
been developed. Both are flexible diarylpyrimidine compounds which possess 
favourable binding interactions toward both the wild-type and mutant HIV, including 
virus harbouring the common K103N mutation which confers resistance to all first 
generation NNRTI
79
. Specifically, structural studies have shown that the 
diarylpyrimidine can adapt to changes in the NNRTI-binding pocket by binding in at 
least two conformationally distinct modes: (a) within a given binding mode, torsional 
flexibility of these analogues permits access to numerous conformational variants and 
(b) the compact design of the analogues permits significant repositioning and 
reorientation within the pocket. In 2008, the US Food and Drug Administration (FDA) 
and the European Medicines Agency (EMEA) granted accelerated approval of ETV 
based on data from the phase III DUET_1 and DUET_2 studies, in which patients in the 
ETV arm achieved better virologic and immunologic responses compared with the 
placebo when combined with an optimised background regimen of RTV boosted DRV 
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with or without the fusion inhibitor enfuvirtide
80-82
. Similarly RPV, has been shown to 
be effective in phase III trials for use in both ART-naïve
83, 84
 and ART-experienced
85
 
patients. 
1.2.2.3 Protease Inhibitors (PI) 
The first protease inhibitor, saquinavir (SQV), was introduced in December 1995. Since 
then the PIs have remained an essential component of cART, particularly among 
treatment experienced patients. The PIs target the HIV protease enzyme, responsible for 
cleaving large HIV precursor proteins into infectious viral particles that are able to bud 
through the host cell membrane. The drugs bind tightly to a peptide moiety within the 
catalytic pocket of the protease enzyme and prevent it from cleaving HIV polyproteins 
into the functional proteins. As a result, the virus cannot mature and non-infectious viral 
particles are produced. 
The PI undergo extensive CYP450 mediated metabolism via CYP3A4 and to a lesser 
extent by CYP2D6 and CYP2C19, which renders them prone to variable 
pharmacokinetics and extensive drug-drug interactions when given in combination or 
with other concomitant medications
86
. Moreover, they can variably affect their own 
metabolism through induction and inhibition of these enzymes
87-89
. All PIs inhibit 
CYP3A4, with ritonavir (RTV) being the most potent and is extensively used at sub-
therapeutic doses (100mg or 200mg) as a pharmacokinetic enhancer to “boost” the 
plasma concentrations of concomitant PI
90
. Boosting with RTV increases drug exposure 
and/or prolongs the elimination half-life, allowing for a reduction in pill burden and 
dosing frequency, which, in turn improves patient adherence and limits the development 
of resistance. 
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The RTV-boosted PIs recommended for initial treatment in naïve patients include 
atazanavir (ATV), lopinavir (LPV), amprenavir [APV; administered as the pro-drug 
fosamprenavir (FPV)] and SQV. In addition, boosted darunavir (DRV), which is active 
against multi-drug resistant strains of HIV-1 and shown to be superior to LPV in 
patients with HIV RNA > 100,000 copies/ml
91
 has been approved for initial treatment in 
early 2009. Kaletra (LPV/r) is the only licensed PI to contain a fixed booster dose of 
ritonavir and is the only PI available in Ghana and is reserved as a component of second 
line therapy for treatment failures. 
Boosted PIs have a higher genetic barrier to resistance and exhibit improved 
immunological responses compared to the NNRTI
92
. However, most PIs (excluding 
ATV) are commonly associated with undesirable effects on lipid metabolism, including 
hyperlipidemia [an increase in total and low density (LDL) cholesterol and triglyceride 
levels, which poses an increased cardiovascular risk] and lipodystrophy (redistribution 
of body fat, often with fat wasting at the extremities and around the face, and fat 
deposition around the trunk). 
1.2.2.4 Entry inhibitors 
For treatment experienced patients harbouring resistance virus and those failing 
multiple regimens, antiretroviral drug combinations have become increasingly complex 
and in recent years new and more potent agents have been introduced which possess 
activity against both wild-type and resistant strains. 
Inhibition of viral entry is a promising target for therapeutic intervention, since neither 
NRTI/ NNRTI nor PI prevent viral entry. In theory all stages of viral entry can be 
inhibited, including, attachment or binding to the CD4 receptor, binding to coreceptors 
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and fusion of the virus and host membranes. Hence entry inhibitors can be divided into 
three classes: attachment inhibitors, coreceptor antagonists and fusion inhibitors. 
Attachment inhibitors 
These agents interfere with the interaction between the HIV glycoprotein gp120 and the 
CD4 receptor, which is the first step towards viral entry into the target cell. Attachment 
inhibitors are very heterogeneous class because sites on the CD4 receptor as well as the 
binding site for gp120 can be blocked; both are currently being investigated. 
Compounds under investigation include ibaluzimab (formerly TNX-355)
93
, a 
humanised monoclonal antibody that binds to the domain 2 of the extracellular portion 
of the CD4 receptor as well as BMS-663068 
94
 and BMS-488043
95
 which binds to the 
CD4 binding pocket of the viral envelope gp120 to interfere with CD4 binding. These 
are in the early stages of development. 
Co-receptor antagonists 
In addition to the CD4 receptor, HIV also requires co-receptors to gain entry into a 
target cell. Co-receptor antagonists block either CCR5 or CXCR4 in a similar way to 
endogenous chemokines, whose structure they partially resemble. The CCR5 
antagonists, in particular, are in the later stages of development. Maraviroc (MVC) is 
the first licensed co-receptor (CCR5 receptor) antagonist and was approved in August 
2007. It has activity specifically against CCR5-trophic HIV by preventing the virus 
from engaging with the CCR5 co-receptor located on the host cell membrane
96
. MVC is 
efficacious in patients with R5 virus, failing other antiretroviral classes
97
. However, it is 
not active against CXCR4-tropic and mixed or dually-tropic strains, which become 
increasingly dominant in the later stages of HIV infection. Thus, an initial determination 
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of co-receptor tropism is necessary prior to initiating therapy. Furthermore, it is possible 
that blocking one type of co-receptor may itself induce a switch in viral tropism. There 
are also long-term safety concerns of blocking a human receptor, as opposed to a viral 
target. Initial data from a study evaluating MVC in treatment naïve patients (MERIT) 
suggest that it was inferior to standard-of-care EFV when using <50 copies/ml cut-off
98
. 
However in a subsequent analysis, which used a more sensitive tropism testing assay 
than the one originally used and retrospectively excluded patients with non CCR5-tropic 
HIV-1 infection, MVC demonstrated noninferiority to efavirenz on primary virological 
end-points
98
. In treatment-naïve patients, vicriviroc administered with dual NRTIs in 
treatment-naïve subjects with HIV-1 infection has increased rates of virologic failure 
compared with efavirenz plus dual NRTIs
99
.  
Fusion inhibitors 
Enfuvirtide (T-20) is the only fusion inhibitor approved for clinical use, although other 
compounds of this class are currently in development. T-20 binds to an intermediated 
structure of the gp41 protein to prevent the formation of the HR-1:HR-2 complex and 
ultimately fusion of HIV with the target cell. It is a large peptide molecule (36 amino 
acids) and is homologous to HR-2 
100
. A practical limitation to clinical use however is 
that, because of its size, T-20 has to be administered via subcutaneous injection
101
. T-20 
is used primarily in patients harbouring multi-resistant strains, for the so-called ‘salvage 
therapy’ in cases where other treatment options have been exhausted. Improved efficacy 
by incorporating T-20 into an optimised HAART regimen in extensively pre-treated 
patients was demonstrated by the TORO_1 and TORO_2 studies, respectively 
102-104
. 
1.2.2.5 Integrase Inhibitors 
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The viral enzyme integrase, which is encoded by the HIV pol gene, is involved in the 
integration of viral DNA into the host genome; rendering it a key pharmacological 
target
105
. Moreover, the enzyme is unlikely to be present in human cells. Integration of 
viral DNA is a stepwise process, all of which can be theoretically inhibited. Raltegravir 
(RAL) is the first integrase inhibitor to be licensed by the FDA and EMEA in 2007. The 
drug specifically inhibits the strand transfer step in the integration process, by 
preventing the docking and irreversible binding of the hydroxyl ends of viral DNA to 
the phosphodiesterase bridges of the host DNA. RAL is efficacious against both R5 and 
X4 tropic viruses and has demonstrated potent antiviral activity in multi-drug 
experienced patients, as presented in the BENCHMARK trial
106
; although, due to 
concerns over genetic frailty, it needs to be supported by other active agents. Unlike 
most antiretrovirals, RAL is eliminated primarily by UDP-glucoronyltransferase 
(UGT1A1) mediated glucoronidation, and thus has less potential for CYP-related drug 
interactions
107
. An additional integrase inhibitor, elvitegravir
108
, also a strand transfer 
inhibitor, is in the late stages of clinical development, but has yet to be approved. 
Elvitegravir is currently boosted with RTV but a new boosting agent, GS9350, is 
currently been trialled. GS9350 does not have anti HIV activity and is well tolerated
109
. 
Recently, elvitegravir (EVG) co-formulated with the CYP3A4 inhibitor cobicistat 
(COBI), emtricitabine (FTC) and tenofovir (TDF) in a single tablet given once daily 
was shown to be virologically non-inferior to once daily EFV/FTC/TDF at 48-weeks in 
ART-naïve patients
110
 showing that if regulatory approval is given, 
EVG/COBI/FTC/TDF (Quad) would be the only single tablet, once-daily, integrase-
inhibitor-based regimen for initial treatment of HIV infection. 
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In summary the over past 25 years tremendous strides have been made in antiretroviral 
drug development. Data from the MOTIVATE (maravaroc), BENCHMARK 
(raltegravir), TORO (T-20) and DUET (etravarine) studies have shown clear benefit of 
adding a fully active drug to an existing optimised regimen in multi-drug experienced 
patients. Therefore, it is hoped that with access to these additional classes, patients with 
extensive multi-drug resistance can realistically achieve the same virologic and 
immunologic responses seen in naïve patients. However these novel antiretroviral drug 
classes are expensive and may become accessible to the majority of people living with 
HIV in resource limited settings in the coming years. 
1.2.3 Initiating first line combination antiretroviral therapy 
1.2.3.1. When to start 
One of the most crucial decisions is when to initiate antiretroviral therapy (ART), as this 
can influence a patient’s long term response to treatment. Most of the early treatment 
guidelines recommended that treatment be delayed until the CD4 cell count had fallen 
below 200 cells//l. However over time, treatments have improved and the number of 
treatment options available to patients has increased. Current international guidelines 
state that all symptomatic and asymptomatic patients with a CD4 count less than 350 
cells/l according to the BHIVA guidelines111. According to the recent WHO 
guidelines, all adolescents and adults including pregnant women with HIV infection and 
CD4 counts of ≤ 350 cells/mm3, should start ART, regardless of the presence or absence 
of clinical symptoms. Those with severe or advanced clinical disease i.e WHO clinical 
stage 3 or 4) should start ART irrespective of their CD4 cell count
112
.  
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Asymptomatic patients with CD4 counts >500 cells/l have a low short-term risk of 
disease progression; thus it is recommended that treatment in these subjects should be 
deferred in the majority of cases. The question of whether to initiate ART in 
asymptomatic patients with CD4 counts >350 cells/l (and even > 500 cells/l) is 
uncertain. Recent cohort studies, most significantly, SMART and NA-ACCORD, 
suggest that early initiation of therapy [>350 cells/l113 and >350 and >500 cells/l114 
improved survival rates and was associated with a reduced incidence of non-AIDS 
malignancies and cardiovascular diseases compared with deferred therapy. Indeed, 
previous concerns with respect to starting therapy early has been based on the toxicity 
risks (for example, metabolic complications) associated with long-term antiretroviral 
therapy. However, because simpler, less toxic and more tolerated agents are now 
available, as well as an increased number of options in the case of virologic failure, 
early initiation of therapy is becoming an increasing viable consideration at least in the 
resource-endowed settings. The Strategic Timing of Antiretroviral Treatment (START) 
trial due to report in 2015 will provide the first randomised evidence of whether 
immediate initiation of treatment in patients with CD4 cell counts more than 500 cell/l 
is superior to delaying initiation of HAART until the CD4 cell counts falls below 350 
cells/l. 
1.2.3.2. What to start with 
The preferred options for adults and adolescents in the 2010 WHO recommendations 
for starting first line cART in developing countries such as Ghana for patients with 
HIV-1 infection include either AZT or TDF + 3TC or FTC with either EFV or NVP. 
The backbone of AZT+3TC is avoided in patients with moderate to severe anaemia. 
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Previously D4T+3TC was recommended as part of first line therapy, but D4T although 
relatively inexpensive is being phased out in most treatment programmes in developing 
countries to avoid the disfiguring, unpleasant and potentially life-threatening toxicity.  
In comparison the current 2012 BHIVA guidelines recommend for treatment naïve 
patients, a combination of three or more antiretroviral agents: an NNRTI or a RTV-
boosted PI in combination with a dual NRTI backbone (preferably containing either 
FTC or 3TC). These recommendations are summarised in Table 2.2. Since ART is life-
long, it is crucial that initial drug regimens are tailored towards an individual patient’s 
needs, taking into account any concurrent illnesses and concomitant medications, in 
order to achieve the maximum potency and tolerability, and avoid long-term 
complications and possible drug interactions. 
Table 1.2 Current (2012) British HIV Association (BHIVA) recommendations for 
initial treatment of HIV infection. 
 Preferred Alternative 
NRTI backbone Tenofovir and 
emtricitabine 
Abacavir and lamivudine
1,3 
Third agent Atazanavir/Ritonavir 
Darunavir/Ritonavir 
Efavirenz 
Raltegravir 
Lopinavir/Ritonavir 
Fosamprenavir/Ritonavir 
Nevirapine
2 
Rilpivirine
3 
1. Abacavir is contraindicated if HLA B*5701 is positive 
2. Nevirapine is contraindicated if baseline CD4 is greater than 250/400 cell/µl in 
women/men. 
3. Use recommended only if baseline viral load less than 100,000 copies/ml: rilpivirine 
as a third agent, Abacavir+Lamivudine as NRTI back bone. 
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1.2.4 Factors influencing response to cART 
The primary goal of ART in naive patients is to achieve an undetectable pVL of <50 
copies/ml within the first 4-6 months of initiating treatment
111
. If virologic suppression 
is not attained, or the log reduction in pVL from baseline is insufficient, patients are 
described to have ‘failed’ therapy. If antiretroviral drug classes fail virologically and 
there are little or no remaining options for the patient concerned, clinicians must take 
decisive action and explore all possible avenues of treatment; this therapeutic approach 
is often referred to as ‘salvage’ therapy. In the past few years, with the advent of new 
and more potent antiretroviral classes which possess activity against an array of drug 
resistant strains, the outlook for these patients is increasingly promising. 
An individual’s response to ART is dependent on many confounding variables, which 
relate to the patient or ‘host’, the virus and the drug(s) administered. Thus, treatment 
failure can occur due to physiological, pathological, genetic and behavioural factors, 
and pharmacologically, due to poor pharmacokinetics, drug interactions, a lack of 
treatment efficacy or the development of viral resistance; all of which are explored 
further in the following sections. 
1.2.4.1. Viral factors 
Drug resistance 
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Treatment failure is often indicated by a high pVL in a patient on ART and it implies 
that the virus has acquired resistance to a drug, or a whole drug class (cross-resistance). 
Resistance occurs when viruses acquire mutations that render them slightly different 
from the original wild- type population. The development of resistance in HIV is rather 
ubiquitous because of both the rapid and error prone replication, as the reverse 
transcriptase enzyme does not contain a DNA proofreading stage like other 
retroviruses
115
. Specifically, mutations that confer drug resistance accumulate when 
viral replication occurs in the presence of selective pressure from antiretrovirals and /or 
immune response. The potential for selection of drug resistant strains is, therefore, 
substantially higher in the presence of suboptimal antiretroviral concentrations, when 
the replicative capacity of the virus becomes greater. For this reason, effective 
monitoring of antiretroviral concentrations may be a viable tool for evaluating or 
predicting the risk of resistance in patients, particularly those with high pVL and/or 
suspected adherence issues. 
However, many drug resistant mutations which emerge during antiretroviral treatment 
have a detrimental effect on viral fitness and replication. In general, mutations 
conferring resistance to the NRTIs and NNRTIs do not reduce viral fitness to the same 
extent as those conferring resistance to the PIs. For example, the D30N primary 
mutation for nelfinavir (NFV) reduces the replicative capacity of the virus but does not 
impact the efficacy of other PI
116
. By contrast, the single point mutation K103N is 
enough to cause cross-resistance to all first generation NNRTI and does not change the 
replicative capacity of HIV 
115, 117
, so a prompt change in therapy is vital to avoid 
NNRTI exclusion, and preserve future options. Furthermore, in the era of cART, the 
transmission of resistant strains is an emerging problem which has clear implications for 
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long-term treatment options. As a result, where available newly diagnosed patients are 
screened for resistant strains prior to initiation of therapy in the resource-endowed 
settings. 
1.2.4.2. Pharmacological factors 
Pharmacological factors that may incur therapeutic failure include poor drug 
pharmacokinetics, inadequate potency and a low genetic barrier to resistance, 
unfavourable toxicity profiles and poor penetration of antiretrovirals into viral sanctuary 
sites. 
Pharmacokinetics 
Pharmacokinetics is the area of pharmacology which describes the Absorption, 
Distribution, Metabolism and Elimination (ADME) of drugs by physiological systems 
in the body. In the field of HIV, acquiring and maintaining antiretroviral concentrations 
within the systemic circulation is essential in ensuring that therapeutic drug 
concentrations reach their local receptor site (i.e. within CD4+ cells) in order to exert 
the desired pharmacological response. 
Most significantly, the NNRTIs and PIs have well-defined pharmacokinetic/ 
pharmacodynamic (PK/PD) and pharmacokinetic/toxicity relationships in which, 
systemic (plasma) drug levels have been shown to correlate with observed virologic 
response, or to independently predict the risk of treatment failure/success
118 - 121
 or 
toxicity
122 - 124
. Thus, characterisation of the relationship between antiretroviral 
pharmacokinetics (systemic exposure or a single concentration) and drug response 
(beneficial and/or adverse) is key to the selection of an optimal dose for a drug, 
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understanding inter and intra-subject variability, and to design strategies to optimise 
response and tolerability whilst avoiding unwanted toxicity. 
Furthermore, it is essential that antiretroviral concentrations remain above a so-called 
minimum effective concentration (MEC) in order to ensure adequate potency and avoid 
viral rebound or development of resistance. On the other hand, concentrations must not 
be so high as to cause unwanted toxicity 
125,126
. These concentration-based therapeutic 
cut-offs (MEC) which are well defined for most NNRTIs and PIs 
127
 are utilised in both 
prospective and observational pharmacokinetic studies, and in routine therapeutic drug 
monitoring (TDM) in resource endowed settings. When evaluated alongside virological 
(pVL) and immunological (CD4 counts) markers, they may aid in the interpretation of 
an individual’s response to therapy enabling physicians to make more rational or 
‘evidence- based’ decisions regarding dose adjustment in case of sub-therapeutic 
concentrations or an unsuppressed pVL. Nevertheless, these values serve only as 
estimates, and because they are derived primarily from accumulated pharmacokinetic 
data obtained from controlled trials, they may not reflect ‘real-life’ clinical situations, 
such as the effects of drug interactions, co-infections and pregnancy as well as 
differences in age, race and disease status upon overall drug exposure. Indeed, in reality, 
there is higher inter and intra-individual variation in antiretroviral plasma 
concentrations, even in patients receiving equivalent dose
126
. The foundations for such 
an effect is not fully understood, although it is possible that pharmacokinetic factors, 
such as differences in drug absorption, metabolism and distribution, along with external 
patient or ‘host’ influences (as discussed below) could contribute to the underlying 
variability in antiretroviral concentrations seen in HIV-infected patients. 
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All antiretrovirals, with the exception of T-20, are administered orally; thus, in order to 
reach the systemic circulation and be distributed throughout the body, they must be 
absorbed through the enterocytes and the gut wall. The rate and extent of drug 
absorption is highly dependent upon an agent’s physicochemical properties, such as its 
lipophilicity (as determined by its partition or distribution coefficient; logP/logD) and 
its solubility (dissociation constant; pKa); but may also be regulated by gastrointestinal 
motility, gastric and gastrointestinal pH and blood flow which, in turn, can be affected 
by food (mainly fat) intake, pregnancy, disease states and circadian differences. Most 
antiretrovirals, excluding the NRTI, which are eliminated renally upon reaching the 
liver, undergo phase I biotransformation via oxidative reactions involving the CYP450 
superfamily, followed by phase II conjugation reactions before being eliminated in 
urine or bile. The primary routes of metabolism and elimination of antiretroviral drugs 
are summarised in Table 1.3, respectively. In addition, prior to passage through the 
liver, agents may also be subjected to metabolism and cellular efflux by CYP450 
enzymes and transporters present in the gastrointestinal tract. The removal of drugs via 
these processes is termed ‘first pass metabolism’, and can significantly reduce drug oral 
bioavailability; that is, the fraction of unchanged drug reaching the systemic circulation 
upon administration of an oral dose. 
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Table 1.3 Metabolism of antiretroviral drugs 
Drug Metabolic pathway 
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NTRI) 
Zidovudine (AZT) Glucuronidation (glucuronyltransferase UGT2B7), renal excretion (glomerular 
filtration and active tubular secretion) 
Didanosine (ddI) Renal excretion (glomerular filtration and active tubular secretion)  
Stavudine (d4T) Renal excretion 
Lamivudine (3TC) Renal excretion 
Tenofovir (TDF) Renal excretion (glomerular filtration and active tubular secretion) 
Abacavir (ABC) Hepatic metabolism (glucuronyltransferase and alcohol dehydrogenase), subsequent 
renal excretion of metabolites 
Emtracitabine (FTC) Renal excretion, oxidation and glucuroconjugation (<10%) 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
Efavirenz (EFV) P450 (CYP3A4, CYP2B6) 
Nevirapine (NVP) P450 (CYP3A4, CYP2B6) 
Etravirine (ETV) P450 (CYP3A4, CYP2C9, CYP2C19) 
Protease Inhibitors (PI) 
Fosamprenavir (FPV) P450 (CYP3A4) 
Atazanavir (ATV) P450 (CYP3A4) 
Indinavir (IDV) P450 (CYP3A4) 
Lopinavir/Ritonavir(LPV/r)  P450 (CYP3A4) 
Nelfinavir (NFV) P450 (CYP3A4, CYP2C9, CYP2C19, CYP2D6) 
Ritonavir (RTV) P450 (CYP3A4, CYP2C9) 
Saquinavir (SQV) P450 (CYP3A4) 
Taprinavir (TPV) P450 (CYP3A4) 
Darunavir (DRV) P450 (CYP3A4) 
Entry inhibitors 
Enfuvirtide (T-20) Catabolism to amino acids 
Maraviroc (MVC) P450 (CYP3A4) 
Integrase Inhibitors 
Raltegravir (RAL) Glucuronidation (UDP-glucuronyltransferase, UGT1A1) 
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The NNRTI and PI undergo CYP450 mediated metabolism via CYP3A4 and to a lesser 
extent by CYP2B6, CYP2D6 and CYP2C19 which renders them prone to variable 
pharmacokinetics and extensive drug-drug interactions when given in combination or 
with other concomitant medications
128
. The PIs, in particular, have unfavourable 
pharmacokinetic profiles, due to their extensive first pass metabolism; and are therefore 
characterised by a low oral bioavailability and short elimination half-lives, which 
necessitates frequent dosing and a high pill burden. The PI are also substrates, inhibitors 
and inducers of P-glycoprotein (P-gp), an ATP-dependent transmembrane glycoprotein 
which functions as an efflux pump for a wide variety of compounds and shows a degree 
of overlap in substrate specificity with CYP3A4
129-131
. Furthermore, the organic anion 
transport polypeptides (OATPs: influx transporters)
132
 and multidrug resistance 
associated proteins (MRP1/MRP2) are also involved in the disposition of certain PI
133-
137
. For this reason, and as previously described, the PI are combined with sub-
therapeutic RTV doses (100mg or 200mg) as a means of ‘boosting’ drug levels. RTV 
elevates concurrent PI plasma levels via inhibition of hepatic and intestinal CYP3A4, 
the major enzyme involved in the biotransformation of PIs. In addition, it may also 
inhibit the efflux transporter P-gp, for which PI possess varying affinity, and hence limit 
cellular drug efflux
138, 139
. Boosting variably results in an increase in the minimum or 
trough plasma concentration (Ctrough), maximum concentration (Cmax) and the 
elimination half-life (t1/2), although the overall effect depend on the metabolic properties 
of the concomitant PI. Interestingly, PIs that are boosted by RTV may themselves affect 
RTV pharmacokinetics. For instance, while slightly higher than expected concentrations 
of RTV have been observed following the administration of 100mg of RTV with ATV, 
63 
 65 
slightly lower concentrations have been observed in the presence of LPV, FPV, and 
TPV
140
. This may be due to differential effects (induction versus inhibition) that the PI 
exert on CYP3A4 activity, since this isoenzyme is also responsible for RTV metabolism 
itself.  
Once a drug reaches the systemic circulation it is distributed within the blood and 
extravascular tissue compartments depending on its lipophilicity and affinity for plasma 
proteins. Since only unbound (free) drug can penetrate cell membranes, distribution will 
continue until the concentrations of the unbound drug in plasma and tissue water reach 
equilibrium. The apparent volume of distribution (Vd) is a measure of the extent of a 
drug’s distribution outside of plasma once this equilibrium is reached. Many of the 
antiretrovirals have moderate to relatively large Vd (>0.7L/kg body weight), which 
means that most of the drug within the body actually resides outside of plasma, within 
the tissue compartment
106
. 
The NNRTI and PI are highly (80-99%) bound to plasma proteins, with the exception of 
NVP and IDV which are only moderately (60%) bound141. The NNRTIs are weakly 
acidic compounds and preferentially bind to human serum albumin (HSA), whereas the 
PI are weakly basic and predominantly bind to the acute phase protein alpha-1 acid 
glycoprotein (AAG). 
Sanctuary sites 
HIV is also present outside the blood compartment in sanctuary site including the male 
and female genital tract (semen and cervicovaginal secretions), lymphoid tissue and the 
CNS (cerebrospinal fluid; CSF), so called because they act as regions within the body 
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scarcely accessible by antiretroviral drugs. These anatomical sanctuary sites should be 
distinguished from cellular sanctuary sites (or viral reservoirs; which represent the pool 
of latently infected resting CD4+ T-cells containing non-replicating integrated HIV 
provirus) 
142, 143
 as virus is actively replicating in these sites, thus viral rebound can 
occur if the antiretroviral therapy is discontinued. Adequate penetration of active drug 
within such areas has implications in preventing sexual and vertical (mother-to-child) 
transmission of the virus and in the incidence of HIV associated neuropathies. 
Differential penetration of antiretrovirals into sanctuary sites is attributed, at least in 
part, to their affinity for drug transporting proteins and binding to plasma proteins. The 
PIs generally show poor penetration into the brain and genital tract. For example 
concentrations of LPV in semen were shown to approximate only 2-3% of that in 
plasma
144
 and ATV levels in CSF were less than 1% of concentrations in plasma, 
respectively
145
. 
1.2.4.3. Host factors 
External and internal influences relating to the patient or ‘host’ may further contribute 
to the observed inter-subject variation in drug concentrations and response to treatment. 
Such factors can be psychological, such as the patient’s life-style and adherence to 
therapy, pathological (the stage of HIV infection and the presence of concomitant 
diseases particularly co-infections), or physiological (age and gender-related 
differences, or changes in body weight and composition). 
Adherence 
Patient non-adherence to therapy has been cited as one of the main causes of treatment 
failure in HIV patients
146
. Past studies have demonstrated that >95% adherence is 
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essential for achieving viral suppression and treatment success
147, 148
. If the drugs are 
not taken appropriately, plasma concentrations may not be maintained above their 
therapeutic thresholds, resulting in suboptimal viral suppression and therefore an 
increased risk of viral rebound or development of resistance. Furthermore, non-
compliant patients may compromise the treatment of others, as they have a potential for 
transmission of resistant viruses. 
ART is for life, and continuous adherence to therapy can be challenging even for the 
most willing of patients given the high pill burden of some regimens and necessity for 
frequent and accurately timed dosing. Moreover, the treatment of, what is essentially in 
newly infected patients, an ‘asymptomatic’ disease, means patients may be less willing 
to adhere to their medication in the case of unwanted side effects. For example, the lipid 
abnormalities associated with the PI have often led to treatment discontinuation
149
. 
Previous studies have demonstrated that the PI-based regimens in particular require 
greater than 90% adherence to achieve durable viral suppression, most likely due to 
their short elimination t1/2 
148, 150 - 152
. Also, accumulating evidence suggests that 
adherence is higher and dose timing accuracy improved in patients receiving once daily 
(q.d.) compared to twice (b.i.d.) and thrice (t.i.d.) daily regimens
153, 154
. However, 
irrespective of improved adherence, when considering antiretroviral forgiveness (which 
refers to the ability of a dose of a drug to maintain adequate concentrations in the face 
of late or omitted subsequent doses), the relative benefit of q.d. regimens is by no means 
irrefutable, since a single missed q.d. dose may give rise to a higher risk of suboptimal 
concentrations as the drug can be absent over a 24 hour period. As antiretroviral 
forgiveness is dependent on both potency (genetic barrier to resistance) and t1/2, most 
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NNRTIs and NRTIs approved for q.d. dosing are suitable based on their prolonged t1/2; 
however there is a degree of uncertainty regarding the use of PI-based q.d. regimens
155
. 
Indeed in the FOTO study by Cohen et al
155
 to study the feasibility of intermittent 
antiretroviral combination therapy taken five days a week, with two consecutive days 
off, found that for regimens containing drugs with long t1/2, such as the NNRTI (EFV), 
missed doses had no detrimental effect upon virologic suppression; whereas, the 
strategy appeared much riskier for patients receiving PI-based regimens. In fact, 5 of the 
6 individuals on LPV/r or SQV/r had sub-therapeutic drug concentrations at the end of 
the second day off therapy; suggesting that despite the presence of the RTV, LPV and 
SQV plasma concentrations decline rapidly, and may therefore be comparatively less 
‘forgiving’ than the NNRTI155. 
As the issue of patient adherence is continually being addressed, the previous consensus 
that almost 100% adherence is paramount for achieving virologic success
147, 148
 may no 
longer hold true. In recent years, the introduction of drugs with longer t1/2, higher 
genetic barriers to resistance and improved pharmacokinetic properties enable greater 
flexibility in dosing and are likely to be more forgiving in the case of missed doses. 
Furthermore, the availability of dual and triple NRTI combinations, the boosting of PI 
and the development of new formulations of existing drugs with improved oral 
bioavailability, have all helped to reduce pill burden and improve the convenience of 
therapy. Indeed, one of the most significant steps forward in HIV therapy has been the 
approval of the first fixed-dose formulation (Atripla) which contains 2 distinct 
antiretroviral classes, EFV, FTC + TDF, and allows for one tablet once daily dosing for 
virologically suppressed patients. 
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Gender  
Despite women making up nearly 50% of all people living with HIV worldwide and 
almost 61% of those infected in Sub-Saharan Africa (UNAIDS/WHO 2007), they are 
underrepresented in clinical programs. There are number of reasons for this including 
the risk of pregnancy (and teratogenicity) in women of child-bearing age, unwanted 
interactions from concurrent drugs (e.g. oral contraceptives) and concern over certain 
social responsibilities (e.g. child care) which may have a detrimental effect on a 
woman’s ability to adhere to the study medication and present regularly to clinic. 
Several studies have described differences between men and women in their response to 
ART and drug pharmacokinetics. Although there is no apparent effect of gender on HIV 
progression (both in the presence and absence of ART)
 156, 157
 in developing countries, 
there is evidence to suggest better clinical outcomes for women than men
158
 but women 
are seemingly more prone to adverse effects from antiretroviral treatment and have 
higher drug exposure
159-162
. Some evidence exists for gender-related differences in the 
pharmacokinetics of the PIs. For example, SQV, ATV and IDV plasma concentrations 
were shown in a number of studies, to be notably higher in women
163 - 165
; although 
other studies observed no gender-related differences in LPV and IDV plasma 
concentrations, respectively
166, 167
. 
It is likely that differences in the level of drug exposure between males and females are 
primarily driven by differences in body weight and composition. Indeed, reduced body 
weight alone in females may independently account for the majority of gender-related 
differences in drug levels, response and toxicity, because crucially the dosing of 
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antiretrovirals in HIV-infected individuals is not adjusted for body weight. Women also 
possess a relatively higher amount of adipose tissue, a lower skeletal muscle mass and a 
higher content of body fat than men. Increased fat distribution can lead to a greater 
accumulation of lipophilic compounds within the tissue compartment and therefore an 
increased volume of distribution, which, depending on drug clearance can result in an 
increased t1/2 and potentially a prolonged pharmacological effect in women
168
. 
Additionally, changes in drug metabolism, through differential expression and activity 
of CYP450 enzymes and influx/ efflux transporters, and modulation of these systems by 
fluctuating reproductive hormones and the presence of concomitant medications, may 
also impact the sex-related differences in drug exposure. Indeed, some gender related 
differences in the expression and activity have been reported for CYP2B6, CYP3A4 and 
P-gp, with lower expression in females respectively
169
. However, the likelihood of 
identifying a definitive genetic or CYP-mediated effect is slim given the difficulties in 
adjusting for multiple confounders (e.g. age, weight, ethnicity, disease status etc). 
Finally, social and behavioural factors may also determine differences in patient 
adherence and treatment discontinuation between sexes. 
Age (Children and adolescents) 
It is estimated that approximately 15% of all HIV-infected individuals are children
1
, but 
the vast majority in the developing countries lack access to cART, which can drastically 
reduce morbidity and mortality
170
. Furthermore, of the 25 antiretroviral drugs currently 
approved by the EMEA for use in the treatment of HIV-infected adults and adolescents, 
only 16 of these drugs are approved for use in children. Like adults and adolescents, 
children should receive a dual NRTI backbone plus a third potent agent from a different 
 71 
class; either an NNRTI or a RTV- boosted PI
171
. However, there are many challenges 
involved in treating HIV-infected children, including an uncertainty about when to start 
treatment, the need for paediatric formulations, a lack of pharmacokinetic studies on 
existing and new drugs and incomplete dosing guidelines
172
. 
1.2.5. The therapeutic efficacy of efavirenz (the evidence) 
The efficacy of efavirenz compared with other classes of antiretrovirals has been 
established in numerous randomised controlled trials and observational studies in 
cART-naïve patients as well as in treatment-experienced patients. Because one cardinal 
aim of this dissertation was to compare the effectiveness of efavirenz-based cART with 
nevirapine-based cART over the long-term, the review under this section begins by 
presenting evidence of treatment effectiveness of efavirenz-based cART compared with 
nevirapine based cART from the high-income compared with the middle-to-low income 
countries. This is followed by review of evidence of efficacy of efavirenz compared 
with other classes of antiretrovirals in combination therapy focusing only on data from 
naïve patients since the patients in the cohort presented in this dissertation were ART 
naive.  
1.2.5.1 comparison of efavirenz with nevirapine 
1.2.5.1.1. Evidence of therapeutic efficacy from randomised controlled and 
observational studies: Few randomised studies have been performed to compare 
efavirenz with nevirapine, the only other NNRTI currently licensed for use as first-line 
therapy. The 2NN study, is the first large, randomised, placebo- controlled trial of 
nevirapine and efavirenz using a stavudine-lamivudine backbone. At 48 weeks, 70% of 
patients treated with efavirenz achieved an HIV-1 RNA below the level of detection 
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compared to 65% of the patients treated with the standard dosage of nevirapine. Thus 
nevirapine did not meet the criteria for non-inferiority as compared with efavirenz
4
. A 
recently published Cochrane meta-analysis of data from 7 randomised controlled-trials
31
 
involving 1,688 participants concluded that there were no critical differences between 
efavirenz and nevirapine in levels of virological suppression except for differences in 
side effects. Compared with nevirapine given once daily, there were more CNS side 
effects in the efavirenz arms while the risk of transaminasaemia (on both NVP 200mg 
twice daily and NVP 400mg once daily) and neutropaenia (on NVP 200mg twice daily) 
was commoner on nevirapine arm. There were higher discontinuation rates in the EFV 
arm when compared to the NVP 400mg daily but EFV was slightly less likely than 
twice daily NVP to be associated with development of antiretroviral resistance. It is 
noteworthy that the 7 experimental studies included in the meta-analysis varied greatly 
in the length of follow-up time, cut-off point for undetectable viral load, dosage of NVP 
and study setting and sub-group analysis did not take NRTI backbones which is a major 
determinant of virological success and treatment failure
5
 into account. 
Large observational studies have reported superior virological, immunological and 
clinical outcomes with efavirenz over nevirapine
5-19
. In a recent study, involving 14,857 
patients from North American and European cohorts in the HIV-CAUSAL 
collaboration, efavirenz was shown to be associated with lower mortality, lower 
incidence of AIDS-defining illnesses, a larger increase in CD4 count at 12 months and a 
smaller risk of virologic failure at 12 months compared with nevirapine
20
. In the ART-
CC cohort, nevirapine initiation was associated with an adjusted OR for 24-week 
virological failure of 1.87 (95% CI 1.58 - 2.22) versus efavirenz
173
. Furthermore, 
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nevirapine use was associated with a significantly higher incidence of AIDS events or 
death over 2 years, compared with efavirenz.  
Overall, a systematic examination of evidence of data from 24 observational studies 
from low-, middle- and high-income countries showed somewhat different results from 
those from experimental studies
31
. Observational studies conducted in low- and middle-
income countries generally favoured EFV over NVP in terms of virologic suppression
7, 
8, 14, 15
 but favoured NVP over EFV for immunological response
7,9
. In contrast, studies 
conducted in high-income countries found a more heterogeneous result in terms of 
virological suppression
5, 16-18
 and favoured EFV over NVP in terms of immunological 
response
17, 174
. Furthermore, a single study by Braithwaite et al.
17
 in a high-income 
country found that EFV was superior to NVP in terms of completion of the initial 
course of therapy without switching but four studies from low- to middle-income 
countries found mixed results
6, 8, 175, 176
. The reported rates of severe adverse events 
were comparable in low- and middle-income countries
6-12, 177
 compared to those in high-
income countries
13, 24, 178, 179
. Efavirenz resistance mutations were significantly more 
common in stably treated patients receiving nevirapine than efavirenz (OR 2.73; 95%CI 
1.62-4.62; p<0.001)
180
 . The most likely explanation for these conflicting findings is the 
uncontrolled bias inherent in observational studies, but the findings may also indicate a 
subtle difference between the two drugs, which has not been captured in trials. 
1.2.5.1.2. Toxicity of efavirenz compared with nevirapine 
Skin rashes, neuropsychiatric events and hepatotoxicity are the principal adverse drug 
reactions associated with the use of nevirapine and efavirenz
4, 181
. Their individual 
propensities to cause these adverse events differ, with nevirapine showing a higher risk 
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of cutaneous and hepatic reactions, and efavirenz a higher risk of central nervous 
system effects
4, 182-184
. The risk of drug-induced toxicity is increased when nevirapine 
and efavirenz are combined
185, 186
. This sub-section of the review focuses on these three 
common NNRTI related adverse toxicities.  
1.2.5.1.2.i. Cutaneous reactions: Skin rashes manifests in the early weeks of treatment 
with either NNRTI but it appear to be more commonly associated with nevirapine 
affecting between 4% to 38% of patients
4, 21, 22
 compared with efavirenz at a slightly 
lower frequency of approximately 4.6% to 20%
4, 22, 23
. Postulations for the 
pathophysiology of these cutaneous reactions from limited human and animal data 
suggests that these rashes are probably cell-mediated hypersensitivity reactions
22, 187, 188
. 
The increased risk of rash in patients with higher CD4+ lymphocyte counts supports 
this postulation, particularly for nevirapine
189
. Risk factors for a greater risk of 
nevirapine-related rash include female sex, ethnicity (Hispanic, Chinese, and African), 
and individuals with earlier stages of HIV disease or a more profound initial increase in 
CD4+ lymphocyte count after initiation of treatment
21, 22, 190, 191
. Emerging evidence also 
suggests a genetic predisposition might exist for nevirapine hypersensitivity
192,193
. The 
risk factors for efavirenz-induced rash are less well described
21
. 
Clinically, rashes caused by NNRTIs are typically erythematous and maculopapular. 
Diffuse erythroderma, urticaria, erythema multiforme, blistering, desquamation, and 
mucosal involvement can occur. Life-threatening cases of Stevens-Johnson syndrome, 
toxic epidermal necrolysis, and erythema multiforme being reported in 0.1% of patients 
on efavirenz, compared with 0.3-1% reported with nevirapine
190, 194, 195
. The DRESS 
(Drug rash with eosinophilia and systemic symptoms) syndrome, often accompanied by 
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fever and hepatitis, is well documented with nevirapine
196
, but there is one reported case 
attributed to efavirenz
197
. 
There is evidence to support an initial 2-week lead-in period at half the recommended 
dose has been shown to reduce the risk of skin rashes with nevirapine by at least 
50%
198,199
. Unfortunately, prophylactic use of corticosteroids or antihistamines to 
prevent hypersensitivity reactions due to nevirapine hypersensitivity reactions has not 
been shown to be of benefit, and indeed there is evidence to suggest that these 
interventions could in fact, increased risk of developing rash.
200
 
1.2.5.1.2.ii. Neuro-psychiatric toxicity: Central nervous system (CNS) or 
neuropsychiatric disturbances have been reported in 25%-70% of patients receiving 
efavirenz.
23,201-204
 Symptoms include dizziness, headaches, confusion, impaired 
concentration, agitation, amnesia, psychotic symptoms, sleep abnormalities, abnormal 
dreams and insomnia. These symptoms usually arise within the first few days of 
treatment and lead to early discontinuation of efavirenz in 4% -10% of patients, 
although some investigators have reported higher discontinuation rates
205
. The 
prevalence of most neuropsychiatric symptoms declines within a few weeks if therapy 
is continued
23, 201 - 204, 206
. In a substudy of ACTG A5095 study, measures of 
neuropsychological performance revealed no significant difference between patients 
who did and did not receive efavirenz
207
. While efavirenz recipients experienced more 
neurological symptoms at week 1 (p<0.001), this was not the case at week 4, 12 or 24.  
It has however been noted in a minority of patients that, neuropsychiatric disturbances 
persist for several months or longer,
205, 206
 or appear for the first time after several 
months of treatment with efavirenz
208
. Importantly, neuropsychiatric side-effects are an 
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important risk factor for failure of therapy and for ‘blips’ in the HIV RNA level208. And 
although the mechanism of neuropsychiatric disturbances is not fully understood, they 
may be partly related to previous psychiatric disturbances or to neuropathic effects of 
HIV itself
205
.
 
Studies in animals have suggested that the effects of efavirenz on 
cytokines may play a role in depression associated with efavirenz
206
. Sleep disturbances 
may play a role in the development of neuropsychiatric symptoms
205
. Neuropsychiatric 
disturbances appear to be more common in African Americans patients than in 
European American or Hispanic patients. This may be a consequence of a higher 
prevalence of the CYP2B6 T/T genotype, resulting in slower metabolism of efavirenz 
and higher plasma exposure
209
. Other studies have also given some (but not conclusive) 
evidence that a higher plasma level of efavirenz increases the risk of these problems
203, 
205, 206
. Plasma monitoring may be considered in patients with persistent symptoms. 
Nevirapine does not appear to be associated with a high level of neuropsychiatric events 
and is considered in patients at a high risk of these symptoms
4, 203
. 
1.2.5.1.2.iii. Hepatotoxicity: Both efavirenz and nevirapine have been associated with 
hepatotoxicity, which may result in fulminant hepatitis and death
10, 25
. Hepatotoxicity 
occurs more frequently with nevirapine (1.4% to 17% of patients) than with efavirenz 
(1.1% to 8%)
24-28
. Most nevirapine hepatotoxicity is of early onset occurring within 12 
weeks of initiating therapy
10
. The early onset and association with rash, fever and other 
constitutional symptoms suggests a probable immune-mediated mechanism for 
nevirapine hepatotoxicity
10,26
. There are reports from studies conducted in populations 
with a high prevalence of hepatitis B or hepatitis C co-infection documenting a later 
onset NNRTI hepatotoxicity, which is thought to be dose-related
24, 28, 210, 211
. In addition 
nevirapine-associated hepatotoxicity is associated with female gender, a low body mass 
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index, and a high CD4 counts
10, 26, 190
. Evidence from the 2NN study suggested that high 
plasma trough concentrations of efavirenz, but not nevirapine, were associated with a 
higher risk of hepatotoxicity
212
.
 
In a smaller cohort study, there was a correlation 
between higher plasma trough concentrations of nevirapine and hepatotoxicity, mainly 
in those co-infected with hepatitis C
210
. The cause-effect relation between high drug 
plasma concentrations and the risk of hepatotoxicity in patients with liver disease is 
controversial, since the high levels may correlate with more severe liver disease rather 
than reflect a dose-related toxicity
213
. Pharmacogenetic differences between populations 
that result in reduced NNRTI clearance could also account in part for the differences in 
the risk of hepatotoxicity observed in the different studies
214
, if the mechanism is dose-
related.  
1.2.5.1.2.iv. Cross-reactivity between nevirapine and efavirenz: The WHO recommends 
substitution with efavirenz if nevirapine has to be discontinued because of cutaneous 
hypersensitivity (provided this was not life-threatening) or hepatotoxicity
181
. However, 
the extent of cross-reactivity between efavirenz and nevirapine is not clear. The 
molecular structures of efavirenz and nevirapine are very different suggesting that 
cross-reactivity may be less likely. A review of published literature from mainly 
retrospective studies, many of which were small, seems to suggest that there is cross-
reactivity between efavirenz and nevirapine for cutaneous hypersensitivity
215
. The 
authors reported that recurrent reactions occurred in 30 (12.6%) of 239 reported patients 
with rash who were switched from nevirapine to efavirenz, compared with 8 (50%) of 
16 patients who switched from efavirenz to nevirapine. Also, hepatitis did not recur in 
either the 11 reported patients who switched from nevirapine to efavirenz, or in the one 
patient who switched from efavirenz to nevirapine
215
. 
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1.2.5.2 comparison of efavirenz with protease inhibitors 
In combination with a backbone of two NRTIs, efavirenz has been shown to be superior 
to unboosted Indinavir
204, 216
, more effective than unboosted nelfinavir
217, 218
 and as 
effective as unboosted atazanavir
219
. The landmark ACTG A5142 study was a 
randomised, open-label, 96-week study of efavirenz versus ritonavir-boosted lopinavir-
each administered with lamivudine plus zidovudine, stavudine or tenofovir- and 
efavirenz plus boosted lopinavir (an NRTI-sparing regimen). The primary endpoint 
analysis was the time to virological failure, defined as a lack of VL suppression by 1 
log10 HIV RNA copies/ml or rebound before week 32, or a lack of VL suppression to 
<200 copies/ml or rebound after week 32. The group on efavirenz demonstrated a 
significantly longer time to this endpoint with a relative hazard ratio (HR) of 0.63 (95% 
confidence interval (CI) 0.45-0.87, P=0.006) 
220
. The time to regimen failure (defined as 
virological failure or toxicity-related discontinuation of any component of the 
randomised regimen) also showed a benefit for efavirenz over boosted lopinavir (0.75; 
95% CI 0.57-0.98; P=0.03), although this failed to reach the significance threshold 
adjusted for multiple comparisons (p=0.014). At 96 weeks, recurrent or new AIDS-
defining conditions occurred in 4% of patients receiving efavirenz-based therapy versus 
6% of those in the other arms. Immunologically, the efavirenz arm had the smallest 
median increase in CD4 count and virologically, significantly more patients treated with 
efavirenz-based therapy achieved a VL of <200 copies/ml or <50 copies/ml at 96 weeks 
than did boosted lopinavir-treated patients. 
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1.2.5.3 comparison of efavirenz with triple NRTIs 
The ACTG A5095 double-blind randomised trial compared the use of the triple NRTI 
combination of zidovudine plus lamivudine and abacavir with efavirenz plus two or 
three NRTIs. This study was halted when an interim analysis at 32 weeks revealed that 
virological failure had occurred in almost twice as many of the patients treated with the 
triple NRTI regimen (21%) as in those on efavirenz plus either two or three NRTIs 
(11%; p<0.0001) 
221
. Efavirenz-based therapy maintained high levels of efficacy over 3 
years, with Abacavir adding no further benefit over efavirenz plus lamivudine and 
zidovudine
222, 223
. 
1.2.5.4 Comparisons of efavirenz with novel classes of antiretroviral agents. 
[a] Integrase inhibitors: Raltegravir is an integrase inhibitor which has been compared 
with efavirenz in treatment-naïve patients in the 004 and STARTMRK studies. These 
two randomised controlled studies demonstrated comparable virologic efficacy of 
raltegravir to efavirenz, with CD4 increases and tolerability favouring raltegravir over 
efavirenz at the end of 96 weeks for 004 
224, 225
 and 48 weeks for STARTMRK
226
 
respectively.  
[b] CCR5 antagonists: Maraviroc is a CCR5 antagonist that inhibits virus/cell binding 
via inhibition of the co-receptor target CCR5 on the surface of host CD4 cells and thus 
demonstrates treatment effect in patients infected with the R5-using strain of the HIV-1 
virus. The randomised, double-blind MERIT study compared the efficacy and 
tolerability of maraviroc (n=360) with efavirenz (n=361) in treatment-naïve patients 
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infected with R5 HIV-1, with both treatment groups also receiving combivir 
(zidovudine/lamivudine)
227
. At 48 weeks, maraviroc did show non-inferiority (margin 
10%) compared with efavirenz for the primary endpoint of a VL<50 copies/mL (65.3% 
versus 69.3%; lower limit of one-sided 97% CI-10.9%). However, the mean change 
from baseline in CD4 cell count was greater for patients receiving maraviroc than in the 
efavirenz arm. Further analysis at 96-weeks confirmed the 48-week observations
228
. A 
Phase II dose-finding study of the CCR5 antagonist vicriviroc was discontinued because 
of a higher incidence of virological failure among patients randomised to vicriviroc 
25mg or 50mg twice daily
229
. 
[c] novel  NNRTIs: Rilpivirine (TMC278) and Etravirine (TMC125) are novel second 
generation NNRTIs. The Study of Etravirine Neuropsychiatric Symptoms versus 
Efavirenz (SENSE) trial was a phase 2 double-blind, randomised trial comparing 
etravirine with efavirenz in treatment naïve patients with the primary endpoint of 
neuropsychiatric events up to week 12 and HIV RNA suppression at week 48 as a 
secondary endpoint
230
. This study showed 400mg of etravarine and 2 NRTIs led to 
similar rates of HIV RNA suppression, compared with efavirenz with 2 NRTIs; 76% vs 
74% respectively but 6.3% of patients on etravirine had on-going neuropsychiatric 
adverse events at week 48 visit compared with 21.5% for patients on efavirenz 
(p=0.011).  
A dose-ranging study compared 25, 75 or 150mg of rilpivirine once daily with 600mg 
of efavirenz once daily (each added to two NRTIs) in 368 treatment-naïve patients. The 
primary end point was the proportion of patients with a VL of <50 copies/mL at 48 
weeks, which was reached by 80%, 80% and 77% of patients treated with rilpivirine 25, 
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75 and 150mg, respectively versus 81% of those receiving efavirenz which were 
sustained at 96 weeks
231
. Both treatments were generally well tolerated; rash and 
nervous system disorders were less common with rilpivirine than with efavirenz. 
Rilpivirine continued to show sustained efficacy similar to efavirenz at week 192 with a 
generally more favourable safety profile
232
. 
In summary, there is at present no evidence that integrase inhibitors, CCR5 antagonists 
or novel NNRTIs are more effective than efavirenz in treatment-naïve patients, but 
further studies are in progress. These new agents are generally well tolerated and may 
have important roles after failure of initial therapy. 
1.2.5.5. Efficacy of efavirenz in relation to HIV subtypes 
NNRTIs are highly selective for HIV-1 and do not inhibit HIV-2. Efavirenz treatment 
has predominantly been studied in patients with HIV-1 subtype B, the most prevalent 
form in developed countries
233
. However, almost 90% of people infected with HIV 
worldwide do not subtype B virus
234
; globally 50% are infected with subtype C
235
. 
Studies have shown that subtypes B and C exhibit similar virological responses to 
efavirenz
234, 236, 237
. Soares et al
234
 have reported that there is no difference in the 
accumulation of NNRTI resistance mutations between subtypes B and C. 
1.2.5.6. Safety and tolerability of efavirenz 
Efavirenz has been generally well tolerated in clinical trials. The risk of central nervous 
system toxicity on efavirenz has been review in sub-section 1.2.5.1.2.iv, however the 
use of efavirenz may be associated with the development of lipoatrophy and 
derangements of plasma lipids. The occurrence of lipoatrophy on efavirenz may result 
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partly from effects on adipocytes including inhibition of lipogenesis and 
differentiation
238
. Lipodystrophy is more common when thymidine analogues, 
particularly stavudine, are included, in the NRTI backbone
239
.  
Efavirenz-containing regimens may modestly increase plasma lipid levels compared 
with a triple NRTI regimen
240
. The ACTG A5142 study showed no significant 
difference in the incidence of grade 3-4 elevations in low-density lipo-protein 
cholesterol with efavirenz versus boosted lopinavir
220
. However, grade 3-4 increases in 
triglyceride levels were significantly less common with efavirenz (2%) than with 
boosted lopinavir (6%; p<0.05) or efavirenz plus boosted lopinavir (14%; p<0.05). 
Overall, efavirenz appears to have generally neutral effects on lipids, but this is depends 
to a large extent on the accompanying NRTIs
239
. 
1.2.5.7. Use of efavirenz in special groups 
1.2.5.7.i. Use of efavirenz in women of reproductive age 
Recent statistics from the Antiretroviral Pregnancy Registry showed no increase in the 
risk of overall birth defects associated with drugs having sufficient reports of first-
trimester exposure to detect at a 2-fold increase in risk
29
. There has been 18 reported 
birth defects out of 679 live births from first trimester exposures to efavirenz giving a 
prevalence of 2.7% (95% CI of 1.6% to 4.2%) which is a proportion deemed not 
substantially different than the CDC’s birth defects of 2.72 per 100 live births identified 
among births from 1989 through 2003 
29
. Despite these observations, “efavirenz should 
not be used in pregnant women unless the patient’s clinical condition requires such 
treatment”, and “women of child bearing potential should undergo pregnancy testing 
before initiation of efavirenz” 30. 
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1.2.5.7.ii. Hepatitis B/C co-infection 
Patients with HIV co-infected with hepatitis B virus (HBV) or hepatits C virus (HCV) 
have a significantly worse prognosis than those infected with HIV alone, and guidelines 
recommend early treatment of both conditions
111, 241
. In patients with HBV co-infection 
the NRTI backbone should include tenofovir plus lamivudine or emtricitabine because 
these agents have activitiy against both HIV and HBV. All antiretroviral agents have 
potential for hepatotoxicity, which is potentiated in the presence of HBV/HCV co-
infection. Increased hepatotoxicity, including elevated liver enzymes, has been seen in 
patients co-infected with HBV/HCV (particularly HCV) receiving efavirenz-based 
regimens
28, 242-244
. It has been postulated that HBV/HCV co-infection results in higher 
exposure to efavirenz, leading to the hepatic side-effects observed. However, recent 
studies in patients with HIV have found no significant differences in efavirenz plasma 
levels between those with and without HBV/HCV co-infection
245, 246
. Thus the cause of 
the increased risk of liver toxicity remains to be elucidated. Overall, the available 
evidence suggests that NNRTIs have an important role in the management of 
HBV/HCV co-infected patients, with vigilant monitoring of hepatic function. The data 
are insufficient at this stage to indicate whether efavirenz or nevirapine should be 
preferred. 
1.2.5.8. Effect of adherence on efavirenz on risk of virologic resistance 
Adherence is undoubtedly a major determinant of virological failure and may lead to the 
emergence of resistance in patients with HIV, but the relationship between resistance 
development and adherence differ between antiretroviral drug classes
247, 248
. This is 
illustrated in a study involving 1191 patients initiating cART where it was found that 
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those with <95% adherence to NNRTIs were significantly more likely to accumulate 
resistance mutations than those with 95% adherence (HR 7.0; 95%CI 3.4-14.5; 
p=0.0001), while adherence rates had little effect on resistance for PIs and NRTIs
249
. 
The proposed explanations for these observed class differences in risk for resistance 
selection, virological suppression and adherence are; differences in the relative fitness 
of resistant viruses (versus susceptible strains) in the presence of the drugs
250
 as well as 
the pharmacokinetic and pharmacodynamic differences between the classes
251
. 
1.2.5.9. Quality of life on efavirenz 
The use of efavirenz has been shown to improve health-related quality of life in the 
2NN sub-study
252
 and the INITO trial
253
 where efavirenz-based cART was compared 
with nelfinavir-based cART. Neuropsychiatric symptoms with efavirenz impair quality 
of life in some patients, especially at the start of therapy
203, 205, 206
. In turn lower quality 
of life during treatment with efavirenz is a predictor of virological failure
254
. However, 
one report suggests that if patients are able to continue long-term efavirenz-based 
therapy, their quality of life can be good despite persisting symptoms 
255
. 
1.2.6 Monitoring antiretroviral effectiveness in resource-limited settings  
Access to antiretroviral therapy (ART) in Africa has increased remarkably over the past 
decade, beginning with a few thousand people and reaching five million people by mid-
2010 
1
. This advance was because of the reduced cost of drugs, increased resources, 
expanded HIV testing, and activism. Other obstacles continue to limit the number of 
people taking ART and the ability of health systems to effectively monitor patients, 
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including inadequate number of physicians and allied health staff
256
 and limited 
laboratory capacity
257
. 
In many African countries the annual cost of quarterly CD4 cell counts and 
measurements of viral load exceeds the cost of generic first line ART
258
. In addition, 
establishing sophisticated laboratory services at relatively poorly equipped health 
facilities remains challenging. Consequently, many people taking ART in Africa receive 
either no routine laboratory follow-up or infrequent measurements of CD4 cell 
counts
257
. When CD4 testing is used as a routine component of care, most programmes 
offer it only every six or 12 months
259, 260
 with a smaller proportion providing routine 
viral load testing
261, 262
. 
It is well known that high viral load and low CD4 cell count are independently 
associated with mortality
263-265
, and changes in viral load and CD4 cell count during 
treatment have been associated with survival
265
. Routine monitoring of viral load and 
CD4 cell counts during ART, however, was adopted in well-resourced settings without 
studies indicating improved survival compared with careful clinical monitoring. One 
recent mathematical model showed little benefit and considerable cost even during 20 
years of follow-up
266
. Furthermore, programmes in Haiti
267
 and Malawi
268
 have reported 
treatment success with clinical monitoring alone, although no groups with laboratory 
monitoring were available for comparison. By reducing or eliminating frequent 
laboratory monitoring, there is potential for increasing the number of people who could 
be treated. Reduced laboratory monitoring, however, might lead to premature or 
delayed changes to second line therapy, more antiretroviral resistance, or increased 
morbidity. Changes in CD4 cell counts do not accurately predict suppression of viral 
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load
269-271
. A recently reported randomised clinical trial examined different monitoring 
strategies for individuals receiving ART found only marginal clinical benefits in terms 
of mortality associated with providing six monthly monitoring of CD4 cell count in 
addition to clinical monitoring in Uganda and Zimbabwe
272
. The authors of the DART 
study concluded that the addition of monitoring CD4 cell counts was not cost effective 
according to current WHO guidelines. Subsequently, a randomised clinical trial among 
patients receiving ART for HIV infection in Uganda found that routine laboratory 
monitoring using CD4 counts was associated with improved health and survival 
compared with clinical monitoring alone
273
. 
1.2.7. Pharmacology of efavirenz 
The focus of this section of literature review is to highlight the impact of single 
nucleotide polymorphisms (SNPs) of hepatic enzymes involved in the metabolism of 
efavirenz on efavirenz exposure with particular emphasis on cytochrome P450 2B6 the 
major enzyme responsible for the phase I metabolism of efavirenz. This section begins 
with basic information on the pharmacokinetics of efavirenz, introduces the concept of 
pharmacogenomics of antiretrovirals, examines factors responsible for the modulation 
of the expression and function of CYP2B6, and concludes on the impact of potential 
and known pharmacokinetic interactions between antimalarials and efavirenz. This is 
because two chapters of this thesis are devoted to the pharmacology of efavirenz among 
Ghanaian HIV-infected patients. Chapter 8 explores the impact of single nucleotide 
polymorphisms in hepatic enzymes- cytochrome P450 2B6, 2A6 and UGT2B7 as well 
as the constitutive androstane receptor; a regulator of CYP2B6 induction- on mid-dose 
efavirenz exposure while chapter 7 examines the pharmacokinetic interactions between 
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efavirenz and the antimalarial, artesunate which is a component of the recommended 
antimalarial combination therapy. 
 
1.2.7.1. Pharmacokinetics of efavirenz 
1.2.7.1.i. Absorption 
Peak efavirenz plasma concentrations are reached by 5 hours following single oral 
doses in uninfected volunteers
30
. The time to peak plasma concentrations is  3 to 5 
hours and steady-state plasma concentrations of efavirenz are reached in 6 to 7 days
30
. 
The bioavailability of a single 600mg dose of efavirenz hard capsules in uninfected 
volunteers is increased by 17% to 22% by food
30
. Efavirenz is highly bound ( 99.5% to 
99.75%) to human plasma proteins, predominantly albumin
30, 274
. 
1.2.7.1.ii. Biotransformation 
Efavirenz is oxidised to inactive 8-hydroxy, 8,14-dihydroxy, and 7-hydroxy efavirenz 
metabolites by the cytochrome P450 system predominantly by hepatic CYP2B6 with 
minor contributions from CYP3A4/5 and CYP2A6 
275, 276
. Efavirenz and its 3 hydroxy- 
metabolites undergoes conjugation to form N-glucuronides with UDP-
glucuronosyltransferase (UGT) 2B7 as the main UGT isoform responsible for 
glucuronidation of efavirenz
276-279
. The CYP2B6 gene is highly polymorphic and is 
subject of considerable inter-individual variability in expression and function
280
. Also 
polymorphisms in CYP2A6 
281, 282
 and UGT2B7 
283
 have been shown to influence 
efavirenz exposure and will be subsequently reviewed. 
1.2.7.1.iii. Elimination 
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Efavirenz has a terminal half-life of at least 52 hours after single doses and 40 to 55 
hours after multiple doses
30
. Approximately 14% to 34% of a radio-labelled dose of 
efavirenz is recovered in the urine and <1% of the dose is excreted in urine 
unchanged
30
. The long half-life of efavirenz makes it suitable for once-daily dosing. 
The recommended dosage in adults is 600mg once daily. Genotypic testing for variants 
of the CYP2B6 allele could detect individuals at increased risk of neuropsychiatric 
adverse events but this is not routine practise. There is also no recommendation to 
adjust the dose of efavirenz according to race or sex. 
1.2.7.2. Pharmcogenomics of antiretroviral medications 
Cohort studies from the USA and Europe suggest that up to 50% of patients may 
modify their regimen and 25% may discontinue therapy, the majority for reasons of 
drug toxicity but also a significant number developing virological failure
284 - 288
.  Both 
treatment failure and toxicity are costly: drug toxicity carries significant morbidity and 
salvage regimens are associated with higher pill burden and risk of adverse reactions, 
and drug treatment becomes more expensive with each successive failure.  Strategies to 
make HIV treatment safer and more effective are urgently required. More than 20 
approved antiretroviral (ARV) drugs from 6 mechanistic classes- nucleoside/-tide 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), CCR5 
antagonists and fusion inhibitors (FIs) are available for the treatment of HIV infection. 
Combination anti-retroviral therapy (ART) comprises three or more drugs from any of 
these classes. Following standard doses of anti-retroviral drugs, huge inter-individual 
variability has been observed, up to (coefficient of variation %) of 75% to >110% 
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occurs for NNRTIs and PIs, from prospective clinical trials and surveys of the 
Liverpool HIV Therapeutic Drug Monitoring (TDM) Registry
289
. The profound 
variability in exposure to antiretroviral drugs has important clinical implications and on 
the basis of the known plasma concentration-therapeutic response and concentration-
toxicity correlation for NNRTIs and PIs, a therapeutic drug monitoring (TDM) has been 
proposed to optimize the exposure to these agents
290
. 
The causes of this variability are multifactorial and include poor adherence, body 
weight, gender and interacting medications
291
.  Host genetic polymorphisms may 
account for some of the variation in pharmacokinetics and responses to ART.  Ethnic 
differences in drug exposure are recognised: for example, drug exposure (AUC, Cmin) 
to indinavir (IDV) and saquinavir (SQV) is significantly increased in Thai patients 
compared to Caucasians
292
.  There is also an observed longer elimination half-life of the 
NNRTI efavirenz (EFV) in African women discontinuing therapy compared with 
Caucasians
293
.  In the 2NN study patients from Thailand and S Africa had lower 
clearances of EFV
294
 than those from Europe or the Americas.  
Genetic variability in the drug metabolising enzymes such as cytochrome P450, 
glucoronyl transferase) or drug transporters (e.g. MDR1, MRP1 & 2), prevalent at 
differing frequencies across ethnic groups probably explain some of the differences 
between populations, although other factors such as body weight may also contribute.  
For instance, considerable polymorphisms exist for cytochrome P450 2B6 
280
 the major 
enzyme for detoxification of the NNRTIs efavirenz and nevirapine. In addition genetic 
variability exists for other cytochrome P450 enzymes involved in the metabolism of 
HIV drugs. Indinavir for instance is metabolized by the isoenzyme CYP3A5, which 
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shows high genetic variability
295
. CYP3A5 expression is detectable in only 10-20% of 
Caucasians, 33% of Japanese and 55% of African-Americans
296
. The primary mutation 
responsible for lowered CYP3A5 expression (CYP3A5*3) results in erroneous mRNA 
splicing and reduced translation of functional protein. The presence of this variant has 
been associated with low or null expression of the CYP3A5 protein and consequently 
lead to a lower clearance of Indinavir with the attendant increased associated risk of 
renal calculi formation under Indinavir therapy
297
. Along the glucuronidation axis, 
mutations in UGT1A1 have been associated with hyperbilirubinaemia following therapy 
with indinavir
298
 or atazanavir
299
.  Whilst basal expression may be unaffected, the 
inducibility of these drug metabolising enzymes by rifampicin or other compounds may 
vary according to polymorphisms affecting gene regulation such as promoter variation 
or nuclear factors (PXR, CAR). These observations highlight the role of single 
nucleotide polymorphisms on the inter-individual variability of exposure to 
antiretroviral therapy. A thorough review of pharmacogenomics of all classes of 
antiretroviral therapy is beyond the scope of this literature review. However because the 
pharmacogenomics of efavirenz is of importance in this thesis, I will now focus the 
review on the highly polymorphic CYP2B6 and its correlates with efavirenz exposure.  
1.2.7.3. The highly inducible and polymorphic cytochrome P450 2B6 gene and 
efavirenz exposure 
It has been traditionally thought that CYP2B6 accounted for a minor proportion (<1%) 
of the total hepatic cytochrome P450 (CYP) content
300, 301
 and played a negligible role 
in human drug metabolism in contrast to the predominant hepatic isoenzyme CYP3A4. 
However by utilising more sensitive and specific immunochemical detection methods 
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subsequent evidence indicated that the average relative contribution of CYP2B6 to total 
hepatic CYP content ranges between 2% to 10% 
302-306
. Furthermore it became obvious 
from these studies that the expression of CYP2B6 exhibited 20- to 250-fold inter-
individual variability
280, 302-308
. It is conceivable that such inter-individual differences in 
hepatic CYP2B6 expression and enzyme activities may culminate in variable systemic 
exposure and therapeutic response to the growing list of drugs and chemicals known to 
be metabolised by this enzyme. 
Elucidating the predominant mechanisms underlying the inter-individual variability in 
CYP2B6 expression has become the focus of several investigators and evidence is 
accumulating on plausible mechanisms such as polymorphisms in the CYP2B6 gene, 
transcriptional suppression by cytokines
309, 310
, transcriptional activation by inducers
311, 
312
, enzyme inhibition, and allosteric activation
313
. There is a strong suspicion that 
genetic polymorphisms and/or differences in gene regulation may be the most 
significant contributors to the observed inter-individual variation in CYP2B6 expression 
in vivo.  
1.2.7.3.i. Induction and Transcriptional regulation of CYP 2B6 Expression 
The regulation of CYP2B6 transcription is recognised as one of the major contributors 
for the observed dramatic inter-individual variations in this isoenzyme. Mounting 
evidence reveals that the transcriptional regulation of this isoenzyme is intricate and 
multi-faceted. First, CYP2B6 shares mechanisms of transcriptional regulation with 
several other important drug metabolising genes such that a large number of CYP2B6 
inducers have also been shown to induce CYP3A4, UGT1A1 (UDP-
glucuronyltransferase 1A1) and several drug transporters such as the efflux drug 
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transporter MDR 1 as well 
314-317
. Second, among CYP2B6 inducers, some are also 
substrates for CYP2B6 and hence accelerate their own metabolism affecting clearance 
or toxicity. Such auto-induction of CYP2B6 has been observed with the non-nucleoside 
reverse transcriptase inhibitor efavirenz and the antimalarial artemisinin
315, 318-320
. 
Third, transcription of CYP2B6 is also regulated by delicate mechanisms at promoter 
sites by nuclear receptors. To date three promoter domains whose activation induces the 
transcription of CYP2B6 have been identified. These include a Phenobarbital-
responsive enhancer module (PBREM) 
321-323
, a xenobiotic responsive enhancer module 
(XREM) 
324
 and more recently an okadaic acid responsive element 
325
. Among the 
nuclear receptors involved in the regulation of CYP2B6 expression, two are crucial to 
the induction of the promoter sites and hence activation of the CYP2B6 gene. The first 
nuclear receptor to be identified in this context was the Constitutive Androstane 
Receptor 
321
 henceforth referred to as CAR and subsequently the Pregnane X 
Receptor
312, 326
 also referred to as PXR. CAR has been shown to modulate CYP2B6 
expression by binding to the nuclear receptor binding site 1 and 2- (NR1) and (NR2) 
sites within the PBREM domain and also to the XREM at its NR3 site 
312
. PXR has also 
been demonstrated to bind to similar sites as CAR. Indeed both CAR and PXR bind to 
the NR1 domain of the PBREM with a stronger affinity than to the NR2 
312
. Secondly 
CAR and PXR bind to the NR1 and NR2 motifs of the PBREM and the NR3 motif of 
XREM as CAR-RXR and PXR-RXR heterodimers with RXR (Retinoid X Receptor) 
respectively.  
There are however some differences in the interactions of CAR and PXR with the CYP 
2B promoter sites with regards to the specificity of their ligand binding, the flexibility 
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in their interaction with xenobiotics and their propensity to induce CYP3A4 alongside 
CYP2B6. For instance PXR ligands such as rifampicin and clotrimazole have been 
shown to induce CYP2B6 transcription along with CYP3A4 with little bias
312, 315, 327
 
whereas CAR specific ligands such as efavirenz, nevirapine, carbamazepine and 
phenytoin have a preference for induction of CYP2B6 over CYP3A4 
318, 328-330
. 
Furthermore CAR is less flexible in its interaction with xenobiotic ligands compared to 
the highly promiscuous PXR due to its smaller 675Å
3
 ligand binding pocket as opposed 
to the larger 1290-1540 Å
3 
binding pocket for PXR 
331-334
. In spite of these differences 
accumulating evidence suggests that there is still a considerable substrate overlap 
between CAR and PXR and that the outcome of CYP2B induction is co-regulated by 
these 2 nuclear receptors. In summary, CYP2B6 gene expression is regulated by 
induction at proximal and distal promoter sites by the binding of heterodimers of either 
CAR-RXR or PXR-RXR. Efavirenz and nevirapine are specific ligands of human CAR 
and thence CYP2B6 inducers.   
1.2.7.3.ii. CYP2B6 Gene Polymorphisms 
Basis of genetic polymorphisms 
Genetic polymorphisms arise as a result of an alteration in the nucleoside base sequence 
of the DNA composition of a gene. The most common genetic polymorphisms involve 
single nucleotide polymorphisms (SNP) where one base is substituted for another and is 
observed at a frequency of one SNP per every 1000 base pairs (bp) in the human 
genome. Polymorphisms may also arise from either an insertion or deletion of one, two 
or several base pairs (indels) or from gene duplication or from insertion or deletion of 
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several copies of repeated base pair units called Variable Number Tandem Repeats 
(VNTRs). 
By definition a single base change, occurring in a population at a frequency of more 
than 1% is termed a single nucleotide polymorphism (SNP). When a base change occurs 
at <1% of the population, it is termed a mutation. A transitional SNP involves the 
substitution of a purine such adenine (A) or guanine (G) for another purine or one 
pyrimidine such as cytosine (C) or thymidine (T) for another. A transversional SNP 
involves a change of a purine (A, G) for a pyrimidine (C,T) and vice versa. By 
nomenclature G>A means G which is the wild type has been substituted by the mutant 
A. G>A and C>T transitions account for approximately 25% of all SNPs in the human 
genome.  
SNPs may affect the regulatory, the non-coding (intronic) or the coding (exonic) regions 
of a gene with differing resultant effects. A regulatory SNP may affect transcription 
factor binding and therefore affect gene expression. An intronic SNP may affect mRNA 
splicing and influence either the expression of the mRNA positively or negatively or 
affect mRNA activity as result of incorrect splicing. An exonic SNP may either alter 
amino acid structure of a protein referred to as a non-synonymous SNP or may not alter 
the amino acid structure called synonymous SNP. Synonymous SNP also called silent 
mutations may affect gene expression whiles non-synonymous SNP may affect activity 
via alteration of the tertiary structure of a protein or its post-translational modification.    
CYP2B6 Single Nucleotide Polymorphisms 
The genetic variations of CYP2B6 and its potential clinical significance have only been 
realised in recent years. Nevertheless, along with the realisation of the remarkable inter-
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individual variations in CYP2B6 expression and activity, the number of 
pharmacogenetic studies on this isoenzyme has been growing rapidly. To date, 28 
characterised alleles, over 50 determined haplotypes and more than 100 described SNPs 
of the CYP2B6 gene have been documented and listed on the CYP allele nomenclature 
website (http://www.cypalleles.ki.se). Several genetic variations of CYP2B6 have been 
identified throughout its gene sequence including the 5´ promoter, introns and coding 
(exonic) regions. Functionally these genetic polymorphic alleles translate into a variety 
of phenotypic outcomes that include proteins with significantly reduced catalytic 
activity or a complete loss of CYP2B6 expression
280, 335
. 
CYP2B6 SNPs in coding regions 
Lang and colleagues performed the first systematic analysis of the CYP2B6 genetic 
polymorphisms and focused on the nine exons in the coding region
280
. Their study led 
to the identification of nine base pair single mutations, of which five were non-
synonymous amino acid alterations and 4 silent mutations. These SNPs alone or in 
combination resulted in six different CYP2B6 alleles designated as CYP2B6*2 
(64C>T), CYP2B6*3(777C>A), CYP2B6*4 (785A>G), CYP2B6*5 (1459C>T), 
CYP2B6*6 (516G>T and 785A>G) and CYP2B6*7 (516G>T, 785A>G and 1459C>T). 
Among these alleles, CYP2B6*6, characterised by the combination of 516G>T in exon 
4 and 785A>G in exon 5, was detected in about 15-40% of Asians and over 50% of 
African-Americans 
280, 336, 337
. Further analysis of human liver mRNA discovered that 
aberrant splicing of the CYP2B6 gene resulted in the 2B6*6 allele which lacks exons 4, 
5 and 6 and consequently displays a reduced function of mRNA and protein
338
. 
Phenotypically both heterozygous and homozygous carriers of CYP2B6*6 alleles 
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exhibit a profoundly lower catalytic activity and a remarkably decreased protein 
expression, compared to the wild-type CYP2B6*1 allele carriers. Indeed CYP2B6*6 
has been associated with aberrant efavirenz metabolism resulting in significantly supra-
therapeutic plasma concentrations with its attendant therapeutic toxicities. The allelic 
variant (G516T) which is more common in African Americans (TT 20%) than 
Hispanics (6.7%) or Caucasians (3.4%) was associated with slower clearance of EFV 
leading to a hierarchy of EFV exposure (and associated CNS toxicity) in the rank order: 
African Americans  > Hispanics  > Caucasians
209
. Through the dedicated works of 
several independent research groups 19 more alleles in the coding region of CYP2B6 
have been defined 
301,308, 339
. Novel alleles which have also been characterised include 
CYP2B6*16 (785A>G and 983T>C), *18(983T>C), *27(593T>C) and *28(1132C>T) 
as well as four phenotypic null alleles *8 (415A>G), *11 (136A>G), *12 (296G>A), 
and *15 (1172T>A) http://www.cypalleles.ki.se/cyp2b6.htm. Although all these alleles 
are associated with amino acid changes, the functional consequences of each on 
CYP2B6 expression or function have varied extensively.  
Among Ghanaians a number of mutations, particularly the G516T and T983C in 
CYP2B6, have been found to be relatively common, 
35, 36
 with the latter mutation 
having a gene frequency of around 7.3%. Whilst considerable work has been done 
showing the effect of the G516T mutation on efavirenz levels, less is known about the 
effect of the T983C mutation on either efavirenz or nevirapine levels. There is a strong 
suspicion that homozygotes for this mutation effectively have a null allele, since 2 
homozygotes have been identified with severe efavirenz toxicity and estimated half 
lives of efavirenz over 3 months. It therefore seems likely that heterozygotes may have 
an intermediate phenotype with reduced metabolism of drugs such as efavirenz. The 
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potential clinical implications for such patients are that patients with mutations such as 
the CYP2B6 G516T or T983C may develop toxicity to efavirenz more frequently, or be 
more likely to develop NNRTI resistance after stopping this drug, as has been suggested 
for the T983C mutation
340
. However few adequately powered studies have been 
conducted in Sub-Saharan Africa to investigate the role of SNPs in the CYP2B6 
G516T/T983C composite genes and its impact on efavirenz pharmacokinetics and 
clinically relevant pharmacodynamic outcomes. Certainly in populations where there is 
a high frequency of mutant variants of clinically relevant SNPs in the CYP2B6 gene, 
the accessory/minor pathways for efavirenz namely the CYP2A6 and UGT2B7 may 
assume importance in clearance of this NNRTI, thus SNPs in the genes of these other 
enzymes could be additional sources for the wide inter-individual variability in mid-
dose efavirenz exposure. Furthermore, given the high frequency of use of antimalarial 
drugs such as artesunate in this population, which are also metabolised by CYP2B6, 
there may be may be significant drug interactions and toxicity from such agents. 
1.2.8. Interactions between antimalarials and antiretroviral medications 
Both malaria and HIV/AIDS are important public health challenges in Sub-Saharan 
Africa because of their individual and combined impact on morbidity and mortality
341
. 
According to WHO recommendations, the first-line treatment for malaria in areas of 
endemicity is an artemisinin-based combination therapy containing a combination of 
either artesunate plus (amodiaquine, mefloquine, or sulfadoxine-pyrimethamine), 
artemether plus lumefantrine, or dihydroartemisinin-piperaquine
342
. Most HIV-infected 
patients in these malaria endemic regions receive a first-line antiretroviral regimen 
containing efavirenz
112
. Khoo S et al
343
 and Skinner-Adams TS et al
344
 have reviewed 
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the pharmacological interactions between antiretroviral and antimalarial drugs in detail 
but the focus of this review is on the predicted and known interactions between 
artemisinin-based antimalarials and efavirenz of which few studies have explored the 
subject.  
Among healthy volunteers, a 3-day amodiaquine-artesunate regimen was accompanied 
by increases in transaminase concentrations in two of five subjects receiving efavirenz, 
several weeks after completion of antimalarials
345
. The authors of this study
345
 observed 
large increases in the amodiaquine area under the plasma concentration-time curve, 
maximum plasma concentration, and half-life. Hepatotoxicity of amodiaquine has been 
ascribed to the amodiaquine-quinoneimine metabolite
346
, the extent of which may be 
increased by CYP3A4 induction. Given that efavirenz is known to induce CYP3A4, it 
has been inferred that the transaminitis observed and subsequent discontinuation of the 
study by German and co-workers
345
 might have been due to increased production this 
hepatotoxic metabolite during efavirenz CYP3A4 induction. Furthermore, two cases of 
fulminant hepatitis during a short curative treatment with artesunate-amodiaquine in 
HIV-uninfected patients have been reported
347
. Indeed some authors on the basis of this 
study have contraindicated amodiaquine in patients receiving efavirenz
348
 but the latest 
WHO guidelines on the treatment of malaria do not recommend any specific 
antimalarial treatment in HIV-infected patients
349
. It is noteworthy that the activation of 
artemisinins requires CYP3A4 thus the effect of administration of artesunate plus 
amodiaquine in patients receiving an efavirenz-based regimen may be difficult to 
analyse. Further studies are thus needed to evaluate these interactions separately, 
particularly the safety and tolerability of artemisinins used in HIV patients taking 
efavirenz because interactions leading to sub-therapeutic exposure of artemisinins could 
 99 
compromise the efficacy of this class of antimalarials in HIV-infected patients and 
potentially engender to emergence of artemisinin resistance. Conversely, if the 
interaction between artesunate and efavirenz leads to supra-therapeutic exposures to 
artemisinins the potential exists for toxicity to this antimalarial. 
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CHAPTER TWO 
Methodology for chapters three to eight 
2.0 Introduction 
It became apparent during the writing up of this dissertation that the methods sections of 
the main chapters were lengthy in some chapters, themes of were overlapping in others 
and common statistical methods were employed. Thus it was thought that to make the 
transition from the introduction section of chapters to the results sections easier to 
follow, this chapter be devoted to describing methods used in the main chapters from 
three to eight. The sub-sections in this chapter are given numerical annotations in 
reference to the chapters they are used to hopefully make referencing easier. 
2.1 Ethics approvals: Ethical permission for this study was given by the Committee on 
Human Research Publications and Ethics of the Kwame Nkrumah University of Science 
and Technology and the Komfo Anokye Teaching Hospital, Kumasi, Ghana (appendix 
1). 
2.2 Study settings and ART program in Ghana: All the studies conducted and 
compiled in this dissertation were performed at the HIV clinic at the Komfo Anokye 
Teaching Hospital. In January 2004, the HIV Clinic at the Komfo Anokye Teaching 
Hospital in Kumasi called “Chest Clinic” to avoid stigma was set up by the National 
AIDS Programme (NACP) to provide clinical care for patients living with HIV/ AIDS. 
Support for the clinic was provided by the Global Health fund for infectious diseases 
and Family Health International through the NACP. The Ghana Ministry of Health 
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provided support for training of clinical and para-medical staff and anti-retroviral drugs 
through its various donor agencies. 
At its inception the Chest Clinic in Kumasi was one of two Government approved 
centres for care of HIV patients. Patients with documentation of HIV infection were 
accepted for evaluation at the Chest Clinic as referrals from any public or private source 
within the Ashanti region and 6 other neighbouring regions due to the central location 
of Kumasi in Ghana. Other HIV seropositive cases were also referred to the clinic from 
voluntary counselling and testing unit situated at the Komfo Anokye Teaching Hospital. 
The vast majority of patients (>99%) evaluated were Ghanaians, but the programme is 
open to all ethnicities and to citizens from other countries. Clinical care of patients was 
provided by doctors, comprising of physician specialists, medical residents and house 
officers, nurses, public health nurses, pharmacists and dispensing technicians. Trained 
laboratory technologists were also provided to perform HIV serological screening and 
confirmation and CD4 T-cell enumeration.  
To ensure a standard and complete approach to evaluating patients, a case record book 
was created where demographic data, clinical and laboratory information, treatments 
administered and clinical events were recorded. Initial evaluation of patients were often 
performed by trained and experienced nurses and includes medical history, physical 
examination, CD4 cell count and HIV sero-type 1 or 2. The objective of this initial 
assessment is to screen for the presence or otherwise of opportunistic infections and 
malignancies and eligibility for anti-retroviral therapy as well as prophylaxis with Co-
trimoxazole according to Ghanaian national guidelines. In the first months of the 
programme, ART was initiated for individuals with either CD4 cell count of less than 
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200/l or those in World Health Organisation (WHO) stage III or IV. In 2007 however 
these guidelines were revised to initiate ART for HIV patients with CD4 cell counts 
below 350/l regardless of (WHO) clinical stage. All patients, whether starting ART or 
not were prescribed multivitamins. Patients not meeting eligibility criteria for ART 
were monitored six monthly by CD4 counts and clinical examination for new 
opportunistic infections. For those eligible for ART, further laboratory tests assessing 
haemoglobin concentration, serum urea and creatinine, serum alanine transaminase 
(ALT), serum aspartate transaminase (AST) and recently fasting serum total cholesterol, 
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C) and triglyceride concentrations were then performed to guide ART selection. 
Patients who were eligible for ART must have disclosed their serostatus to an adherence 
monitor who would supervise ART intake and help bring the patient to the clinic in the 
event of any serious adverse events, new opportunistic infections or malignancies and 
report any mortality to the clinic. 
First-line ART regimens were prescribed by doctors and comprised of lamivudine 
(3TC) plus either zidovudine (AZT) or stavudine (d4T) plus either nevirapine (NVP) or 
efavirenz (EFV). The choice between the use of either AZT or d4T is determined 
primarily by availability but AZT is avoided in anaemic patients with haemoglobin 
concentration below 10g/dl. Efavirenz was avoided in females in their reproductive age 
due to reported teratogenicity. ART initiation was deferred in patients on intensive 
phase of anti-tuberculous therapy and started during the continuation phase with an 
efavirenz based ART to avoid NVP-rifampicin interactions. For patients with CD4 cell 
counts less than 200/l or in WHO stage III or IV, co-trimoxazole was administered. 
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Patients who were found to have either HIV-1/ -2 dual or HIV-2 mono-infection were 
initiated on 2 NRTI’s and a protease inhibitor of either nelfinavir or ritonavir boosted 
lopinavir. 
The initial follow-up schedule for those starting cART includes 4 visits during the first 
3 months, with special focus on adherence and detection of adverse events. During these 
first 3 months, haemoglobin concentration, serum ALT and AST are determined at 
week 2, 4, 8 and or 12 weeks post-initiation to detect incident or worsening anemia 
especially in patients on AZT-containing regimen, skin rash and hepatotoxicity in those 
on either NVP or EFV-containing ART. Subsequently follow up occurs every 3 months 
with CD4 cell counts, haemoglobin concentrations, ALT and AST performed every 6 
months unless there is a clinical indication to otherwise perform more frequent 
laboratory monitoring. Those patients receiving cART present monthly to the clinic to 
collect their antiretroviral medications. Each dispensation includes a 2- to 3-day buffer 
of extra pills. Pre-registered family members or other treatment partners, also called 
“monitors”, were permitted to collect a patient’s medication. Adherence counselling 
was performed by nurses and pharmacy technicians. Patients on ART who defaulted on 
scheduled visits for more than 2 weeks were traced up in their homes by community 
health workers and peer education officers. However, due to wide geographical 
distribution of cases, incorrect residential identification numbers and large enrolment 
numbers our ability to track all such patients were outstripped. Therefore, the clinic was 
not able to attempt home visits for all defaulting patients however those with access to 
mobile phone were contacted using telecommunication.  
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Because routine use of viral load testing was not a part of the Ghanaian national 
guidelines, we relied principally on clinical and immunological estimates of treatment 
failure. Treatment failure is defined in our programme as (1) Clinical failure is the 
occurrence of a new opportunistic infection or malignancy signifying clinical disease 
progression, the recurrence of prior opportunistic infection or onset/recurrence of WHO 
stage 3 or 4 conditions and/or (2) Immunologic failure is the return of CD4 counts to 
pre-therapy baseline, or below and/or more than 50% fall from on-therapy CD4 peak-
level (and/or more than 50% fall in CD4), or persistent low CD4 of less than 100 
cells/µl after one year of therapy without other concomitant infection to explain the low 
CD4. Where clinical or immunological failure is suspected or confirmed, clinicians 
would request for a viral load test to be performed at the patients expense to inform a 
decision to switch to second line ART. However the high cost of viral load testing has 
prohibited its routine use in clinical decision-making. Until 2011, second line 
nucleoside/-tide reverse transcriptase options included tenofovir, abacavir and 
didanosine and protease inhibitors (PI) available were nelfinavir or ritonavir-boosted 
lopinavir. 
Laboratory testing 
A CD4 cell enumeration was performed at a central laboratory with a Beckman Coulter 
Epics XL-MCL 4-colour Flow Cytometer (Beckman Coulter, Inc, Miami, Fla). 
Complete blood counts with haemoglobin concentrations, white blood cells and 
platelets counts were done centrally using Sysmex XT-1800i automated haematology 
analyser (USA).  A limited number of serum biochemical tests offered free of charge to 
the patients were performed namely alanine transaminase and aspartate transaminase to 
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assess hepatic injury, serum creatinine concentrations for evaluating the renal function 
and fasting lipid profile were performed at the Chemical Department of KATH using 
the multi-parameter Roche Cobas Integra
®
 400 plus, Roche Diagnostics, Mannheim, 
Germany. Hepatitis B serology was performed to determine HBSAg seropositivity 
using the Determine kit routinely when kits were available at the department of serology 
at the Komfo Anokye Teaching Hospital. As part of another study called the HEPIK 
(HIV HBV Project in Kumasi) study, hepatitis B screening serology has been 
performed for a proportion of patients in the clinic.  
Data collection and analysis 
Since the inception of the clinic in 2004, nearly 11,000 HIV patients have enrolled to 
date, out of which about 5000 patients have been started on ART however no systematic 
data collection and analysis has been conducted to date. Thus, detailed information on 
effectiveness of cART, the proportion and reasons for loss to follow-up (LTFU), and 
incidence and impact of TB and other opportunistic infections, are widely lacking. 
Although the public health unit of the Komfo Anokye Teaching Hospital collects data 
on patients registered in the clinic and follow up clinical and laboratory data, initial 
attempts to use that database proved problematic since collection of data were not 
structured and data was not of sufficient quality. 
To standardise data collection for the present analysis, I designed a data collection 
proforma (see appendix 2) for this purpose. Information on patient registration, initial 
clinical assessment for antiretroviral medication eligibility, follow-up visits and 
laboratory data recorded in patient folders (see appendix 3) were extracted on to the 
data collection proforma. Patients were included in analysis only when there was 
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evidence in their folders that ART was initiated from January 2004 to December 31
st
 
2010. Patients initiating therapy within 2011 were excluded from the present analysis 
because the primary objective of the present analysis was to determine the long-term 
effectiveness of first-line ART which required at least one year of follow-up. Each 
folder was examined by FSS for initiation of ART and data collected unto this proforma 
under the supervision of ROP who served as the local supervisor. Baseline data 
collected included age, gender, residential address, WHO clinical stage and the HIV-
associated co-morbidities for the WHO clinical stage, weight and height for body mass 
index calculation, hepatitis B sero-status and HIV sero-type if known together with 
baseline CD4 count at initiation often done within the last 3 months before therapy 
initiation, haemoglobin concentration, ALT and AST as well as creatinine and fasting 
lipid profile if available. During therapy, CD4 counts, AST, ALT, haemoglobin and 
seldomly serum creatinine concentrations were recorded along with body weight 
changes and any documented ART-related toxicity, AIDS-defining and non-AIDS-
defining events as well as clinically and immunologically defined treatment failure, 
drug substitutions and switches to second line cART. After data had been collected on 
the proforma, they were given to a data entry clerk to enter data into an excel spread 
sheet. Validity of data recorded from folders onto proformas and subsequently onto the 
excel spread sheet was assessed by ROP who randomly took 10 folders from every 100 
folders assessed. When occasional inconsistencies were observed they were corrected 
upon consensus. Data collected in this manner were analysed to answer specific 
questions in chapters 3 to 7. Pregnant women initiating antiretroviral therapy were 
excluded from all analysis. 
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2.3. Methods for chapter three 
The study presented in this chapter is cross-sectional and descriptive in design with the 
primary objective of presenting data on the baseline characteristics of patients initiating 
cART in this cohort and their vital status at closure of data for analysis. The severity of 
anaemia and baseline derangement in liver functions tests and renal impairment were 
assessed as follows: 
Severity of anemia was classified as follows: severe anemia=haemoglobin <8 g/dl, 
moderate anemia= haemoglobin 8-10g/dl in females and 8-11g/dl in males, mild 
anaemia= haemoglobin 10-12 g/dl in females and 11-13 g/dl in males; 
none=haemoglobin >12g/dl in females and >13g/dl in males. 
Severity of hepatic damage were graded based on the ALT level and defined in 
accordance with AIDS Clinical Trials Group criteria
350
 in the following manner: grade 
1, 1.25 – 2.5 times the upper limit of normal (X ULN); grade 2, 2.6-5.0 X ULN; grade 
3, 5.1 – 10.0 X ULN; grade 4, >10 X ULN. For purposes of analysis, grade 1 and 2 
hepatotoxicity was classified as mild whereas grades 3 and 4 hepatotoxicity were 
graded as severe.  
Three formulae were used to calculate estimated glomerular filtration rate from serum 
creatinine concentrations namely the Cockroft-Gault
351
 equation, the 4-variable 
Modified Diet in Renal Disease (MDRD)
352
 equation and the Chronic Kidney Disease- 
Epidemiological Collaboration (CKD-EPI)
353
 equation. The formulae used are 
presented below: 
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Cockroft-Gault formula:  
eGFR= (140-age) x weight (in kilograms) x [constant]/serum creatinine in mol/l 
constant= 1.23 for men and 1.04 for women. 
MDRD formula: 
eGFR= 32788 x serum creatinine 
-1.154
 x Age
-0.203
 x [1.212 if black] x [0.742 if female] 
Where serum creatinine is in mol/l. 
CKD-EPI formula:  
eGFR=141 x min (SCr/k, 1)
a  
x max (SCr/k, 1)
-1.209
 x 1.018 if female x 1.159 if black. 
SCr = serum in mg/dl,  
k=0.7 for females and 0.9 for males,  
a is -0.329 for females and -0.411 for males.  
Min indicates the minimum of the SCr/k or 1, and max indicates the minimum of SCr/k 
or 1. After calculating the eGFR, correction for body surface area was then performed. 
The MDRD and CKD-EPI- derived eGFRs are expressed as ml/min/1.73 m
2
 because 
the equations were derived by comparison with iothalamate-measured GFR, which itself 
is expressed as ml/min 1.73 m
2
. However the eGFR derived by using the Cockroft-
Gault equation was converted from ml/min to ml/min/1.73 m
2 
by multiplying calculated 
values by 1.73, and dividing by body surface area (BSA). BSA was calculated using the 
following formula
354
: 
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Body surface area = 0.007184 x height
0.725
 x weight
0.425   
Stages of renal impairment were classified using the Kidney Disease Outcome Quality 
Initiative staging criteria
355
 as shown in Table 2.1 below. Stages 1 and 2 are usually 
applied to patients with evidence of kidney disease (other than reduced GFR), such as 
proteinuria, haematuria and known kidney disease. However in this study urine analysis 
data was not available because it is not routinely performed in the initial assessment of 
patients in evaluating for eligibility for initiation of cART. 
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Table 2.1 Stages of chronic renal disease. 
Stage Clinical GFR (ml/min) 
1 Normal >90 
2 Mild impairment 60-89 
3 Moderate impairment 30-59 
4 Severe impairment 15-29 
5 End-stage renal failure <15 
 
Hypocholesterolaemia were defined according to the US National Cholesterol 
Education Programme guidelines
356
 as fasting cholesterol concentrations of < 150mg/dl 
while hypertriglyceridaemia was defined as fasting triglyceride concentration 
>200mg/dl.  
At closure of data for analysis it was realised that nearly 24% of patients were lost to 
follow up. To gain an insight into their vital status and also the potential reasons for 
loss-to-follow up, a telephone survey was conducted among 210 patients or contacts 
who had given their telephone details primarily to assess the vital status of patients as 
dead or alive. 
Statistical analysis (chapter 3) 
Normality of distribution of continuous data was assessed using the Kolmogorov-
Smirnov (KS) test. Univariate comparisons of continuous of data were performed using 
either the Mann-Whitney’s U-test or the Wilcoxon rank sum test for data that did not 
follow a Gaussian distribution while Student’s t-test was used to compare means of data 
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of Gaussian distribution between two groups. For more than two groups, an analysis of 
variance (ANOVA) was performed for data with Normal distribution with Bonferroni’s 
test to adjust for p-values to account for multiple comparisons while the Kruskal-Wallis 
test was used for comparison of data which did not follow a Normal distribution. 
Comparisons of dichotomous data were performed using the chi-squared test or Fisher’s 
exact test and multiple logistic regression analysis was performed to identify factors 
associated with HIV-related renal impairment and elevated alanine transaminase among 
patients before initiating therapy. Kappa statistics was used to assess agreement 
between the 3 formulae used to calculate eGFR. In assessing the inter-rater agreement 
between the 3 formulae for stages of renal impairment using eGFR, the Cohen kappa 
statistic -value with the standard error as well as a linearly weighted Fleiss’ kappa 
values were reported. 
All univariate analyses were performed using GraphPad Prism version 4. Multivariable 
logistic regressions performed using SPSS version 17. For all analysis, a 2-sided p-
value <0.05 was set as the level of statistical significance. 
 
2.4. Methods for chapter four 
The design of this study was retrospective, longitudinal and analytical among patients 
who started cART in the cohort. For this analysis, AIDS-defining event, non-AIDS 
defining clinical event, immune reconstitution inflammatory syndrome, loss-to-follow 
up, death and adherence to therapy were defined as follows:  
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An AIDS-defining clinical event was defined as the occurrence of any stage 3 or 4 
opportunistic infectious or malignancy according the World Health Organisation 
(WHO)
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 criteria while patient was on cART. This staging system is based on clinical 
findings that guide the diagnosis, evaluation, and management of HIV/AIDS in 
resource-limited settings and it does not require a CD4 cell count. The list of AIDS-
defining events under the WHO criteria is shown in Table 1.1 under section 1.2.1.6 in 
the literature review. 
The diagnosis of a non-AIDS clinical event was defined using established Division of 
AIDS (DAIDS) tables for Grading Severity of Adult Adverse Experiences (NADEs). 
The conditions classified under NADEs included cerebrovascular accident (stroke), 
cerebral/sub-arachnoid haemorrhage, myocardial infarction, coronary artery disease, 
congestive cardiac failure, end-stage renal disease, renal failure, cirrhosis of the liver, 
esophageal varices, hepatic failure, hepatic coma, hepatic encephalopathy, intestinal 
adenocarcinoma/lymphoma, penile carcinoma, small cell lung carcinoma, malignant 
melanoma, hepatocellular carcinoma, squamous cell carcinoma, and squamous cell 
carcinoma of the anus
358, 359
.  
Other medical diagnoses that did not fulfil the criteria for AIDS-defining events or 
serious NADEs (as defined above) were recorded and presented as “medical co-
morbidities on cART”. These included conditions such as malaria, urinary tract 
infections, new onset diabetes mellitus or systemic arterial hypertension, and so forth. 
 Immune reconstitution inflammatory syndrome (IRIS) is defined as a paradoxical 
worsening of treated opportunistic infections or the unmasking of previously sub-
clinical, untreated opportunistic infections or malignancies
360
. In the present cohort, 
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IRIS was detected clinically in most instances and defined as the paradoxical worsening 
of a previously treated opportunistic infection for which the clinician was able to 
demonstrate radiological evidence of exacerbation in the cases of tuberculosis or 
cerebral toxoplasmosis, fundoscopic evidence of vitreous inflammation in the case of 
CMV retinitis. Cases of herpes zoster IRIS were defined clinically. Due to the inherent 
difficulty of differentiating an opportunistic infection with normal presentation and a 
disorder with presentation that is compatible with unmasking IRIS in our setting, the 
unmasking type is IRIS was not documented in charts in this cohort. 
Loss to follow up was defined as missing a clinic appointment by at least 3 months of 
the last scheduled visit to clinic. 
Death was defined as the demise of a patient from causes related to HIV/AIDS or from 
toxicity from antiretrovirals or other non-AIDS related causes if known. Confirmation 
of death were by death certification by medical doctors and verbal autopsy by patients. 
Adherence in the clinic is routinely assessed using pill counts. Patients’ adherence were 
therefore routinely classified as excellent at each clinic visit if adherence level of ≥95% 
was achieved. Poor adherence was defined as any documented evidence of <95% of 
adherence during follow up. 
Statistical analysis (chapter 4) 
Median of CD4 counts and body mass indices were compared longitudinally with 
baseline values in patients who remained on treatment using Mann-Whitney U-test. 
Crude incidence rate of events were calculated in person-years of follow-up with 95% 
confidence intervals calculated using Normal approximation to the Poisson distribution. 
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Risk factors associated with death, loss to follow-up, AIDS-defining events were 
assessed using multivariable Cox proportional hazards regression with factors attaining 
a significance level of <0.10 in univariate analyses included in the final model. For 
these survival analyses, the month in which patients started cART was set as month zero 
and one day of follow-up was added to patients who did not attend any follow-up visits 
after initiating therapy. Time to events of interest namely AIDS-defining events, loss-to-
follow up or mortality was calculated by subtracting the date of the event from the date 
on which the patient was started on cART. Patients were censored at December 31, 
2011 if there were no event of interest. Explanatory variables included in survival 
analyses were selected on the basis of their well-recognised impact on clinical outcomes 
such as AIDS-defining events, loss-to-follow up and deaths. The cumulative incidence 
of loss to follow up and deaths were calculated using the Kaplan Meier methodology. 
Adjusted analysis was performed to determine the independent effect of baseline renal 
impairment on the risk of death by a primary and sensitivity analysis. In primary 
analysis patients were right-censored as described above but in sensitivity analysis 
patients lost-to-follow up were assumed to have died (missing=failure). Risk factors 
associated with poor adherence were analysed using a multiple logistic regression 
analysis. For all analysis, a 2-sided p-value <0.05 was set as the level of statistical 
significance. 
2.5. Methods for chapter five 
Clinical and laboratory data recorded in patient folders were retrospectively collected 
using a data collection proforma (refer to appendix 2). 
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Data collection (description of criteria relevant to this chapter) 
All patients were routinely screened clinically for toxicity on cART at each clinic visit 
in a standardised approach and recorded in case notes. Amongst the NNRTIs data was 
collected on skin rash, neuropsychiatric adverse events, and hepatotoxicity. 
Mitochondrial toxicity namely peripheral neuropathy and lipoatrophy are recorded as 
NRTI-related toxicity and anaemia was attributed to zidovudine unless there was 
another more probable cause. 
Anaemia: To enable clinicians to detect anaemia due to toxicity or other causes, routine 
full blood counts were performed half-yearly or upon clinical suspicion of anaemia. 
Anaemia was defined as a haemoglobin concentration of  12g/dl for women and  
14g/dl for men
350
. Anaemia was graded as severe or life-threatening if the haemoglobin 
concentration was  8g/dl. In patients who had any degree of anaemia before starting 
therapy, worsening anaemia was defined a haemoglobin concentration  8g/dl or if 
there were a decline by more than 2.5g/dl from baseline
350
. Zidovudine was implicated 
as the cause of anaemia for patients taking this medication unless another clinical 
explanation was recorded in the folder of patient.  
Less common side effects of zidovudine such as hyperpigmentation and hypersalivation 
were also recorded. 
Skin rash definitions: The types and severity of skin rash were commonly described by 
clinicians in patients’ folders. Based on these descriptive accounts severity of skin rash 
was staged, using criteria published by from the 2NN sub-study
361
 as Level I: erythema 
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or hyperpigmented rash; level IIA: diffuse maculopapular rash; level IIB: urticaria; level 
III: rash plus constitutional symptoms such as fever, myalgia, pruritus and malaise or 
angiooedema, serum sickness-like reactions, Steven’s Johnson syndrome; level IV: 
toxic epidermal necrolysis. A cross-reactivity NNRTI-cutaneous reaction was defined 
as the re-appearance of a rash attributable to NNRTI, after substituting one NNRTI for 
another
14
. When the physician did not attribute skin rash to drug toxicity, the cause of 
the skin rash was recorded but not included in the analysis for toxicity. FSS and ROP 
staged the severity of skin rash based on description of rash in the patient’s folder when 
this was not clearly documented in the folder.  
Definitions of hepatotoxicity grades:  Hepatotoxicity grades were based on ALT level 
and defined in accordance with AIDS Clinical Trials Group criteria
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 in the following 
manner: grade 1, 1.25-2.5 times the upper limit of normal (x ULN); grade 2, 2.6-5.0 x 
ULN; grade 3, 5.1-10 x ULN; grade 4, >10 x ULN. In order to avoid selection bias 
favouring the inclusion of patients with very high baseline ALT levels, severe 
hepatotoxicity was defined as grade 3 or 4 increases in ALT level or an increase in ALT 
level of greater than 100 IU/l from baseline as previously described
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. Furthermore, 
when a patient was noted to have had hepatic enzyme elevations, the reasons for those 
elevations as recorded by the attending clinicians were noted and if was thought not to 
be antiretroviral therapy related, that data was not included. Among factors that could 
cause hepatic enzyme elevations were heavy alcohol use which were screened for 
routinely during follow up.  
Neuropsychiatric symptoms associated with use of NNRTI’s especially those on 
efavirenz were routinely recorded without any standardised assessment of severity. 
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Individual neuropsychiatric symptoms recorded in patients’ records for which the 
attending clinician attributed to NNRTI were noted. 
Mitochondrial toxicity Mitochondrial toxicity data was collected with emphasis on the 
4 common events namely peripheral neuropathy, lipoatrophy, symptomatic lactic 
acidosis and pancreatitis. Neuropathy was clinically assessed based on patients’ 
symptoms and stavudine or zidovudine was substituted in severe cases upon the clinical 
judgement of HIV physician. Patients were assessed for lipoatrophy (loss of 
subcutaneous fat in the face, arms, legs, cheeks, buttocks) at every encounter by self-
report and clinical assessment. Decisions to substitute stavudine were guided by the 
clinical severity of lipoatrophy based on the combined assessment of the clinician and 
the patient’s preference and perception of the body changes. Lactic acidosis was 
diagnosed symptomatically since there were no facilities to routinely measure serum 
lactate concentrations. Clinical suspicions of pancreatitis were corroborated by 
performing serum amylase. 
Outcome measures 
The primary outcome was time to occurrence of a specific ART-associated toxicity. 
Statistical analysis (chapter 5) 
The cumulative incidence of each specific ART-associated toxicity was calculated using 
the Kaplan-Meier methodology and the median time to occurrence of the first event 
calculated using the Mann-Whitney’s U-test, when the median time could not be 
determined by Kaplan-Meier methodology. Patients were censored either at the date of 
first ART-related toxicity, at the last visit for patients that died, were transferred out or 
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were lost to follow-up and at December 31, 2011 for the remainder. Patients switched to 
second line ART regimens due to either clinical or immunological failure were censored 
at the date of switching and defined as having experienced no specific first line drug-
related toxicity event. A risk factor analysis was performed using multivariate Cox 
proportional hazards regression model. Collinearity between variables was assessed. A 
backward selection method, retaining those variables with p-values <0.10 in the final 
model. In order to evaluate the associations between individual ART-associated toxicity 
and all-cause toxicity on the risk of poor adherence, a multiple logistic regression 
analysis was performed. Risk factors identified to be independently and significantly 
associated with the risk of poor adherence were adjusted for in the final logistic 
regression models to assess the independent effects of specific and all-cause ART-
related toxicity on adherence. The level of significance was set at p<0.05. 
 
2.6. Methods for chapter six 
Inclusion criteria: Patients were included in this analysis if they started ART within 1
st
 
January 2004 to 31
st
 December 2010. They should have been ART naïve, more than 15 
years, and should have started either efavirenz or nevirapine with a backbone of either 
zidovudine plus lamivudine or stavudine plus lamivudine. Data were closed at 31
st
 
December, 2011. 
Outcome measures: The primary outcome measure of treatment effectiveness for this 
comparison between EFV vs NVP-based cART was treatment failure defined as a 
composite of deaths, clinical disease progression and all-cause treatment 
discontinuation.  
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1. Clinical progression after initiating cART is the occurrence of a new opportunistic 
infection or malignancy, the recurrence of prior opportunistic infection or 
onset/recurrence of WHO stage 3 or 4 conditions. 
2. All-cause treatment discontinuation includes treatment discontinuations due to drug 
toxicity, treatment failure necessitating change to second line therapy and other 
physician and patient preferences. 
In secondary analysis, the outcome measures of interest were: 
1. Changes in the CD4 + T-cell counts over time. 
2. Changes in body mass index over time 
3. The impact of the NRTI backbone on the primary and secondary outcome measures. 
Statistical methods (chapter 6) 
Differences in baseline characteristics such as age, CD4 cell counts, haemoglobin 
concentration and serum biochemistry results were compared using either the Mann-
Whitney U-test for continuous variables that did not follow normal distribution or 
unpaired student’s t-test for normally distributed continuous variables. Dichotomous or 
nominal variables such as gender, year of initiation of treatment as well as the cART 
regimens initiated were compared using the Chi-squared test.  
In evaluating the primary outcome measure, two types of analyses were performed 
namely the Cox proportional hazards regression to model time to therapeutic failure and 
logistic regression analyses to model risk of therapeutic failure. Cox proportional 
hazards regression were used to model the individual and simultaneous effects of the 
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initial NNRTI, baseline variables and pill count assessed adherence on time to the 
composite end point of deaths, clinical progression and NNRTI discontinuation.  All 
available variables were included a priori in multivariate models and were stratified into 
discrete categories: sex (male vs female), age ( 40 years vs < 40 years), WHO clinical 
stage (3 and 4 vs 1 and 2), BMI (16kg/m
2
 vs 16 kg/m2 ), CD4 count (<200 cells/mm3 
vs 200 cells/mm3), haemoglobin concentration (<8g/dl vs 8g/dl), calender year 
(2004-2006 vs 2007-2010), NRTI backbone (stavudine plus lamivudine vs zidovudine 
plus lamivudine), adherence (excellent vs poor) and NNRTI (efavirenz vs nevirapine). 
These variables were chosen because they were potential confounders of therapeutic 
failure.  
Composite primary end-point analysis:  In analysing the primary outcome measure of 
treatment failure defined as either death or clinical progression or discontinuation of 
NNRTI for any reason, time to the first occurrence of any of the three components of 
the co-primary outcome measure was calculated by subtracting the date of the event 
from the date of initiation of cART. Patients were censored if none of the events in the 
co-primary endpoint was not observed at the time of last visit for patients that were 
transferred out or were lost to follow-up and at 31
st
 December, 2011 for the remainder. 
Treatment modifications in the NRTI backbone were disregarded. In both the Cox 
regression and logistic regression models, therapeutic failure was defined as (as defined 
above) i.e missing = censored for primary analysis. In sensitivity analysis patients lost 
to follow-up were considered to failed therapy (missing=failure). Interaction between 
covariates was tested by including multiplicative terms in regression models. For these 
analyses any factor that was significant at the 10% level in univariate analyses (p<0.1) 
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was included in multivariate analysis. In multivariate analysis, statistical significance 
was attained if p<0.05. All p-values were exact and two-tailed. 
Imputation of data for missing data for Cox and logistic regression analyses: Missing 
CD4 counts were imputed as below 200 cells/mm
3
 (n=30; 24 for efavirenz and 6 for 
nevirapine), missing WHO clinical classification was imputed as having AIDS defining 
event at baseline (n=456; 269 for efavirenz vs 187 for nevirapine), missing BMI 
(n=100, 70 for efavirenz and 30 for nevirapine) for females and males were imputed 
with the average of the median BMI for both sexes respectively. 
Changes in CD4 counts and BMI: Immunologic response measured by CD4+ T-cell 
count changes and anthropometric changes assessed using body mass index were 
compared by pair-wise comparisons of medians at 2months and subsequently 6 monthly 
intervals between the two groups. Where repeated comparisons are performed a p-value 
<0.01 was set as the level of significance to detect a difference between two groups. 
Changes in CD4 counts over time on cART were modelled with a generalised mixed 
effects linear model by using log link and Poisson distribution. The treatment 
(nevirapine and efavirenz), time since the initiation of therapy, backbone (AZT plus 
3TC or d4T plus 3TC) and their interactions were specified as fixed effects in the model 
whilst the patients were specified random effects in order to account for the repeated 
observations per patient over time. Changes in BMI was modelled using a linear mixed 
effects model with identity link and Gaussian distribution. The model for change in 
BMI by NRTI backbone with NNRTI (nevirapine and efavirenz) and time since the 
initiation of therapy and their interactions specified as fixed effects and patients as 
random effects. Thus both the mean CD4 cell counts and BMI before therapy and the 
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slope of change over follow-up time in the nevirapine and efavirenz groups could be 
compared by the Fisher’s F test. BMI, gender and WHO clinical stages were included 
as explanatory variables in both models. Also, pre-therapy CD4 and pre-therapy BMI 
were included in the two models respectively.  
2.7. Methods for chapter seven 
The study was a prospective, open label, observational pharmacokinetics study 
including HIV-infected patients on efavirenz-based cART with control patients whose 
HIV status were unknown. The primary objective was to determine the effect of steady 
state therapy of efavirenz on artesunate/DHA pharmacokinetics. Secondary objectives 
were to investigate the effect of artesunate on steady state concentrations of efavirenz 
and to evaluate symptoms or laboratory features of toxicity of artesunate/DHA and 
efavirenz. 
Sample size calculation  
Basing the sample size on the primary comparison, namely artesunate PK in patients on 
steady state efavirenz, the sample size was calculated on the basis of a previous study of 
coartemether
363
. Using this data, assuming a first dose AUC (SD) of 204 (107) ng*h/mL 
and a last dose value of 63.6 (72.5) ng*h/mL, a total of 20 patients in each group will 
provide 83% power to detect a 50% difference in AUC for artesunate between each 
group.  
Ethical Considerations 
The main ethical issue in this study was the potential to recruit patients who are treated 
for malaria with what may be regarded as sub-optimal therapy, namely artesunate 
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without an additional antimalarial drug, which was not in line with current WHO 
recommendations. On the other hand, a significant number of patients in Ghana (and 
other malaria-endemic countries) are treated with artesunate alone due to issues of 
affordability of combination therapy, drug supply and toxicity of some combination 
therapies. Patients who are treated with artesunate alone, were only approached 
regarding inclusion in the study if the patient has been informed that artesunate 
monotherapy is probably inferior to combination therapies, and the patient’s physician 
has already decided to treat the patient with artesunate alone, rather than combination 
therapy. If antimalarial therapy with artesunate failed, patients were to be re-treated 
with combination artemisinin based anti-malarial therapy. Ethical permission for the 
study was given by the Committee for Human Research Publication and Ethics of the 
Kwame Nkrumah University of Science and Technology and the Komfo Anokye 
Teaching Hospital.  
Study participants and study sites 
Study participants were HIV-positive adult volunteers taking efavirenz-based cART 
(with >90% adherence) for a minimum of 2 weeks whose physician has decided to treat 
them for malaria with artesunate monotherapy based on complaints of symptoms of 
malaria at the chest clinic where HIV infected adults are routinely managed on out-
patient basis.  Controls who were patients not known to have HIV infection were 
recruited from the Polyclinic unit of the Komfo Anokye Teaching Hospital when their 
physicians had decided to treat uncomplicated malaria with artesunate monotherapy. 
Subjects were included if they were above 18 years, had given a written informed 
consent and willing to attend for study procedures. Patients were excluded if they had 
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current or recent (within previous week) therapy with any known inhibitors or inducers 
of cytochrome P450 or P-glycoprotein, aside from antiretroviral drugs, pregnancy, 
current or recent therapy with traditional medicines (or intention to use such medicines) 
vomiting profusely or had known history malabsorption or if they required hospital 
admission. Both groups were treated with Artesunate 200 mg twice daily for 5 days. If 
patients showed signs or symptoms of failing to respond to antimalarial therapy at Day 
5, the treating physician may decide to give an alternative antimalarial combination, in 
which case all subsequent data were not be used in the study, and the patient were given 
the option to withdraw from the study. Patients were recruited between May 2009 and 
January 2010. 
Follow-up and sampling 
After obtaining informed consent and after full explanation of the objectives of the 
study (in local language by a study nurse) a standard study Clinical Report Form (CRF) 
(see appendix 4) was used to record all data, including results of laboratory tests. The 
patients’ medical and drug histories were taken prior to enrolment (Day 1). The first 
dose of Artesunate 200mg was administered under supervision. Drug adherence sheets 
were completed prior to the study and at each visit (Day 1 and Day 5), patients were 
requested to complete an adherence questionnaire and a symptom questionnaire. All 
subjects were fully examined and completed a symptom questionnaire at each visit. An 
initially proposed sampling schedule on day 1 at 0, 15, 30, 60, 90 and 120 minutes 
followed by further sampling at 4, 6, 8 and 12 hours were not acceptable to all the target 
HIV-infected and controls approached about the study. A revised pharmacokinetic 
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sampling on day 1 at 0, 1, 4 and 6 hours after the first supervised dose of Artesunate 
200mg and on day 5 at 6 hours post last dose was then agreed upon.   
6ml of venous blood samples were collected at baseline and on Day 5 for malaria film, 
for full blood count and for biochemistry to assess the liver function test and renal 
function test. All plasma and serum samples were stored at -70
o
C prior to transportation 
on dry ice to the UK. For determination of plasma efavirenz concentrations, blood 
samples were drawn at baseline (day 1) and on day 5 at the scheduled PK time points 
described for artesunate and DHA above. Plasma samples were transported to the 
Department of Pharmacology and Therapeutics (Liverpool, UK) for measurement of 
steady state plasma efavirenz concentrations and for Artesunate plus dihyroartemisinin 
at the Liverpool School of Tropical Medicine.  
Blood smears for identification and enumeration of malaria parasites: Confirmation 
diagnosis of malaria and parasite count were made using thick and thin blood smears 
(day 1) prepared with peripheral blood, stained with Field’s stain and Giemsa, 
respectively, and viewed in 100x microscopic fields. Parasite density was calculated by 
counting the number of asexual parasites against 200 leukocytes in the thick blood film 
by using a hand tally counter. If less than 10 parasites were found before reaching 200 
leukocytes, then counting was continued until 500 leukocytes were counted. Parasite 
density (expressed as the number of asexual parasites per microliter) was calculated by 
dividing the number of asexual parasites by the number of leukocytes counted and then 
multiplying by an assumed leukocyte density of 8,000 leukocytes/l.  
Complete blood counts with haemoglobin concentrations, white blood cells and 
platelets counts were done centrally using Sysmex XT-1800i automated haematology 
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analyser (USA). Serum biochemistry testing for liver and renal function tests were 
performed at the Chemical Department of KATH using the multi-parameter Roche 
Cobas Integra
®
 400 plus, Roche Diagnostics, Mannheim, Germany. 
Drug Assays 
Quantification of plasma artesunate and dihydroartemisinin concentrations in HIV 
infected patients and controls. 
Plasma concentrations of Artesunate and its active metabolite Dihydroartemisinin 
(DHA) were determined by high performance liquid chromatography coupled to tandem 
mass spectrometry (HPLC-MS/MS) by a validated assay at the Liverpool School of 
Tropical Medicine and Hygiene. Plasma samples were heated at 58
o
C for 1 hour to 
inactivate any residual HIV before measurements of Artesunate and Dihydroartemisinin 
concentrations could be performed.  
Equipment and reagents 
The Thermo Accela HPLC system consisted of Surveyor AS autosampler (200 vial 
capacity set at a temperature of 15
0
C) and a Surveyor LC pump (Thermo Electron 
Corporation, Hemel Hempstead, UK). A Betasil (C8) phenyl-hexyl column (5m: 
50mm x 2.1mm) connected/interfaced with a 10mm guard column of same packing 
material (Thermo Electron Corporation, Runcon, Cheshire, UK) set at an oven 
temperature of 26
0
C was used to elute analytes and internal standard. The HPLC system 
was interfaced with a Thermo TSQ Quantum access triple-quadrupole mass-
spectrometer with a positive electron spray ionisation scan mode. LC-MS grade 
acetonitrile (ACN) was obtained from Fisher Scientific (Loughborough, UK). Data 
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acquisition and quantification were performed using Analyst 1.4 (Applied 
Biosystems/MDS SCIEX, Foster City, USA). 
Analytical and Pharmacokinetic Methods 
Plasma concentrations of Artesunate (ARTS) and Dihydroartemisinin (DHA) at various 
time points of the study were measured using a validated HPLC-MS/MS methodology. 
Patient samples were analysed in singlicate (100l) as follows: Internal standard (IS) 
[deoxyartemisinin (50l, 10g/ml)] was added to all patient samples and serial dilutions 
of DHA standards followed by the addition of 200l of precipitating solvent, ice cold 
acetonitrile. Samples were vortexed for 2-5 seconds and centrifuged at 13000rpm at 4
0
C 
for 5 minutes. The solvent phase was then transferred into clean glass vials ready for 
injection (20l) into the LC-MS system. The analytes were resolved on a betasil phenyl 
hexyl column using an isocratic mobile phase of 65:35 (vol/vol) of acetonitrile and 
0.1M ammonium acetate at a flow rate of 0.45ml/min with a run time of 4 minutes and a 
wash out gradient. The Thermo TSQ Quantum access triple-quadrupole mass-
spectrometer with a positive electron spray ionisation scan mode was used for the 
multiple reaction monitoring (MRM) LC-MS/MS analysis. The mass spectrometric 
conditions were optimized for the compounds by infusing a 100ng/ml standard solution 
in mobile phase at 10l/min using a Harvard infusion pump connected directly to the 
mass spectrometer. An additional tuning optimization of gas flows and temperatures 
was performed by continuously infusing the same standard solution at 10l/min via a 
“T” connector into the post-column mobile phase flow (500l/min). The ionization 
source temperature was maintained at 475
o
C and the ionization source voltage set at 
4500V. The curtain gas was set to 25.0psi, and the nebuliser (GS1) and ionization 
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source (GS2) gases at 55.0 and 60.0 psi, respectively. The CAD gas in the collision cell 
was set at 5 psi.  DHA, ARTS and IS eluted at 1.27, 1.56 and 1.96 minutes respectively 
as shown in figure (Figure 2.1) and were detected by selected reaction monitoring 
(SRM). The intensities of the ammonium adducts of the parent compounds and 
fragment (daughter) ions mass-to-charge ratios [m/z], 302.2 and 267.0 for DHA, 402.2 
and 267.0 for ARTS and 267.0 and 203.0 for deoxyartemisinin (shown in Figures 2A-
C) were measured and total plasma concentrations were ascertained from the intensity 
of separate analyte: internal standard daughter ion ratios by comparison to the relevant 
calibrator of known concentration. The validated assay concentrations ranged from 5 – 
2000ng/ml. Samples from both HIV-infected patients and controls were tested in one 
batch. 
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DHA 1.27 min
ARTS 1.56 min
I.S. 1.96 min
Runtime 4 min.
 
Figure 2.1. Chromatographic separation of Dihydroartemisinin (DHA), artesunate 
(ARTS) and internal standard (IS). 
 
   
 
 Figure 2.2A. Mass spectrometry of artesunate (ARTS) after direct injection in to mass-spectrometer, parent compound  
          was observed at m/z 402.2 (M+[NH4]
+
) and major MS:MS fragmented ion of parent molecule was observed at m/z 267.0 
 
                 128 
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Figure 2.2B. Mass spectrometry of dihydroartemisinin (DHA) after direct injection in to mass-spectrometer,  
parent compound was observed at m/z 302.2 (M+[NH4]
+
) and major MS:MS fragmented ion of parent molecule was observed at m/z 
267.0. 
 132 
 
 
Figure 2.2C. Mass spectrometry of deoxyartemisinin (IS) after direct injection in to mass-spectrometer, parent compound was observed 
at m/z 267.0 (M+H
+
) and major MS:MS fragmented  ion of parent molecule was observed at m/z 203.0. IS= internal standard
   
Quantification of plasma concentrations of efavirenz 
Plasma efavirenz concentrations were measured as using HPLC coupled with UV 
detection as described under methods under section 2.8. 
Pharmacokinetic and statistical analysis 
The pharmacokinetic parameters tested were area under the curve, time to maximum 
concentration (Tmax) and maximum concentration (Cmax) for dihyroartemisinin (DHA). 
The area-under-curve from time zero to 6 hours (AUC0-6) was calculated using the 
linear trapezoid rule without extrapolation beyond this time period for 
dihydroartemisinin. The effect of artesunate on efavirenz steady state concentration was 
assessed by determining the percentage change in the concentration at times 1, 4, 6 
hours after the first dose of Artesunate and also 6 hours after the last dose of Artesunate 
on day 5 compared with time 0 hours on the first day. Medians and means between 
cases and controls were compared using either Mann-Whitney’s U-test or student’s t-
test respectively. Pharmacokinetic modeling of Dihydroartemisinin concentrations in 
serum over the first 6 hours was performed using the GraphPad 4 Prism software. No 
adjustments were made for multiple comparisons. 
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2.8.1. Methods for chapter eight 
2.8.1.1 Study participants 
800 patients with confirmed HIV infection were recruited into the first part of the study 
evaluating the frequencies of common SNPs along the metabolic axis of efavirenz in 
our study population. In the second part, subset of patients on efavirenz based cART 
with genotype data were analysed to examine the impact of selected polymorphisms in 
efavirenz metabolising enzymes on steady state concentrations of plasma efavirenz. To 
be included in the study, patients should be aged at least 15 years and those on efavirenz 
should be taking it at the fixed dose 600mg daily plus two nucleoside reverse 
transcriptase inhibitors based on pharmacy records.  
2.8.1.2. Pharmacokinetic sampling: Mid-dose sampling is frequently used in clinical 
studies of efavirenz disposition for patient convenience as the drug is invariably taken at 
bedtime to minimize central nervous system side effects during the day
8
. Mid-dose 
blood samples were obtained from patients at the Serology department of KATH where 
patients routinely go for phlebotomy to obtain samples for CD4 count enumeration. 
Plasma and sera were separated by centrifugation at 4
0
C, aliquots were collected and 
stored at -20
0
C. Samples for this study were selected from plasma and sera repository in 
Kumasi set up for HIV research since 2005. Patients who were on efavirenz-based 
cART from pharmacy records had their samples traced from this repository for the 
present analysis. Samples were shipped from Ghana to the Department of 
Pharmacology and Therapeutics of Liverpool University, United Kingdom on dry ice. 
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 Upon receipt, plasma samples were heat inactivated in a water bath at 58
0
C for 40 
minutes and stored at -20
0
C prior to further analysis.  
 
2.8.1.3. Quantification of plasma efavirenz concentration 
Plasma concentrations of efavirenz was measured using reverse phase high performance 
liquid chromatography (HPLC) with UV detection of efavirenz at 250nm by a validated 
assay at the Liverpool University, department of Pharmacology and Therapeutics. The 
laboratory at the University of Liverpool participates in an external international quality 
assurance scheme (KKGT, The Netherlands). The methodology for the preparation of 
plasma samples for quantification of efavirenz is described below:  
Equipment: Efavirenz concentrations were determined by HPLC-UV. The HPLC 
system consisted of a HPLC 465 autosampler and a 325 pump (Kontron Instruments 
Ltd; Hertfordshire, UK) and a Spectra System UV1000 detector (Thermo Separation 
Products; Hemel Hempstead) set at wavelength of 250nm. A Hypurity C18 column (5m 
150 x 4.6mm, Thermo Electron Corporation) was used to elute analytes and internal 
standard, and was interfaced with a 2m guard column (Si 60, 5m; Merck, Germany). 
Peak integration, data acquisition and processing were performed using Chromeleon 
Software (Version 6.40, Dionex UK Ltd, Surrey, UK).  
Reagents: HPLC grade de-ionised water was produced from an Elga Option 4 water 
purifier (Elga LabWater, High Wycombe, UK).  Analytical grade acetonitrile (ACN), 
ethyl acetate, n-hexane and methanol were obtained from VWR International Ltd. Drug 
free plasma was obtained from the National Blood Service (Liverpool, UK).  
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Analytical Methods: 200l of singlicate patient samples, quality control samples and 
blank plasma containing serial dilutions of efavirenz standards were carefully pipetted 
into glass tubes and spiked with 20l of 250g/ml of an internal standard [Ro 31-9564, 
Roche Discovery Welwyn, UK]. To this was added 100l of K2CO3 (approximate pH 
of 11) to enhance the efficiency of EFV extraction following which 3ml of an extraction 
solvent comprising of 50:50 (v/v) ethyl acetate: n-hexane was also added. All samples 
were thoroughly mixed on a rotary mixer (Rotadrive STR4, Stuart Scientific) for 30 
minutes and then centrifuged for 5 minutes at 4000 rpm. The lower aqueous phase was 
frozen in a cryogenic bath (of dry ice in methanol) and the upper organic phase 
transferred into fresh 5ml glass tubes and evaporated to dryness in a rotary evaporator 
(RC10.22, Jouan). Samples were reconstituted in 150l of mobile phase (50:50 [v/v]; 
deionised water with 10mM ammonium acetate buffer: acetonitrile), vortexed and then 
transferred to autosampler vials ready for injection (50l) onto the HPLC column. 
Efavirenz and internal standard were resolved on Hypurity C18 column (5m 150 x 
4.6mm, Thermo Electron Corporation) with an isocratic mobile phase (50:50 [v/v]; 
deionised water: acetonitrile at a flow rate of 1.2ml/min. EFV was eluted over 20 
minutes and its concentration derived by dividing its integrated area under the curve by 
that of the internal standard. The lower limit of quantification was 99ng/ml (± 2SD), 
and inter and intra-assay variability was <10% and <10% respectively. 
2.8.1.4. Genotyping of CYP2B6, CYP2A6, UGT2B7 and CAR SNPs 
DNA extraction from serum samples: Before extracting genomic DNA from sera of 
patients, samples were brought to room temperature (15-25
0
C) and heated in a water 
bath at a temperature of 56
0
C to inactivate HIV that may be present in these samples. 
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DNA was extracted from sera samples using a Qiagen DNA extraction mini kit 
according to manufacturer’s instructions. Briefly, 60l of Qiagen protease was pipetted 
into a 1.5ml sterile eppendorf tube followed by the addition of 600l of a well-mixed 
serum sample and 600l of lysis buffer AL. The resultant 1260l solution was pulse -
vortexed for 15 seconds, incubated at 56
0
C for 10 minutes, spun briefly for 1 minute at 
6000 x g and divided into 2 sterile eppendorf tubes. Into the contents of each of these 
two tubes 300l of 100% ethanol was added and pulse-vortexed for 15s, spun at 6000 x 
g for 1 minute, carefully transferred to a spin column without wetting the rim of the 
filter and spun again at 6000 x g for 1 minute. After discarding the filtrate, the DNA on 
the filter membrane was purified by placing the filter unto a new clean collection tube, 
adding 500l of wash buffer AW1 to the spin column and spinning at 6000 x g for 1 
minute. The purification step was repeated using 500l of wash buffer AW2 followed 
by centrifugation at 13,000g for 3 minutes to dry the membrane completely. Cleaned 
DNA from the filter membrane was eluted into a new sterile eppendorf tube by 
carefully applying 50l of elution buffer AE to the filter membrane, incubating at room 
temperature for 3 minutes and spinning at 6000 x g for 1 minute. Elution was performed 
twice and genomic DNA stored at -20
0
C for later analysis.  
a. CYP2B6 genotyping: Pre-amplification for exon 4 and exons 7 and 8 (combined) was 
first conducted to discriminate from the CYP2B6 pseudogene (CYP2B7). Genotyping 
for G516T and T983C was then performed on the resultant amplicons by real-time PCR 
allelic discrimination. Briefly 1l of genomic DNA was added to a PCR mix 
comprising 1l of 10x buffer II (Applied Biosystems), 0.6 l of 25mM MgCl2 (Applied 
Biosystems), 0.4 l each of Exon4 forward (1M) and reverse (M) primers, 0.2l of 
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10M dNTP (dATP, dCTP, dGTP, dTTP) (Applied Biosystems), 0.2l of amplitaq 
5u/l (Applied Biosystems) and 6.2l of sterile water. E4 forward and reverse primer 
sequences were 5-GGTCTGCCCATCTATAAAC-3 and 5-
CTGATTCTTCACATGTCTGCG-3 respectively. PCR conditions were 950C for 5 
minutes followed by 45 cycles of 30s at 95
0
C, 30s at 58
0
C, 45s at 72
0
C and a final stage 
of 72
0
C for 5 minutes before holding at 4
0
C in a thermocycler (Applied Biosystems). 
Pre-amplification of exons 7 and 8 combined was performed under similar conditions: 
Exon 7 forward primer sequence was GTGATTATTCATTAATTGGGTTC and Exon 8 
reverse primer sequence was TGCAATGGTTGATTGATGCTC.  
Genotyping for 516G>T and 983T>T was then performed on the resultant amplicons by 
real-time PCR allelic discrimination. Briefly 2l of amplicon material was added to a 
PCR mix of 12.5l of ABgene QPCR master mix (2X) (Abgene, Epsom, UK), 1.25l of 
primer mix (20X) (Abgene, Epsom, UK), 1.25l of probe mix (20X) (Abgene, Epsom, 
UK) and 8l of sterile water (Sigma, UK) in a white MJ plate (Biorad laboratories Ltd, 
UK) and sealed with an Abgene plate seal. Plate was spun briefly at 1300g following 
which PCR was performed on a qPCR-Opticon monitor (MJ Research Inc., USA). 
PCR conditions were 95
0
C for 5 minutes followed by 50 cycles of 95
0
C for 15s and 
60
0
C for 1 minute and a plate read with the FAM and VIC dyes reporting T and G 
respectively for 516G>T while the FAM and VIC dyes reported T and C respectively 
for 983T>C. G516T-GTOTF forward primer sequence was 
CTTGACCTGCTGCTTCTTTCCTA and the G516T-GTOTR reverse primer sequence 
was AGACGATGGAGCAGATGATGTTG. G516T-GTOT VIC sequence was 
TTCCAGTCCATTACCG and G516T-GTOTM1 FAM sequence was 
 139 
TTCCATTCCATTACCG. CYP2B6E7-TTOCF forward primer sequence was 
GCCTGAAATGCCTCTTTAAAATGAGATTC and the CYP2B6E7-TTOCR reverse 
primer sequence was GCGATGTGGGCCAATCAC. T983C-TTOCV2 VIC sequence 
was CTGTTCAGTCTCCC and the T983C-TTOCM2 FAM sequence was 
CTGTTCAATCTCCC.  
b. CYP2A6 genotyping: The CYP2A6 allele genotyped was the CYP2A6*9B by real-
time PCR allelic discrimination. A similar procedure was employed as for that 
described for the CYP2B6 with the following exceptions: 
 genomic DNA material was used for the real-time PCR without a pre-amplification 
step. 
 40 cycles of qPCR was performed instead of 50 for the 2 CYP2B6 alleles described 
above  
 FAM and VIC dyes reported C and A for the CYP2A6*9B-A/C (rs8192726) SNP 
respectively.   
c. UGT2B7 genotyping: Genotypes for the UGT2B7 exon 2 SNPs namely UGT2B7*1A 
and UGT2B7*2 were determined by real-time PCR allelic discrimination. The protocol 
was similar to that described for CYP2A6 above with the following exceptions:  
 FAM and VIC dyes reported T and C for the UGT2B7*2_802C>T SNP and G and A 
for the UGT2B7*1A_735A>G SNP respectively.  
 UGT2B7_802_F forward primer sequence was 
CTGACGTATGGCTTATTCGAAACTC and the UGT2B7_802_R reverse primer 
sequence was TGGAGTCCTCCAACAAAATCAACAT. UGT2B7_802 VIC sequence 
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was AGTGGATGAGGAAACTT and UGT2B7_802 FAM sequence was 
AGAGTGGATAAGGAAACTT.  
 UGT2B7*1A_735_F forward primer sequence was 
CCTAAAGTAATTATCTTGTGTCATCCACCTT and the UGT2B7*1A_735_R 
reverse primer sequence was CGTCAGCTTTCCCCATTGTCT. UGT2B7*1A_735 
VIC sequence was ACCCACTACATTATCTGT and the UGT2B7*1A_735 FAM 
sequence was CCCACTACGTTATCTGT.  
d. Constitutive Androstane Receptor (CAR) genotyping: Genotyping for the C>T 
(rs2307424) SNP for CAR was conducted by real-time PCR using a pre-validated 
Applied Biosystems assay ID C_25746794_20.  
Analysis of real-time PCR data: After PCR amplification, the endpoint plate read was 
performed using an Applied Biosystems Sequence Detection System (SDS). The SDS 
software uses the fluorescence measurements made during the plate read to plot 
fluorescence (Rn) values based on the signals from each well. The plotted fluorescence 
signals indicated which alleles are in each sample. A cycling threshold for each dye was 
set as shown in figure 2.3. An allelic discrimination plate read document is set up on the 
SDS instrument to analyse the plate read document to either make manual allele calls or 
review automatic allele calls followed by conversion of allele calls to genotypes as 
shown in figure 2.4. 
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Figure 2.3. Real-time PCR results in FAM (upper pane) and VIC (lower pane) dyes 
after 50 cycles for UGT2B7_802. Cycling threshold (broken lines) set manually at 
fluorescence intensity of 0.1 and 0.2 for FAM and VIC dyes respectively. 
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Figure 2.4 showing the genotypic read out of one run of real time PCR of 57 samples 
for UGT2B7*2. The VIC dye signalled the wild type allele C while the FAM dye 
signalled the mutant allele T of the UGT2B7 SNP at position 802. There were 30 
patients with normal genotype CC, 20 with heterozygous genotype CT and 7 with 
homozygous variant allele TT. 
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2.8.1.5 Statistical analysis (chapter 8) 
The concentration of serum efavirenz was log transformed to achieve normalisation and 
equal variance. Chi-squared test was employed to assess whether the observed and 
expected genotype frequencies were in Hardy –Weinberg equilibrium. Univariate 
statistical analyses examining the effects of patient demographics and genotypes on the 
efavirenz mid-dose concentrations were assessed by Mann-Whitney U-test (for gender 
and for two genotype groups), analysis of variance (ANOVA) (for three genotype 
groups) or by simple linear regression (continuous data such as age, body weight, height 
and body mass index (BMI) using Pearson’s r correlation coefficient. A two-way 
ANOVA, which incorporates an interaction model was employed to evaluate the effects 
of gene-gene interactions among the selected SNPs.  Where the ANOVA (one-way or 
two-way) yielded a significant effect (p<0.05), a post hoc multiple pair-wise 
comparison testing was performed using the Mann-Whitney’s U-test to identify groups 
that were significantly different from each other. A multivariate analysis was then 
conducted to construct a predictive model using patient demographic, anthropometric 
and genotypes as independent variables and efavirenz concentrations as the dependent 
variable. Dichotomous variables, including gender, CYP2B6 983T>C, CYP2A6*9B, 
CAR C>Trs2307424 genotypes were coded as 0 or 1 while CYP2B6 516G>T; 
UGT2B7_735A>G and UGT2B7_802C>T were coded as 0,1 and 2 for homozygous 
wild type, heterozygous mutants and homozygous mutants respectively while age, 
weight, height and BMI were included as continuous variables. Thus genotypes with 
rare double mutants (defined by < 3 in the total sample population) were treated as one 
genotype with the heterozygous mutant in these analyses. A multiple linear regression 
using best subset selection was then performed with stepwise removal of non-significant 
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variables until all remaining independent variables had coefficients with p-values<0.05. 
The risks of immunological failure and central nervous system toxicity on efavirenz-
based cART in relation to selected SNPs and mid-dose efavirenz were assessed using a 
Kaplan-Meier analysis. Statistical analyses were performed using the SPSS version 17 
and Prisms Graphpad4.
   
CHAPTER THREE 
A descriptive analysis of baseline characteristics, vital status, risk factors for renal 
impairment and elevated transaminases among HIV-infected Ghanaians initiating 
cART in Kumasi, Ghana. 
Introduction 
Human immunodeficiency virus (HIV) infection is still a global public health issue, 
contributing to approximately more than 2 million deaths each year. Sub Saharan Africa 
remains by far the worst affected region, harbouring more than two thirds of HIV-
infections worldwide. Scaling up access to treatment is one priority of the worldwide 
activities in the fight against the HIV epidemic. An increase of 1.2 million people, or 
30%, was achieved only in 2009. Still, of about 15 million people in need of ART in 
low- and middle-income countries, only about 36% (5.2 million) were receiving ART at 
the end of 2009
1
. At the same time, the numbers of patients who have been on ART for 
5 years and more is increasing, and thus the number of patients at risk for failure of 
first-line ART, is increasing rapidly.  
It was clearly demonstrated that ART in resource poor settings can be successful. 
Therapy outcomes in Sub Saharan treatment programmes were mainly reported to be 
favourable and comparable to the levels achieved in industrialised countries
1, 364-368
. 
Large scale ART roll-out in Sub Saharan Africa was launched only 2002/2003, and 
absolute numbers of patients newly started on ARV are still increasing. Thus, the 
drawbacks of the ART rollout are also expected to become evident only with delay 
compared to industrialised countries, where HAART was introduced in 1996. However, 
data on the long term efficacy of ART in Sub Saharan Africa is scarce and initial 
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optimistic reports on the success rates of ART programmes are debatable considering 
short follow-up periods, high rates of loss to follow-up (LTFU) and deaths.  
In Ghana, around 3% of the population is HIV infected and since January 2004, highly-
subsidised antiretroviral therapy (ART) has become available through the Global Fund 
for Infectious Diseases and Family Health International, via the National AIDS Control 
Programme in Ghana. Whilst only around 3% of the population in Ghana is infected 
with HIV-1, a relatively large proportion (5-10%) is infected, either alone or in addition 
to HIV-1, with HIV-2. Kumasi is the second largest city in Ghana with a population of 
2 million. The Komfo Anokye Teaching Hospital (KATH) is the main university-
affiliated teaching hospital in Kumasi, which provides HIV care through the 
Department of Medicine, and over 11,000 patients have now been enrolled at KATH as 
at end of 2011, of which around 5,000 have started a predominantly NNRTI-based 
ART.  
This chapter introduces the patients who initiated cART as prelude to chapters 4 to 6 
within which the long-term effectiveness of NNRTI-based cART among Ghanaian 
HIV-infected patients have been evaluated. The aim of this chapter is therefore to 
describe the baseline characteristics of 4,039 HIV infected Ghanaians initiating anti-
retroviral therapy in a busy out-patient clinic in a tertiary referral hospital between 
January 2004 and 31
st
 December 2010. The focus is to highlight the demographic 
characteristics of HIV infected patients in this cohort, describe the burden of HIV 
associated disease prior to initiation of therapy, describe baseline risk factors associated 
with HIV-related kidney disease and HIV-associated hepatic injury. Baseline 
demographic, clinical and laboratory parameters are compared in patients initiating an 
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efavirenz, nevirapine or a protease inhibitor based anti-retroviral therapy. Data on sero-
prevalence of Hepatitis B co-infection are also provided and its impact on ART 
outcomes and risk for hepatoxicity on ART are analysed in subsequent chapters of this 
dissertation. To gain further insight into the vital status of patients lost-to-follow up, a 
telephone survey was conducted among a proportion of patients or their contacts. 
Finally, a preliminary analysis of baseline factors of patients initiating ART influencing 
the vital status at the time of censoring data for analysis are provided as an introduction 
for the subsequent chapters of this thesis. 
Methods 
Please refer to chapter 2 sections 2.3. 
Results 
Demographic characteristics of patients initiating ART in Kumasi, Ghana. 
Four thousand and thirty-nine (4,039) adult patients were initiated on anti-retroviral 
therapy between January 2004 and December 2010 in Kumasi, Ghana. There were 
1,287 male and 2,752 female patients with a preponderance of females with a female to 
male ratio of 2.1:1.0. Table 3.1 shows the age and gender distribution of study 
participants with an overall median (range) age of 38 (14 – 77) years. Male patients 
were significantly older than female patients initiating ART with a median (range) age 
of 41 (14 – 77) years versus 37 (14 – 76) years respectively, p<0.0001 by Mann-
Whitney, U-test. 
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Table 3.1. Age and gender distribution of HIV infected Ghanaians initiating ART 
in Kumasi, Ghana. 
Age range (years) Male 
n (%) 
Female 
n (%) 
Total 
n(%) 
≤ 20 
 
21 - 30 
 
31 – 40 
 
41 – 50 
 
51 – 60 
 
>60 
10 (0.8) 
 
94 (7.3) 
 
515 (40.0) 
 
484 (37.6) 
 
146 (11.3) 
 
38 (3.0) 
35 (1.3) 
 
617 (22.4) 
 
1,170 (42.5) 
 
628 (22.8) 
 
236 (8.6) 
 
66 (2.4) 
45 (1.1) 
 
711 (17.6) 
 
1,685 (41.7) 
 
1,112 (27.5) 
 
382 (9.5) 
 
104 (2.6) 
 
 
Sub-total 1,287 (100.0) 2,752 (100.0) 4,039 (100.0) 
 
Table 3.2 and Figure 3.1 shows the regional / geographical distribution of patients 
accessing care at the clinic situated in Kumasi, the regional capital of the Ashanti region 
of Ghana.  A significant proportion of patients were from the Ashanti region (93%), 
followed by the Brong-Ahafo, Central and Western regions respectively. Of the 3,768 
cases from the Ashanti region initiating therapy, 75% of cases were from the Kumasi 
metropolitan city with the remainder coming from major district capitals such as Obuasi 
(3%), Offinso (1%), Ejisu (1%) and so forth. 
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Table 3.2. Regional distribution of patients accessing ART in Kumasi, Ghana. 
Region Number of patients % of total 
Ashanti 3,768 93.3 
Brong-Ahafo 88 2.2 
Western 33 0.8 
Central 23 0.6 
Upper East 19 0.5 
Northern 9 0.2 
Eastern 5 0.1 
Upper West 4 0.1 
Greater Accra 1 0.0 
Volta 1 0.0 
No data 88 2.2 
 
 
Figure 3.1. The map of Ghana showing the 10 administrative regions with their regional 
capital cities/towns. Kumasi is the capital city of the Ashanti region where the HIV 
clinic is situated. 
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HIV associated morbidity before initiation of therapy. 
Two hundred and seventy-three (273) patients corresponding to 6.8% of the total 
number of patients were in clinical stage 1, 487(12.1%) were in clinical stage 2 while 
2,164 (53.6%) and 646 (16.0%) patients were in clinical stages 3 and 4 respectively 
prior to initiation of ART as shown in Table 3.3. Proportionally, there were no 
significant differences in gender with respect to severity of disease. Nearly 12% of 
patients had no data on their clinical stages prior to initiation of therapy. 
Table 3.3. WHO clinical staging of patients according to gender. 
WHO Clinical 
stage 
Male 
n (%) 
Female 
n (%) 
Total 
n (%) 
Chi-squared 
test, p-value 
1 
 
2 
 
3 
 
4 
 
No data 
75 (5.8) 
 
153 (11.9) 
 
687 (53.4) 
 
214 (16.6) 
 
158 (12.3) 
198 (7.2) 
 
334 (12.1) 
 
1,477 (53.7) 
 
432 (15.7) 
 
311 (11.3) 
273 (6.8) 
 
487 (12.1) 
 
2,164 (53.6) 
 
646 (16.0) 
 
469 (11.6) 
3.68, p=0.45 
Total 1,287 (100.0) 2,752 (100.0) 4,039 (100.0)  
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Table 3.4 summarises the morbidity of HIV associated opportunistic infections and 
malignancies before initiation of therapy. Only 678 patients corresponding to a 
frequency of 16.8 per 100 persons were asymptomatic before starting treatment. The 
commonest manifestation of HIV disease was significant weight loss, present at a 
frequency of 30.8 per 100 persons, followed by oro-oesophageal candidiasis at a 
combined frequency of 15.5 per 100 persons and then tuberculosis (including current, 
previous, pulmonary and extra-pulmonary) at a frequency of 11.5 per 100 persons. 
Muco-cutaneous manifestations of HIV infection occurred at a frequency of 12.7 per 
100 persons with a non-specific non-pruritic, hyperpigmented skin rash being the 
commonest cutaneous disorder followed by herpes zoster and pruritic papular 
dermatitis. Nervous system disorders were clinically detected and recorded at a 
frequency of 4.0 per 100 persons and included entities such as cerebral toxoplasmosis 
manifesting predominantly as either seizure disorder or motor weakness, AIDS 
dementia complex and CMV retinitis. 
The body mass index (BMI) of patients at initiation of cART followed a normal 
distribution. The mean ± SEM BMI of patients prior to initiation of cART was 20.3 ± 
0.07 with 35% of patients with BMI below the ideal body mass index of 18.5 kg/m
2
. 
The mean ± SEM BMI in males of 20.3 ± 0.08 kg/m
2
 was comparable to that in females 
of 20.2 ± 0.10 kg/m
2, p=0.7 by student’s unpaired t-test. 
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Table 3.4. Frequency of HIV associated opportunistic infections and malignancies 
among 4,039 Ghanaian HIV infected patients initiating cART. 
Conditions Number of 
patients 
Frequency 
/100 patients 
Asymptomatic 678 16.8 
Constitutional disorders   
           Weight loss>10% 1,245 30.8 
           Wasting syndrome 123 3.0 
           Prolonged fever 10 0.3 
           Progressive generalised lymphadenopathy 10 0.3 
          Others 12 0.3 
                                                               Sub-total 1,400 34.7 
Gastrointestinal disorders   
           Chronic diarrhoea 422 10.5 
           Oesophageal candidiasis 321 7.9 
           Oral candidiasis 307 7.6 
           Ano-rectal lesions 12 0.3 
           Others 24 0.6 
                                                              Sub-total 1,086 26.9 
Pulmonary disorders   
           Pulmonary tuberculosis on therapy 284 7.0 
           Chronic cough (cause unknown) 203 5.0 
           Pulmonary tuberculosis previously 145 3.6 
           Bacterial pneumonia previously 80 2.0 
           Extrapulmonary tuberculosis 36 0.9 
           Others 7 0.2 
                                                             Subtotal 755 18.7 
Muco-cutaneous disorders   
           Non-specific dermatosis 169 4.2 
           Herpes zoster 150 3.7 
           Pruritic popular eruptions 97 2.4 
           Kaposi sarcoma 57 1.4 
           Others 41 1.0 
                                                            Subtotal 514 12.7 
Nervous system disorders   
           Cerebral toxoplasmosis 55 1.4 
           AIDS Dementia Complex 29 0.7 
           CMV retinitis 25 0.6 
           Peripheral neuropathy 15 0.4 
           Others 36 0.9 
                                                            Subtotal 160 4.0 
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Medical co-morbidities present before initiation of cART included systemic arterial 
hypertension at a frequency of 2.0 per 100 persons, diabetes mellitus at 0.9 per 100 
persons, bronchial asthma, sickle cell disease and cardiac disorders such as rheumatic 
heart disease, ventricular septal defect and one patient on cardiac pacemaker on account 
of HIV associated cardiomyopathy as shown in Table 3.5. 
Table 3.5. Frequency of medical co-morbidities among 4,039 Ghanaian HIV-
infected patients initiating cART. 
Condition Number of cases Frequency/100 
patients 
Systemic arterial hypertension 79 2.0 
Diabetes mellitus 36 0.9 
Bronchial asthma 11 0.3 
Sickle Cell Anemia 5 0.1 
 
Laboratory characteristics of patients at initiation of cART 
Baseline CD4 counts of patients did not follow a normal distribution curve. The overall 
median (range) CD4 T-cell count before ART was 134 (0 – 1,134) cells/mm3 with 
median CD4 T-cell count in female patients significantly higher than that of males, 147 
(0 – 1,134) vs 108 (1 – 789) respectively, p<0.0001. As expected the median CD4 T-
cell count was significantly higher for patients with early clinical stages of HIV disease 
compared to those with later advanced disease: those with stage 1,2,3 and 4 disease had 
median (IQR) CD4 counts of 219.0 (143.0 – 296.0), 160.0 (80.0 – 226.0), 124.0 (47.0 – 
205.0) and 82.0 (20.0 – 180.0) cells/mm3 respectively with p<0.0001 by Kruskal Wallis 
test.  
The median (range) haemoglobin concentration before ART overall was 10.2 (2.6 – 
19.8 g/dl, n=3918). 75% of patients had various degrees of anaemia before ART – 34% 
had mild anaemia, 37% had moderate anaemia and 14% had severe anaemia - while 
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only 15% had no anaemia. The median (IQR) haemoglobin concentration in males of 
10.6 (9.0 – 12.2 g/dl) was significantly higher than that of female patients of 10.3 (9.3 – 
11.4 g/dl), p=0.02. 
HIV-related kidney disease: Baseline serum creatinine measurements were available for 
3,137 (77.7%) of patients of which eGFR could be calculated using the Cockroft Gault, 
MDRD and CKD-EPI formulae for 3,054 (97.4%), 3130 (99.8%) and 3130 (99.8%) 
patients respectively as shown in table 3.6. There was a very good agreement between 
stages of renal impairment assessed using eGFR calculated using MDRD and CKD-EPI 
with a -value (95% CI) of 0.94 (0.93 to 0.95) and a weighted -value of 0.96. The 
agreement between stages of renal impairment estimated using the Cockcroft-Gault and 
either the MDRD or CKD-EPI showed fair degrees of agreements with -values 0.23 
and 0.22 respectively and moderate agreements in linearly weighted kappa(Table3.6). 
   
Table 3.6. Frequency of stages of renal impairment estimated by creatinine clearance using Cockroft-Gault, MDRD and CKD-
EPI equations. 
Stage of renal 
impairment 
 Frequency 
(%) by 
Cockroft-
Gault 
 
Frequency 
(%) by MDRD 
Frequency 
(%) by CKD-
EPI 
 statistic, 
(95% CI), 
Weighted  
CG vs 
MDRD  
 statistic, 
(95% CI), 
Weighted  
CG vs CKD-
EPI 
 statistic 
(95% CI); 
Weighted  
CKD-EPI vs 
MDRD 
Stage 1 >90 ml/min 693   (22.7) 1636 (52.3) 1696 (54.2) 0.23  
(0.21-0.26);  
0.418 
0.22 
(0.20-0.25); 
0.410 
0.94  
(0.93 - 0.95); 
0.959 
Stage 2 60-89ml/min 1175 (38.5) 1065 (34.0) 1000 (31.9) 
Stage 3A 45-59ml/min 644    (21.1) 241    (7.7) 231    (7.4) 
Stage 3B 30-44ml/min 368    (12.0) 92       (2.9) 106    (3.4) 
Stage 4 15-29ml/min 130    (4.3) 62       (2.0) 61       (1.9) 
Stage 5 <15 ml/min 44       (1.4) 34       (1.1) 36       (1.2) 
Total  3,054 3,130 3,130 3,054 3,054 3,130 
 
CG is Cockroft-Gault; MDRD is Modified Diet for Renal Disease; CKD-EPI is Chronic Kidney Disease- Epidemiological Collaboration 
equations
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The frequencies (95% CI) of renal impairment determined by an eGFR of <60ml/min 
using the Cockroft-Gault, MDRD and CKD-EPI formulae were 38.8% (37.1% - 
40.5%), 13.7% (12.6% to 15.0%) and 13.9% (12.7% to 15.1%) respectively, while the 
frequencies of severe renal impairment with eGFR <30ml/min were 5.7% (4.9% to 
6.6%), 3.1% (2.5% to 3.7%) and 3.1% (2.6% to 3.8%) respectively. Given that none of 
these formulae has been validated for use in HIV-infected patients, results of analysis of 
the risk factors for HIV-related renal impairment were conducted using all 3 formulae 
and those for Cockroft-Gault and the CKD-EPI are shown. On adjusted analysis, the 
risk factors associated with an eGFR of <60ml/min calculated using the Cockroft Gault 
formula were increasing age - increased risk of 108% for each 10 years older, male 
gender - 51% lower risk compared with females, CD4 count at baseline - a 5% lower 
risk for each 50 cells increase in baseline CD4 count and advanced WHO clinical stages 
of HIV disease - 35% higher risk for each stage higher. However, using the CKD-EPI, 
only increasing age was significantly associated with the risk of developing HIV-related 
renal-impairment (Table 3.7).  
Severe renal impairment with eGFR <30ml/min calculated using Cockroft Gault was 
significantly associated with increasing age, low CD4 counts, advanced WHO clinical 
stages and having a diagnosis of systemic arterial hypertension at baseline. Using the 
CKD-EPI formula, the only factor associated significantly with severe renal impairment 
was a low CD4 count at baseline with marginal but non-significant associations 
between increasing age and WHO clinical stage (Table 3.8). 
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Table 3.7. Risk factors for estimated glomerular filtration rate <60ml/min. 
Variable eGFR by Cockroft-Gault formula eGFR by CKD-EPI 
 Unadjusted OR 
(95%CI) 
p-value Adjusted OR 
(95%CI) 
p-value Unadjusted OR 
(95%CI) 
p-value Adjusted OR 
(95%CI) 
p-value 
Age /10 year higher 1.93 
(1.77-2.11) 
0.0000 2.08 
(1.90-2.29) 
0.0000 1.60 
(1.44-1.79) 
0.0000 1.59 
(1.42-1.77) 
0.0000 
Male gender 0.68 
(0.58-0.81) 
0.0000 0.49 
(0.40-0.58) 
0.0000 0.90 
(0.71-1.14) 
0.39 - - 
CD4 /every 50 cells higher 0.97 
(0.93-1.00) 
0.07 0.95 
(0.91-0.99) 
0.016 0.98 
(0.93-1.03) 
0.48 - - 
WHO stage/ each stage higher 1.35 
(1.22-1.50) 
0.0000 1.35 
(1.20-1.51) 
0.0000 1.06 
(0.92-1.23) 
0.38 - - 
Hypertension 2.25 
(1.28-3.95) 
0.047 1.18 
(0.62-2.24) 
0.62 2.66 
(1.45-4.90) 
0.0017 1.32 
(0.65-2.68) 
0.44 
Diabetes mellitus 2.03 
(0.89-4.64) 
0.09 1.28 
(0.45-3.67) 
0.64 3.91 
(1.70-9.00) 
0.003 2.05 
(0.70-6.00) 
0.19 
Hypertension & Diabetes 
mellitus 
7.79 
(0.91-66.76) 
0.06 3.95 
(0.32-48.75) 
0.28 12.93 
(2.36-70.84) 
0.003 3.81 
(0.46-31.92) 
0.22 
 
155 
 158 
 
Table 3.8. Risk factors for estimated glomerular filtration rate of <30ml/min. 
Variable eGFR by Cockroft-Gault formula eGFR by CKD-EPI 
 Unadjusted OR 
(95%CI) 
p-value Adjusted OR 
(95%CI) 
p-value Unadjusted OR 
(95%CI) 
p-value Adjusted OR 
(95%CI) 
p-value 
Age /10 year higher 1.65 
(1.41-1.92) 
0.0000 1.62  
(1.38-1.90) 
0.0000 1.23 
(1.00-1.52) 
0.05 1.21  
(0.98-1.50) 
0.08 
Male gender 0.91 
(0.64-1.30) 
0.61 - - 1.00 
(0.64-1.59) 
0.99 - - 
CD4 /every 50 cells higher 0.89 
(0.82-0.97) 
0.008 0.91  
(0.83-0.99) 
0.03 0.87  
(0.78-0.98) 
0.02 0.89  
(0.78-1.00) 
0.05 
WHO stage/ 1 stage higher 1.61 
(1.27-2.04) 
0.0000 1.54 
(1.20-1.97) 
0.0006 1.41  
(1.04-1.90) 
0.03 1.32 
(0.97-1.81) 
0.08 
Hypertension 3.20 
(1.48-6.94) 
0.003 2.52 
(1.13-5.65) 
0.02 2.67 
(0.94-7.59) 
0.06 2.20 
(0.65-7.44) 
0.21 
Diabetes mellitus 1.59  
(0.37-6.84) 
0.53 - - 1.36 
(0.18-10.18) 
0.77 - - 
Hypertension & Diabetes 
mellitus 
- - - - 6.29 
(0.73-54.45) 
0.09 2.40 
(0.21-28.04) 
0.49 
 
   
HBV co-infection rates and hepatic transaminase concentrations in the cohort: 1,534 
(38.0%) patients had HBV serology results available, out of which 233 were sero-
positive giving an estimated prevalence of 15.2%. Baseline serum ALT and AST values 
were available for 3,702 (91.6%) and 3,745 (92.7%) patients respectively. The mean ± 
SEM concentrations of ALT and AST prior to initiation of therapy were 37.1 ± 0.60 
IU/L and 50.2 ± 0.68 IU/L respectively. Although the mean ± SEM serum ALT 
concentrations in male patients were significantly higher than in females, namely 39.3 ± 
1.06 IU/L vs 36.1 ± 0.73 IU/L, p=0.0135, their serum AST concentrations were not; 
49.7 ± 1.03 vs 50.6 ± 0.88, p=0.5. The mean ± SEM concentrations of AST and ALT in 
HBV HIV co-infected patients (n=223) were significantly higher than in HIV+HBV- 
(n=1,202) patients: 59.7 ± 3.81 U/L vs 48.5 ± 1.07 U/L, p=0.0002 for AST 
concentrations and 43.9 ± 2.60 U/L vs 37.0 ± 0.92 U/L, p= 0.0043 for ALT values 
respectively. Overall, 3,205 (86.6%) had no derangements in serum ALT, often taken as 
a specific marker of hepatocyte damage compared with AST which has several other 
sources aside hepatocytes, 404 (10.9%) had grade 1, 73(2.0%) had grade 2, 14 (0.4%) 
had grade 3 and 5 (0.1%) had grade 4 derangements in serum ALT concentrations. 
Baseline factors associated with the odds of an elevated ALT on univariate analysis 
were male gender, increasing WHO stage of HIV disease, decreasing CD4 count and 
increasing age but not HBV co-infection. On multivariate analysis, factors that 
remained significantly associated with the risk of an elevated baseline ALT were male 
sex (35% increased odds compared with females), increasing WHO clinical stage of 
HIV disease (17% increased odds for each unit rise in WHO stage with stage 1 as 
reference stage) while increasing baseline CD4 cell count was associated with a 
decreased odds of an elevated ALT (15% decreased odds for each 50 cells rise in CD4 
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count) as shown in Table 3.9. When a similar analysis was conducted to evaluate risk 
factors associated with severe liver disease corresponding to grades 3 and 4 
transaminitis, no significant associations were noted for the aforementioned risk factors 
(data not shown). 
Table 3.9. Baseline risk factors associated with elevated ALT levels in HIV infected 
Ghanaians by univariate and multivariate logistic regression models. 
Baseline characteristic Unadjusted OR 
(95% CI) 
p-value Adjusted OR 
(95% CI) 
p-value 
Sex (male vs female) 1.38 (1.13-1.68) 0.0013 1.35 (1.09-1.68) 0.0062 
WHO stage (per each stage 
rise) 
1.29 (1.13-1.48) 0.0003 1.17 (1.01-1.35) 0.0321 
CD4 T-cell count (per each 50 
cells increase) 
0.83 (0.79-0.88) 0.0000 0.85 (0.81-0.91) 0.0000 
Age (per 10 year increase) 0.90 (0.81-0.99) 0.0418 0.93 (0.83-1.03) 0.1671 
HBV co-infection (positive vs 
negative) 
1.28 (0.88 –1.87) 0.1899   
Overall model fit for 5 baseline predictors for elevated serum ALT in a multivariable 
model: Chi-square= 59.46, df=4, p=0.0000. 
 
Serum lipid profile of cohort: A limited number of patients had lipid profile assessed 
before initiation of cART. The median (IQR) concentrations of serum total cholesterol 
was 4.0 (3.2 – 4.8 mmol/l, n=688), serum low-density cholesterol (LDL-C) was 2.4 (1.7 
– 3.2 mmol/l, n=458), serum high-density cholesterol (HDL-C) was 1.0 (0.8 – 
1.4mmol/l, n=481) and serum triglyceride was 1.5 (1.1 – 2.1 mmol/l, n=722). 135 
(20%) had hypocholesterolaemia, 503 (73%) had normal serum cholesterol 
concentrations while 50 (7%) had hypercholesterolaemia. During the course of HIV 
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disease, a complex, dynamic and bi-directional interaction between progression of HIV 
disease and serum lipid profile has been reported with hypocholesterolemia 
characterising early stages of HIV disease and hypertriglyceridaemia associated with 
later stages
369 - 374
. An exploratory analysis was therefore performed to ascertain these 
observations in the present cohort. As noted above 135 out of 688 (20%) patients with 
available data had hypocholesterolaemia while 114 out of 722 (16%) had 
hypertriglyceridaemia. On univariate analysis, baseline factors significantly associated 
with hypocholesterolemia were WHO clinical stage, baseline CD4 T-cell count and 
BMI but not gender nor age. Furthermore on multivariate analyses, significant adjusted 
odds ratio (95% CI) for hypocholesterolemia were 1.69 (1.14 -2.51, p=0.009) for each 
increment in WHO clinical stage and 0.42 (0.28 – 0.64, p=0.0000) for each 5kg/m2 
increment in BMI. However when similar logistic regression analyses were performed 
to identify baseline risk factors for hypertriglyceridaemia, none of the variables - 
namely age, gender, WHO stage, CD4 count nor BMI - were significantly associated 
with hypertriglyceridaemia on univariate analysis. Thus in this cohort, risk of 
hypocholesterolaemia was strongly associated with progressive or late HIV disease and 
low body mass index. Additional analysis was carried out to identify factors associated 
with hypercholesterolaemia at baseline which was present in 7% of subjects. The only 
significant factor associated with risk for hypercholesterolemia identified on 
multivariable analysis was WHO clinical stage with an adjusted odds ratio (95% CI) of 
2.16 (1.22 – 3.82, p=0.008) per each stage higher. 
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Demographic, clinical and laboratory features of patients according to NNRTI/PI 
A descriptive comparison of baseline clinical and laboratory characteristics of patients 
according the either the NNRTI or PI base chosen to initiate cART is shown in Table 
3.10. Briefly, 2,376 (58.8%) patients were started on efavirenz (EFV) based cART 
compared with 1,623 (40.2%) on nevirapine (NVP) based cART while only 40 (1.0%) 
were initiated on protease inhibitor based cART. Of the 40 patients who started a PI-
based cART, due to HIV-2 mono- or HIV-1/2 dual infections, 23 were started on 
ritonavir-boosted lopinavir with the remaining 17 starting on nelfinavir. Two thousand 
one hundred and three (2,103) patients representing 52.1% of patients were started on 
an NRTI backbone of stavudine (d4T) and lamivudine (3TC) while 1,925 (47.7%) were 
initiated on zidovudine (AZT) plus lamivudine (3TC) with 11 (0.2%) patients 
commencing on other backbone NRTIs such as tenofovir (TDF) plus lamivudine (3TC)-
5 patients, didanosine (ddI) plus abacavir (ABC)-4 patients, abacavir plus lamivudine-1 
patient and didanosine plus stavudine-1 patient. 
Significantly more females than males were initiated on NVP-based cART compared 
with EFV-based cART while those initiating EFV-based cART were significantly older 
than those on NVP-based cART. There were no significant differences in the clinical 
stage of patients at initiation of therapy with respect to the NNRTI or PI used. The mean 
± SEM BMI (in kg/m
2
) of patients commencing therapy EFV-based cART was 20.1 
±0.09 vs 20.5 ± 0.10 for those on NVP-based cART and 21.0±0.62 for those initiating a 
PI-based cART, p=0.0025 (ANOVA). The median (range) CD4 T-cell counts in 
patients initiating EFV-based cART of 127.5 (1-1,085/mm
3
) was significantly lower 
than those of patients initiating NVP-based cART of 140.0 (0-676/mm
3
) vs 186.0 (1-
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1134) of those on PI-based cART, p=0.0006. No differences were observed in the 
median haemoglobin concentration between the 3 groups at baseline. However serum 
ALT and AST concentrations were significantly higher among patients initiating EFV-
based cART vs those on PI-based cART and NVP-based cART in descending order. 
Again, patients initiating EFV-based cART had a significantly lower median (IQR) 
estimated glomerular filtration rate of 64.0 (47.0-83.0ml/min/1.73m
2
) vs 66.5 (54.5 – 
89.5ml/min/1.73m
2
) for those on PI-based cART and 71.0 (54.0 – 89.0ml/min/1.73m2) 
for those on NVP-based cART, p<0.0001. Finally, there were no significant differences 
in the proportions of patients with HBV co-infection among the 3 groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Table 3.10. Baseline demographic, clinical and laboratory characteristics of patients 
initiating cART in Kumasi, Ghana. 
Characteristic Efavirenz 
n=2,376 
Nevirapine 
n=1,623 
Protease 
inhibitors 
n=40 
Total 
n= 4,039 
p-value 
Male : female 1,028: 1,348 248:1,375 11: 29 1,287: 2,752 <0.0001 
Median (range) age 40 
(14 – 77) 
35 
(15 – 75) 
36 
(25 – 65) 
38 
(14 – 77) 
<0.0001 
WHO clinical stage n 
(%) 
 0.09 
               1 165 (6.9) 106 (6.5) 2 (5.0) 273 (6.8) 
               2 258 (10.9) 225 (13.9) 6 (15.0) 489 (12.1) 
               3 1274 (53.6) 867 (53.4) 25 (62.5) 2166 (53.6) 
               4 407 (17.1) 238 (14.7) 10 (10.0) 649 (16.1) 
               No data 272 (11.4) 187 (11.5) 3 (7.5) 462 (11.4) 
Mean BMI ± SEM 20.1±0.09 20.5±0.10 21.0±0.62 20.3 ± 0.07 0.0025 
           <18.5 kg/m
2 
868 (36.5) 543 (33.5) 11 (27.5) 1422 (35.2) 0.0047 
          18.5 – 24.5 kg/m2 1145 (48.2) 804 (49.5) 20 (50.0) 1969 (48.8) 
          >24.5 kg/m
2 
291 (12.3) 246 (15.2) 6 (15.0) 543 (13.4) 
          No data 72 (3.0) 30 (1.8) 3 (7.5) 105 (2.6) 
Median (range) CD4 
count 
127.5 
(1 – 1085) 
140.0 
( 0 – 676) 
186.0 
( 1 – 1134) 
134 
(0 – 1134) 
0.0006 
           <200 cells/ml 1684 (70.9) 1080 (66.5) 21 (52.5) 2785 (69.0) <0.0001 
           200-350 cells/ml 611 (25.7) 495 (30.5) 12 (30.0) 1118 (27.7) 
           >350 cells/ml 53 (2.2) 41 (2.5) 7 (17.5) 101 (2.5) 
          No data 28 (1.2) 7 (0.5) 0 (0.0) 35 (0.9) 
Median (range) 
Haemoglobin conc. 
(g/dl) 
10.2 
(2.6 – 19.4) 
10.2 
(3.2 – 19.8) 
10.9 
(6.8 – 16.3) 
10.2 
(2.6 – 19.8) 
0.07 
Mean ± SEM ALT (U/L) 40.5 ± 0.87 32.0 ± 0.75 39.3 ± 6.64 37.1 ± 0.60 <0.0001 
Mean± SEM AST (U/L) 53.6 ± 0.93 45.2 ± 0.95 51.0 ± 11.6 50.2 ± 0.68 <0.0001 
Median (IQR) eGFR 
ml/min/1.73m
2 
, n 
64.0 
(47.0 –83.0) 
n=1791 
71.0 
(54.0 – 89.0) 
n=1240 
66.5 
(54.5 – 89.5) 
n=32 
66.0 
(50.0 -86.0) 
n=3063 
<0.0001 
       > 60ml/min 1028 (57.4) 849 (68.5) 21 (65.6) 1898 (62.0) <0.0001 
      30 – 59 ml/min 638 (35.6) 345 (27.8) 11 (34.4) 994   (32.5) 
      15 – 29 ml/min 92 (5.1) 35 (2.8) 0 (0.0) 127   (4.1) 
      <15ml/min 33 (1.8) 11 (0.9) 0 (0.0) 44    (1.4) 
HBV co-infection 
Positive/Negative (%) 
143/761 
18.8% 
87/527 
16.5% 
3/13 
23.1% 
233/1301 
17.9% 
>0.05 
NRTI backbone 
     AZT + 3TC 
     d4T + 3TC 
    Others 
 
1083 (45.6) 
1286 (54.1) 
7       (0.3) 
 
819 (50.5) 
804 (49.5) 
 
23 (57.5) 
13 (32.5) 
4   (10.0) 
 
1925 (47.7) 
2103 (52.1) 
11    (0.2) 
 
<0.0001 
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Follow-up and vital status of patients at time of closing data for analysis 
Ten thousand five hundred (10,500) patents with HIV infection enrolled at the clinic to 
receive care from January 2004 to 31
st 
December, 2010. It is notable that the number of 
cases enrolling for care dipped between 2009 and 2010 because the clinic stopped 
enrolment of new cases due to increasing numbers of patients who were overwhelming 
limited number of care givers in the clinic. Patients who enrolled in the year 2011 were 
excluded from the present analysis because I wanted to examine patients who had had 
opportunity to receive at least 12 months of ART. Data was closed for analysis on the 
31
st
 of December 2011. Four thousand and thirty-nine (4,039) patients representing 
38.8% of patients enrolled initiated cART, the yearly breakdown shown in Table 3.11. 
This figure may be an underestimation because some folders were missing and it is 
uncertain whether these missing folders were for patients who initiated cART or not. 
Although no further analysis was performed for the vast majority of patients who did 
not start cART (62% of registered patients) at the time of data analysis, most of these 
patients never returned back to the clinic after initial registration and were lost to follow 
up. 
The recommended CD4 cut-off for initiation of ART was 200 cells/mm
3
 between 2003 
to 2007 and this threshold was increased to 350 cells/mm
3
 from 2008 to date. 
Remarkably, there have been no corresponding differences in the median CD4 counts 
over the years of observation with the median yearly CD4 counts at initiation of ART 
ranging between the lowest of 124 cells/mm
3
 in 2007 to 149 cells/mm
3
 in 2010.
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Table 3.11. Enrolment, characteristics, follow-up and vital status of patients initiating cART according to year of enrolment.  
                   Year 
 
Characteristic 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
2009 
 
2010 
 
TOTAL 
 
p-value 
No. enrolled 
for ART 
1,700 2,020 1,819 1,782 1,738 636 705 10,400  
No. starting 
ART 
769 695 819 658 590 272 236 4039  
% starting ART 45.2 34.4 45.0 36.9 33.9 42.8 33.5 38.8  
WHO Clinical 
stage, n (%)
§
 
        <0.0001 
         1 52 (7%) 33 (5%) 43 (5%) 47 (7%) 53 (9%) 28 (10%) 16 (7%) 273 (7%) 
         2 109 (14%) 80 (12%) 113 (14%) 70 (11%) 63 (11%) 25 (9%) 29 (12%) 489 (12%) 
         3 460 (60%) 402 (58%) 420 (51%) 355 (54%) 280 (47%) 134 (49%) 115 (49%) 2166 (54%) 
         4 126 (16%) 121 (17%) 145 (18%) 98 (15%) 80 (14%) 38 (14%) 41 (17%) 649 (16%) 
         No data 22 (3%) 59 (8%) 98 (12%) 88 (13%) 114 (19%) 47 (16%) 35 (15%) 452 (11%) 
Median (IQR) 
CD4 count 
136 
(51 - 213) 
136 
(65 - 211) 
133 
(51 - 212) 
124 
(33 – 220) 
131 
(48 - 228) 
128 
(41-251) 
149 
(57 – 231) 
134 
(51 – 218) 
0.23 
Vital status          
<0.0001          Alive* 503(65%) 426(61%) 541(66%) 467(71%) 438(74%) 186(68%) 187(79%) 2748(68%) 
         Dead 35(5%) 40(6%) 50(6%) 104(16%) 63(11%) 14(5%) 18 (8%) 324(8%) 
         Lost 231(30%) 229(33%) 228(28%) 87 (13%) 89(15%) 72(27%) 31(13%) 967(24%) 
Person follow up 
years 
3565.1 2531.8 2158.7 1393.8 936.4 455.2 195.8 11236.8  
* And accessing the clinic, 
§
 % of patients initiating cART.
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There were 11,236.8 person years of follow-up on ART with 2,748 patients (68%) still 
alive, 967 (24%) lost to follow up and 324 (8%) deaths at the time of closing data for 
this analysis. The median (IQR) follow up time per patient overall was 30 (12 – 54) 
months with a range from 0 to 90 months. The median (IQR) time of follow up of 
patients still alive, lost to follow up and dead at time of censoring were 42 (24-60) 
months, 6 (2-18) months and 2 (2-6) months respectively, p<0.0001. Table 3.12 shows a 
summary of a comparison of baseline characteristics of patients according to their vital 
status at censoring. It is evident that there are significant differences in clinical stage, 
body weight or BMI, CD4 T-cell counts, haemoglobin concentration, serum alanine 
transaminase, aspartate transaminase, total cholesterol, triglyceride and estimated 
glomerular filtration rate between survivors, lost to follow up and cases that died. The 
only baseline characteristic that did not significantly differ between the three groups was 
the median age. Compared to patients who died, patients who survived had lower 
clinical stage of disease, had higher mean body weight (in kg), had higher body mass 
index, had higher baseline median (IQR) CD4 counts, had higher baseline haemoglobin 
concentration, higher estimated glomerular filtration rate and higher serum total 
cholesterol, but had lower serum triglyceride concentration as well as lower AST and 
ALT concentrations as shown in Table 3.12. 
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Table 3.12. Comparison of baseline characteristics according to vital status of 
patients at close of data for analysis. 
Characteristic Alive* 
n=2748 
Dead 
n=324 
Lost 
n=967 
Total 
n=4039 
p-value 
Male : female 788 : 1960 136 : 188 363 : 604 1287 : 2752 <0.0001 
Median (IQR) age 38 
(32 – 45) 
38 
(32 – 46) 
38 
(32 – 45) 
38 
(32 – 45) 
0.91 
Median (IQR) time of 
follow up in months 
42 
(24 – 60) 
2 
(2 – 6) 
6 
(2 – 18) 
30 
(12 – 54) 
<0.0001 
WHO stage     <0.0001 
              1 226 11 36 273 
              2 377 14 98 489 
              3 1425 178 563 2166 
              4 364 99 186 649 
             No data 356 22 84 462 
Mean ± SEM weight 
(kg) 
53.2 ± 0.22 47.1 ± 0.60 50.5 ± 0.36 52.1 ± 0.18 <0.0001 
Median (IQR) BMI 
(kg/m
2
) 
20.3 
(18.0 –23.1) 
17.6 
(15.6-20.0) 
18.8 
(16.9-21.8) 
19.8 
(17.5-22.7) 
<0.0001 
Median (IQR) CD4 
count 
151 
(68 – 229) 
58 
(13 – 146) 
105 
(34 – 193) 
134 
(51 - 218) 
<0.0001 
Median (IQR) 
haemoglobin g/dl 
10.4 
(9.0 – 11.6) 
9.4 
(7.9 – 10.8) 
9.7 
(8.4 – 11.2) 
10.2 
(8.8 – 11.5) 
<0.0001 
Mean ± SEM AST IU/l 48.8 ± 0.81 61.5 ± 3.22 50.8 ± 1.29 50.2 ± 0.68 <0.0001 
Mean ± SEM ALT IU/l 36.3 ± 0.71 47.6 ± 3.29 35.7 ± 1.00 37.1 ± 0.60 <0.0001 
Median (IQR) eGFR 
ml/min 
67.8 
(52.3-87.8) 
54.0 
(38.5-75.4) 
65.3 
(47.7-85.0) 
66.4 
(50.1-86.1) 
<0.0001 
Median (IQR) total 
cholesterol mmol/l 
4.1 
(3.3-4.9) 
3.3 
(2.6-4.6) 
3.6 
(3.0-4.5) 
4.0 
(3.2-4.8) 
<0.0001 
Median (IQR) serum 
triglycerides mmol/l 
1.4 
(1.1-2.0) 
1.7 
(1.2-2.3) 
1.6 
(1.2-2.3) 
1.5 
(1.1-2.1) 
0.022 
* And accessing the clinic 
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The high number of patients lost to follow up prompted a sub-study to evaluate the vital 
status of this category of patients. Given the wide geographic distribution of patients 
within the clinic, this survey was limited only to patients who gave telephone contacts. 
Two hundred and ten (210) patients out of 967 (22%) had telephone contacts for this 
survey. 51% of these contacts could not be reached by their telephone and therefore 
could not be analysed further. Overall, 39 (19%) of patients lost to follow up were still 
alive, the majority still on cART, 64 (30%) had died from AIDS related illnesses and 
107 (51%) could not be contacted and therefore their vital status could not be 
ascertained as shown in Table 3.13. 
   
Table 3.13. Vital status from a telephone survey of contacts of 210 patients lost to follow- 
up. 
Vital status Alive Dead “Lost” Total 
Year of 
registration 
2004 4 5 10 19 
2005 4 15 22 41 
2006 3 7 10 20 
2007 3 12 15 30 
2008 1 1 3 5 
2009 19 10 27 56 
2010 5 14 20 39 
Total 39 (19%) 64  (30%) 107 (51%) 210 
“Lost” refers to no response from contact. 
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Discussion 
Although antiretroviral therapy has significantly improved morbidity and mortality 
outcomes in Africa, it has become important to evaluate the long-term effectiveness of 
the recommended first line cART in routine use. Important lessons drawn from these 
evaluations hopefully will point us towards the direction of rational use of antiretroviral 
medications in a region which has severe constraints on resources but is the home of 
60% of the world’s population of those living with HIV1. It is well-known that baseline 
factors such as AIDS diagnosis, severe anaemia, low body mass index and reduced CD4 
counts are few amongst several other important determinants of both short-term and 
long-term outcomes of treatment in both developed and developing countries
375-381
. As a 
prelude to three subsequent chapters that examine rates of ART-related toxicity 
(Chapter 5) and clinical/immunological outcomes of ART (Chapters 4 and 6), this 
chapter focuses on a descriptive cross-sectional analysis of baseline characteristics of a 
cohort of HIV-infected patients who started ART in Kumasi, Ghana. 
Since its inception in 2004 to December 31
st
 2010, nearly 10,500 patients enrolled for 
HIV care of which only 4,039 (38%) patients were started on cART. Thus the 
significant majority of patients accessing ART care (62%) never started the journey and 
most of these patients were lost to follow up from their first visit (personal observations 
from inspecting their folders). This pre-treatment attrition rate recorded is very high 
compared with reported rates of between 14.0% to 32.1% from other ART programmes 
in Africa such as South Africa
382
, Malawi
383
, Uganda
384
 and the Gambia
385
. Although 
factors for this high pre-treatment attrition rate were not explored in this study, the 
commonly cited reasons for pre-treatment attrition are loss-to-follow ups and deaths, 
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with the latter strongly influenced by low CD4 counts and advanced clinical disease
386
. 
There is the need to explore the factors associated with pre-treatment attrition among 
HIV care seekers in the Ghanaian ART programme.  
The clinical and demographic characteristics of the patients who started cART were no 
different from those reported from similar other cohorts in Africa. Patients were young, 
median age of 38 years, with a preponderance of females and had advanced clinical 
disease- nearly 80% had WHO clinical stages 3 and 4 disease. The common AIDS 
defining conditions identified among patients initiating cART in our programme were 
severe weight loss, oro-oesophageal candidiasis and tuberculosis. The poor outcomes of 
starting cART among patients who were severely immunocompromised prompted a 
policy change in 2007 by the national programme in conformity with the WHO 
guidelines for the CD4 threshold at initiating cART to be lifted from below 200 
cells/mm
3
 to 350 cells/mm
3
. However as Table 3.11 shows, after 7 years of the 
programme in Ghana, the starting CD4 counts, proportions with severe HIV disease 
initiating therapy and pre-treatment attrition rates have not changed significantly. Also, 
more females initiated cART than male, which has also been observed in several 
cohorts across Africa. One likely reason is the expansion of HIV testing for pregnant 
women in antenatal care through PMTCT programs leading to identification of HIV 
among asymptomatic women
387, 388
. The weak health care infrastructure and the lack of 
integration of health pathways have been identified as the major hurdles to timely 
initiation of cART
389-391
. Thus there is the urgent need to refocus on a strengthened 
delivery system that will minimize delays in initiation of ART and help mitigate the 
clinical, social and economic barriers to accessing ART among eligible HIV infected 
patients. Clearly, measures to increase uptake of HIV testing in healthcare facilities and 
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in other settings such as in schools, workplaces, and in churches may increase early 
diagnosis of HIV to engender early initiation of therapy especially in men.  
Combination antiretroviral therapy used in initiating therapy in many programmatic 
settings comprises of a backbone of two thymidine nucleoside reverse transcriptase 
inhibitors namely zidovudine or stavudine plus lamivudine with one non-nucleoside 
reverse transcriptase inhibitor of either nevirapine or efavirenz. In our programme, a 
significantly higher proportion of patients started efavirenz- compared to nevirapine-
based cART and the likely reason for this is that nevirapine was contraindicated in 
many patients who were on anti-tuberculous medications when cART was initiated. 
This together with the fact that significantly more males were started on efavirenz 
compared with females could explain why the CD4 counts of patients initiating 
efavirenz-based cART was significantly lower than those starting nevirapine-based 
cART (Table 3.10). Whether these factors would affect the effectiveness of efavirenz 
compared with nevirapine is explored in chapter 6 of this dissertation. 
From the metabolic point of view, the integrity of the renal and liver functions are 
important determinants for the initial selection of cART as well as the predisposition to 
potential adverse events. Whereas NRTIs are metabolised and excreted principally by 
the kidneys, the NNRTIs are dependent on processing by hepatic metabolic pathways 
(reviewed under section 1.2.4.2). Thus consideration should be given to the incidence 
and risk factors of HIV-associated kidney disease and liver dysfunction in these 
settings. 
Using the Cockroft Gault formula to determine the eGFR, we found 38.8% of patients 
initiating therapy had renal dysfunction with an eGFR< 60ml/min. This is in agreement 
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with the prevalence of 38.0% among a Nigerian
392 
cohort but higher than 11.5%, 8.7%, 
7.0% and 4.9% among Kenyan
393
, Zambian
394
, Ugandan
395
, Zimbabwean
395
 and 
Burundian
396
 cohorts of naïve HIV-infected patients respectively. The risk factors 
identified among Ghanaian patients were female gender, increasing age, advanced stage 
of HIV disease and decreased body mass index. Among the Nigerian cohort
392
, patients 
with renal dysfunction defined by proteinuria as well as raised serum creatinine were 
more likely to be older, have a lower BMI and lower CD4 counts, findings which are 
comparable with those from the present study. Various authors have shown that high 
viral load and low CD4+ T-cell lymphocyte counts
397-402
 are pathogenically associated 
with an increased risk of developing an HIV-related CKD, reflecting the increased 
incidence of CKD in individuals with poorly controlled HIV. These observations 
underline the fact that renal impairment is an indicator of progressive HIV disease, 
hence routine screening of all patients enrolled in cART programmes across SSA 
should be encouraged and treatment initiated among those with renal impairment. 
Although diabetes mellitus and hypertension are known to be associated with renal 
impairment, patients with these co-morbidities were included in analysis to determine 
the association between these 2 common causes of renal insufficiency in a cohort 
known to have HIV-infection and as shown in Table 3.8, hypertension was associated 
with the higher risk of severe renal insufficiency. 
There is a wide spectra of HIV-related kidney diseases of which the commonest 
histological entity is called HIV-associated nephropathy which is commoner with 
advanced HIV disease and has an increased predilection for African American 
patients
402 - 404
. Among African Americans, genetic studies have recently identified a 
higher frequency of recessive polymorphisms in the MYH9 gene and the neighbouring 
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APOL1 gene both located on chromosome 22q13 locus which predisposes to an 
increased risk for HIV-1-associated nephropathy and idiopathic focal segmental 
glomerulosclerosis
405 - 408
.  
A limitation of using creatinine assessments without analysis of proteinuria is that there 
is a tendency to underestimate the prevalence of chronic renal failure and tubular 
dysfunction which may not be detected by creatinine measurements. Although none of 
the 3 formulae used to calculate eGFR have been validated for HIV-infected patients, 
the National Kidney Foundation guidelines generally recommends creatinine-based 
GFR estimation and is preferred to serum creatinine alone, which is accepted to have a 
lower sensitivity for detecting renal impairment
409, 410
. Among these three equations 
used to determine eGFR, both the MDRD and CKD-EPI were shown in a large 
Ghanaian predominantly Ashanti adult population to over-estimate the creatinine 
clearance by 18.2 and 19.0 ml/min/1.73 m
2
 respectively whereas the mean GFR 
estimated using the Cockroft-Gault equation was 9.4 ml/min/1.73 m
2 
lower
411
. The 
findings from the Ghanaian study
411
 which was conducted in the same geographical 
location where most of patients in this cohort resided, suggest that in lean African 
populations, eGFR determined by Cockroft and Gault formula may be closer to 
creatinine clearance since it takes into account the body weight of the subject while the 
MDRD and CKD-EPI does not. Hence in HIV-infected patients with advanced disease 
evidenced by low body mass indices, the Cockroft-Gault equation may approximate the 
creatinine clearance more closely. Certainly further studies are needed to examine 
which of these formulae estimates GFRs more closely, as well as longitudinal studies of 
changes in GFR on antiretroviral therapy and the impact of renal dysfunction on risk for 
mortality.  
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A hepatitis B virus co-infection rate of 15.2% was found among 38% of the cohort who 
had  HBV serology performed. Data in agreement with ours from other West African 
countries have reported co-infection rates of 12% to 17% (Senegal
412
, Burkina Faso
413
, 
Nigeria
 414
 and Ivory Coast
 415
) and 2% to 20% in East and South Africa (Kenya
 416
, 
Uganda
417
 Rwanda
417
, Malawi
418
 and South Africa
419
). The routine testing of HBV 
among HIV patients is important for three principal reasons. First, HIV infection is 
well-known to have a promoting effect on HBV replication and progression of hepatic 
damage
420-423
. Second, in settings where first line therapy usually uses lamivudine in 
combination with either zidovudine or stavudine and nevirapine or efavirenz, patients 
with HBV/HIV co-infection are essentially on lamivudine monotherapy (instead of the 
preferred dual therapy) for HBV with the attendant increased risk of HBV drug 
resistance and progression of liver disease
424
. Until recently tenofovir was often 
reserved for use after failure of the initial regimen. However, in our setting tenofovir is 
the only other antiretroviral with activity against HBV which could be used in 
combination with lamivudine as part of the preferred first line therapy for patients with 
HBV co-infection. Third, there is a known significantly increased risk of hepatotoxicity 
in HBV co-infected patients who initiate NNRTIs with risk particularly pronounced 
with the use of nevirapine. Although a clear association was not demonstrated between 
baseline concentrations of liver enzymes and hepatitis B sero-positivity, it has been 
clearly demonstrated that levels of liver enzymes are not very sensitive predictors of 
extent of hepatic damage in chronic HBV infections. In Chapter 5, further analysis is 
presented on the impact of HBV co-infection and the risk for hepatotoxicity on cART in 
this cohort.  
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This cohort, that has been established in Kumasi for this present analysis and for future 
prospective studies, is reasonably large with long follow-up periods for most patients, 
median follow up of 30 months (range of 0 to 7 years) and has 11,236.8 person years of 
follow-up treatment experience on ART in a programmatic setting at censoring. At the 
close of 31
st
 December 2011, 2,748 patients (68%) were still alive and accessing the 
clinic, 967 (24%) were lost to follow up and 324 (8%) had died. In a systematic review 
by Rosen and colleagues, retention in ART programmes in SSA ranged between 39.2% 
to 90.3% over a follow-up period of 6 to 46 months in 33 patient cohorts from 13 
countries
425
. The risk factors and predictors of deaths and loss-to-follow up are further 
examined in Chapter 4. However, it suffices to say at this point that a majority of those 
lost from the programme may have died. In similar cohorts, it has been shown that 
significant majority of patients lost to follow up in the first year of initiating cART had 
died. In support of this, the telephone survey from the present study showed that about 
half of 210 patients were contactable, of which over 60% had died. This provides some 
basis for the speculation that most patients who are lost-to-follow up from ART 
programmes may have died.  
In conclusion, there is a high frequency of cART pre-treatment attrition among HIV-
infected patients accessing cART in a busy HIV clinic in Kumasi. Those initiating 
cART are profoundly immunosuppressed and have advanced clinical stages of HIV 
infection with a high frequency of renal impairment. A higher proportion of patients 
commenced a predominantly NNRTI-based cART of either efavirenz or nevirapine on a 
dual backbone of either stavudine plus lamivudine or zidovudine plus lamivudine. 
Attrition from the programme were comparable to those from other ART programmes 
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across SSA and factors influencing attrition and long-term responses are evaluated in 
the next chapter.  
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CHAPTER FOUR 
4.0 The long-term immunological and clinical effectiveness of combination 
antiretroviral therapy among Ghanaian HIV-infected patients. 
4.1 Introduction 
Combination anti-retroviral therapy (cART) for the long-term management of HIV 
infection is administered to people living with HIV/AIDS primarily to achieve long-
term suppression of virological replication and to maintain CD4 cell counts at a level 
that reduces the risk of morbidity and mortality. Indeed there are many cohort studies in 
both the developing and the developed countries that have compared the short- to 
medium-term effectiveness of different cART regimens. It is encouraging that the 
effectiveness of cART in developing countries in Sub-Saharan Africa has been reported 
to be similar, and often superior in clinical and immunologic outcomes when compared 
with those from the developed countries
426-433
. Whether these initial favourable 
immunological and clinical responses are sustained over the long-term remains to be 
determined. 
Deaths in the era of cART has largely been due to AIDS-defining clinical events in 
many such reports from developing countries but the dynamics of mortality is believed 
to be changing in the industrialised countries with Non-AIDS defining clinical events 
assuming importance as causes of death as patients live longer on these potent 
antiretroviral medications
434-436
. Non-AIDS defining events are classified as 
cardiovascular, renal, hepatic-related or non-AIDS-defining malignancies that are likely 
to have an impact on morbidity and mortality
437
. One report from Botswana intimated 
that the age-standardised incidence rates of Non-AIDS defining events were comparable 
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to those in the United States
438
. However, the spectra of disease entities included in this 
definition is debated
436
 and does not capture infectious disorders such as malaria which 
is a common cause of morbidity among patients in Sub-Saharan Africa. In the present 
analysis, the frequencies and incidence rates of NADEs were classified using 
established Division of AIDS (DAIDS) tables for Grading Severity of Adult Adverse 
Experiences (NADEs)
358, 359
. The incidence rates of infectious diseases and other 
medical co-morbidities that cause significant morbidity but which does not meet the 
criteria of AIDS-defining are presented as ‘medical co-morbidity on cART’ separately 
from the conventional NADEs. 
Attrition from ART programmes are withdrawals from programmes due either to 
deaths, loss to follow ups or transfer to another treatment site. Given that death is such 
an important treatment outcome measure, an analysis was performed to determine the 
risk factors and the causes for those in whom it was known. Furthermore due to the high 
prevalence of renal impairment at baseline among this cohort, an analysis was 
performed to determine whether renal impairment was independently associated with 
death. However any analysis of death as an outcome measure of cART is complicated 
by loss-to-follow up. To address this issue of loss-to-follow up, a survey was conducted 
and has been reported in chapter 3 among contacts of a sub-group of patients lost-to-
follow up which suggested that most of these patients might have died. Furthermore, 
analysis of baseline predictors of loss-to-follow up was conducted to determine whether 
they were similar to among patients known to have died. This chapter presents an 
analytical overview of the major immunological and clinical outcomes on long-term 
cART among this cohort of over 4,000 Ghanaian HIV patients initiating cART within 
2004 to 2010. The aims of this chapter are to describe the trends in CD4 and body mass 
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index changes on cART as well as the risk factors and incidence rates for AIDS, non-
AIDS clinical events, adherence, mortality and loss to follow up.  
4.2 METHODS 
Refer to chapter 2 section 4. 
 
4.3 RESULTS 
Baseline demographics and laboratory characteristics of study participants 
Baseline demographic and laboratory characteristics of the study participants are 
described in chapter 3. 
Changes in CD4 counts with cART 
The median (IQR) CD4 count at baseline of 133 (50 – 218) increased to 314 (204 – 
429) within 6 months of initiation of ART, p<0.0001. This initial increment was 
sustained at 12 months with a median (IQR) CD4 at 12 months of 355 (244 – 487), with 
further increases during follow up to month 90 for patients who remained on cART and 
were accessing the clinic as shown in Figure 4.1.  
Immune reconstitution inflammatory disorders: The restitution of the CD4 T-cell 
counts on cART may be accompanied by the occurrence of the well-known Immune 
reconstitution inflammatory response syndrome. In this cohort, there were 45 
documented cases of IRIS with an overall incidence rate of 4.00 (2.92-5.36) 
events/1000 person years under follow up. Tuberculosis-associated IRIS was the 
commonest and manifested clinically as new pulmonary infiltrations (n=16), 
lymphadenitis (n=2) and pleural effusions (n=2) over a median of 2 months (range of 2 
to 12 months). Others included herpes zoster (n=13) and cerebral toxoplasmosis (n=9) 
as shown in Table 4.1. The median age of patients experiencing IRIS was 38 years, 33 
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(73%) were females and the median CD4+ T-cell counts at initiation of cART was 73 
(range, 2 to 314 cells/mm
3
). Combinations of antiretrovirals initiated by these patients 
who subsequently developed IRIS comprised of a backbone of AZT plus 3TC (n=20) 
and D4T plus 3TC (n=25) on an NNRTI-base of either nevirapine (n=22) or efavirenz 
(n=23). At the close of data for analysis, 27 (60%) patients who developed IRIS were 
alive, 6 (13%) patients died and 12 (27%) were lost-to-follow up.  
 
   
 
 
Figure 4.1. Changes in CD4 T-cell counts on cART. Each full square box represents the median, horizontal lines represent the 
Interquartile range and double asterixes indicate statistically significant difference obtained by pair-wise comparison of median with 
month 0 using the Mann-Whitney’s U-test with p<0.0001 representing a statistically significant difference.
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Table 4.1. Frequencies and rates of specific immune reconstitution inflammatory 
disorders among Ghanaian HIV-infected patients on cART. 
Condition Frequency Rate/1000 person years 
follow up (95% CI) 
Tuberculosis-pulmonary 16 1.42 (0.81 – 2.31) 
Herpes zoster 13 1.16 (0.62 – 1.98) 
Cerebral toxoplasmosis 9 0.80 (0.37 - 1.52) 
CMV retinitis 2 0.18 (0.02 – 0.64) 
Tuberculous lymphadenitis 2 0.18 (0.02 – 0.64) 
Tuberculous pleural effusion 2 0.18 (0.02 – 0.64) 
Cryptococcal meningitis 1 0.09 (0.00 – 0.50) 
Total 45 4.00 (2.92 – 5.36) 
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Incidence and risk factors for immunological failure: Although robust CD4 T-cell 
recovery was noted among most patients on cART over the long-term, CD4 counts for 
others failed to increase above 100 cells/mm
3
 after one year of cART or declined by 
more than 50% of its peak value thus fulfilling the WHO criteria for immunological 
failure. There were 407 immunological failures over the 11,236.8 person years of follow 
up giving a crude event rate of 3.62 (3.28-3.99) per 100 person years. The median 
(range) time to occurrence of immunological failure on first line ART was 24 (12 – 78 
months). Factors significantly associated with the risk of immunological failure on 
multivariable Cox proportional hazards analysis were male sex with an adjusted HR of 
1.85 (95% CI of 1.47-2.33, p<0.0001), initiating cART below 40 years of age with an 
adjusted 1.25(1.01-1.55), p<0.04 and baseline CD4 strata below 200 cells/mm
3
 with an 
adjusted HR of 3.62 (95% CI of 2.59-5.07, p<0.0001). Of note neither the NRTI 
backbone nor the NNRTI used to initiate cART was significantly associated with the 
risk for immunological failure as shown in Table 4.2.
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Table 4.2. Univariate and multivariate analysis of factors associated with risk of developing immunological failure on first line 
ART. 
Variable Patient follow-
up time (years) 
Number of 
events 
Crude event rate 
(/100 person 
years) 
Univariate 
hazard ratio 
(95% CI) 
p-value Adjusted hazard 
ratio (95% CI) 
p-value 
Sex        
       Male 3467.2 167 4.82 (4.11-5.60) 1.64(1.34-1.99) <0.0001 1.85(1.47-2.33) <0.0001 
      Female 7769.6 240 3.09 (2.71-3.51) 1.00  1.00  
Age        
     <40 years 6082.0 234 3.85 (3.37-4.37) 1.21 (3.37-4.37) 0.055 1.25(1.01-1.55) 0.04 
      40 years 5161.3 169 3.27 (2.80-3.81) 1.00  1.00  
WHO stage        
    3 or 4 7803.0 295 3.78(3.36-4.24) 1.19 (0.92-1.55) 0.18 - - 
    1 or 2 2370.3 72 3.04(2.38-3.83) 1.00    
Baseline CD4 
strata 
       
   <200 7706.4 359 4.66 (4.19-5.17) 1.16(1.08-1.24) <0.0001 3.62(2.59-5.07) <0.0001 
   >200 3461.8 45 1.30 (0.95-1.74) 1.00  1.00  
NRTI backbone        
   D4T plus 3TC 5276.4 192 3.64 (3.14-4.19) 0.95 (0.78-1.15) 0.59 - - 
   AZT plus 3TC 5939.8 214 3.60 (3.13-4.12) 1.00    
NNRTI        
   Efavirenz 6119.9 216 3.53(3.07-4.03) 0.92 (0.75-1.12) 0.39 - - 
   Nevirapine 5012.5 187 3.73(3.22-4.31) 1.00    
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Clinical events of cART 
Changes in BMI on cART: The median (IQR) body mass index at baseline was 19.8 (17.5 – 
22.7 kg/m
2
) and increased significantly on ART to 20.7 (18.3 – 23.5 kg/m2) p<0.0001 at 
month 2 with further increase at 12 months to 23.2 (20.8 – 26.2 kg/m2), plateauing between 
months 36 through 60 to month 90 at 23.5 (20.9 – 26.7kg/m2) at 36 months, 23.8 (20.9 – 27.5 
kg/m
2
) at 60 months and 24.2 (20.7 – 28.5 kg/m2) at 90 months with p<0.0001 at all time 
points compared with baseline as shown in Figure 4.2. 
Non-AIDS defining clinical events: There were 41 Non-AIDS defining events fulfilling the 
criteria of the DAIDS definition of NADEs with the commonest recorded events being 
hepatic disorders (n=20), cardiovascular events (n=10), new onset severe renal impairment 
with eGFR below 30ml/min (n=6) and hepatocellular carcinoma (n=4) and oesophageal 
carcinoma (n=1) were the only non-AIDS defining malignancies recorded as shown in Table 
4.3. The overall crude NADEs incidence rate (95% CI) was 3.65 (2.62 - 4.95) per 1000 
person years. 
Medical co-morbidity on cART: By far, the largest majority of morbidity was of infectious 
causes of which 2,377 events were documented and presented in Table 4.4 with malaria 
being the commonest event. This is followed by upper and lower respiratory tract infections 
(n=666) such as community-acquired pneumonia (n=274), a range of dermatological 
infections (n=364) such as furunculosis (n=116), herpes zoster (n=56) and tinea corporis 
(n=26) and then various gastroenteritides and urinary tract infections. Included in the 
category of miscellaneous events were dyspeptic disorders such as gastro-oesophageal reflux 
disease and duodenal ulcers; others include post-herpetic neuralgia and previously 
undiagnosed seizure disorders on cART with no intracranial masses on CT scan of the brain. 
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Of the non-infectious medical comorbidities recorded, ninety-four (94) and 9 patients 
developed systemic arterial hypertension and type 2 diabetes mellitus respectively while on 
cART. 
   
 
 
Figure 4.2.  Changes in body mass index of patients on cART over time. Each closed box represents the median, horizontal lines 
represent the Interquartile range and ** shows median BMI compared with baseline shows significant statistical difference of <0.0001.
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Table 4.3 Number and rates of  Non-AIDS defining events on first line ART among 
Ghanaians. 
Condition Number of 
events 
Rate/1000 person years 
follow up (95% CI) 
Hepatic disorders   
            Chronic liver disease 13 1.16 (0.62 – 1.98) 
            Hepatitis B viral infection flares 7 0.62 (0.25 – 1.28) 
Cardiovascular events   
               Stroke 8 0.71 (0.31 – 1.40) 
               Congestive cardiac failure 2 0.18 (0.02 – 0.64) 
Renal disorders   
           Stage 4 or 5 renal impairment 6 0.53 (0.19-1.16) 
Non-AIDS malignancies   
            Hepatocellular carcinoma 4 0.36 (0.10 – 0.91) 
             Oesophageal carcinoma 1 0.09 (0.00 – 0.05) 
Total 41 3.64 (2.61 – 4.95) 
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Table 4.4. Frequencies and rates of other medical morbidity on cART among 
Ghanaians 
 
Condition Number of 
events 
Rate/1000 person years 
follow up (95% CI) 
Non-AIDS defining infectious disorders   
   Malaria 746 66.39 (61.71 – 71.32) 
   Upper and lower respiratory infections 666 59.27 (54.85 – 63.95) 
   Dermatological infections 364 32.39 (29.15-35.90) 
   Gastroenteritis 314 27.94 (24.94-31.21) 
   Urinary infections 151 13.43 (11.38-15.76) 
   Ear nose and throat infections 102 9.08 (7.40 - 11.02) 
   Sepsis 29 2.58 (1.73 – 3.71) 
   Bacterial meningitis 5  
Miscellaneous disorders   
   Dyspeptic disorders 73 6.50 (5.09 – 8.17) 
   Post-herpetic neuralgia 52 4.63 (3.46 – 6.07) 
   Seizure disorders 24 2.14 (1.37 – 3.18) 
   Paraparesis (unknown cause) 10 0.88 (0.43 – 1.64) 
   Hemiparesis (unknown cause) 9 0.80 (0.37 – 1.52) 
   Monoparesis (unknown cause) 6 0.53 (0.19 – 1.16) 
   Proximal myopathy 3 0.27 (0.06 – 0.78) 
Cardiovascular risk co-morbidity   
  Systemic arterial hypertension 94 8.36 (6.76 – 10.24) 
  Diabetes mellitus 9 0.80 (0.37 – 1.52) 
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The causes and factors associated with incidence of AIDS-defining conditions on 
ART 
Six hundred (600) patients experienced a reported number of 681 AIDS-defining events 
during follow up on ART with a crude (95% CI) event rate of 60.60 (56.14 – 65.33) per 
1000 person years of follow up. 531 (88.5%) patients had 1 AIDS-defining event, 59 
(9.8%) had 2 events, 8 (1.3%) had 3 events, 1 (0.2%) had 4 events and 1 (0.2%) had 5 
events under follow up. The median (range) time to development of first AIDS-defining 
event was 6 (2-90 months). The frequencies of 19 AIDS-defining conditions recorded 
during follow-up on ART are presented in Table 4.5. The leading five AIDS-defining 
events that occurred while on ART were pulmonary tuberculosis, chronic diarrhoea, 
oesophageal candidiasis, recurrent pneumonias and oral candidiasis at rates (95% CI) of 
15.93 (13.68 – 18.44), 13.79 (11.71 – 16.14), 6.67 (5.25 – 8.36), 5.16 (3.92 – 6.67) and 
4.00 (2.92 – 5.36) per 1000 person-years respectively of follow-up on cART. Nine 
patients were documented to have had computed tomographic evidence of an 
intracranial space occupying lesions while on cART, but clinicians did not document 
the etiology of these mass lesions but for the purposes of the present study, they 
adjudged to be AIDS-defining events. 
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Table 4.5. The frequencies and rates of various AIDS-defining conditions among 
Ghanaian HIV-infected patients on first line cART. 
Condition Frequency Rate/1000 person years 
follow up (95% CI) 
Pulmonary tuberculosis 179 15.93 (13.68 – 18.44) 
Chronic diarrhoea 155 13.79 (11.71 – 16.14) 
Oesophageal candidiasis 75   6.67 (5.25 – 8.36) 
Recurrent pneumonia 58   5.16 (3.92 – 6.67) 
Oral candidiasis 45   4.00 (2.92 – 5.36) 
Cerebral toxoplasmosis 38   3.38 (2.39 – 4.64) 
Extrapulmonary tuberculosis 33   2.94 (2.02 – 4.12) 
Kaposi sarcoma 31   2.76 (1.87 – 3.92) 
CMV retinitis 17   1.51 (0.88 – 2.42) 
HIV encephalopathy 16   1.42 (0.81 – 2.31) 
Cryptococcal meningitis 12   1.07 (0.55 - 1.87) 
Intracranial space occupying lesion* 9   0.80 (0.37 – 1.52) 
Non-Hodgkin’s disease 5   0.44 (0.14 – 1.04) 
HIV wasting syndrome 3   0.27 (0.05 – 0.78) 
Pneumocystis jirovercii pneumonia 2   0.18 (0.02 – 0.64) 
CNS lymphoma 1   0.09 (0.00 – 0.50) 
Herpes oesophagitis 1   0.09 (0.00 – 0.50) 
Invasive cervical carcinoma 1   0.09 (0.00 – 0.50) 
Total 681  60.60 (56.14 – 65.33) 
AIDS defining events were defined using WHO clinical criteria. * Causes of Intracranial space occupying 
lesion on CT scan were not documented but were presumed to be AIDS-defining events. 
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Table 4.6 shows results of univariate and multivariate analyses of predictive factors 
associated with risk of developing an AIDS defining illness after initiating cART. In 
this analysis, the outcome of interest was time to development of an AIDS defining 
event. Patients who were alive at the end of the study censoring or closing time set at 
31
st
 December, 2011 or were lost-to-follow up before this date without an AIDS-
defining event were right-censored. Factors significantly associated with the risk of 
developing an AIDS-defining event on cART on adjusted analyses were low body mass 
index below 16kg/m
2
, WHO clinical stages 3 or 4 at baseline and CD4 strata below 200 
cells/mm
3
 at initiation of therapy. Initiating a D4T plus 3TC backbone was marginally 
associated with an increased risk of developing an AIDS- defining event, adjusted HR 
of 1.08 (0.90-1.30), p=0.09. 
Of the 600 patients who developed various AIDS-defining events on cART, 317 
(52.8%) were alive as at time of closure of data but 153 (25.5%) were subsequently lost-
to-follow-up and 130 (21.7%) subsequently died. The median (range, IQR) duration 
between the first AIDS-defining diagnosis and death was 0.25 months (0 to 72, 0 to 2 
months respectively) and that for loss-to-follow up was 4 months (0 to 76, 0 to 12 
months respectively). Patients who developed AIDS-defining event and were alive at 
the time of closure of data for analysis survived for a median of 34 months (range of 0 
to 88 months, IQR of 18 to 52 months). 
192 
   
Table 4.6. Univariate and multivariate analysis of factors associated with risk of developing AIDS on cART. 
Variable Person follow-
up time (yrs) 
Number of 
events 
Crude event rate 
(/1000 py), 95% CI 
Unadjusted HR 
(95% CI) 
p-value Adjusted HR 
(95% CI) 
p-value 
Sex        
  Male 3467 193 55.67 (48.09 - 64.10) 1.06(0.89-1.25) 0.53 - - 
  Female 7770 406 52.25 (47.29 - 57.59) 1.00    
Age        
   40 years 5161 268 51.93 (45.90 - 58.53) 1.00 (0.94-1.07) 0.90 - - 
  <40 years 6082 331 54.42 (48.72 - 60.61) 1.00    
WHO stage        
  3 or 4 7803 477 61.13 (55.77 –66.87) 1.73(1.37-2.18) <0.0001 1.45(1.13-1.86) 0.0031 
  1 or 2 2370 84 35.44 (28.27 -43.88) 1.00  1.00  
Baseline CD4 strata        
  <200 7706 481 62.42 (56.96 -68.25) 2.00(1.64-2.45) <0.0001 1.87(1.49-2.35) <0.0001 
  >200 3462 117 33.80 (27.95 -40.50) 1.00  1.00  
Baseline BMI        
  <16 kg/m
2 
901 99 109.9 (89.3 -133.8) 1.91(1.54-2.38) <0.0001 1.53(1.20-1.94) 0.0005 
  16 kg/m2 9189 483 52.56 (47.98 - 57.47) 1.00  1.00  
Baseline Hb        
  <8g/dl 1176 87 73.98 (59.25 - 91.25) 0.92 (0.83-1.01) 0.06 1.01(0.78-1.31) 0.94 
  8g/dl 8590 494 57.51 (52.55 - 62.81) 1.00  1.00  
NRTI backbone        
  D4T plus 3TC 5276 322 61.03 (54.55 –68.07) 1.18(1.01-1.39) 0.04 1.08 (0.90-1.30) 0.09 
  AZT plus 3TC 5940 274 46.13 (40.83 -51.93) 1.00  1.00  
NNRTI        
  Efavirenz 6120 330 53.92 (48.26-60.06) 0.92(0.78-1.08) 0.29 - - 
  Nevirapine 5013 261 52.06 (45.94 -58.78) 1.00    
Adherence        
  Poor 3835 237 61.80 (54.18 -70.18) 1.17(0.99-1.38) 0.06 1.06(0.89-1.27) 0.51 
  Excellent 6345 363 57.21 (51.48 –63.41) 1.00  1.00  
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Factors associated with loss to follow up 
Nine hundred and fifty-eight (958) patients were lost to follow up (24.0%). Of the 967 
patients identified as lost, 131 (13.7%) never returned for further visits after the first 
clinic visit when ART was dispensed. The Kaplan Meier estimated cumulative 
incidence of loss-to-follow up at 6, 12, 36 and 72 months were 12.7%, 15.5%, 22.6% 
and 29.6% respectively. 
Factors associated with loss to follow up are shown in Table 4.7. Risk factors 
significantly associated with loss to follow up in univariate analysis were male gender, 
advanced clinical disease, starting CD4 count lower than 200, severe anaemia with 
Hb<8.0g/dl at baseline, low BMI of less than 16kg/m
2
, initiating backbone NRTI of 
D4T plus 3TC backbone, use of efavirenz (HR of 1.20, 95%CI: 1.05 – 1.36). Patient age 
and residence outside Kumasi (where the HIV clinic is situated) were not significantly 
associated with risk of loss to follow up. In the adjusted Cox regression analysis, risk of 
loss to follow up remained significantly associated with male gender, WHO clinical 
stages III or IV, CD4 T-cell count at time of ART initiation below 200 cells/mm
3
, BMI 
below 16kg/m
2
 and initiating an NRTI backbone comprising of D4T plus 3TC.
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Table 4.7. Univariate and multivariate factorial analysis of factors associated with loss to follow-up on cART. 
Variable Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
Sex     
Male 1.36 (1.19 – 1.55) <0.0001 1.39 (1.18 – 1.62) 0.0001 
Female 1.00  1.00  
Age     
 40 years 0.98 (0.86 – 1.11) 0.76 - - 
<40 years 1.00    
WHO stage     
3 or 4 1.72 (1.43 – 2.06) <0.0001 1.40 (1.14 – 1.70) 0.001 
1 or 2 1.00  1.00  
Baseline CD4 strata     
<200 1.67 (1.44 – 1.95) <0.0001 1.41 (1.18 – 1.68) 0.0001 
>200 1.00  1.00  
Baseline BMI     
<16 kg/m
2 
1.96 (1.64 – 2.33) <0.0001 1.62 (1.33 – 1.96) <0.0001 
16 kg/m2 1.00  1.00  
Baseline Hb     
<8g/dl 1.56 (1.32 – 1.85) <0.0001 1.19 (0.98 – 1.45) 0.10 
8g/dl 1.00  1.00  
NRTI backbone     
D4T plus 3TC 1.34 (1.18 – 1.52) <0.0001 1.17 (1.01 – 1.36) 0.04 
AZT plus 3TC 1.00  1.00  
NNRTI     
Efavirenz 1.20 (1.05 – 1.36) 0.006 1.05 (0.89 – 1.22) 0.57 
Nevirapine 1.00  1.00  
Residence location     
Outside Kumasi 1.12 (0.97 – 1.28) 0.12 - - 
Within Kumasi 1.00    
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The incidence, causes and risk factors associated with mortality. 
There were 324 deaths over the 11,263.8 person follow-up years giving a crude (95% 
CI) event rate of 28.83 (25.78 – 32.15) deaths per 1000-person follow up years. The 
median (range) time to death was 2 months (0 – 66) by Mann Whitney’s U-test. 202 
(62.3%) of deaths occurred within the first 90-days of initiation of therapy, 88 (27.2%) 
from month 4 to month 12, 16 (4.9%) within the second year, 9 (2.8%) within the third 
year, 3 (0.9%) within the fourth year and 6 (1.9%) within the fifth year of follow up. 
The Kaplan Meier estimated cumulative incidence of mortality at 6, 12, 36 and 72 
months were 6.8%, 7.9%, 9.0% and 9.8%  respectively. 
On univariate analysis, factors significantly associated with hazard of death included 
male gender, advanced clinical stage of HIV disease (Stage 3 or 4), baseline CD4 strata 
<200 cells/mm
3
, baseline BMI of below 16kg/m
2
, baseline haemoglobin of less than 
8g/dl, starting D4T plus 3TC, starting EFV-based ART and poor adherence to therapy. 
As shown in Table 4.8, significant factors associated with mortality in this model were 
male gender with an adjusted HR (95% CI) of 1.69 (1.29-2.21), advanced HIV disease- 
stages 3 or 4 with an adjusted HR (95% CI) of 2.20 (1.42 – 3.41), low CD4 strata below 
200 cells/mm
3 
with an adjusted HR (95% CI) of 2.39 (1.64-3.49), baseline BMI below 
16kg/m
2
 with an adjusted HR (95% CI) of 2.60 (1.92-3.53) and starting on an NRTI 
backbone of D4T plus 3TC with an adjusted HR of 1.60 (1.21-2.11). Starting on an 
EFV-based ART compared with NVP-based ART in this model was not found to be 
significantly associated with risk of death with an adjusted HR of 1.15 (0.87 – 1.51), 
p=0.32. Other baseline factors associated with significant risk of mortality identified in 
univariate analyses included low estimated glomerular filtration rate (elaborated further 
in next sub-section), low total serum cholesterol with an HR of 3.47 (2.95 – 12.58), 
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p<0.0001 (not shown) and raised liver transminases – ALT >40IU/l and AST >40IU/l 
with unadjusted HRs of 1.75 (95% CI of 1.42 to 2.49), p<0.0001 and 1.66 (95%CI of 
1.29 to 2.14), p<0.0001 respectively. 
In a series of 188 deaths, the causes of death were identified from patient records and 
the frequencies of the conditions certified by physicians to be the cause of mortality are 
as shown in Table 4.9. The leading causes of death in this subset of patients were 
pulmonary tuberculosis, severe diarrhoea with hypovolemic shock, severe anaemia, 
pneumonia and sepsis. 
   
Table 4.8. Univariate and multivariate analysis of factors associated with risk of death on cART among Ghanaians. 
Variable Patient 
follow-up 
time (years) 
Number 
of events 
Crude event rate 
(/1000 person 
years) 
Unadjusted 
hazard ratio 
(95% CI) 
p-value Adjusted hazard 
ratio (95% CI) 
p-value 
Sex        
Male 3467 188 54.23 (46.75 - 62.56) 1.71(1.37-2.14) <0.0001 1.69(1.29-2.21) 0.0001 
Female 7770 136 17.50 (14.69 - 20.70) 1.00  1.00  
Age        
 40 years 5161 143 27.71 (23.35 – 32.64) 0.94(0.75-1.17) 0.55 - - 
<40 years 6082 180 29.60 (25.43 – 34.25) 1.00    
WHO stage        
3 or 4 7803 277 35.50 (31.44 – 39.94) 3.52 (2.34-5.30) <0.0001 2.20(1.42-3.41) 0.0004 
1 or 2 2370 25 10.55 (6.82 -15.57) 1.00    
Baseline CD4 strata        
<200 7706 276 35.81 (31.72 – 40.30) 3.13 (2.29-4.29) <0.0001 2.39 (1.64-3.49) <0.0001 
>200 3462 45 13.00 (9.48 – 17.39) 1.00    
Baseline BMI        
<16 kg/m
2 
901 88 97.67 (78.33 - 120.33) 3.79 (2.95-4.85) <0.0001 2.60 (1.92-3.53) <0.0001 
16 kg/m2 9189 214 23.29 (20.27 – 26.63) 1.00    
Baseline Hb        
<8g/dl 1176 76 64.63 (50.92 – 80.89) 2.43(1.88-3.16) <0.0001 1.28 (0.95-1.75) 0.11 
8g/dl 8590 227 26.43 (23.10 – 30.10) 1.00    
NRTI backbone        
D4T plus 3TC 5276 216 40.94 (35.66 – 46.78) 2.04 (1.62-2.58) <0.0001 1.60 (1.21-2.11) 0.001 
AZT plus 3TC 5940 106 17.85 (14.61 – 21.58) 1.00    
NNRTI        
Efavirenz 6120 212 34.64 (30.13 – 39.63) 1.43(1.14-1.81) 0.0024 1.15 (0.87-1.51) 0.32 
Nevirapine 5013 108 21.54 (17.67 – 26.01) 1.00    
Adherence        
Poor 3835 147 38.33 (32.39 – 45.05) 1.52 (1.22-1.89) 0.0002 1.21 (0.95-1.56) 0.12 
Excellent 6345 177 27.90 (23.94 – 32.32) 1.00    
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Table 4.9 Causes of death among 188 patients who died on first line cART in 
descending order of frequency. 
Cause of death Frequency 
  Pulmonary tuberculosis 37 
  Diarrhoea with hypovolaemic shock 30 
  Severe anaemia 19 
  Pneumonia 18 
  Sepsis 16 
  Cerebral toxoplasmosis 12 
  HIV Encephalopathy 7 
  TB Immune reconstitution inflammatory syndrome 7 
  Disseminated Kaposi sarcoma 6 
  Enteric fever 4 
  End stage kidney failure 4 
  Lactic acidosis 4 
  Bacterial meningitis 4 
  Chronic liver disease 2 
  Cryptococcal meningitis 2 
  Steven’s Jonhnsons syndrome due to nevirapine therapy 2 
  Miscellaneous* 14 
TOTAL 188 
* Miscellaneous comprises of 1 case each of acute abdomen, amoebic liver abscess, 
CNS lymphoma, gluteal abscess, hepatocellular carcinoma, HBV flare, high grade Non-
Hodgkin’s lymphoma, hyperglycemic hyperosmolar syndrome, strangulated umbilical 
hernia, otitis media, Pneumocystis jirovercii pneumonia, systemic candidiasis, 
tuberculous colitis, fulminant vasculitis with gangrene of toes and fingers. 
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The impact of baseline renal impairment on survival after initiating cART 
In chapter 3, the prevalence of renal impairment determined by estimated glomerular 
filtration rate of <60ml/min using the Cockroft-Gault and CKD-EPI formulae were 
38.8% and 13.9% respectively. However during cART, very infrequent serum 
creatinine measurements were performed thus precluding analysis of trends in eGFR 
over time. For instance, out of 3,136 measurements at baseline only 432 had repeat 
creatinine measurements at 2 months, 220 at 6 months and 93 at 12 months. A limited 
analysis of changes in eGFR over the first 8 weeks was performed with a trend towards 
improvement in eGFR among patients who started with mild to moderate renal 
impairment (data not shown).  
However, in survival analysis using baseline eGFR, there was a significant trend 
towards increased risk of death according to decreasing baseline eGFR as shown in 
Figures 4.3 (missing = censored analysis) and 4.4 (missing = death analysis). In a 
multivariate Cox proportional hazard analysis (missing = censored analysis) with 
adjustment for gender, age, baseline CD4 counts, WHO clinical stage, NNRTI 
backbone and NNRTI, there was a significantly increased hazard of death with an eGFR 
of <60ml/min using either the Cockroft-Gault or the CKD-EPI formulae with adjusted 
HRs of 1.46 (95%CI of 1.31 to 1.63), p<0.0001 and 1.29 (95%CI of 1.16-1.44), 
p<0.0001 respectively for each tertile lower than an eGFR of 90ml/min. Tables 4.10A 
and 4.10B summarise the impact of baseline eGFR on the risk of death on cART using 
either the Cockroft-Gault or the CKD-EPI formulae respectively, with similar trends 
also observed using the MDRD formula (not shown). 
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Figure 4.3. Kaplan –Meier risk analysis for death according to baseline estimated glomerular filtration rate using the Cockroft-Gault 
formula (missing patient were censored). 
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Figure 4.4. Kaplan –Meier risk analysis for death according to baseline estimated glomerular filtration rate using the Cockroft-Gault 
formula (missing patient = death). 
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Table 4.10A. Cox proportional hazard regression analysis for risk of death on cART according to estimated glomerular filtration 
rate (by Cockroft-Gault equation) at baseline. 
                                   Missing = Censored (Primary analysis)                            Missing = death (Sensitivity analysis) 
Variable Unadjusted HR p-value Adjusted HR p-value Unadjusted HR p-value Adjusted HR p-value 
eGFR         
>90ml/min 1.00  1.00  1.00  1.00  
60-89ml/min 1.34 (0.86-2.10) 0.19 1.29 (0.83-2.03) 0.26 1.22 (1.01-1.47) 0.04 1.20 (1.00-1.45) 0.05 
45-59 ml/min 2.14 (1.35-3.38) 0.0012 1.95 (1.21-3.12) 0.0057 1.16 (0.94-1.44) 0.18 1.09 (0.87-1.36) 0.46 
30-44ml/min 3.41 (2.13-5.44) 0.0000 2.55 (1.55-4.17) 0.0002 1.89 (1.51-2.36) 0.0000 1.64 (1.29-2.07) 0.0000 
<30ml/min 5.75 (3.45-9.59) 0.0000 4.08 (2.34-7.11) 0.0000 2.47 (1.88-3.24) 0.0000 2.05 (1.52-2.75) 0.0000 
 
Table 4.10B. Cox proportional hazard regression analysis for risk of death on cART according to estimated glomerular filtration 
rate (by CKD-EPI equation) at baseline. 
                                   Missing = Censored (Primary analysis)                            Missing = failure (Sensitivity analysis) 
Variable Unadjusted HR p-value Adjusted HR p-value Unadjusted HR p-value Adjusted HR p-value 
eGFR         
>90ml/min 1.00  1.00  1.00  1.00  
60-89ml/min 1.13 (0.84-1.52) 0.43 1.29 (0.96-1.75) 0.09 0.99 (0.85-1.14) 0.85 1.08 (0.93-1.26) 0.30 
45-59 ml/min 1.77 (1.14-2.76) 0.01 1.84 (1.18-2.89) 0.0076 1.36 (1.07-1.73) 0.01 1.41 (1.11-1.79) 0.0056 
30-44ml/min 2.30 (1.32-4.01) 0.0034 1.99 (1.13-3.50) 0.018 1.69 (1.24-2.30) 0.0009 1.57 (1.15-2.16) 0.0046 
<30ml/min 3.24 (1.94-5.41) 0.0000 2.82 (1.68-4.74) 0.0001 1.98 (1.45-2.70) 0.0000 1.78 (1.30-2.43) 0.0003 
Adjusted analysis includes adjustment for gender, age, baseline CD4 counts, WHO clinical stage, NRTI backbone and NNRTI base
   
Adherence to cART: Adherence was assessed using pill counts at every clinic visit and 
classified as adherent if patient had taken >95% of prescribed pills and non-adherent if 
patient had taken <95%. A patient was classified as non-adherent if there is any 
reported history of poor compliance to therapy during follow-up. 1,509 (38%) patients 
who had at least one visit after initiating cART had a history of poor adherence. Risk 
factors associated with a significant odds of poor adherence were advanced WHO 
clinical stage with each increase in clinical stage the OR (95% CI) was 1.15 (1.06 – 
1.26), p=0.002; starting therapy with a BMI lower than 16kg/m
2
 is associated with OR 
(95% CI) of 1.33 (1.10 – 1.61), p=0.0041, for each 100 cells increase in baseline CD4 
count the OR (95% CI) of poor adherence was 0.86 (0.81 – 0.91), p<0.0001 and 
initiating an efavirenz-based ART is associated with an OR (95% CI) of 1.14 (1.00 – 
1.30), p=0.05. Gender, age and NRTI backbone used was not associated with significant 
odds of poor adherence. In a multiple logistic regression model the only factor 
significantly associated with poor adherence was baseline CD4 count where for every 
100 cells increase in CD4 count, there is a 13% decrease in risk for poor adherence with 
an OR (95% CI) of 0.87 (0.82 – 0.93), p=0.0001.  
Rates of major clinical events on cART: In summary Figure 4.5 graphically depicts the 
overall decline in the period prevalence rates of AIDS-defining events, non-AIDS 
clinical events, mortality and loss to follow up over time on cART. The highest 
incidence rates of these events were observed within the first two months of initiating 
cART with rates of 22.1 non-AIDS clinical events per 100 patients, 10.7 lost-to-follow 
up per 100 patients, 5.9 AIDS defining events per 100 patients and 5.0 deaths per 100 
patients under follow-up. Overall, the Kaplan-Meier estimates of percentage attrition 
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from treatment programme due to either death or loss to follow up at 6, 12, 24, 48, 72 
and 90 months were 17.3%, 20.7%, 25.1%, 29.0%, 34.5% and 36.5% respectively.  
   
 
 
Figure 4.5. Six monthly incidence rates of Non-AIDS and AIDS events, deaths, loss to follow up and asymptomatic events among 
Ghanaian HIV-infected patients on long-term cART. Non-AIDS events comprised all medical conditions which are non-AIDS defining 
by WHO criteria. 
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4.4 DISCUSSION 
The data presented in this chapter shows that there is a sustained and robust 
immunological recovery on combination antiretroviral therapy among this Ghanaian 
cohort of HIV Infected patients. This immune restoration occurs in the accompaniment 
of improvement in morbidity as evidenced by the increasing proportion of patients who 
became asymptomatic over the course of treatment, the increasing body mass indices of 
patients, and the steady decline in the incidence of deaths, patients lost to follow-up, 
AIDS-defining and non-AIDS defining clinical events. Attrition from the programme 
due mainly to deaths and loss-to-follow up as well as AIDS-defining events occurred 
predominantly within the first year of treatment and were predicted by clinical and 
laboratory indicators of advanced HIV disease at initiation of cART. The data presented 
also shows a strong and independent, dose-response association between baseline renal 
impairment assessed by eGFR from creatinine measurement and the subsequent risk of 
death after commencing cART among this cohort. 
Several studies from both developed
439-443
 and developing countries
426, 444-449
 have 
reported short-, medium- and recently long-term CD4 responses on cART. The findings 
from this study shows that within a programme setting in Sub-Saharan Africa, 
immunological responses to cART is sustainable over the long-term on a predominantly 
limited repertoire of first-line therapy. As expected, the median (IQR) CD4 counts at 
initiation of therapy of 133 (50 – 218) cells/mm3 was low and comparable with those 
from several cohorts from developing countries
444-454
 and serves as an indicator of the 
advanced stages of immunosuppression at which cART is initiated in these settings
455
. 
This notwithstanding, cART was associated with a near doubling in median CD4 counts 
within 6 months of therapy followed by a more gradual and sustained increases 
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throughout the period of observation for patients remaining under care. The initial 
profound recovery in CD4 counts on cART is thought to be due to the redistribution of 
cells from lymphoid tissue over the first few months of therapy as suppression of viral 
replication reduces immune activation
456-459
. The vigorous restitution of CD4 cell counts 
within the first six months of therapy was as expected accompanied by the occurrence 
of the immune reconstitution inflammatory syndrome in some patients of which 
tuberculosis was the commonest reported cause followed by herpes zoster and cerebral 
toxoplasmosis. Admittedly, compared with other cohorts where the reported frequency 
of IRIS has varied between 10% to 25% of all patients initiating cART
360, 460-464
, the 
overall frequency of 1.1% of IRIS reported among this cohort is low, and probably a 
reflection the well-known difficulties in the diagnosis of this clinical syndrome within 
settings of limited laboratory support. Events considered as IRIS were those clinicians 
felt they had sufficient clinical and laboratory evidence to corroborate their suspicions. 
Since the phenomenon of IRIS represents an exaggerated immune response to tissue 
antigens of specific pathogens during immune recovery
 
on cART, it is uncertain 
whether it could be classified as a failure of cART. However for patients who stayed on 
cART, 407 (10.1%) developed immunological failure according to WHO guidelines. It 
is obvious that the spectra of clinical events classified as IRIS (Table 4.1) overlaps very 
well with those diagnosed as AIDS-defining events (Table 4.5) of which 681 were 
recorded among the entire cohort at a frequency of 17%. AIDS-defining events on 
cART occurred at a median time of 6 months (range 2 to 90 months), were predicted by 
low CD4 cell counts, prior AIDS and low BMI at initiation of therapy and were 
associated with increased risk of subsequent attrition from the programme in 47.2% of 
events. These suggest that the occurrence of AIDS-defining events in the proximal 
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phases of cART is an indicator of early treatment failure and is representative of an 
inexorable progression of HIV disease for which cART may be incapable of halting, 
even when the appropriate treatment for the opportunistic infection is concurrently 
commenced. The implication is that cART should be started much earlier, when patients 
are diagnosed earlier as has been suggested by others
455, 465
.  
The crude incidence rates of Non-AIDS-defining events of 3.64/1000 person-years 
(95% CI of 2.61 – 4.95/1000 person years) is lower compared to that of cohorts from 
Botswana
438 
and the United States
438
 of 10.0 (95% CI of 6.3-15.9/1000 py, n=650) and 
12.4 (95% CI of 8.4 to 18.4 py, n=1,129) respectively, that of a multicentre Latin 
American cohort
466
 of 8.4/1000 person-years and that of the Eurosida cohort
467
 of 17.7 
(95% CI of 16.6 to 18.7/1000 py, n=12,844).  Of the 41 NADEs in this Ghanaian 
cohort, hepatic disorders (n=20) were the commonest NADE followed by 
cardiovascular events (n=10), end-stage renal disease (n=6) and non-AIDS 
malignancies of which hepatocellular carcinoma (n=4) and one case of oesophageal 
carcinoma were reported. The order of events were different from those in the cohort 
from Botswana where out of 18 NADEs, 9 were cardiovascular, 4 were renal, five were 
malignancies and none were of hepatic in etiology
438
. As a composite outcome measure, 
non-AIDS events are a heterogeneous collection of several end-points with 
multifactorial aetiologies and risk factors such as increasing age on cART, presence of 
co-morbid medical disorders such as hypertension, diabetes mellitus and dyslipidaemia 
as well as lifestyle, for example smoking or alcohol abuse, and also the presence of 
chronic hepatitis B co-infection and chronic vascular inflammatory state due to 
persistence of HIV viral replication
468-477
. The multi-dimensional composition of risk 
factors for NADEs together with the relative limited observation of events and some 
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missing data at baseline and follow up restricted analysis of risk factors for these events 
in this cohort. 
Malaria was the leading cause of non-AIDS-defining infectious morbidity on cART and 
was often treated with artemisinin-based antimalarial therapy leading to resolution of 
symptoms. However the safety and effectiveness of this class of antimalarials among 
HIV-infected patients on cART has not been assessed within the Ghanaian context. 
Thus the impact of pharmacodynamic and pharmacokinetic interactions between 
artemisinins and efavirenz is explored further in chapter 7. The fact that within this HIV 
cohort, tuberculosis and malaria were the leading causes of AIDS and non-AIDS 
infectious morbidity respectively underpins these three infectious diseases as the most 
important public health challenges Sub-Saharan Africa is attempting to overcome to 
enhance longevity of its population.  
Unlike in the developed countries where AIDS-related mortality on cART is being 
superseded by Non-AIDS-related mortality
477
, causes of death in this cohort were 
predominantly driven by AIDS-related events of which tuberculosis was the leading 
cause followed by diarrhoea, severe anaemia and pneumonia as in other cohorts from 
developing countries. Of the NADEs, end-stage kidney disease and liver-related disease 
were among the common causes of mortality. Renal impairment, defined by eGFR of 
<60ml/min, was very frequent prior to initiation of therapy with a prevalence of 38.8% 
and 13.9% respectively using either the Cockroft-Gault or the CKD-EPI formulae 
respectively. This study shows a graded increase in the risk of death according to 
baseline eGFR with adjusted HRs of 4.08 (95% CI 2.34-7.11), 2.55 (1.55-4.17) and 1.95 
(1.21-3.12) at eGFRs of <30ml/min, 30-44ml/min and 45-59ml/min compared with 
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>90ml/min (Table 4.10A). This trend was consistently demonstrated whether eGFR was 
estimated with Cockroft-Gault (Table 4.10A) or CKD-EPI (Table 4.10B) and whether 
missing patients were censored (Figure 4.4) or were considered as dead (Figure 4.5). 
These findings are in agreement with the recently published data from the UK CHIC 
cohort
478
.  It is also noteworthy that 6 deaths were attributed directly to ART related 
toxicity: 2 cases of Stevens Johnson’s syndrome from nevirapine and four cases of 
clinically suspected lactic acidosis from stavudine. ART toxicity is a cardinal factor 
influencing the durability and therefore the effectiveness of cART and this is explored 
in some detail in the next chapter. Use of a stavudine backbone was independently 
associated with increased risk of death (Table 4.8) and loss-to-follow up (Table 4.7), 
hence the withdrawal of this antiretroviral from the Ghanaian ART programme is 
justified and its associated risk of mitochondrial-related toxicity with long-term use is 
explored further in chapter 5. Given the high prevalence of renal impairment among this 
cohort, replacement of stavudine by tenofovir backbone should however be approached 
with caution due to well known association between tenofovir and risk for renal tubular 
toxicity. It is encouraging that the DART study has provided some reassuring data on 
the safety of tenofovir among Africans
395
, nevertheless regional differences in 
prevalence of renal impairment across Africa should be borne in mind. More frequent 
assessment of renal function using urine dipsticks and creatinine measurements are 
needed to detect worsening of renal function should this occur.   
The analyses presented in this chapter have limitations worth noting. The trajectories of 
CD4 and body mass index over time reflect those of patients who remained on cART 
and thus are influenced by survivor bias. Baseline predictors of the trajectories of CD4 
counts were not explored in this chapter but are considered in chapter 6 where the 
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effectiveness of efavirenz-based cART is compared with that of NVP-based cART. 
Also the outcomes of renal function after initiation of cART could not be assessed 
because of less frequent monitoring of renal function by creatinine measurements. 
Indeed in a very limited analysis of patients who had repeat measurements of creatinine 
performed within 8 weeks of starting cART, there was a trend towards a down-staging 
of baseline renal impairment among those with eGFR of <60ml/min as has been 
previously shown
478
. Also of note is the fact that adherence to therapy was assessed 
from records of pill counts and graded into a binary outcome of excellent or poor. 
Previous studies have modelled risk factors for adherence using either the GEE
479
 or 
log-binomial models
446
 but there was failure to achieve convergence using these 
methods for reasons still not apparent to the author. Corroboration with pharmacy refills 
could have improved the assessment of adherence. Furthermore the sources of 
ascertainment of causes of deaths were mostly done by verbal autopsy by relatives and 
may not have been accurate, others were inferred from the last diagnosis of the patients 
before death occurred as well as those from medical certificates of death. In spite of 
these the specific causes of death could be verified in only 188 (58%) out of 324 events. 
Similarly, the classification of AIDS-defining events, IRIS and NADEs were influenced 
by availability of data and arrived at by consensus between the author and his local 
supervisor (ROP) since no structured- proforma has been designed to capture and 
classify these events in the ART programme.  
In summary, cART is effective over the long-term among this Ghanaian cohort of HIV-
infected patients. Two deaths were due to nevirapine related toxicity but the risk of 
immunological failure, death, loss-to-follow up and disease progression were similar 
between nevirapine and efavirenz. The effectiveness of these two NNRTIs are directly 
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compared in chapter 6 of this dissertation. Stavudine was associated with increased risk 
of death and loss-to-follow up supporting the recommendations to withdraw it from 
ART programmes across Africa. Within the constraints of limited resources as it 
pertains to the ART programme in Ghana, cART was associated with sustained and 
durable immunological recovery, an improvement in the morbidity from HIV-infection 
and trend towards reduction in mortality over the long-term among patients remaining 
on therapy and under care.  
   
CHAPTER FIVE 
Incidence and risk factors associated with toxicity on first line anti-retroviral 
therapy among Ghanaian HIV infected patients. 
Introduction 
Over the last several years, a successful scaling-up of antiretroviral therapy in most 
resource-constrained countries has occurred with currently over 5 million individuals on 
treatment
1
. The availability of cheap, generic fixed-dose combination (FDC) has been a 
key issue in achieving this
480
. In line with WHO recommendations at the start of the 
ART roll-out, almost all national programmes have implemented first line treatment 
consisting of a FDC containing stavudine (D4T)/ zidovudine (AZT), lamivudine (3TC) 
and nevirapine (NVP)/ efavirenz (EFV)
481
. The continual use of these first line cART 
regimens - a measure of their durability - is dependent on their efficacy and toxicity 
profile over long-term usage. Adverse effects have been reported with all antiretrovirals 
and are one of the most common reasons for discontinuation of treatment
149, 482, 483 
. 
Some events such as hypersensitivity, cutaneous and hepatotoxic reactions to NNRTI 
occur rapidly, within the first few months of starting treatment. Others such as 
lipoatrophy on thymidine NRTI evolve over long-term usage, still others such as 
anaemia due to zidovudine may occur unpredictably. 
Surveillance data on long-term toxicity of antiretrovirals are important within the 
programmatic settings where cART is administered to inform policy change where 
necessary. For instance, the increasing reports of stavudine-related mitochondrial 
toxicities, including neuropathy, lactic acidosis and lipoatrophy led to the WHO in its 
2006 guidelines to recommend phasing-out D4T and replacing it with alternative 
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drugs
484
. It is common practise, based on treatment recommendations, to substitute 
drugs within a particular class on account of toxicity, but risk of recurrent adverse 
events due to cross-reactivity among drug classes particularly the NNRTIs has not been 
explored within cohorts in Africa. Given that toxicity on ART may cause patients to 
adhere less to therapy and therefore engender treatment failure it is important to explore 
risk factors associated with the incidence of severe toxicity among the currently 
available first line therapy. The aims of this chapter are first, to evaluate the incidence 
rates and risk factors for antiretroviral therapy related-toxicities; second, to compare the 
rates of discontinuation within two ART classes due to toxicity (i.e efavirenz vs 
nevirapine and stavudine vs zidovudine); third, to examine the impact of specific ART-
related toxicity on adherence to therapy. Since the focus of this dissertation is to 
examine the effectiveness of efavirenz with nevirapine as a comparator, the analysis for 
each specific toxicity in this chapter is performed with these two medications in 
consideration regardless of whether they are implicated as the cause of the toxicity or 
not. 
Methods 
Please refer to chapter 2 sections 2.5. 
Results 
Incidence and timing of Specific ART-related toxicity 
Eight hundred and ninety-five (895) patients experienced a total of 1,627 ART related 
toxicities over 11,236.8 person years of follow up. As shown in Table 5.1, anaemia, 
skin rash, neuro-psychiatric disorders, peripheral neuropathy, hepatotoxicity and 
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lipoatrophy were the commonest ART associated toxicities recorded. An analysis of the 
incidence rates and risk factors associated with these six frequently reported ART 
toxicities are found below: 
   
Table 5.1: Frequencies, incidence rates and median time of first occurrence of specific toxicities on ART among Ghanaian HIV 
patients. 
Toxicity Number 
of events  
n= 1,627 
Frequency of 
events 
Median (range) 
time in months 
Incidence rate /100 person years 
follow up (95% CI) 
Severe anaemia 675 41.5% 2 (2 – 78) 6.01 (5.56 – 6.48) 
Skin rash 299 18.4% 2 (2 – 48) 2.66 (2.37 – 2.98) 
Neuropsychiatric disorders 235 14.4% 2 (2 – 78) 2.09 (1.83 –2.38) 
Peripheral neuropathy 181  11.2% 6 (2 – 72) 1.61 (1.38 – 1.86) 
Hepatotoxicity 160  9.8% 12 (2 – 84) 1.42 (1.21 – 1.66) 
Lipoatrophy 40  2.5% 42 (2 – 66) 0.36 (0.25 – 0.48 ) 
Ptylism 14 0.9%  0.12 (0.07 – 0.21) 
Gastrointestinal disorders 12 0.7%  0.11 (0.06 – 0.19) 
Lactic acidosis 4 0.2%  0.04 (0.01 – 0.09) 
Hyperpigmentation 3 0.2%  0.03 (0.01 – 0.08) 
Myalgia 3 0.2%  0.03 (0.01 – 0.08) 
Pancreatitis 1 0.1%  0.01 (0.00 – 0.05) 
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(1) Incidence and risk factors for developing severe anaemia on ART among 
Ghanaian HIV infected patients 
Incidence rates: 527 patients experienced a total of 675 episodes of severe anaemia 
defined by haemoglobin concentration of <8.0g/dl, giving an event rate (95% CI) of 
6.01 (5.56 - 6.48 per 100 person -years). 427 patients experienced 1 episode of severe 
anaemia while 78 had 2 episodes, 9 had 3 episodes, 5 had 4 episodes, 4 had 5 episodes, 
3 had 6 episodes and 1 patient had 7 episodes of severe anaemia during follow-up. The 
median time to onset of first episode of severe anaemia was 2 months (range of 2-78 
months). The median (IQR) haemoglobin concentration of patients initiating 
zidovudine-containing ART was 11.0g/dl (9.9 – 12.3) compared with 9.4g/dl (8.2 – 
10.9), p<0.0001 for those initiating stavudine-containing regimen. Overall, the median 
time to first episode of severe anaemia was 2 months (range of 2 to 78 months), that for 
zidovudine-recipients of 2 months (range, 2-78 months) was not significantly different 
from D4T recipients of 2 months (range, 2-72 months), p=0.88. 
To identify the risk factors for this common toxicity, a general model for predicting the 
occurrence of severe anaemia defined as haemoglobin concentration below 8g/dl is first 
presented. This is followed by two separate models the explores the risk factors for 
developing severe anaemia among two categories of patients: those whose haemoglobin 
concentrations were within normal limits at the start of therapy and then those who had 
some degree of anaemia at baseline but experienced a further deterioration or 
persistence of anaemia after starting ART. 
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(i) General model for predicting severe anaemia on cART: The risk factors identified on 
univariate and multivariate Cox proportional hazard analyses in association with severe 
anaemia during ART are shown in Table 5.2. Baseline univariate predictors of severe 
anaemia included BMI below 18.5kg/m
2
 with HR (95% CI) of 1.69 (1.42 – 2.01), WHO 
clinical stages 3 or 4 disease with HR (95% CI) of 1.79 (1.38 – 2.31), CD4 count below 
200 cells/mm
3
 with HR (95% CI) of 1.67 (1.36 – 2.05), initiating ART with severe 
anaemia HR (95% CI) of 3.49 (2.90 – 4.19). Gender, age, baseline estimated GFR and 
NNRTI used to initiate therapy were not significantly associated with risk of anaemia 
while initiating AZT-containing regimen was associated with a HR (95% CI) of 0.67 
(0.57 – 0.81) of developing anaemia compared with a D4T-containing regimen. In 
multivariate analysis (n=3,436), factors that remained significantly associated with the 
risk of developing severe anaemia included advanced WHO clinical stage at initiation 
of ART, CD4 cell count below 200 cells/mm
3
 at baseline, a BMI below 18.5 kg/m
2
 at 
baseline and severe anaemia at baseline prior to initiating therapy.  
In this model neither NRTI namely zidovudine nor stavudine was independently 
associated with the risk for developing severe anaemia. However, given that the 
recommended guidelines for management stipulate the avoidance of zidovudine in 
patients with haemoglobin concentration below 10g/dl, it is possible that this 
observation could have been driven by confounding due to an indication bias. To 
explore this issue further, the risk factors for developing severe anaemia was explored 
among those who had any degree of anaemia at initiation of therapy and those who 
started therapy without any degree of anaemia in separate analyses. 
 
   
Table 5.2. The risk factors for developing severe anaemia on cART among Ghanaian HIV-infected patients 
Predictor Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
Gender     
      Female 1.01 (0.84 – 1.21) 0.95 - - 
      Male 1.00    
Age     
     40 years 0.95 (0.80 – 1.12) 0.52 - - 
     <40 years 1.00    
BMI      
    <18.5 kg/m
2
 1.69 (1.42 – 2.01) <0.0001 1.27 (1.04 – 1.55) 0.01 
     18.5 kg/m2 1.00    
WHO clinical stage     
    stage 3 or 4 1.79 (1.38 – 2.31) <0.0001 1.43 (1.09 – 1.88) 0.01 
    stage 1 or 2 1.00  1.00  
Baseline CD4 counts      
    <200 cells/mm
3 
1.67 (1.36 – 2.05) <0.0001 1.34 (1.07 – 1.68) 0.01 
    200 cells/mm3 1.00    
Baseline HB     
     <8.0g/dl 3.49 (2.91 – 4.19) <0.0001 2.79 (2.27 – 3.43) <0.0001 
      8.0g/dl 1.00  1.00  
eGFR     
     <60ml/min 0.86 (0.68 – 1.08) 0.19 - - 
      60ml/min 1.00    
NRTI     
       Zidovudine 0.68 (0.57 – 0.81) <0.0001 0.87 (0.71 – 1.07) 0.18 
       Stavudine 1.00  1.00  
NNRTI     
       Efavirenz 1.15 (0.96 – 1.37) 0.13 - - 
       Nevirapine 1.00    
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(ii) Model for predicting factors associated with the risk of developing severe anaemia 
among patients with some degree of anaemia at the start of cART 
Included are 2,943 patients who had some degree of anaemia at baseline and at least one 
haemoglobin concentration determination during follow-up on cART. Figure 5.1 shows 
the changes in haemoglobin concentration from baseline values among this subset of 
patients while on cART. Overall, there was an increase in the median of change in 
haemoglobin concentration on cART, however among this high-risk group of patients, 
some experienced severe to life-threatening reductions in haemoglobin concentrations 
defined as a drop in haemoglobin concentration of 2.5g/dl from baseline value or 
haemoglobin concentration of <8g/dl. By this definition 531 (18.0%) patients had at 
least one episode of worsening of anaemia on cART out of which 86 patients 
experienced recurrent anaemia defined by at least 2 episodes of severe to life-
threatening anaemia (range of 2-8 episodes) on follow-up.   
Significant baseline factors associated with the risk of developing severe anaemia 
among this subset of patients initiating cART with some degree of anaemia included 
CD4 count <100 cells/mm
3
, AIDS diagnosis and BMI <18.5 kg/m
2 
with unadjusted HRs 
(95% CI) of 1.18 (1.00-1.45), 1.60 (1.24-1.97) and 1.45 (1.27-1.85) respectively while 
male gender was marginally significant with HR of 1.17 (0.99-1.45), p=0.06. Of 
interest, patients commenced on zidovudine (n=1364) were not at a higher risk of 
developing a worsening of anaemia compared with those initiated on stavudine 
(n=1579), HR (95% CI) of 0.90 (0.75-1.07), p=0.23. In a survival analysis using 
Kaplan-Meier methodology which took into account censoring due to discontinuation of 
NNRTI for any reason, 321 (18.1%) patients on efavirenz-based cART (n=1769) 
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compared with 196 (16.7%) patients on nevirapine-based cART (n= 1174) experienced 
at least one episode of severe to life-threatening anaemia giving an unadjusted HR (95% 
CI) of 1.11 (0.93-1.35), p=0.22. The factors which remained significant in the adjusted 
analysis was low BMI<18.5 kg/m
2
 and having AIDS diagnosis at baseline. 
 
 
 
 
 
   
 
Figure 5.1. Changes in haemoglobin concentration from baseline in patients with some degree of anaemia at initiation of cART. Each dot 
represents a subject and the horizontal lines are the median of haemoglobin concentration change. 
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(iii) Model for predictive factors associated with the risk of developing severe anaemia 
among patients without anaemia at the start of cART. 
Four hundred and seventy-seven (477) patients included in this sub-analysis initiated 
cART without anaemia. 358 (75.0%) patients in this subset of patients experienced 
some degree of anaemia with only 21 (4.4%) experiencing at least one episode of severe 
anaemia. Recurrent anaemia of more than one episode occurred in 248 (52.0%) patients 
under follow-up with a range of 2 to 15 episodes per patient.  
On adjusted multivariate analyses, females had a 20% lower risk of developing any 
degree of anaemia compared with males (HR 0.80; 95% CI 0.46-0.96; p=0.03), and 
patients on zidovudine had a 31% higher risk of anaemia compared with those on 
stavudine (HR 1.31; 95% CI 1.14-2.02; p=0.004). There was no significant difference in 
the risk of developing anaemia on efavirenz (HR 1.14; 95% CI 0.94-1.62; p=0.13) 
compared with nevirapine. Also, of the 21 patients who experienced severe anaemia in 
this sub-category of study subjects, all 21 patients were females, 17 were on zidovudine 
vs 4 on stavudine and 14 were nevirapine vs 7 on efavirenz. The small number of 
clinical events limited the ability to perform further analysis. Evidence of 
haemoglobinopathies, parasitic infestations and other causes of anaemia such as heavy 
menstrual blood loss in females were not recorded in patient database and therefore 
could not be accounted for in these analyses.  
Treatment-limiting toxicity: Out of the 675 episodes of severe anaemia, only 62 (9%) 
events - all among patients on zidovudine-containing regimens - were considered severe 
enough to warrant therapy change to stavudine. 
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(2) Incidence and risk factors for developing skin rash on cART 
Incidence rates of skin rash: There were 341 cases of skin rash recorded while patients 
were on ART giving an incidence rate of 3.03 events per 100 person-years of follow up. 
295 patients had one episode of skin rash, 21 patients had 2 episodes and 1 patient had 4 
episodes of skin rash on follow up. The median time to onset of first episode of all skin 
rash was 2 months (range 2-48 months). 299 events of skin rash were NNRTI-related 
while 42 were not NNRTI-related. Reasons other than NNRTI-associated skin rash 
were HIV-associated nodular prurigo (n=28), pruritic papular dermatitis (n=7), varicella 
zoster rash (n=3), septrin rash (n=2), tinea corporis (n=1), abacavir hypersensitivity rash 
(n=1).  
180 out of 341 (53%) skin rashes occurred in patients on nevirapine-based ART while 
158 out of 341 (46%) skin rashes occurred in patients on efavirenz-based ART and 3 
(1%) occurred in patients in patients on ritonavir-boosted lopinavir-based ART. The 
odds ratio of developing any skin rash on a nevirapine-based ART compared with 
efavirenz-based ART was 1.75 (1.40 – 2.19), p<0.0001. 
Incidence of NNRTI-related skin rash: 281 (7.0% of 3,999 patients who started NNRTI) 
patients experienced 299 events of NNRTI-related rash, 264 patients had one episode 
and 17 had more than one episode of rash: 16 had 2 episodes and one patient had 3 
episodes of mild grade 1 rash at months 2, 6, and 12. The frequency of nevirapine-
associated rash was 10.2% (n=1,623) while efavirenz-associated rash was 5.6% 
(n=2,376). Table 5.3 shows the frequencies of the various grades of NNRTI-related skin 
rash. 90 (30%) of the NNRTI skin rash were grade I, 70 (23%) were grade IIA, 122 
(41%) were grade IIB, 15 (5%) were grade III and 2 (1%) were grade IV. Grade III skin 
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rash included Stevens Johnson syndrome (n=7), generalised maculopapular rash with 
constitutional symptoms such as fever and malaise (n=5), and maculopapular rash with 
hepatotoxicity (n=3).  The frequency of severe to life-threatening skin rash on 
nevirapine was 0.7% (n=1,623) and on efavirenz was 0.2% (n=2,376). There were no 
significant differences in the severity of NNRTI-related skin rash although grade 3 and 
4 skin rash were commoner among patients on nevirapine-based ART compared with 
those on efavirenz-based ART.  
Table 5.3: Severity of NNRTI-related skin rash among Ghanaian HIV patients 
Type Nevirapine  
n=165 (%) 
Efavirenz 
n=134 (%) 
Total 
n=299 (%) 
Chi-square test 
p-value 
I 44 (27%) 46 (34%) 90   (30%) 0.13 
IIA 43 (26%) 27 (20%) 70  (23%) 0.27 
IIB 66 (40%) 56 (42%) 122 (41%) 0.80 
III 10 (6%) 5   (4%) 15    (5%) 0.35 
IV 2   (1%) 0    (0%) 2     (1%) 0.20 
 
Grade I –erythema/hyperpigmented rash localised, Grade IIA – diffuse maculopapular 
rash, Grade IIB- urticaria, Grade III- grade I,II + constitutional symptoms or 
angioedema or serum sickness-like reaction or Stevens Johnson Syndrome. Grade IV- 
toxic epidermal necrolysis. 
 
Risk factors for NNRTI-related skin rash: Use of nevirapine based ART was associated 
with an unadjusted hazard ratio (95%CI) of 1.83 (1.48 – 2.41), p<0.0001 of developing 
an NNRTI-related skin rash compared with use of an efavirenz based ART. Other 
baseline risk factors significantly associated with NNRTI-related skin rash on univariate 
analyses were female gender with HR of 1.57 (1.18 – 1.97), low body mass index, 
advanced WHO clinical stage (Figure 5.2), low CD4 (Figure 5.3) and hepatitis B virus 
seropositivity as shown in Table 5.4. Age, ALT and AST baseline concentrations were 
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not associated with risk of NNRTI-related skin rash. In a Cox proportional hazards 
multivariate model, use of NVP was associated with an adjusted HR (95%CI) of 1.67 
(1.28 – 2.10), p=0.0002. Other factors which remained significantly associated with risk 
of developing NNRTI-related skin rash included female gender HR (95% CI) of 1.39 
(1.01 – 1.92), p=0.04 and CD4 counts with HR (95%CI) of 0.88 (0.82 – 0.95) p=0.0005 
with each 50 cells increment in baseline CD4. Although HBV seropositivity as 
associated with risk of NNRTI-related skin rash in the univariate model, this factor was 
not included in the final baseline multivariate model (n=3417) because the number of 
observations in this variable limited the power of this model.  
Immunological basis for NNRTI-related skin rash?: Profound increases in CD4 T-cell 
counts during the initial phases of treatment has been proposed as one of the possible 
explanations for the development of NNRTI-skin rash
18,19
. Given that the risk for 
developing skin rash was significantly higher for those with low CD4 counts at 
baseline, a comparison of the percentage and absolute changes in CD4 counts within the 
first 12 months of therapy was performed among those who developed NNRTI-skin 
rash and those who did not. The median (IQR) of the percentage change in CD4+ T-cell 
counts at 6 months among patients who developed NNRTI-skin rash was +190% (+93% 
to +576%, n=219) compared with +119% (+57% to +272.5%, n=2512), p<0.0001 for 
those without skin rash and +250% (+103% to +724%, n=229) versus +143% (+71% to 
325.5%, n=2471) p<0.0001, respectively at 12 months. The median (IQR) of the 
absolute change in CD4+ T-cell counts from baseline among patients who developed 
NNRTI-skin rash compared with those did not develop this event at 6 and 12 months 
were 172 (108-283/mm
3
) vs 159 (85-248/mm
3
) p=0.02 and 237 (147.5-335.5/mm
3
) vs 
199 (114-304/mm
3
) p=0.0008 respectively. Thus compared with those who had no skin 
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rash, patients who developed NNRTI-related skin rash had more profound increases in 
CD4 counts from baseline. Changes in the median ALT and AST concentration at 
months 2, 6 and 12 between those with or without NNRTI-rash were not significantly 
different (data not shown). 
 
 
   
  
Figure 5.2. Kaplan-Meier estimates of risk for NNRTI-related skin rash according to WHO clinical stage at baseline. 
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Figure 5.3. Kaplan-Meier estimates of risk for NNRTI-related skin rash according to CD4 count at baseline.
   
Table 5.4. Baseline risk factors associated with NNRTI-related skin rash among Ghanaian HIV patients on cART. 
Variable Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
NNRTI     
    Nevirapine 1.83 (1.48 – 2.41) <0.0001 1.67 (1.28 – 2.19) 0.0002 
    Efavirenz 1.00  1.00  
Gender     
    Female 1.57 (1.18 – 1.97) 0.0013 1.39 (1.01 – 1.92) 0.04 
    Male 1.00  1.00  
Age      
    <40 years 1.34 (1.06 – 1.71) 0.01 1.11 (0.85-1.45) 0.45 
     40 years 1.00  1.00  
BMI per 5kg/m
2
 increase      
 0.86 (0.73 – 0.99) 0.05 0.94 (0.79 – 1.11) 0.47 
Clinical stage per each WHO stage 
higher 
    
 1.21 (1.02 – 1.42) 0.03 1.13 (0.94 – 1.35) 0.20 
CD4 counts per 50 cells increase     
 0.89 (0.83 – 0.94) 0.0001 0.88 (0.82 – 0.95) 0.0005 
HBV status     
     positive 1.48 (1.03 – 2.49) 0.04 Not included* - 
     negative 1.00    
ALT per 10IU/l higher     
 1.01 (0.99 – 1.04) 0.33 - - 
* Not included number of patients whose HBV sero-status was small. 
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NVP-rash versus EFV-rash: Although the risk factors for NVP-rash have been well 
characterised, those for EFV-rash still remains to be elucidated. Thus, an analysis was 
performed to identify whether risk factors predisposing to NVP-rash were different 
from those of EFV-rash. First, the median (range) time to the first reported rash was not 
significantly different for NVP-rash 2 months (2-36) compared with EFV-rash 2 months 
(2-48), p=0.12. Second, both NVP-rash and EFV-rash shared a predilection for 
occurring among patients starting with a low CD4 count with the adjusted HRs of 
developing NVP-rash or EFV-rash with CD4 counts below 100 cell/mm
3
 of 1.48 (1.09 – 
2.03), p=0.01 and 1.61 (1.09 – 2.39), p=0.02 respectively. Third, significant differences 
in associations were not found in the risk for either specific NNRTI-rash in relation to 
baseline age, NRTI backbone upon which the NNRTI is started on, or ALT/AST 
concentrations either at baseline or their changes at 2, 6 and 12 months on treatment 
(data not shown). Thus although NVP-rash is more frequent than EFV-rash, both appear 
to share common risk factors in this cohort. 
Treatment-limiting toxicity Forty-four (44) cases of NNRTI-related rash were treatment-
limiting requiring modifications in therapy. These included 2 cases of grade IV skin 
rash, 10 cases of grade III, 16 cases of grade IIB skin rash and 16 cases of grade IIA. 
These treatment-limiting adverse events were observed in 41 out of 165 (25%) patients 
on NVP compared with 3 out of 134 (2%) on EFV giving rise to a relative risk ratio 
(95% CI) of 11.10 (3.51 – 35.06), p<0.0001. Among the 41 NVP-treatment-limiting 
skin rash, 39 were switched to EFV-based ART, 1 to nelfinavir-based ART and 1 to 
ritonavir-boosted lopinavir. Of the 3 cases of EFV-associated skin rash one was 
changed to ritonavir-boosted lopinavir and two others to nelfinavir. As mentioned in 
chapter 4, two patients died from nevirapine-associated Stevens Johnsons’ syndrome. 
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Cross-reactivity cutaneous reaction: There were 4 probable cases of cross-reactivity 
cutaneous reactions after substituting one NNRTI for the other. The baseline 
characteristics, cART regimens, description of the first and second rash and outcomes 
are as shown in Table 5.5 below. All four cases involved a substitution for efavirenz on 
account of nevirapine-associated rash. These rashes resolved initially upon substituting 
nevirapine but patients experienced another on efavirenz rash thought to be NNRTI-
related. However, these rashes resolved without any further recourse to further 
substitutions of NNRTI with one patient requiring an antihistamine for symptomatic 
management of pruritus. 
   
Table 5.5. Four cases of probable cross-reactive cutaneous reactions due to NNRTI class substitutions 
Gender Age WHO 
clinical 
stage 
CD4 
count 
mm
3 
cART regimen Time to 
1
st
 rash 
(months) 
Description 
and stage of 
1
st
 rash 
cART regimen 
changed to 
Time 
to 2
nd
 
rash 
months 
Description and 
stage of 2
nd
 rash 
Outcome of 
2
nd
 rash 
Female 39 4 26 D4T+3TC+NVP 2 Diffuse 
pruritic rash, 
IIB 
D4T+3TC+EFV 6  Hyperpigmented 
rash, I 
Resolved 
without any 
intervention 
Male 40 Not 
recorded 
210 AZT+3TC+NVP 2 Generalised 
maculo-
papular rash, 
IIA 
AZT+3TC+EFV 6 Hyperpigmented, 
pruritic rash, I 
Resolved 
without any 
intervention 
Female 52 3 7 D4T+3TC+NVP 2  Generalised 
maculo-
papular rash 
with mucosal 
involvement 
and ulceration, 
IV 
D4T+3TC+EFV 6 Hyperpigmented 
rash, I 
Resolved 
without any 
intervention 
Female 34 3 56 AZT+3TC+NVP 2  Generalised 
maculopapular 
rash, IIA 
AZT+3TC+EFV 12 Generalised 
pruritic rash, III 
Resolved on 
antihistamines 
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(3) Incidence and risk factors for neuro-psychiatric toxicity on ART 
Incidence rates: 218 patients experienced a total of 235 events of neuropsychiatric 
toxicities during follow up. 203 patients had one event, 13 patients experienced 2 events 
and 2 patients experienced 3 episodes of neuropsychiatric events during follow up. Thus 
the frequency of reported neuropsychiatric toxicity was 5.5% (n=3,999) with 7.6% 
(n=2,376) of efavirenz recipients and 2.4% (n=1,623) of nevirapine recipients 
experiencing this adverse event. The median (range) time to first episode of 
neuropsychiatric toxicity was 2 months (2-84 months). Most neuropsychiatric toxicities 
were reported in the first year of therapy after which incidence of events decline as 
shown in Figure 5.4. 195 events were reported among patients on efavirenz-based ART 
compared to 40 events among those on nevirapine-based ART, odds ratio of 3.54 (2.50 
– 5.00), p<0.0001. A total of 252 neuropsychiatric symptoms were reported, the 
commonest being insomnia (n=126), headaches (n=19), dizziness (n=17), abnormal 
dreams (n=14) and drowsiness (13) are shown in Table 5.6. Insomnia, headaches, 
abnormal dreams and drowsiness were significantly commoner among patients on EFV-
based ART compared with NVP-based ART. Other notable but rarely reported NNRTI 
neuropsychiatric toxicity includes cerebellar ataxia (n=2), dysarthria (n=5) and seizures 
(n=3). 
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Figure 5.4. A graph showing the incidence rates of neuropsychiatric symptoms attributed to toxicity over follow-up on ART among 
Ghanaian HIV-infected patients. 
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Table 5.6. Frequency of neuro-psychiatric side effects of ART among Ghanaian HIV patients 
Neuro-psychiatric toxicity Patients on efavirenz 
with toxicity 
n=208 (%) 
Patients on nevirapine 
with  toxicity n=44 (%) 
p-value Total number of 
events n=252 (%) 
Insomnia 103 (49.5) 23  (52.3) <0.0001 126  (50.0) 
Headaches 16    (7.7) 3     (6.8) 0.05 19     (7.5) 
Dizziness 12    (5.8) 5     (11.4) 0.49 17     (6.7) 
Abnormal dreams 13    (6.3) 1     (2.3) 0.02 14     (5.6) 
Drowsiness 13    (6.3) 0     (0.0) 0.007 13     (5.2) 
Aggressive behaviour 8      (3.8) 2     (4.5) 0.31 10     (4.0) 
Incoherent speech 6      (2.9) 1     (2.3) 0.30 7        (2.8) 
Myalgia 3      (1.4) 4     (9.1) 0.61 7        (2.8) 
Dysarthria 4      (1.9) 1     (2.3) 0.63 5        (2.0) 
Dystonia 5      (2.4) 0     (0.0) 0.16 5        (2.0) 
Mood changes 5      (2.4) 0     (0.0) 0.16 5        (2.0) 
Tremors 2      (1.0) 3     (6.8) 0.67 5        (2.0) 
Confusion 3      (1.4) 0     (0.0) 0.40 3        (1.2) 
Seizures 3      (1.4) 0     (0.0) 0.40 3        (1.2) 
Cerebellar ataxia 2      (1.0) 0     (0.0) 0.65 2        (0.8) 
Psychosis 2      (1.0) 0     (0.0) 0.65 2        (0.8) 
Somnolence 1      (0.5) 1     (2.3) 0.65 2        (0.8) 
Vertigo 2      (1.0) 0     (0.0) 0.65 2        (0.8) 
Anxiety 1      (0.5) 0     (0.0) 0.85 1        (0.4) 
Erectile dysfunction 1      (0.5) 0     (0.0) 0.85 1        (0.4) 
Hyperactivity 1      (0.5) 0     (0.0) 0.85 1        (0.4) 
Impaired concentration 1      (0.5) 0     (0.0) 0.85 1        (0.4) 
Suicidal ideation and attempt 1      (0.5) 0     (0.0) 0.85 1        (0.4) 
TOTAL 208 44 <0.0001 252 
   
 
Risk factors for neuropsychiatric toxicity: Predictor variables included in univariate 
analysis of risk factors for neuro-psychiatric toxicity included gender, age, BMI, CD4 
cell count at baseline, WHO clinical stage, HBV sero-status and NNRTI on which 
patient developed toxicity. As shown in Table 5.7, the only factors identified to be 
associated with neuro-psychiatric toxicity included age 35 years at initiation of therapy 
with HR (95% CI) of 1.55 (1.16 – 2.00), p=0.003, BMI<16kg/m2 with HR (95% CI) of 
1.45 (1.03 – 2.04), p=0.04 and use of efavirenz with HR (95% CI) of 3.43 (2.16 – 3.72), 
p<0.0001. Furthermore on multivariate analysis, BMI<16kg/m
2
 and use of efavirenz 
were significantly associated with risk of developing neuro-psychiatric toxicity on ART 
among Ghanaian HIV-infected patients with HR (95% CI) of 1.44 (1.02 – 2.03),p=0.04 
and 3.29 (2.32 – 4.69),p<0.0001 respectively. 
Treatment limiting adverse toxicity: 33 of 195 events (17%) among patients on EFV-
based ART led to substitution of efavirenz by nevirapine while 6 of 40 (15%) events 
among patients on NVP-based ART led to substitution of nevirapine by efavirenz (n=5) 
and nelfinavir (n=1). The substitutions of nevirapine by efavirenz on account of neuro-
psychiatric events were performed in 5 patients because they were to initiate anti-
tuberculous therapy at the time when those toxicities occurred on nevirapine. This was 
to avoid drug interactions between nevirapine and rifampicin-which is used as a 
component of the quadruple antituberculous drug regimen. However, most 
neuropsychiatric symptoms resolved under continual therapy without having to alter 
NNRTI on account of neuro-psychiatric toxicity. 
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Table 5.7. Risk factors associated with developing neuro-psychiatric toxicity among Ghanaians HIV patients 
Predictor Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
Gender     
   Male 0.87 (0.65 – 1.15) 0.32 - - 
   Female 1.00    
Age     
   35 years 1.55 (1.16 – 2.00) 0.003 1.22 (0.90 – 1.64) 0.19 
   <35 years 1.00  1.00  
BMI      
   <16kg/m
2
 1.45 (1.03 – 2.04) 0.04 1.44 (1.02 – 2.03) 0.04 
    16kg/m2 1.00  1.00  
WHO clinical stage     
   stage 3 or 4 0.91 (0.65 – 1.28) 0.60 - - 
   stage 1 or 2 1.00    
Baseline CD4 counts      
   <200 0.97 (0.72 – 1.30) 0.83 - - 
   200 1.00    
HBV status     
   positive 1.53 (0.98 – 2.39) 0.06* - - 
   negative 1.00    
NNRTI     
   Efavirenz 3.43 (2.16 – 3.72) <0.0001 3.29 (2.32 – 4.69) <0.0001 
   Nevirapine 1.00  1.00  
 * Not included number of patients whose HBV sero-status was small. 
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 (4) Incidence and risk factors for developing severe hepatotoxicity on ART 
Incidence rates: Before treatment there were 3702 measurements of ALT for 4039 
patients (76%) of which 2813 (76.0%) had normal ALT levels, 865 (23.4%) had grade 1 
or 2 hepatotoxicity and 24 (0.6%) had grade 3 or 4 hepatotoxicity. For patients who 
remained on therapy during follow up, there was a general increase in the proportion of 
patients with normal ALT levels up to 93% at 90 months follow up as shown in Figure 
5.5.  
Overall, 143 patients experienced severe hepatotoxicity defined as elevated serum ALT 
levels 5 times the upper limit of normal or elevation of ALT by more than 100IU/l 
above baseline concentration during 11,236.8 person-years of follow up with an 
incidence rate of 1.27/100 person-years, 95%CI of 1.07 – 1.49/100 person years. 131 
patients experienced one episode, 9 experienced 2 episodes, 2 experienced 3 episodes 
and 1 experienced 5 episodes of severe hepatotoxicity during follow-up giving a total of 
160 events with an event rate of 1.42/100 person years. The median (range) time to the 
onset of first episode of severe hepatotoxicity was 12 months (2-84). Overall, the 
frequency of severe hepatotoxicity was 3.9% (143 patients of 3702 evaluable with ALT 
measurements at baseline). By Kaplan Meier methodology, the estimated percent 
cumulative incidence (95% CI) of severe hepatotoxicity at 12, 36, 72 and 90 months 
were 2.3% (1.8% - 2.8%), 3.5% (2.8% - 4.2%), 5.6% (4.4% - 6.8%) and 6.7% (5.1% - 
8.3%) respectively.  
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Figure 5.5. Proportion of patients with grades of hepatotoxicity before and during cART among Ghanaian HIV-infected patients. Grade 
0- ALT within ULN, Grade 1- ALT 1.1-2.5 ULN, Grade 2- ALT 2.6 – 5.0ULN, Grade 3- ALT 5.1 – 10.0 ULN, Grade 4- ALT>10.0 
ULN. Grade 3 or 4 are regarded as severe hepatotoxicity. 
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The frequencies of severe hepatotoxicity among efavirenz and nevirapine recipients 
were 3.7% (78 of 2376 patients who started EFV) and 3.8% (62 of 1,623 who started on 
NVP). The median time of first episode of severe hepatotoxicity among NVP-recipients 
of 6 months (range of 2 to 84 months) was significantly earlier than those among EFV-
recipients of 12 months (range of 2 to 78 months), p=0.03.  
Risk factors: Hepatitis B sero-positivity was significantly associated with risk of 
developing severe hepatotoxicity with a HR (95%CI) of 1.99 (1.16 – 3.40), p=0.01 
shown in Figure 5.6. The only other significant risk factor identified in univariate 
analyses was baseline body mass index with an HR (95% CI) of 1.21 (1.00 – 1.47) for 
each 5kg/m
2
 increase in BMI. Factors such as age, gender, WHO clinical stage, CD4 
counts at baseline and its changes within first 12 months of ART, NNRTI and NRTI 
used were all not associated with risk of developing severe hepatotoxicity. Changes in 
BMI during therapy was not associated with risk of hepatotoxicity (data not shown). On 
multivariate analysis, the only factor significantly associated with risk of severe 
hepatotoxicity was hepatitis B sero-positivity as shown in Table 6.8. The cumulative 
frequency of severe hepatotoxicity by Kaplan Meier estimates among HBV sero-
positive patients during follow up was 12.9% (95% CI of 5.9% to 20.0%) compared to 
6.7% (95% CI of 4.3% - 9.0%) among HBV sero-negative patients. Among HBV sero-
positive patients, the cumulative frequency among efavirenz recipients of 12.5% was 
not significantly different from those on nevirapine of 12.0%.  
Of the 143 events of severe hepatoxicity, 83 events occurred in patients on efavirenz-
based ART, 56 events occurred in patients on nevirapine-based ART and 4 events on a 
protease inhibitor-based ART (3 on ritonavir-boosted lopinavir and 1 on nelfinavir).  
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Treatment limiting toxicity: Only 8 of these events, all in patients on NVP-based ART 
were considered treatment-limiting requiring substitution with efavirenz (n=8).  
   
 
Figure 5.6. Kaplan-Meier survival analysis of risk of severe hepatotoxicity on NNRTI-based ART according to HBSAg sero-status 
among Ghanaian HIV patients. HBSAg= Hepatitis B Surface Antigen, HR=hazard ratio. 
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Table 5.8. Risk factors of severe hepatotoxicity on ART among Ghanaian HIV-infected patients 
Predictor Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
Gender     
   Female 0.83 (0.59 – 1.18) 0.31 - - 
   Male 1.00    
Age per 10 year increase     
 0.85 (0.71 – 1.02) 0.08 - - 
BMI per 5kg/m
2
 increase     
 1.21 (1.00 – 1.47) 0.04 1.02 (0.77 – 1.36) 0.89 
WHO clinical stage     
   stage 3 or 4 1.46 (0.92 -2.31) 0.11 - - 
   stage 1 or 2 1.00    
Baseline CD4 counts per 50 cells increase     
 1.02 (0.95 – 1.11) 0.54 - - 
HBV status     
   positive 1.99 (1.16 – 3.40) 0.01 1.99 (1.16 -3.40) 0.01 
   negative 1.00    
NNRTI     
   Nevirapine 1.04 (0.74 – 1.45) 0.84 - - 
   Efavirenz 1.00    
NRTI     
   Stavidine 1.02 (0.96 – 1.09) 0.48 - - 
   Zidovudine 1.00    
CD4 change in 6 months per each 50 cells 
increase 
0.99 (0.92 – 1.06) 0.68 - - 
CD4 change in 12 months per each 50 cells 
increase 
0.99 (0.93 – 1.04) 0.62 - - 
   
(5) Incidence and risk factors for NRTI mitochondria-related ART toxicities 
among Ghanaian HIV infected patients 
Incidence rates: 222 patients reported experiencing at least one episode of NRTI 
mitochondria-related ART toxicity during follow up. These included peripheral 
neuropathy (n=181), lipoatrophy (n=40), lactic acidosis (n=4) and pancreatitis (n=1). 
Overall the median time to onset of first reported mitochondria-related toxicity is 12 
months (range of 2-72 months), with the median time of onset of first episode of 
peripheral neuropathy and lipoatrophy of 6 months (range of 2-72 months) and 42 
months (range of 2-66 months) respectively. 193 of the mitochondrial-related toxicity 
occurred among patients on stavudine, 27 occurred among patients on zidovudine, 1 
patient on didanosine and 1 patient on tenofovir. 
The percent cumulative incidence (95% CI) by Kaplan-Meier estimates of peripheral 
neuropathy at 12, 36, and 72 months were 3.4% (2.8% - 4.0%), 5.7% (4.8% - 6.5%) and 
6.7% (5.6% - 7.8%) respectively. The percent cumulative frequencies specifically 
among recipients of stavudine at 12, 36 and 66 months were 5.6% (4.5% - 6.7%), 9.6% 
(8.1% - 11.2%) and 11.3% (9.3% -1 3.2%) respectively. The cumulative incidence of 
lipoatrophy among patients on stavudine at 12, 36 and 66 months were 0.1% (0% - 
0.2%), 1.6% (0.8% - 2.4%) and 6.5% (4.3% - 8.8%) respectively.   
Risk factors for mitochondria-associated toxicity: The risk factors identified for NRTI 
mitochondria-related toxicity on univariate analysis with their associated HR (95% CI) 
and p-values are as follows: female gender 1.47 (1.08 – 2.00), p=0.02; age above 40 
years at initiation of therapy-1.98 (1.51-2.59), p<0.0001; initiating therapy with clinical 
stages III or IV disease compared with stages I or II- 1.52 (1.05 – 2.19), p=0.03; 
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baseline haemoglobin concentration below 8g/dl-1.98 (1.44 - 2.73), p<0.0001; baseline 
BMI below 18.5kg/m
2
-1.44 (1.10 – 1.88),p=0.008 and initiating stavudine-containing 
ART compared with zidovudine-containing ART-7.80 (5.21 – 11.67), p<0.0001. 
Factors not significantly associated with NRTI mitochondria-related toxicity included 
baseline CD4 cell count strata of below 200 cells/mm
3
 vs 200 cells/mm3, baseline 
eGFR below 60ml/min vs 60ml/min and NNRTI used to initiate therapy efavirenz vs 
nevirapine. On multivariate analysis, the only factors that were significantly associated 
with risk of developing NRTI mitochondria-related toxicity included female gender 
adjusted HR of 1.40 (95% CI of 1.00-1.96), age above 40 years at initiation of therapy 
with an adjusted HR of 2.08 (95% CI of 1.55-2.79) and stavudine-containing regimen 
with an adjusted HR of 7.09 (95% CI of 4.62- 10.89). 
Risk factors for peripheral neuropathy: As shown in Table 6.9, the risk factors for 
developing peripheral neuropathy on univariate analysis included age 40 years, WHO 
stages III or IV at initiation of ART, baseline haemoglobin concentration below 8g/dl, 
baseline BMI below 18.5kg/m
2
 and starting a stavudine-containing regimen. Age 40 
years and starting a stavudine-containing regimen remaining significant risk factors on 
multivariate analysis.  
 
 
 
 
 
   
Table 5.9. Risk factors for developing peripheral neuropathy on ART among Ghanaian HIV infected patients 
Predictor Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
Gender     
                Female 1.35 (0.96 – 1.89) 0.08 - - 
                Male 1.00    
Age     
              40 years 2.09 (1.54 – 2.83) <0.0001 2.21 (1.59 – 3.07) <0.0001 
             <40 years 1.00  1.00  
BMI      
             <18.5 kg/m
2
 1.35 (1.00 – 1.82) 0.05 0.90 (0.65 – 1.26) 0.56 
               18.5 kg/m2 1.00  1.00  
WHO clinical stage     
             stage 3 or 4 1.63 (1.07 – 2.48) 0.02 1.31 (0.85 – 2.01) 0.22 
             stage 1 or 2 1.00  1.00  
Baseline CD4 counts      
           <200 cells/mm
3 
1.15 (0.83 – 1.57) 0.40 - - 
           200 cells/mm3 1.00    
Baseline HB     
           <8.0g/dl 1.65 (1.14 – 2.39) 0.008 0.98 (0.65 – 1.47) 0.92 
            8.0g/dl 1.00  1.00  
eGFR     
           <60ml/min 1.06 (0.72 – 1.55) 0.77 - - 
           60ml/min 1.00    
NRTI     
             Stavudine 6.13 (4.04 – 9.29) <0.0001 5.63 (3.64 – 8.70) <0.0001 
             Zidovudine 1.00  1.00  
NNRTI     
             Efavirenz 1.04 (0.77 – 1.40) 0.80 - - 
             Nevirapine 1.00    
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Risk factors for lipoatrophy: Because lipoatrophy was reported exclusively among 
patients on stavudine-containing regimen, risk factors analysis was performed among 
patients who either initiated a d4T-containing ART regimen or were switched to a 
stavudine-regimen during follow up. The risk factors for developing stavuudine-
associated lipoatrophy on univariate analysis were female gender and starting stavudine 
with baseline haemoglobin concentration below 8g/dl with only baseline haemoglobin 
concentration below 8g/dl as the only significant risk factor for developing stavudine-
associated lipoatrophy with an adjusted HR of 2.75 (1.37 – 5.53), p=0.005. 
Probable lactic acidosis: There were 4 documented cases of probable lactic acidosis all 
among recipients of stavudine which culminated in deaths as recorded in chapter 4. A 
descriptive account of one such case is given below: The patient was a 42-year-old 
female who started an ART regimen comprising stavudine plus lamivudine with 
nevirapine on 22/08/2008. At the time of treatment initiation, her haemoglobin 
concentration was 7.1g/dl, had a WHO clinical stage III disease with a CD4 count of 
182 cells/mm
3
 and had BMI of 14.0kg/m
2
. In the sixth month of follow up, the patient 
presented with general malaise, bodily weakness, vaguely localising abdominal pain 
and hepatomegaly and in shock. She was admitted and a clinical diagnosis of lactic 
acidosis probable from stavudine being made and resuscitated but died within 3 days 
after her admission.   
Treatment-limiting toxicity: Of the 181 recorded cases of peripheral neuropathy on 
ART, 152 (84%) were on stavudine-containing regimen, 26 (14%) were on zidovudine-
containing regimen and the rest were on didanosine-containing regimen. 83 events of 
peripheral neuropathy (46%) all among patients on a stavudine-containing regimen led 
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to drug substitutions predominantly for zidovudine (n=81) and 2 to tenofovir. Only 19 
events led to immediate drug substitutions at time of first report of peripheral 
neuropathy, the remainder had a median time lag to substitution of 6 months (range 4-
70 months).   
Thirty-four (34) out of 40 reported cases of lipoatrophy led to substitution of stavudine 
for zidovudine (n=31), tenofovir (n=2) and abacavir (n=1). In 19 patients substitutions 
were effected upon first report of lipoatrophy by patients, while delays of up to 6 
months (n=6), 12 months (n=1), 16 months (n=1), 42 months (n=1) were observed 
before switching. Of note, in 6 patients a switch to zidovudine at 6 months (n=4) and 12 
months (n=2) was performed to prevent lipoatrophy but patients eventually developed 
this toxicity in spite of this substitution. 
(6) Impact of ART-associated toxicity on adherence 
Table 5.10 shows results of a multiple logistic regression analysis of associations 
between the occurrence of specific and all-cause toxicity and the risk of non-adherence. 
With the exception of developing mitochondrial toxicity, ART-specific toxicities such 
as developing severe anaemia, severe hepatotoxicity, neuropsychiatric toxicity, skin 
rash and all-cause toxicity were all significantly associated with the risk of reported 
non-adherence to ART on univariate analysis. On multivariate analysis where gender, 
baseline WHO clinical stage, baseline CD4 count, baseline BMI and NNRTI were 
adjusted for the risk of non-adherence was increased by 26% in patients who developed 
any ART-related toxicity and by 23%, 72%, 43% and 42% among patients who 
experienced severe anaemia, severe hepatotoxicity, neuropsychiatric toxicity, and skin 
rash compared with those who did not experience these adverse event. The only adverse 
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event not clearly associated with risk for non-adherence was developing mitochondrial 
toxicity such as lipoatrophy or peripheral neuropathy.  
 
Table 5.10. A multivariable logistic regression analysis of risk of non-adherence in 
relation to developing ART-related toxicities among Ghanaian HIV-infected 
patients. 
Toxicity Non-adherence 
Unadjusted 
OR (95% CI) 
p-value Adjusted OR *  
(95% CI) 
p-value 
Severe anaemia 1.29 (1.12-1.49) 0.0004 1.23 (1.05-1.44) 0.0096 
 Severe hepatotoxicity 1.91(1.29-2.83) 0.001 1.72 (1.12-2.64) 0.01 
Neuropsychiatric 
toxicity 
1.49 (1.05-2.09) 0.02 1.43 (1.04-1.97) 0.03 
Mitochondrial toxicity 0.99(0.73-1.36) 0.96 1.07 (0.76-1.50) 0.71 
Skin rash 1.34(1.03-1.74) 0.03 1.42 (1.09-1.85) 0.01 
Any toxicity 1.55(1.30-1.86) <0.0001 1.26 (1.13-1.40) <0.0001 
 
*after adjusting for gender, baseline WHO clinical stage, baseline CD4 count, baseline 
BMI and NNRTI. OR is odds ratio. 
 
(7) All-cause discontinuation of NNRTI due to toxicity 
There were 55 (3.5%, n=1567; n is number of patients who had at least one follow-up 
visit after initiating ART) discontinuations of nevirapine compared with 36 (1.6%, 
n=2234) discontinuations of efavirenz due to drug related toxicity. The median time to 
discontinuation of nevirapine was 2 months (range, 2 to 56 months) compared with 
efavirenz of 12 months (range, 2 to 48 months), p=0.0028 (Mann-Whitney’s U-test). 
The unadjusted hazard ratio of discontinuation of nevirapine compared to efavirenz as a 
result of toxicity was 2.27 (95%CI, 1.55 to 3.46), p<0.0001 as shown in Figure 5.7. In a 
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multivariate Cox proportional model, the risk of discontinuation of nevirapine compared 
with efavirenz on account of toxicity was 1.89 (1.22-2.92), p=0.004 after adjusting for 
gender, CD4 count, WHO clinical stage and NRTI backbone. Also, after adjusted 
analysis females did not have a significantly higher risk of discontinuing NNRTI on 
account of toxicity compared to males in this model. 
 
(8) All-cause discontinuation of NRTI due to toxicity 
There were 62 (3.4%, n=1847) discontinuations of zidovudine due to toxicity compared 
with 117 (6.0%, n=1954) discontinuations of stavudine due to toxicity. The median time 
to discontinuation of zidovudine was 2 months (range, 2 to 54 months) compared with 
stavudine of 18 months (range, 2 to 72 months), p<0.0001 (Mann-Whitney’s U-test). As 
shown in Figure 5.10, the proportionality of baseline hazard assumption was not met for 
this comparison, so the hazard ratio was not quoted because it is reliable only when this 
assumption is met.  
 
   
 
Figure 5.7. Kaplan-Meier estimates of risk of discontinuation of NNRTI due to toxicity. 
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Figure 5.8. Kaplan-Meier estimates of risk of discontinuation of NRTI due to toxicity. 
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Table 5.11. Frequencies of specific toxicities and treatment switches among Ghanaian cohort on long-term cART. 
Toxicity Number of events Frequency of events 
(%) 
Number of treatment 
switched due to toxicity  
Frequency of treatment 
switch due to toxicity 
(%) 
Anaemia 675 41.5 62 9.2 
Skin rash 299 18.4 44 14.7 
Neuropsychiatric toxicity 235 14.4 39 16.6 
Peripheral neuropathy 181 11.2 83 45.9 
Severe hepatotoxicity 160 9.8 8 5.0 
Lipoatrophy 40 2.5 34 85.0 
Ptylism 14 0.9 0 0.0 
Gastrointestinal disorders 12 0.7 0 0.0 
Lactic acidosis 4 0.2 NA NA 
Myalgia 3 0.2 0 0.0 
Hyperpigmentation 3 0.2 0 0.0 
Pancreatitis 1 0.1 1 100.0 
Total events 1,627 100.0% 271 16.7% 
 
Frequency of events = number of specific events / total number of events 
Frequency of treatment switch due to toxicity= number of treatment switched due to specific toxicity/ number of specific events 
 
   
Discussion 
HIV is now viewed as a chronic disease requiring life-long therapy with potent 
combinations of antiretroviral medications. The prevention and management of 
antiretroviral therapy-related toxicity has emerged as one of the major issues for 
HIV/AIDS management
485, 486
. Treatment-associated toxicities has been identified as 
one of the major reasons for treatment discontinuation
149, 482,483
 and an important 
predictor of poor adherence for which reason long-term toxicity data is required, 
particularly in resource limited settings where treatment options are limited. The present 
data shows that there were 1,627 documented episodes of ART-related toxicities among 
4,039 Ghanaian HIV-infected patients who started first line ART with an overall event 
rate of 14.5 events/100 person-years (95% CI of 13.8 to 15.2/100 person-years). As 
summarised in Table 5.11, severe anaemia, skin rash and neuropsychiatric toxicity were 
the commonest reported adverse events with an overall treatment modification 
frequency of 16.7%, however treatment limiting events necessitating a switch varied 
between 0% to 100% depending on the specific toxicity.  
Severe anaemia was the commonest toxicity recorded among this Ghanaian cohort 
occurring at a frequency of 41.5% of all ART-related toxicities and at a median time of 
2 months with a range of 2 to 78 months. In a multivariate analysis, the risk factors 
identified for the development of severe anaemia among our cohort were severe 
anaemia at baseline, a low BMI below 18.5kg/m
2
, AIDS diagnosis at baseline and a 
CD4 count below 200 cells/mm
3
. Of interest, neither the use of zidovudine vs stavudine 
nor efavirenz vs nevirapine was clearly associated with the risk of developing severe 
anaemia in this analysis. This would indicate that the occurrence of anaemia as a 
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toxicity is determined by baseline characteristics of the patients with those with 
advanced disease more likely to develop this event than those with earlier disease. 
Evidence from the DART study shows that in resource-limited settings, the risk factors 
for developing severe anaemia after initiating ART are female sex, baseline anaemia, 
low CD4 counts and low BMI with our data confirming 3 out of these 4 reported risk 
factors
487
. Furthermore, these same risk factors were identified to be associated with 
severe anaemia even before initiation of ART in another study
488
. Consequently 
attributing the cause of severe anaemia as toxicity to ART within the first few months of 
initiating therapy particularly among patients with advanced disease may be 
problematic hence the analysis thus presented should be viewed as one of associations 
not causative factors of anaemia. Another reason for this supposition from our data is 
the median time to occurrence of severe anaemia was within 2 months of initiating 
therapy. Clearly, these patients may not have had enough time on treatment to recover 
from the profound effects of HIV infection at this time point. There is the potential for 
on-going symptoms of HIV to be mis-diagnosed as toxicities necessitating premature 
treatment changes, hence stricter definitions of clinical toxicities may be useful to assist 
in diagnostic overlaps. The proposed mechanisms of anaemia in HIV disease involves 
an interruption of haematopoiesis through disruption of several cytokine mechanisms by 
HIV infection of bone marrow stromal cells and macrophages
489
. Use of zidovudine 
may be associated with severe anaemia however two separate models that took into 
account whether anaemia was present or absent at time of initiating cART did not reveal 
an independent association between zidovudine and risk of severe anaemia. Our data 
therefore suggests if zidovudine is carefully selected as part of initial ART regimens, 
the risk of developing severe anaemia on ART were similar among zidovudine- and 
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stavudine-recipients and that this risk is defined by patients characteristics rather than 
the specific components of the cART. Thus said among a subset of patients who started 
with no baseline anaemia, the use of zidovudine was more frequently associated with 
profound and life-threatening decreases in haemoglobin concentrations.  
Skin rash was the most commonly reported NNRTI-related adverse event with an 
incidence rate (95% CI) of 2.66 (2.37 – 2.98) events/100 person-years of follow up with 
a median time to occurrence of 2 months. The overall frequency of NNRTI-related skin 
rash in our cohort was 7.0% with a higher frequency of 10.2% among patients on 
nevirapine than 5.6% among efavirenz recipients. The reported frequencies of 
nevirapine-related rash range between 4% -38% 
4, 21, 22
 of patients while that of 
efavirenz is between 4.6%-20% among different ethnicities
4, 22, 23
. Thus the incidence of 
NNRTI-related skin rash within the present cohort is at the lower end of the spectrum. 
Severe to life-threatening skin rash were reported at a low frequency of 0.7% of 
nevirapine recipients and 0.2% of efavirenz recipients with 2 fatalities associated with 
nevirapine related skin rash, although this may be an under-estimation as potentially 
those who develop life-threatening and fatal skin rash may not have reported back to the 
clinic. Nevirapine was administered at a dose of 200mg once daily for the first two 
weeks as a lead-in dose followed by an escalation to 200mg twice daily according to 
locally recommended guidelines. When administered in this fashion, the risk for 
nevirapine related skin rash has been found to be reduced by 50%
198,199
.The risk factors 
identified in association with skin rash on adjusted analysis included nevirapine use, 
female gender and low baseline CD4 T-cell counts while higher WHO clinical stage, 
age lower than 40 years, lower BMI and hepatitis B sero-positivity were found to be of 
significance in unadjusted analysis (Table 5.4). 
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A cell-mediated hypersensitivity reaction has been postulated as one of the possible 
mechanisms for the development of NNRTI related skin rashes
21, 22, 190, 191
. Indeed in 
our cohort, a lower CD4 T-cell count at the time of initiating therapy followed by a 
more profound recovery in CD4 counts measured within 6 and 12 months were factors 
identified in association with NNRTI-related skin rash.  Thus our data support a 
mechanism akin to an immune reconstitution inflammatory syndrome where rapid 
restoration of CD4 T-cells elicit inflammatory responses to as yet to-be identified 
antigenic epitopes of which the NNRTI itself could be one among several other 
potential candidates. There is however a contrast between our data and that reported 
among Thai patients
22
 (n=210), in whom NNRTI skin rash was commoner among 
patients who had higher CD4 counts at baseline, had earlier clinical stages of HIV 
disease and had higher BMI. These differences could be due to differences in ethnicity 
and possibly genetic predispositions. Female gender was significantly associated with 
NNRTI-related rash as has been reported elsewhere
490-492
 and it is thought to be related 
to hormonal differences, gender related differences in cytochrome P450 metabolism or 
body size. However in many cohorts like ours, females are more adherent, less likely to 
withdraw from ART care and therefore more likely to report any adverse events. 
Neuropsychiatric toxicity due to NNRTI use has predominantly been reported among 
efavirenz recipients with a frequency ranging from 25% to 70% in various studies
23 ,201-
204
. In this cohort, the reported frequency of neuropsychiatric toxicity on efavirenz was 
7.6% while that on nevirapine was 2.4% with an admittedly low overall frequency of 
5.5% compared with other reports. It is well-known that most neuropsychiatric 
toxicities are mild to moderate and resolve after the first few weeks of therapy
23, 201 - 204, 
206
 and therefore may not have been reported or documented in patients’ records. As 
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expected, the median time to first episode of neuropsychiatric toxicity was within the 
first 2 months upon initiating therapy with most events occurring within the first year 
but as noted in Figure 5.4, even after the first year of therapy, some patients experienced 
toxicity as indicated by other
205, 206, 208
 authors. Whether the reported toxicities after 
more than 1 year of therapy represents exacerbations of chronic undocumented toxicity 
or new events occurring after continual use of efavirenz cannot be confidently 
ascertained due to the retrospective nature of this study. Again, the severity of 
neuropsychiatric toxicity and its impact on quality of life was not assessed with 
objective instruments such the Profile of Mood State (POMS-A) and Medical Outcomes 
Study-HIV (MOS-HIV)
493
 questionnaires and requires more studies to evaluate them 
further in the Ghanaian context.  
Most studies reporting efavirenz associated neuropsychiatric toxicity have been based 
on short-term follow-up of a few weeks but a cross-sectional study by Fumaz et al. 
among patients (n=60) who had been on efavirenz for a mean time of 91.1  39.5 weeks 
found that mild and clinically tolerable neuropsychiatric disorders persisted
255
. Our data 
shows that even up to 90 months, some patients reported experiencing efavirenz related 
neurotoxicity for which therapy changes were not performed, indicating that they may 
have been tolerable for the patients. Among our cohort, insomnia, headache, dizziness, 
abnormal dreams and drowsiness were reported at overall frequencies of 50.0%, 7.5%, 
6.7%, 5.6% and 5.2% respectively with higher incidences among efavirenz recipients 
compared with nevirapine recipients. Rarely reported events such as seizures, cerebellar 
disorders and suicidal ideations were reportedly attributed to efavirenz recipients by 
treating clinicians and these resolved after discontinuation of the implicated efavirenz. 
Cranial computed tomography scans were performed in the 3 reported cases of seizures 
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and 2 cases of cerebellar ataxia but were found normal. However it is well known that 
seizures and cerebellar disorders could be due to non-space occupying lesions such as 
HIV infection itself. But the resolution of these events upon discontinuation of efavirenz 
suggests that efavirenz may have contributed to its occurrence.  
The mechanisms for CNS toxicity caused by efavirenz remains to be elucidated. There 
are suggestions that exposure to supra-therapeutic levels due to slower metabolism of 
efavirenz from the highly prevalent CYP2B6 516 G>T polymorphisms among African 
Americans for instance could explain why neuropsychiatric disturbances are commoner 
among them than in European American or Hispanic patients
209
. Others have postulated 
that the neuropathic effects of HIV itself, the effect of efavirenz on cytokine 
homeostasis, previous predisposition towards neuropsychiatric disturbances and sleep 
disturbances may all contribute to central nervous system (CNS) toxicity
205, 206
. In this 
cohort, the only risk factors for neuropsychiatric toxicity were the use of efavirenz, 
229% higher risk compared with nevirapine, and a low body mass index below 16kg/m
2
 
with a 44% higher risk in adjusted multivariate analysis. This suggests that patients of 
low body weight may be exposed to higher concentrations of a fixed dosage of 600mg 
daily and thus predispose them to neuropsychiatric toxicity. In our cohort 17% of 
patients with documented CNS toxicity discontinued efavirenz due to neurotoxicity 
which is slightly on the higher side of the reported 4% to 10% of patients who 
discontinued efavirenz due to CNS or neuropsychiatric toxicity
23, 201 - 206
. This higher 
proportion of treatment-limiting CNS toxicity on efavirenz should viewed within a 
context of the possibility of under-reported events. However, the possibility also exists 
for higher therapeutic exposure to efavirenz because of the ethnicity defined high 
prevalence of mutant polymorphisms in the hepatic enzymes responsible for the 
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metabolism of efavirenz as has been explored in chapter 8. The lower incidence of these 
neuropsychiatric events among patients on nevirapine compared with efavirenz and the 
fact that all patients who switched from efavirenz to nevirapine did not experience any 
further episodes supports the recommendations for efavirenz to be switched to 
nevirapine in the few patients in whom CNS toxicity persists, is severe or have 
increased predisposition for developing them.  
Hepatotoxicity is one of the well-recognised components of the broad spectrum of 
antiretroviral therapy toxicity and elevations in serum hepatic enzymes have been 
described in association with all the major classes of antiretroviral drugs
28, 211, 494-501
. 
The frequency of severe hepatotoxicity among our cohort was 3.9%. There was no 
difference in the frequency of severe hepatotoxicity among efavirenz recipients-3.7% 
compared to 3.8% among nevirapine recipients, which are within the lower limits of 
reported frequencies of 1.1-8% and 1.4-17% in various studies
10, 24-28
. Thus the 
predisposition to this toxicity was comparable between the two NNRTIs among this 
Ghanaian cohort although nevirapine-associated hepatotoxicity occurred at an earlier 
median time of 6 months compared with 12 months in efavirenz-related hepatotoxicity, 
p=0.03. 
Among the several mechanisms proposed for the occurrence severe hepatotoxicity are: 
hypersensitivity reaction in association with non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), mitochondrial toxicity in association with several nucleoside 
reverse transcriptase inhibitors (NRTIs) and immune reconstitution inflammatory 
syndrome in association with chronic viral hepatitis
28, 211, 494-501
. Of these proposed 
mechanisms our data supports the role of chronic viral hepatitis in causing severe 
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hepatotoxicity on antiretroviral therapy in the Ghanaian population. Patients with 
hepatitis B co-infection had a 99% (95% CI 16% to 240%, p=0.01) higher risk of 
experiencing severe hepatotoxicity compared with sero-negative patients. It should be 
emphasized that hepatitis B screening data was not available for all patients and thus 
these results should be viewed as a sub-analysis of the whole cohort and thus incidence 
rates should be interpreted cautiously. HCV serology was also not available for all 
patients. Although the incidence of severe hepatotoxicity was high among HBV sero-
positive patients there were not differences in the risk among patients who were either 
on nevirapine or efavirenz. Among Thais, the risk of severe hepatotoxicity was highest 
among HBV sero-positive patients on nevirapine
362
 but this was not the case in our 
cohort. Over the long-term, these severe hepatoxicity were not associated with adverse 
outcomes such as death, in fact most transaminitis resolved with continual follow up 
with only 5.6% of events leading to NNRTI switch.  
The two most commonly reported mitochondrial toxities in this cohort were peripheral 
neuropathy and lipoatrophy with reported overall frequencies of 6.7% (95% CI of 5.6% 
to 7.8%) and 2.9% (95% CI of 1.9% - 3.8%) respectively. Among patients who were on 
stavudine the principal cause of these two toxicities, the frequencies were 11.3% 
(95%CI of 9.3% to 13.2%) and 6.5% (95% CI of 4.3% to 8.8%) over the median 
follow-up duration of 30 months (range 0-90 months). Among African cohorts the 
reported frequency of peripheral neuropathy and lipoatrophy was 20.7% and 2.2% 
(n=1,286) among Kenyans after 2 years of follow up
433
. However in a Cambodian 
cohort where patients were intensively screened for stavudine related toxicity, the 
frequency of peripheral neuropathy and lipoatrophy among stavudine recipients were 
19.0% and 72.4% respectively after follow up of 60 months
502
. Thus the low frequency 
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again could to due to under-reporting or could be due to the phasing out of stavudine 
usage from our national programme since the early 2009 upon recommendations of the 
WHO. Among the various ART medications the one most discontinued among 
Ghanaians is stavudine.  
The median time to the onset of peripheral neuropathy was 6 months and that of 
lipoatrophy was 42 months which generally supports the idea that these two principally 
stavudine-mediated toxicities are slow in developing. Thus in settings such as ours 
where options for changing are limited, a strategic phasing out of stavudine as has 
already been started may be implemented among carefully selected patients based on 
risk factors specific to this population. Among the risk factors identified in association 
with stavudine related toxicity were female gender, age>40 years and low haemoglobin 
concentrations as has also been reported among Cambodians
502
. Anaemia at baseline 
though is the primary reason for selecting stavudine for these patients and therefore it is 
difficult to completely extricate the cause- and effect- association here. Four fatal cases 
of suspected lactic acidosis was reported in our cohort. Indeed, it is possible that the 
incidence of lactic acidosis on stavudine may be higher than reported as can be 
observed by the high numbers of patients on stavudine who died or were lost to follow 
up within the first 6 months of initiating therapy (chapter 4). The true incidence of lactic 
acidosis or hyperlacticacidaemia is difficult to estimate due to the lack of facilities for 
its routine measurement.  
It has been clearly demonstrated in that the occurrence of adverse events on cART is 
linked with the risk of poor adherence to therapy
503-505
. Our data corroborates these 
observations by showing that the occurrence of any toxicity on cART was associated 
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with a 26% higher odds of sub-optimal adherence to therapy. This figure varied with 
different toxicities as shown in Table 5.10 with varied treatment discontinuation 
responses by clinicians (Table 5.11). For instance, it was observed that experiencing 
severe hepatotoxicity was associated with a higher odds of 72%, p=0.001 for sub-
optimal adherence however clinicians were willing to change therapy in only 5.6% of 
patients with this event. These low treatment discontinuations rates due to toxicity may 
reflect clinician preferences and limited options for changing therapy. These 
observations draw links between toxicity and adherence which consequently affects the 
long-term durability of cART.  
Certainly the durability of any cART regimen depends amongst other factors on its 
tolerability and its efficacy and this analysis in agreement with other published data 
suggests a significantly higher rate and earlier onset of discontinuation of nevirapine 
compared with efavirenz due to toxicity. Specifically, compared with efavirenz-based 
cART, patients initiating nevirapine-based cART were at a 89% higher risk of 
discontinuation due to treatment-limiting toxicity (p<0.0001). The common reasons for 
discontinuation of nevirapine as highlighted are hypersensitivity reactions such as skin-
rash and severe hepatotoxicity while efavirenz was commonly discontinued on account 
of neuropsychiatric toxicity. This is a significant observation highlighting a greater risk 
of treatment-limiting toxicity on nevirapine compared with efavirenz and has 
implications for developing strategies for identifying patients at higher risk for 
nevirapine toxicity and thus initiating therapy with efavirenz instead. These issues are 
dealt with in further details in chapter 6. 
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A number of limitations are worth mentioning in interpreting the data presented. This is 
a retrospective analysis, using data from a treatment programme setting. Therefore the 
reported rates of events are likely to under-estimate the real rates since some patients 
with severe toxicity may have been lost to attrition from the programme. For instance, 
the high withdrawal rates among males (chapter 4) means that any associations of 
between toxicity and gender should be interpreted with caution. There is also the 
possibility that events that were of mild nature may not have documented. However, 
patients were systematically evaluated at each clinical visit by clinicians, with standard 
clinical assessment, patient management and reporting. Still, it remains that the 
unavailability of technical investigations to more rigourously diagnose the different 
toxicites could have led to misclassifications. For example, there were no facilities on 
site to measure lactic acid concentrations in the sera of patients to better diagnose 
hyperlacticacidaemia nor was a dual energy X-ray absorptiometry (DEXA) scan 
available for accurate characterisation of lipoatrophy which had a low documented 
incidence overall. Thus said, the reported data demonstrate associations, and not 
causation.  
In summary, although toxicities due to specific agents were commonly reported, their 
incidence rates were generally lower than reported from other cohorts. Treatment 
discontinuations were few and patients generally did not experience worsening of 
events when maintained on their medications. Patients were more likely to discontinue 
nevirapine than efavirenz on account of documented toxicity. Toxicity was associated 
strongly with the risk for sub-optimal adherence. We next explore the long-term 
effectiveness of efavirenz-based cART with nevirapine based cART (chapter 6) and in 
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chapter 8 associations between random plasma concentrations of efavirenz and risk for 
CNS toxicity and immunological failure is presented.  
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CHAPTER SIX 
6.0 Comparison of long-term clinical and immunological responses to efavirenz- or 
nevirapine-based first line antiretroviral therapy among Ghanaians 
6.1 Introduction 
The World Health Organisation guidelines recommend that for resource-constrained 
settings, combination antiretroviral therapy (cART) should be initiated with a non-
nucleoside reverse transcriptase inhibitor (NNRTI), specifically either efavirenz or 
nevirapine with two nucleoside reverse transcriptase inhibitors (NRTIs) as 
backbone
1,506
. In spite of the widespread use of these NNRTIs, evidence of their 
effectiveness has been conflicting. A systematic review
31
 of seven randomised 
controlled trials found clinical equivalence of efavirenz and nevirapine
4, 507-512
. However 
clinical, immunological, virological and toxicity data from observational studies
5-20
 
conducted in low-, middle-, and high-income countries are quite disparate from those of 
experimental studies. For instance, the 2NN study (a large, placebo, open-label 
randomised controlled study) showed non-inferiority of nevirapine to efavirenz
4
. 
However, in one large observational well-attended, private-sector cohort study, among 
2,817 HIV-infected South Africans who initiated either efavirenz-based (64.7%) or 
nevirapine-based cART (35.5%), efavirenz was associated with superior clinical and 
virologic outcomes compared with nevirapine over a median follow-up time of 2.2 
years (range of 1 month to 3 years)
8
. 
On the basis of its more favourable toxicity profile and efficacy data, efavirenz is indeed 
preferred to nevirapine for initial therapy in resource-endowed countries
111, 190 
. But a 
WHO-led survey found that almost 67% of countries in Sub-Saharan Africa recommend 
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nevirapine-based regimens for first-line therapy because of lower cost and its 
availability in generic fixed dose combination regimens
513, 514
. But the use of nevirapine 
is limited by its toxicity profile and also by its adverse interactions with anti-tuberculous 
medications given to treat the vast majority of patients with TB-HIV co-infection who 
often would need to initiate therapy for both infections concurrently
515, 516
.  
In a meta-analysis comparing these two NNRTI’s the authors submitted that the 
differences in efficacy between efavirenz- and nevirapine-based cART may be subtle 
and that more studies are required to determine whether differences emerge over the 
long-term use
31
. Furthermore, in spite of the widespread use of these two NNRTI in 
Sub-Saharan Africa in routine clinical care, their long-term clinical and immunological 
outcomes have seldom been evaluated in these programmatic settings. The main 
objective of this chapter is therefore to compare the long term clinical and 
immunological outcomes of efavirenz-based cART with nevirapine-based cART among 
ART naïve HIV infected Ghanaians initiating therapy with two thymidine NRTI 
backbone of either zidovudine plus lamivudine or stavudine plus lamivudine. In chapter 
4 of this dissertation, it was shown that the hazards of disease progression, loss-to-
follow up and death were not significantly different among patients initiating either 
EFV or NVP but in chapter 5 it emerged that the risk for discontinuation of NNRTI on 
account of toxicity was significantly higher for nevirapine than efavirenz. Therefore in 
the present analysis, the primary outcome measure of treatment failure was a composite 
of deaths, clinical progression and all-cause treatment discontinuations using an 
intention-to-treat analysis. Secondary outcome analyses were performed to compare 
CD4 T-cell count changes, changes in body mass index and the impact of the NRTI 
backbone on the primary and secondary outcome measures of these two NNRTIs.  
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6.2 Methods 
Please refer to chapter 2.6 
6.3 Results 
6.3.1 Patient characteristics 
Included in this analysis are a total of 3,990 patients who started either an efavirenz-
based (n=2,369; 59.4%) or nevirapine-based (n=1,621; 40.6%) cART between January 
2004 and December 2010. Forty-nine (49) patients were excluded because they started 
on protease inhibitor-based cART (n=40) and 9 started with NRTI backbones other than 
zidovudine plus lamivudine or stavudine plus lamivudine. 
 As shown in Table 6.1, there is a female predominance in a ratio of 2:1 with a lower 
proportion of patients starting nevirapine-based cART being males (15.2%) compared 
with those starting efavirenz-based cART (43.4%). Patients starting efavirenz-based 
regimen were older [median age of 40 years, IQR of 35 to 47] and heavier [median 
weight of 51kg, IQR of 45 to 60 kg] than those starting nevirapine-based regimen with 
median age of 35 years (IQR, 30-42) and weight of 50kg (IQR, 44-59) respectively. 
There were however no differences in the proportion with prior diagnosis of AIDS in 
the two groups before initiation of therapy. The baseline median (IQR) CD4 count 
among patients initiating efavirenz-based cART was significantly lower compared with 
those initiating nevirapine-based cART; 127 (45-213 cells/mm
3
) vs 140 (56-220 
cells/mm
3
), p=0.004. Although patients starting efavirenz-based cART had significantly 
higher baseline serum concentrations of aspartate transaminase, alanine transaminase 
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and creatinine than those starting nevirapine-based cART, these differences were 
clinically deemed not significant and were thought to reflect the male gender bias 
among those initiating efavirenz. Also there were no differences in the serological status 
of hepatitis B co-infected patients. Of patients who commenced efavirenz-based cART, 
45.7% commenced with an NRTI backbone of zidovudine plus lamivudine compared 
with 50.4% starting on nevirapine-based cART while 54.3% and 49.6% starting 
stavudine plus lamivudine respectively. 
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Table 6.1 Characteristics of patients at time of starting combination anti-retroviral 
therapy. 
Characteristic Efavirenz, n=2,369 Nevirapine, n=1,621 p-value 
n % n % 2 
Gender      
Male 1027 43.4 246 15.2 <0.0001 
Female 1342 56.6 1375 84.8 
Prior AIDS      
Yes 1677 70.8 1105 68.2 0.13 
No 423 17.9 329 20.3 
Unknown 269 11.3 187 11.5 
Hepatitis B status      
Negative 1061 44.8 785 48.4 0.08 
Positive 180 7.6 116 7.2 
Unknown 1128 47.6 720 44.4 
NRTI backbone      
AZT and 3TC 1083 45.7 817 50.4 0.0036 
D4T and 3TC 1286 54.3 804 49.6 
Calender year      
2004 402 17.0 349 21.5 <0.0001 
2005 368 15.5 324 20.0 
2006 429 18.1 384 23.7 
2007 439 18.5 214 13.2 
2008 425 18.0 159 9.8 
2009 175 7.4 96 5.9 
2010 131 5.5 95 5.9 
 
 Median IQR Median IQR U-test 
Age (years) 40 35-47 35 30-41 <0.0001 
Body weight (kg) 51 45-60 50 44-59 0.05 
BMI (kg/m
2
) 19.6 17.4-22.3 19.9 17.6-22.9 0.002 
CD4 count (cells/l) 127 45-213 140 56-220 0.004 
Haemoglobin conc. (g/dl) 10.2 8.8-11.5 10.2 8.8-11.5 0.85 
Serum AST concentration (IU/l) 42 30-60 38 28-52 <0.0001 
Serum ALT concentration (IU/l) 31 21-46 26 19-37 <0.0001 
Serum creatinine conc. (mol/l) 88.4 70.7-110.5 79.6 67.0-98.4 <0.0001 
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6.3.2. Composite end-point analyses 
At closure of data for analysis, 2,096 (52.5%) patients were alive and still under follow 
up with none of the events of the composite outcome measures of treatment failure- 
1,238 (52.3%) were still on efavirenz-based cART and 858 (53.0%) were still on 
nevirapine-based cART without any event as shown in Figure 6.1. Seven hundred and 
sixty-six (19.2%) patients were lost to follow-up without experiencing any of the three 
events used as a composite end-point of therapy failure, 498 (21.0%) were on efavirenz 
and 268 (16.5%) were on nevirapine. One thousand one hundred and twenty-eight 
(1,128) representing 28.3% of patients initiating either one of these NNRTIs had at least 
one event in the composite end-point- 633 (26.7%) for efavirenz versus 495 (30.5%) for 
nevirapine. Among efavirenz recipients with therapy failure, 4 (0.6%) experienced all 
three events, 117 (18.5%) experienced 2 out of 3 events and 512 (80.9%) experienced 1 
out the 3 co-primary events of the composite end-point. Eleven patients (11, 
representing 2.2%) experienced all three events under follow up, 107 (21.6%) 
experienced 2 out of 3 events and 377 (76.2%) experienced one out of 3 co-primary 
events among nevirapine recipients. Although patients could have more than one of 
these events, only the earliest event was modelled in the Cox analysis.
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Figure 6.2 shows the Kaplan-Meier analysis for risk of composite events between the 
two NNRTIs with a hazard ratio and log-rank p-value of 0.90 (95%CI of 0.79 to 1.01) 
and 0.07 respectively among patients on efavirenz compared with nevirapine. In 
primary analyses, the risk of therapy failure among patients on nevirapine compared 
with efavirenz were 1.20 (0.97 to 1.49), p=0.10 in adjusted analysis using the Cox 
proportional hazards regression and 1.09 (0.79 to 1.49), p=0.61 after adjustment in the 
logistic regression model. Given the inequality of loss-to-follow up among the two 
treatment groups, sensitivity analyses compared the risk of therapy failure to account for 
confounding due to missing patients where loss to follow up was treated as failure. 
Similarly, in these sensitivity analyses the adjusted hazards ratio and odds ratio of 
therapy failure among patients on nevirapine compared with efavirenz were 0.97 (0.82-
1.15), p=0.73 and 0.98 (0.77-1.24), p=0.83 respectively.  
The main determinants of the composite outcome in both primary and sensitivity 
analyses with both models were initiating therapy below 40 years old, CD4 T cell 
counts below 200 cells/mm
3
, BMI <16kg/m
2
, AIDS diagnosis at baseline and poor 
adherence to therapy as shown in Tables 6.2 and 6.3. The combination of stavudine plus 
lamivudine was associated with an adverse composite outcome only in sensitivity 
analysis in both models. Because the composite end-point was an admixture of several 
treatment outcome measures, there was the need to explore the risk factors for each of 
these components to examine for differences if any between efavirenz- and nevirapine-
based cART. The risk factors for death, loss to follow up, disease progression on cART 
with respect to NNRTI have already been presented in Chapter four and the risk for 
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discontinuation on NNRTI due to toxicity in Chapter 5. The analyses presented below 
look at the risk for NNRTI discontinuations.  
 
 
   
 
Figure 6.2. Kaplan-Meier analysis showing risk of treatment failure defined as a composite of deaths, disease progression and NNRTI 
discontinuations.  
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Table 6.2. Univariate and multivariate Cox proportional hazards regression analysis of factors associated with composite failure 
on either efavirenz- or nevirapine-based first line cART (showing significant factors only). 
                                   Missing = Censored (Primary analysis)                            Missing = failure (sensitivity analysis) 
Variable Unadjusted HR p-value Adjusted HR p-value Unadjusted HR p-value Adjusted HR p-value 
NNRTI         
Nevirapine 1.07(0.95-1.21) 0.24 1.20(0.97-1.49) 0.10 0.94 (0.86-1.03) 0.17 0.97 (0.82-1.15) 0.73 
Efavirenz 1.00  1.00  1.00  1.00  
NRTI backbone*         
D4T plus 3TC 1.25(1.12-1.41) 0.0002 1.10(0.96-1.25) 0.16 1.30 (1.18-1.42) 0.0000 1.32 (1.05-1.65) 0.02 
AZT plus 3TC 1.00  1.00  1.00    
Age         
<40 years 1.19(1.05-1.34) 0.004 1.31(1.12-1.54) 0.0006 1.11 (1.01-1.22) 0.02 1.17 (1.04-1.31) 0.009 
 40 years 1.00  1.00  1.00  1.00  
Baseline CD4 strata         
<200 cells/mm
3 
1.63(1.42-1.88) 0.0000 1.47(1.27-1.69) 0.0000 1.62 (1.45-1.80) 0.0000 1.42 (1.28-1.59) 0.0000 
200 cells/mm3 1.00  1.00  1.00  1.00  
Baseline BMI         
<16 kg/m
2 
1.90(1.63-2.22) 0.0000 1.64(1.40-1.92) 0.0000 1.86 (1.66-2.10) 0.0000 1.63 (1.44-1.84) 0.0000 
16 kg/m2 1.00  1.00  1.00  1.00  
WHO clinical stage         
3 or 4 1.59(1.35-1.88) 0.0000 1.38(1.16-1.63) 0.0002 1.60 (1.41-1.83) 0.0000 1.38 (1.21-1.58) 0.0000 
1 or 2 1.00    1.00  1.00  
Adherence         
Poor 1.30 (1.16-1.47) 0.0000 1.30(1.16-1.47) 0.0000 1.29 (1.18-1.42) 0.0000 1.26 (1.15-1.38) 0.0000 
Excellent 1.00  1.00  1.00  1.00  
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Table 6.3. Univariate and multivariate logistic regression analysis of factors associated with composite failure on either efavirenz- 
or nevirapine-based first line cART (showing significant factors only). 
                                   Missing = Censored (Primary analysis)                            Missing = failure (Secondary analysis) 
Variable Unadjusted OR p-value Adjusted OR p-value Unadjusted OR p-value Adjusted OR p-value 
NNRTI         
Nevirapine 1.20 (1.04-1.38) 0.01 1.09 (0.79-1.49) 0.61 0.98 (0.87-1.12) 0.79 0.98 (0.77-1.24) 0.83 
Efavirenz 1.00  1.00  1.00  1.00  
NRTI backbone*         
D4T plus 3TC 1.18 (1.03-1.36) 0.02 1.06 (0.91-1.23) 0.48 1.35 (1.19-1.53) 0.0000 1.20 (1.04-1.38) 0.01 
AZT plus 3TC 1.00  1.00  1.00  1.00  
Age         
<40 years 1.25 (1.08-1.43) 0.002 1.40 (1.17-1.69) 0.0003 1.18 (1.04-1.34) 0.0083 1.31 (1.10-1.55) 0.002 
 40 years 1.00  1.00  1.00  1.00  
Baseline CD4 strata         
<200 cells/mm
3 
1.72 (1.46-2.01) 0.0000 1.57 (1.33-1.85) 0.0000 2.02 (1.76-2.33) 0.0000 1.72 (1.48-1.99) 0.0000 
200 cells/mm3 1.00  1.00  1.00  1.00  
Baseline BMI         
<16 kg/m
2 
1.70 (1.43-2.06) 0.0000 1.48 (1.22-1.81) 0.0001 2.18 (1.80-2.63) 0.0000 1.86 (1.52-2.27) 0.0000 
16 kg/m2 1.00  1.00  1.00  1.00  
WHO clinical stage         
3 or 4 1.56 (1.29-1.89) 0.0000 1.37 (1.12-1.66) 0.002 1.83 (1.55-2.16) 0.0000 1.52 (1.28-1.81) 0.0000 
1 or 2 1.00    1.00  1.00  
Adherence         
Poor 1.34 (1.16-1.54) 0.0001 1.30 (1.12-1.50) 0.0004 1.48 (1.30-1.68) 0.0000 1.37 (1.20-1.56) 0.0000 
Excellent 1.00  1.00  1.00  1.00  
   
Discontinuation of NNRTI treatment (all cause) 
For these analyses only patients who had at least one follow-up visit were included 
(n=3801). Four hundred and seventy-three 473 (12.4%) patients discontinued either 
EFV or NVP for all-cause while under care with 219 discontinuations on EFV (9.8%) 
and 254 discontinuations on NVP (16.1%). Figure 6.3 shows the Kaplan-Meier 
estimation of the probability of all-cause discontinuation of NNRTI. At 24 months after 
starting therapy, 13.9% (95% CI of 12.0-15.8%) were estimated to have discontinued 
nevirapine compared with 8.7% (95% CI of 7.4 - 10.0%) for efavirenz. Further on at 48 
months, the corresponding values were 19.8% (95% CI of 17.4 -22.2%) vs 15.0 % (95% 
CI of 12.9 -17.1%) and at 72 months 24.3% (95% CI of 21.2 – 27.4%) discontinued 
nevirapine compared with 18.5% (95% CI of 15.7 – 21.3%).  
On univariate analysis, the hazard ratio of all-cause discontinuation of nevirapine 
compared with efavirenz was 1.53 (95%CI of 1.29 – 1.87), p<0.0001. Other factors 
significantly associated with all-cause discontinuation of NNRTI were female gender 
HR (95% CI) of 1.48 (1.18-1.76), p=0.0002, age <40 years with HR (95% CI) of 1.42 
(1.19-1.71), p=0.0002 and baseline CD4 below 200 with HR (95% CI) of 1.47 (1.25-
1.83). On multivariate analysis, female gender was associated with an adjusted HR 
(95% CI) of 1.29 (1.03-1.63), p=0.03, baseline CD4 count <200 cells was associated 
with an adjusted HR of 1.49 (1.24-1.79), p<0.0001 and age < 40 years was associated 
with HR of 1.25 (95% CI of 1.03-1.51), p=0.03. The adjusted HR (95%CI) for all-cause 
discontinuation of NVP compared with EFV was 1.36 (95% CI of 1.11 – 1.65), 
p=0.003. 
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Figure 6.3. Kaplan-Meier analysis of risk of discontinuation of NNRTI for any reason. 
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Discontinuation of NNRTI due to clinically or immunologically determined treatment 
failure: Out of the 3,801 patients starting an NNRTI containing ART with at least one 
follow-up visit, there were 154 (4.1%) discontinuations as result of treatment failure 
(defined clinically or immunologically) requiring a switch to second line medications.  
83 (3.7%, n=2234) patients on efavirenz-containing ART compared with 71 (4.5%, 
n=1567) patients on nevirapine-containing ART discontinued therapy due to treatment 
failure. The median time to discontinuation of NVP-containing ART due to treatment 
failure of 30 months (range 6-78 months) was significantly longer compared with 24 
months (range 6-78 months) of patients on EFV-containing ART, p <0.0001 (Wilcoxon 
signed rank test). The unadjusted hazard ratio of discontinuing a NVP-containing ART 
compared to an EFV-containing ART regimen as a result of therapy failure was 1.03 
(95% CI of 0.75 to 1.42), p=0.84 (shown in Figure 6.4). After adjusting for gender, CD4 
count, WHO clinical stage and NRTI backbone, the risk of treatment failure indicated 
discontinuation of nevirapine compared with efavirenz was not significantly different, 
HR of 1.21 (95% CI of 0.85 to 1.73), p=0.28. 
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Figure 6.4. Kaplan-Meier risk of discontinuation of NNRTI due to therapy failure.
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Discontinuation of NNRTI due to toxicity: There were 61 (3.9%, n=1567) 
discontinuations of nevirapine compared with 37 (1.7%, n=2234) discontinuations of 
efavirenz due to drug related toxicity. The median time to discontinuation of nevirapine 
was 2 months (range, 2 to 56 months) compared with efavirenz of 12 months (range, 2 
to 48 months), p=0.0028 (Mann-Whitney’s U-test). The unadjusted hazard ratio of 
discontinuation of nevirapine compared to efavirenz as a result of toxicity was 2.27 
(95%CI, 1.55 to 3.46), p<0.0001. In a multivariate Cox proportional model, the risk of 
discontinuation of nevirapine compared with efavirenz on account of toxicity was 1.89 
(1.22-2.92), p=0.004 after adjusting for gender, CD4 count, WHO clinical stage and 
NRTI backbone. Also, after adjusted analysis females did not have a significantly 
higher risk of discontinuing NNRTI on account of toxicity compared to males in this 
model. 
Discontinuation of NNRTI due to other reasons: 120 patients discontinued nevirapine 
and 99 patients discontinued efavirenz due to reasons other therapy failure or drug-
related toxicity.  The other reasons were discontinuations of nevirapine included, (a) 
substitution for efavirenz to prevent drug interaction with rifampicin in patients on 
concurrent anti-tuberculous therapy (n=35), (b) shortage of nevirapine supply (n=6) and 
(c) no recorded reasons (n=79). Similarly, the other reasons for discontinuations of 
efavirenz were, (a) substitution for a protease inhibitor due to the fact that patients had 
HIV-1/2 dual infection (n=2), (b) females got pregnant while taking efavirenz (n=19), 
(c) females in their reproductive age who wished to change efavirenz because they were 
preparing for conception (n=3) and (d) no recorded reason (n=75). Compared with 
efavirenz-based cART, patients initiating nevirapine-based cART had an unadjusted HR 
of 1.56 (95% CI of 1.22 to 2.05, p=0.0005) of discontinuation for other reasons but an 
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adjusted HR of 1.22 (0.92-1.61), p=0.14. The factors which remained significant upon 
adjusted analysis were female gender and age<40 years. 
Subset analysis of primary outcome measure to examine for backbone effect: 
Efavirenz vs nevirapine on a backbone of stavudine plus lamivudine: On adjusted 
analysis with the Cox proportional hazards regression model, the hazard ratios of failure 
on nevirapine compared with efavirenz were 1.03 (0.87-1.22) and 0.95 (0.84-1.08) 
using either a missing= censored or missing = failure approach respectively and 
similarly, the adjusted odds ratios were 1.09 (0.89-1.33) and 0.91 (0.76-1.11) 
respectively using the multiple logistic regression. Thus on a backbone of D4T plus 
3TC, there were no significant differences in the risk for failure on either NVP or EFV. 
Efavirenz vs nevirapine on a backbone of zidovudine plus Lamivudine: On adjusted 
analysis with the Cox proportional hazards regression model, the hazard ratios of failure 
on nevirapine compared with efavirenz were 1.20 (1.00-1.43), p=0.05 and 1.02 (0.88-
1.19), p=0.76 using either missing= censored or missing = failure approach respectively 
and similarly, the adjusted odds ratios were 1.31 (1.06-1.62), p=0.01 and 1.05 (0.85-
1.28), p=0.67 respectively using the multiple logistic regression suggesting a difference 
in favour of EFV over NVP on a backbone of AZT plus 3TC . 
Secondary end-point analyses: 
CD4 T-cell count changes over time 
The median (IQR) CD4 counts of patients initiating EFV-based ART of 127 (45 – 212 
cells/mm
3
, n=2354) was significantly lower than those initiating NVP-based ART of 
141 (56 – 221 cells/mm3, n=1615), p=0.003. Amongst both patient groups similar trends 
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in CD4 increases were also observed as shown in Figure 6.5. Briefly, the changes in the 
median CD4 counts in the EFV-based ART group compared to the NVP-based group 
were 279 (171 – 421, n=1090) vs 284 (177 – 419, n=975), p=0.90 at 24 months, 370 
(245 – 520, n=469) vs 359 (232 – 543, n=583), p=0.81 at 48 months, 390 (245 – 556, 
n=277) vs 377 (236 – 558, n=377), p=0.64 at 60 months, 436 (307 – 633, n=211) vs 418 
(241 – 581, n=289), p=0.13 at 72 months and 513 (367 – 674, n=26) vs 546 (378 – 749, 
n=43), p= 0.75 at 90. 
In a Generalised linear mixed effects model, the changes in CD4 counts of patients on 
d4T-containing cART were generally higher than those on AZT-containing cART with 
slight differences in slopes according the NNRTI-base as shown in Figure 6.6. The 
slope of CD4 change on d4T compared with AZT was 0.08 cells/mm
3
/month (standard 
error of 0.003), p<0.0001 whilst that for EFV compared with NVP increased at a rate of 
0.003 cells/mm
3
/month (standard error of 0.004), p<0.0001. Other factors associated 
with CD4 changes on cART were gender, age and WHO stage with greater increases in 
females compared to males, decreasing age and earlier WHO clinical stages.  
 
 
 
   
 
Figure 6.5. Comparison of median (IQR) of change in CD4 from baseline in patients initiating either EFV-based vs NVP-based cART. 
Double asterixes are for statistically significant difference of <0.01 by Mann-Whitney U-test. 
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Figure 6.6. Generalised linear mixed effects model of changes in CD4 counts with time on cART. AZT:EFV= zidovudine + lamivudine + 
efavirenz; AZT:NVP= zidovudine + lamivudine + nevirapine; D4T : EFV = stavudine + lamivudine + efavirenz; D4T:NVP= stavudine + 
lamivudine + nevirapine. 
   
 Body mass index changes over time 
The median (IQR) BMI of patients starting EFV-based of 19.6 (17.4 – 22.3 kg/m2, 
n=2307) was significantly lower than 19.9 (17.6 – 23.0kg/m2, n=1595) of those 
starting an NVP-based ART, p=0.002. As shown in Figure 6.7, a pair-wise 
comparison of median BMIs on treatment showed that patients on NVP were more 
likely to have a higher BMI than those on EFV. In a linear mixed effects model, 
changes in BMI were comparably higher amongst patients on NVP than those on 
EFV with a backbone of AZT plus 3TC (Figure 6.8A). However on a backbone of 
D4T plus 3TC, non-significant differences in BMI changes over time were identified 
for patients on either NVP or EFV (Figure 6.8B). Also BMI changed by 
0.57kg/m
2
/month (standard error, [SEM] of 0.16) faster amongst females compared 
with males, p=0.0004 and compared with patients with WHO stage 4 at baseline, the 
slope of BMI changes amongst patients with WHO clinical stages 3, 2 and 1 were -
0.59 (SEM of 0.18, p=0.001), -0.79 (SEM of 0.26, p=0.002) and -0.92 (SEM of 0.31, 
p=0.003).
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Figure 6.7. Changes in BMI on either efavirenz or nevirapine-based cART. Each rectangle and bar represents median and Interquartile 
range. 
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Figure 6.8. A linear mixed effects model of changes in BMI with time on cART. (A) compares EFV vs NVP on an AZT + 3TC backbone 
and (B) compares EFV vs NVP on a D4T + 3TC backbone. 
 
   
6.4 Discussion 
For millions of patients with HIV-1 infection in Sub-Saharan Africa antiretroviral 
therapy is initiated with a combination of a non-nucleoside reverse transcriptase 
inhibitor-base of either efavirenz or nevirapine with a backbone of two nucleoside 
reverse transcriptase inhibitors commonly zidovudine plus lamivudine or stavudine plus 
lamivudine within national ART treatment programmes. The choice of the NNRTI is 
driven by clinical indications, physician and or patient preferences, availability of 
medications and ability to monitor for the development of adverse events. This study 
shows that under these settings, the long-term clinical and immunologic treatment 
outcomes are comparable whether efavirenz or nevirapine is chosen to initiate therapy. 
The primary composite outcome measure comprising of deaths, clinical progression and 
discontinuation of NNRTI for all-causes showed that compared with efavirenz, the 
adjusted hazards and odds ratios of therapeutic failure for nevirapine were 1.20 (0.97 to 
1.49), p=0.10 and 1.09 (0.79 to 1.49), p=0.61 respectively. There were no discernible 
differences in the risks for death and disease progression between both group treatment 
groups on adjusted analyses. There was however a divergence in the risk for all-cause 
discontinuation of NNRTI use with a 36% (95% CI of 11% to 65%), p=0.003 higher 
risk of discontinuation of nevirapine compared with efavirenz in adjusted analysis. The 
dominant reason for this observed difference in NNRTI discontinuation was due to the 
89% (95% CI of 22% to 192%) higher risk of nevirapine causing treatment limiting 
toxicity compared with efavirenz, p=0.004. 
As discussed in Chapter 5 of this dissertation, compared to efavirenz, patients on 
nevirapine were more likely to discontinue therapy on account of treatment-limiting 
skin rash or severe to life threatening hepatotoxicity while efavirenz was more likely to 
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be discontinued on account of severe central nervous system adverse events. In various 
studies, the frequencies of severe grade 3 or 4 rash have varied widely with 3.4% among 
patients on nevirapine twice daily dose in the 2NN study
4
, 7% in the ATLANTIC 
study
517
 and 4% in the INCAS study
518
.  Again, there were more treatment 
discontinuations for liver-associated laboratory abnormalities among patients on 
nevirapine than efavirenz, although the frequencies of grade 3 and 4 elevations in liver 
transaminases were comparable for both efavirenz and nevirapine (Chapter 5). These 
results show that overall, efavirenz was better tolerated by patients than nevirapine due 
to toxicity in this cohort with two fatal cases of nevirapine-associated Stevens Johnsons 
syndrome from nevirapine.  
The most significant period for adverse treatment outcomes are within the first six 
months after initiation of treatment. During this period nearly 50% of all deaths, loss to 
follow ups, treatment discontinuations due to toxicities and disease progression were 
observed. The risk of disease progression was comparable among patients on either 
nevirapine or efavirenz. The major determinants of further AIDS defining events on 
treatment were the well established baseline risk factors such as starting with a low CD4 
count, low body mass index and having advanced disease at baseline while the most 
significant on-treatment factor identified in association with clinical progression was 
poor adherence. The commonest amongst the AIDS defining events that occurred was 
tuberculosis, for which reason treatment of nevirapine had to be substituted for 
efavirenz to allow for treatment of tuberculosis with anti-tuberculous medications due to 
the complex interactions that exists between rifampicin and nevirapine
515,516
. This 
interaction is such that co-administration of rifampicin with nevirapine leads to sub-
therapeutic exposure of nevirapine with attendant risk of loss of virologic suppression. 
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Of note a number of patients who developed disease progression were lost to follow-up 
after these events were diagnosed and treatments for these opportunistic infections were 
initiated. Loss-to-follow up is a common outcome or confounder in most HIV 
antiretroviral therapy cohorts in SSA where cART is initiated when patients have 
advanced HIV disease. The risk factors identified for loss-to-follow up in this cohort 
has been discussed in Chapter 4. Loss-to-follow up was not included as an outcome 
measure in the primary analysis because although patients who withdrew from the 
programme may inevitably experience a deterioration of their clinical status without 
cART, such an adverse outcome measure could not be directly attributed to a failure of 
therapy per se. However, it is conceivable that drug toxicities may engender loss-to-
follow up which could be a medication-associated reason for withdrawal from the 
treatment programme. Conversely, most patients lost to follow up were found to have 
died in a survey of 210 patients out of the 934 patients who were lost to follow-up in the 
present cohort (Chapter 3) which suggests the possibility that withdrawal from care may 
be due to either unreported deaths from disease progression, fatal toxicities or migration 
to other treatment centres. Either way, the inclusion of loss-to-follow up as an outcome 
measure in sensitivity analyses where missing was treated as a failure yielded similar 
outcomes in both the Cox and logistic regression models with the adjusted risk of 
treatment failure of 0.97 (0.82 to 1.15) and 0.98 (0.77-1.24), p= 0.73 and 0.83 
respectively comparing efavirenz with nevirapine. 
Deaths were mainly recorded during the very proximal periods of follow up and were 
determined predominantly by the severity of baseline immunosuppression and by 
advanced clinical disease. Interestingly, the state of immunosuppression measured by 
CD4 T-cells counts and clinical stage of disease were independent and non-interactive 
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factors in predicting each of the components of the composite measures of treatment 
failure (data not shown). When the cause of death was known, it was more frequently 
due to tuberculosis. Indeed, the relatively disproportionate numbers of patients who 
started efavirenz compared to nevirapine in this cohort was because of concurrent anti-
tuberculous medications which these patients were taking when cART had to be started. 
This is probably one of the reasons for the significantly lower CD4 counts among 
patients who initiated efavirenz compared with nevirapine, median of 127 vs 140 
cells/mm
3
 respectively, p=0.004. However during follow up, CD4 responses were 
robust among survivors in both treatment groups over time (Figures 6.5 and 6.6) and 
were accompanied by positive changes in body mass index (Figure 6.7). In the 
generalised linear mixed model, the slope of CD4 changes over 90 months follow up 
were comparable overall, although there was a statistically significant higher rate of 
increase among patients on efavirenz compared with nevirapine at a rate of 0.003 
cells/mm
3
/month. In addition patients on a backbone of D4T plus 3TC increased CD4 
counts at a faster rate compared with those on AZT plus 3TC, indicating that the 
backbone selected for initiating cART had an impact on CD4 recovery. It is to be 
recognised though that this difference was statistically significant by virtue of the large 
sample size and may be minimal clinical relevance. However, it is noteworthy that in a 
subset analysis where the two NNRTIs were compared on either an AZT plus 3TC or 
D4T plus 3TC backbone, patients on an AZT+3TC backbone with efavirenz had a 20% 
lower adjusted hazard and 31% lower adjusted odds of composite treatment failure 
(missing= censored analysis) compared with those on nevirapine, p=0.05 and 0.01 
respectively but no such differences were observed on a D4T+3TC backbone. Thus 
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there appears to be subtle differences in risk of treatment failure of NNRTI dependent 
on the NNRTI backbone as has been previously shown by Annan et al
22
. 
To a large extent switching to second line therapy due to treatment failure was 
determined using immunological criteria. The risk of immunologically determined 
treatment failure warranting therapy change to second line were comparable in both 
groups with an adjusted hazard ratio of 1.03 (95% CI of 0.75 to 1.42), p=0.84 among 
nevirapine (71 patients) compared with efavirenz (83 patients). Because immunological 
failure was determined after at least one year of cART, there is a potential risk for 
development of virological falure with emergence of resistance strains and studies are 
proposed to answer these questions in the future. 
 There is some difficulty in comparing this data with those of other cohort studies 
because whereas the effectiveness of the efavirenz- or nevirapine-based cART has been 
compared using predominantly clinical and immunological outcomes over the long-term 
under routine care in a programme setting, the previously reported cohorts have focused 
on short-term virologic and immunologic outcomes with somewhat limited clinical 
outcome measures due to the relatively short durations of follow-up. For instance, in a 
cohort of 888 patients, Matthews and colleagues found a hazard ratio for therapy failure 
at 24 weeks of 2.03 (1.26 to 3.18) for patients starting nevirapine-based cART 
compared with those starting an efavirenz-based cART
18
. Again, in a study by Keiser 
and co-workers
19
, involving 1,078 patients, efavirenz (n=555) was found to be superior 
to nevirapine (n=523) with regard to time to virologic failure and the proportion of 
patients with HIV-1 RNA below the detection limit of <400 copies/mL over 192 weeks 
of observation. Similar results were observed in the Italian cohort of naïve HIV 
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patients
519
 (n=694) and also in the South African cohort
8
 (n=2,817) with adjusted 
hazards ratios of virologic failure of 2.08 (1.37-3.15) and 1.52 (1.24 to 1.86) 
respectively. Annan and colleagues
5
 found among a British cohort of 994 anti-retroviral 
naïve patients that the two NNRTIs were comparable in their 6-month time to 
virological success: efavirenz 71%, nevirapine 72%, p=0.77. In a more recent study, 
involving 14,857 from North American and European cohorts in the HIV-CAUSAL 
collaboration
20
, efavirenz was shown to be associated with lower mortality, lower 
incidence of AIDS-defining illnesses, a larger increase in CD4 count at 12 months and a 
smaller risk of virologic failure at 12 months compared with nevirapine
20
. Virologic 
end-points admittedly are probably the most sensitive surrogate markers of treatment 
efficacy in HIV treatment due to its ability to predict long-term clinical and 
immunological events which this study captures due to its considerable length of follow 
up and the large number of patients compared with previous cohorts.  
The choice of treatment efficacy end-points has varied among different observational 
and experimental studies. In the 2NN study, therapy failure was defined as a composite 
of deaths, withdrawals, treatment discontinuations and virologic failure. In that large 
randomised controlled trial, the treatment efficacy end-points were chosen to compare 
efavirenz with nevirapine with the overall goal that for first line cART to be effective 
and durable, they must have minimal toxicity to have the greatest chance of achieving 
viral suppression. Under these experimental conditions, nevirapine administered twice 
daily was found to be non-inferior to efavirenz, the difference between nevirapine and 
efavirenz was 5.9% (95% CI of -0.9 to 12.8%). The end-points for this study were 
chosen to approximate those of the 2NN study
4
 but of course without viral load 
outcomes and randomisation. On its own merit, although this study lacks the elegance 
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of virologic end-points in the assessment of therapeutic efficacy, the outcome measures 
chosen assess the effectiveness of these NNRTI by comparing tolerability, clinical and 
immunological outcomes. Again, very limited exclusions were imposed in selecting 
patients for this analysis in order to compare the treatment effect of these 2 medications 
as they are used in under field settings. Further the composite outcome measures were 
analysed using both Cox proportional hazards and multiple logistic regressions with 
sensitivity analyses to minimize confounding but in all these analyses, the two 
medications were comparable in the composite outcomes. Finally, with the exception of 
treatment discontinuations due to toxicity, nevirapine was comparable to efavirenz in 
the risks for death, disease progression and proportion with loss to follow-up.  
There are a number of limitations to this study worth noting. The analysis was based on 
data from a retrospective observational cohort study and is subject to all the biases that 
are inherent with cohort studies. Although many biases can be accounted for in adjusted 
analysis, there may still be unmeasured confounders that could not be accounted for. 
This is because unlike randomised controlled trials, cohort studies are prone to biases 
such as confounding by indication or some other factors which may be difficult to 
exclude. For instance, a higher proportion of patients prescribed nevirapine-based cART 
were females (84.7%) compared with males (15.3%) in order to avoid the potentially 
teratogenic effects of efavirenz in a predominantly young female population in their 
reproductive age, which introduced some selection bias. However two robust 
methodologies namely Cox proportional hazards regression and multiple logistic 
regression were used to examine the primary outcome measure with sensitivity analyses 
performed with the aim of minimizing confounding. The composite end-point had as a 
component treatment discontinuations due to other reasons such as non-availability of 
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medications which led to permanent substitutions even though the limited medications 
became available later on. Also, as it is evident from Chapter 5, although grade 3 and 4 
hepatic enzyme elevations were of comparable frequencies in both efavirenz and 
nevirapine users, physicians were more likely to change nevirapine for this event. Thus 
the chosen composite outcome measure had a component which could be influenced by 
patient management by clinicians. Again, some treatment discontinuations were not 
explained because reasons for discontinuations were not always recorded in patient’s 
folders which could potentially introduce information bias. Data on teratogenicity 
among females who became pregnant on efavirenz were not available in the patients’ 
records. The findings from this study are based on observations from a single treatment 
site in West Africa where although uniformity in level of care is expected, there could 
be differences in treatment practises emerging because clinicians providing care for 
HIV patients had different levels of expertise ranging from physician specialists, 
medical officers, nurses and allied health workers in a busy out-patient clinic which 
could influence the quality clinical decision making. This notwithstanding, 
consultations among health workers are routinely held during clinics to assure standard 
practises. Thus said, it should be noted that the main aim of this study was to compare 
efavirenz with nevirapine under operational conditions in programmatic settings in Sub 
Saharan Africa where resources are indeed limited with heavy clinics. Clearly, the 
decision to select one NNRTI over the other or change therapy due to adverse effects in 
a cohort study such as this present one is subject to a selection bias driven by the 
physicians’ preconceived ideas about efficacy and safety of therapy regimen. 
In conclusion, under programme settings as it pertains in most resource constrained 
settings, there were no significant differences in the long-term clinical and 
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immunological outcomes among patients initiating either efavirenz- or nevirapine-based 
cART in this large Ghanaian cohort of naïve HIV-patients. Nevirapine however was 
more likely to be discontinued for adverse toxicity compared with efavirenz. Certainly, 
this cohort has been set up to study these 2 NNRTIs over the long-term with 10-year 
outcome analyses planned in the next two years (2014). The hope is that viral load 
monitoring would have become part of the routine care, so that they could be included 
in these future studies. 
 
   
CHAPTER SEVEN 
A prospective study of tolerability and pharmacokinetic interactions between 
efavirenz and artemisinin-based antimalarial therapy in Ghanaian HIV patients 
Introduction 
Human Immunodeficiency Virus (HIV) and Plasmodium falciparum malaria have a 
large geographical overlap in sub-Saharan Africa, causing significant morbidity and 
mortality and various new therapeutic challenges. Whilst current World Health 
Organisation (WHO) recommendations on the management of malaria do not differ for 
HIV patients, few studies have assessed the interactions between antiretrovirals (ARVs) 
and antimalarials. Indeed a 2004 WHO report identified that urgent research is required 
into the pharmacodynamic and pharmacokinetic interactions between antimalarials and 
ARVs
520
.
 
 
Artemesinins are plant-derived peroxide antimalarials active against the sexual and 
asexual forms of Plasmodium sp and are generally well tolerated, safe and effective (in 
study populations)
521
.
 
Despite recent concerns over the development of resistance in 
western Cambodia, artemesinin-based combination therapy (ACT) remains the policy 
standard first-line treatment for uncomplicated malaria in Africa
522, 523
. The increasing 
use of artemesinins and increasing access to ARVs (in areas of high HIV prevalence) 
raises the likelihood of co-prescriptions, yet minimal data exists for the safety and 
efficacy of ACT in these populations
524
.
 
Many such pharmacokinetic interaction 
outcomes have been predicted and described but published data remains scarce 
343, 525 
.  
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Despite WHO recommendation that artemesinins should be combined with a second 
antimalarial drug with a longer half-life, many countries use artemesinins alone for a 
variety of reasons including tolerability, supply of alternative drugs and cost. Artesunate 
(AS) is a commonly used semi-synthetic water-soluble artemesinin which is safe and 
effective in severe malaria
526
. It is a prodrug which is rapidly biotransformed by 
Cytochrome P450 (CYP450) 3A4 subfamily to dihydroartemsinin (DHA) with a half-
life of 2-5 minutes after intravenous administration
526
. This highly potent active 
metabolite DHA is eliminated by glucoronidation with a half-life between 40-60 
minutes. Artemisinins have been shown to be inducers of CYP3A4 in primary human 
hepatocytes and have been observed to have clinically significant effects on both 
CYP3A4 and CYP2B6
527 - 529
, even after a single dose.
 
Common adverse effects include 
nausea, vomiting and gastrointestinal disturbance, whilst more infrequent side effects 
such as neutropenia, haemoglobinuria and anaemia have been previously reported
530
. 
Neurotoxicity has been proven both in vitro and in experimental animal studies, in 
which there was selective damage to brain stem nuclei
531, 532
. 
 
The significance of this 
neurotoxicity in humans is unclear however isolated case reports and one case series 
have attributed hearing loss
533
, cerebellar dysfunction
534
 and tremor
535
 to artemesinins 
but this has not been validated in further neurophysiological studies or 
neuropathological studies
536, 537
. One of the few studies published on artemisinin drug 
interactions with antiretrovirals looking at artesunate PK (in combination with 
amodiaquine) in patients taking efavirenz was terminated early due to hepatotoxicity in 
several patients 
345, 538, 539 
. 
 302 
The NNRTI efavirenz, widely employed in WHO first line regimens, is primarily 
metabolized by CYP2B6 and is known to induce CYP3A4 
276, 343
. These common 
metabolic pathways mean a significant interaction is likely which may compromise both 
the safety and efficacy of either the antiretroviral or the antimalarial. Under randomized 
trial conditions efavirenz has been found to be safe and well tolerated. However it is not 
certain whether a pharmacokinetic interaction between efavirenz and co-administered 
artesunate could potentiate side effects of either medication and whether this will 
influence their efficacy. In Ghana artesunate is sometimes used as a single antimalarial 
agent providing an opportunity to study this drug alone when co-prescribed with 
efavirenz. The aims of this study were to determine the effect of steady state therapy 
with efavirenz on artesunate/DHA pharmacokinetics, to investigate the effect of 
artesunate on steady state concentrations of efavirenz and to evaluate the safety and 
tolerability of artesunate co-administered with efavirenz by assessing symptoms or 
laboratory features of toxicity of artesunate/DHA and efavirenz and to evaluate other 
surrogate markers for reduced drug levels of antimalarial such as failure of malarial 
parasite clearance - early treatment failure - in those with positive blood films. 
Methods 
Please refer to chapter 2 section 2.7 
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Results 
Baseline demographic, clinical and laboratory features of study participants at 
recruitment. 
Twenty-five (25) HIV-infected patients and 21 patients whose HIV sero-status (referred 
to as controls from hence) was unknown were recruited into the study. Three HIV-
infected patients were excluded because they did not complete the study by missing day 
5 visits. The HIV-infected patients were significantly older than control patients, 
median age of 49 years (range 27-67) compared with 25 years (range 17-45), p<0.05.  
Seventeen (17) HIV-infected patients were females while 12 of the controls were 
females with no significant differences in gender distribution. Among the HIV-infected 
patients, all were on a nucleoside reverse transcriptase inhibitor backbone of zidovudine 
plus lamivudine except two patients who were on stavudine plus lamivudine. The 
median duration on cART for the HIV-infected patients was 26.5 months (range of 1.25 
to 50.75 months) with a median CD4 count at the time of recruitment into study of 407 
(range of 38 to 1035 cells/mm
3
). 
Table 7.1 shows the frequencies of clinical symptoms of both HIV-infected and controls 
at recruitment for suspected malaria with headache, fever and sleeping difficulties often 
the commonest complaints. The HIV-infected group presented after having experienced 
symptoms for a median of 7 days (range 1 to 14 days) compared with 3 days (range of 1 
to 7 days) for the control group, p=0.01.  A significant proportion of HIV-infected 
patients on efavirenz-based cART reported having nightmares compared with control 
group while significantly more among the control group admitted to having nausea and 
vomiting compared to the HIV-infected group. Clinical examinations were not 
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remarkable for both groups of patients except for 6 patients who had pyrexia with 
temperature above 37.8
0
C, 5 in the control group and 1 HIV-infected group. There were 
several dissimilarities in the haematology and serum biochemistry results between the 
two groups as shown in Table 7.2. Briefly, HIV-infected patients had significantly 
lower haemoglobin concentrations with higher mean corpuscular red cell volume and 
haemoglobin and consequently wider red cell distribution width compared with control 
patients. HIV-infected patients had significantly lower total white cell and neutrophil 
counts as well as lower serum creatinine, albumin and total bilirubin concentrations than 
controls. Only 4 controls and 1 HIV-infected patient had malaria parasites on slide 
examination with a geometric mean level of parasitemia of 3,312/l (95% CI of 314.6 
to 34,866/l; range of 255 to 39,300). 
 
   
Table 7.1. Frequency of symptoms of malaria and potential toxicity of efavirenz or artesunate among HIV-infected and control patients.  
Symptoms Number of patients reporting symptoms Fisher’s exact test 
HIV+ (n=22) HIV+ HIV- (n=21) HIV- p-value
1 
p-value
2
 p-value
3
 p-value
4
 
Day 1 Day 5 Day 1 Day 5     
Chest pain 1 1 2 0 ns ns ns ns 
Palpitations 6 4 4 0 ns ns ns ns 
Dizziness 7 2 6 0 ns ns 0.02 ns 
Blackouts 0 0 0 0 ns ns ns ns 
Shortness of breath 1 4 2 0 ns ns ns ns 
Fever 20 0 16 0 <0.0001 ns <0.0001 ns 
Headache 21 2 17 3 <0.0001 ns <0.0001 ns 
Weakness of arms/legs 2 1 5 0 ns ns 0.05 ns 
Difficulty walking 1 0 0 0 ns ns ns ns  
Difficulty sleeping 12 6 7 0 ns ns 0.009 0.02 
Nightmares 9 3 2 0 ns 0.03 ns ns 
Difficulty concentrating 0 0 0 0 ns ns ns ns 
Suicidal thoughts 0 0 0 0 ns ns ns ns 
Visual disturbance 2 2 1 2 ns ns ns ns 
Speech disturbance 0 0 0 0 ns ns ns ns 
Hearing problems 2 1 0 0 ns ns ns ns 
Fits/ faints 0 0 0 0 ns ns ns ns 
Numbness/pins 9 4 7 1 ns ns 0.04 ns 
Tremor 0 1 0 0 ns ns ns ns 
Diarrhoea 0 0 2 0 ns ns ns ns 
Nausea and vomiting 0 1 5 1 ns 0.02 ns ns 
Rectal bleeding/ melena 0 0 0 0 ns ns ns ns 
Jaundice 0 0 0 0 ns ns ns ns 
Pruritus 2 2 2 0 ns ns ns ns 
Skin rash 1 1 1 0 ns ns ns ns 
1 compares proportion with specific symptoms among HIV-infected patients before and after course of Artesunate (day 1 vs day 5); 2 compares HIV-infected and non-infected patients before course of 
Artesunate (day 1); 3 compares HIV-non-infected patients before and after course of Artesunate (day 1 vs day 5); 4 compares HIV-infected and non-infected patients after course of Artesunate (day 5). 
Parenthesis refers to nervous system symptoms. 
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Table 7.2. The haematology and serum biochemistry results among HIV-infected and non-infected controls before and after a 5-day 
course of artesunate 200mg twice daily for clinically suspected malaria.  
Variable HIV patients 
median (range) 
Controls 
median (range) 
HIV patients 
median (range) 
Controls 
median (range) 
p-values
1
 p- 
values
2 
p-values
3 
 Day 1 Day 1 Day 5 Day 5    
Haemoglobin concentration (g/dl) 11.1 (4.5 – 13.5) 12.7 (10.8-16.4) 10.5 (4.1 -12.9) 11.7 (9.8 – 15.6) <0.0001 0.29 0.28 
Mean corpuscular volume (fl) 106.5(90.1-120.1) 85.8 (75.7 – 93.9) 107.3(90.9-122.9) 85.6(75.4-94.4) <0.0001 0.86 0.76 
Mean corpuscular haemoglobin (pg) 36.8 (30.0 – 41.4) 27.9 (22.7 - 31.7) 37.1 (29.6-42.0) 27.3 (24.5-31.7) <0.0001 0.51 0.75 
Red cell distribution width (CV%) 14.4 (13.2 – 34.7) 13.7 (12.6 – 21.0) 14.6 (13.6-21.6) 13.8 (12.6-21.7) 0.009 0.74 0.89 
White cell count (x 10
9
) 4.3 (2.0 – 12.0) 6.1 (3.6 – 9.8) 4.7 (2.2-7.5) 5.7 (3.1-14.3) 0.0004 0.71 0.21 
Neutrophil count (x 10
9
) 1.6 (0.7 – 9.7) 3.6 (1.4 – 7.9) 1.9 (1.0-4.7) 2.3 (1.0-10.4) 0.0004 0.92 0.05 
Platelet count (x10
12
) 208 (56 – 456) 191 (66 – 371) 211 (67-370) 191 (123 – 423) 0.70 0.63 0.94 
Serum alanine transaminase (IU/l) 23 (10 – 49) 13 (7 – 67) 21 (9-64) 13.0 (7.0 – 70.5) 0.09 0.56 0.82 
Serum aspartate transaminase (IU/l) 39 (18 – 204) 32 (16 – 79) 32 (14 – 135) 25.0(17.0 – 66.5) 0.05 0.05 0.17 
Serum total bilirubin (mmol/l) 7 (2 – 31) 15.0 (5.9 – 63.3) 5 (3 – 26) 14.0 (4.6 – 44.9) 0.0004 0.24 0.56 
Serum albumin (g/l) 43 (31 – 48) 46.0 (25.5 – 51.7) 42 (29 – 46) 45.5 (25.5-51.7) 0.05 0.21 0.67 
Serum creatinine (mol/l) 64 (31 – 130) 93.5 (56.0 – 132.0) 68.5 (48.0-155.0) 93.5(56.0-132.0) 0.0006 0.16 0.60 
Serum urea (mmol/l) 3.8 (2.4 – 6.6) 2.8 (1.1 – 6.4) 4.0 (1.8 – 7.0) 2.8 (1.1 – 6.4) 0.20 0.99 0.72 
Serum sodium (mmol/l) 141 (131 – 149) 138 (128 – 150) 139 (132 – 150) 138 (128 -150) 0.08 0.26 1.00 
Serum potassium (mmol/l) 5.1 (3.8 – 9.5) 4.3 (3.9 – 5.6) 4.9 (4.2 – 6.2) 4.3 (3.9 – 5.6) 0.32 0.20 0.01 
 
1 
compares medians at day 1 between HIV-infected patients on efavirenz and patients without known HIV infection (controls). 
2 
compares medians at days 1 and 5 of HIV-infected patients after 5-day course of artesunate for clinically suspected malaria. 
3
 compares medians at days 1 and 5 of patients with suspected malaria without known HIV infection after 5-day Artesunate course. 
   
Clinical and laboratory results upon completion of 5-day course of artesunate for 
treatment of clinically presumed malaria: Upon completing a 5-day course of artesunate 
both groups of patients reported resolution of most of the symptoms presented at 
baseline particularly the proportions with headaches and fevers as shown in Table 8.1. 
Anti-malarial therapy was well tolerated with no adverse side effects in both groups. 
However, among the HIV-infected group some exceptions are worth noting. First, 
whereas all control group patients reported resolution of sleeping difficulty on day 5, 
among the HIV-infected group 6 out 12 who had sleeping difficulty had it persisting 
with significant differences noted in the proportion of patients with this symptom 
between the two groups on day 5. Second, nightmares or abnormal dreams resolved in 
both control patients at day 5 but persisted in 3 out of 9 HIV-infected patients. Third, 
pins- and –needles possibly suggestive of peripheral neuropathy resolved in all but one 
control patient but persisted in 4 out of 9 HIV patients with these symptoms after 
treatment. Thus although the nervous system symptomatology which were present at 
baseline completely resolved in most control patients, among the HIV-infected patients 
some had it persisting with non-significant differences at day 5 compared to day 1. 
Overall, clinical examinations were normal in both groups, with no remarkable 
alterations in haematological and biochemical parameters on day 5 as well. Also no 
malaria parasites were observed after therapy in both groups. 
Steady-state concentrations of efavirenz: Before initiating artesunate, the median 
(range) concentration of efavirenz among HIV-infected patients was 2413 (312.9 – 
13,060ng/ml) and did not significantly change within hours 1, 4 and 6 on day 1 and also 
on hour 6 on day 5 with median concentrations of 2136 (264.3 – 10,615ng/ml), 2357 
(249.3 – 12,024ng/ml), 2196 (249.3 – 11,118ng/ml) and 1586 (1,216 – 11,822ng/ml) 
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respectively. One patient had sub-therapeutic concentrations of plasma efavirenz on day 
1 although he admitted to being adherent and 5 had supra-therapeutic concentrations 
and the remainder were within therapeutic range. The kinetics of efavirenz is shown in 
Figure 8.1. The median percentage change in concentration of efavirenz from baseline 
at times 1, 4, 6 hours on day 1 and on day 5 were -13.5% (range, -29.3% to 121.4%), -
14.8% (range, -53.5 to 120.4%), -21.4% (range, -45.4% to 114.9%) and -13.9 (range, -
35.9 to 134.7%) respectively. 
 
 
 
 
 
 
  
   
 
Figure 7.1. The kinetics of plasma efavirenz concentrations among Ghanaian HIV-infected patients before, during the first 6 hours after 
first dose of 200mg artesunate and 6 hours after the last dose of artesunate on day 5. Each dot represents efavirenz concentration at a time 
point and broken lines are to connect efavirenz concentrations for one patient. 
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Correlation between central nervous system symptomatology and mid-dose efavirenz 
concentrations: CNS symptoms are among the commonest manifestations of efavirenz- 
related toxicity. The three most common CNS symptoms at presentation were 
headaches, difficulty sleeping and nightmares. However, among these 3 symptoms only 
nightmares were present in a significantly higher proportion of HIV-infected patients on 
efavirenz (9/22) than controls (3/21), p=0.03. Among patients on efavirenz, the mid-
dose concentration among those with complaints of nightmares was 3,184ng/ml (range 
of 1,732 to 13,060ng/ml) compared with 2,319ng/ml (range of 312.9 to 4,606ng/ml), 
p=0.025 for those without nightmares. However on day 5, there were no differences in 
the plasma efavirenz concentrations among those with persisting symptoms of 
nightmares and those whose nightmares resolved. Also no significant correlations were 
observed between the number of CNS symptoms and efavirenz concentrations before or 
after the course of artesunate therapy. 
Artesunate and Dihydroartemisinin pharmacokinetics: Artesunate was not detected in 
any of the plasma samples tested whiles its metabolite Dihydroartemisinin (DHA) was 
detected at a much lower than expected concentrations in both groups of patients. These 
unexpected results prompted a search to determine whether the findings were due to 
experimental errors or to biologically plausible reasons. The strongest among the 
authors’ suspicions were experimental errors probably due to heat-inactivation of 
plasma samples prior to drug assays for Artesunate and DHA. To test this hypothesis, 
plasma was spiked with standards of Artesunate and DHA and heated at 58
0
C for 10 
minutes. Heating was shown to degrade both artesunate and dihydroartemisinin as 
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shown in Figures 7.2A and 7.2B. For instance, at a concentration of 1500M of both 
Artesunate and DHA, recovery after heating was 8.7% and 8.5% respectively compared 
with non-heated samples. Back-up plasma samples were then shipped to Liverpool and 
Artesunate and DHA quantification repeated without heating these samples. 
Unfortunately, neither artesunate nor DHA were detected in any of the samples 
probably due to poor storage or sample transfer conditions.  
 
 
 
 
 
 
   
 
Figure 7.2A. The effect of heating plasma spiked with serial dilutions of Artesunate at 58
0
C
 
for 10 minutes in the laboratory. The solid 
lines represent linear regression best-fit plot for samples with no heat treatment while the broken line represent that for heat-treated 
samples. 
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Figure 7.2B. The effect of heating plasma spiked with serial dilutions of Dihydroartemisinin (DHA) at 58
0
C
 
for 10 minutes in the 
laboratory. The solid lines represent linear regression best-fit plot for samples with no heat treatment while the broken line represent that 
for heat-treated samples. 
   
 
In the light of these challenges, pharmacokinetic parameters were only calculated for 
DHA because it could be detected and quantified at a relatively appreciable 
concentrations and are presented below. The median time to maximum concentration of 
DHA in the serum among controls was 2.5 hours (range 1.0 to 4.0 hours) compared 
with HIV-infected patients of 4.0 (range, 0.0 to 4.0 hours), p=0.90. The median of the 
maximum concentration (Cmax) of DHA among controls were significantly higher than 
HIV-infected patients 189.1ng/ml (range, 65.8 – 1930) vs 88.0ng/ml (0.0 – 1465), 
p=0.002. Also the area under the curve AUC0-6h among controls was higher among 
controls than HIV-infected patients: 820.9 (range, 334.3 to 9535ng*hr/mL) vs 353.8 
(range, 55.0 to 7776ng*hour/mL), p=0.0004.  
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Discussion 
This study has attempted to investigate the effect of steady state efavirenz on the PK of 
artesunate/DHA. Primarily results from the PK of artesunate and DHA could not be 
reliably interpreted due to experimental challenges during analysis of plasma samples. 
However among the other objectives of this study, it was observed that during and after 
the administration of artesunate no clinically significant changes in the concentrations 
of efavirenz were noted. Thirdly, this study shows that there is significant resolution of 
symptoms and signs of clinically presumed malaria among both groups of patients after 
a course of artesunate without the occurrence of significant symptomatic or 
haemato/biochemical toxicity from the anti-malarial. Finally, efavirenz was well 
tolerated with no additional adverse toxicity events observed over that which was 
present before artesunate was initiated.  
Following the administration of oral artesunate, it is rapidly absorbed within 15 
minutes, and undergoes extensive first pass metabolism to DHA
540
. From studies that 
have defined both artesunate and DHA PK following oral artesunate intake, DHA Cmax 
and AUC have exceeded those of artesunate with some studies reporting more than a 
10-fold increase in DHA AUC over that of artesunate
541-551
. Thus orally administered 
artesunate is considered a pro-drug of DHA from PK, bioavailability and 
bioequivalence data. These findings could explain why DHA could still be detected in 
samples after being heated compared with artesunate although both compounds 
underwent thermal degradation to similar extents (Figures 7.2A and 7.2B). It is hoped 
that in future studies the observed trend of a lower AUC0-6h and Cmax for DHA among 
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HIV-infected patients compared with control patients would be ascertained and if 
confirmed, its clinical impact assessed.  
During and after the course of artesunate, the steady state concentrations of efavirenz 
were maintained within the therapeutic range of 1,000ng/ml to 4,000ng/ml for the 
significant proportion of patients (n=16) and for patients who were exposed to supra-
therapeutic concentrations (n=5). One patient had sub-therapeutic exposure of efavirenz 
on day 1 due to suspected non-adherence because on day 5, efavirenz drug levels were 
back to within normal levels as shown in Figure 7.1. The reductions in efavirenz steady-
state concentrations observed during and after the administration of artesunate could 
possibly be of minor clinical relevance or could be due to clearance of efavirenz 
towards it Cmin since all patients reported taking their dose at night and sampling was 
performed within 12 to 18 hours post-dose.  
It is well known that high plasma concentrations of efavirenz are associated with the 
development of central nervous system toxicity
122
. Given the prospective design of this 
study, we took advantage to evaluate patients for symptoms of efavirenz toxicity before 
and after taking artesunate. Most of the CNS symptoms reported by patients on 
efavirenz were of recent onset (median of 1 week), had coincided with the symptoms of 
presumed malaria, were not distinguishable from those of control patients at baseline 
except for nightmares and tended to resolve upon treatment of malaria. The significant 
difference in the median concentration of efavirenz among patients with nightmares on 
day 1 was not found among those whose nightmares persisted after treatment of 
malaria. Also among patients with supra-therapeutic exposure (n=5) to efavirenz, CNS 
symptoms had resolved in all on day 5.These findings indicate that it is probably less 
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likely that efavirenz concentrations predict CNS toxicity with specificity among patients 
with symptoms of malaria. It should also be remembered that these patients had been on 
efavirenz for a median of 26.5 months and therefore are expected to have developed 
tolerance for these adverse events. The fact that no symptomatic malaria treatment 
failure was observed on artesunate among HIV-infected patients taking long-term 
efavirenz and that no occurrence or worsening of toxicity of either medications were 
witnessed provides some reassurance for their use hopefully with other long-acting 
antimalarials such as lumefantrine in accordance with WHO recommendations in the 
Ghanaian population. 
There are several limitations to this study worth noting. Sampling for artesunate/DHA 
PK measurements were not as intensive as it should be because initial attempts to 
sample using a schedule of 0, 15, 30, 60, and 90 minutes followed by further sampling 
at 2, 4, 8 and 12 hours were refused by all the initial controls and HIV-infected patients 
who were approached most of whom were not willing to spend that length of time in the 
hospital. Thus a compromise in the sampling schedule was effected which affected the 
ability to study the full pharmacokinetic profile of artesunate or DHA as it well-known 
that a relative lack of sampling points in the early post-dose period can result in much of 
the subjects’ artesunate exposure being missed552. It is unfortunate that plasma samples 
were heated prior to measurement of artesunate and DHA concentrations and this 
undoubtedly has significantly affected the interpretation and applicability of the PK 
results of this study. Heating the samples prior to measurement of artesunate/DHA was 
a laboratory requirement for processing these samples. However, similar or even worse 
results were obtained from back-up samples shipped later from Ghana. These findings 
probably reflect the instability of both artemisinin compounds
553
. The validated liquid 
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chromatography tandem mass spectrometry employed in this study for the detection and 
quantification of artesunate and DHA is considered the gold standard for the analysis of 
these drugs in biological matrices
554, 555
 compared with other modalities such as the on-
line post-column alkali derivatisation with UV detection
556
, electrochemical detection
557
 
and chemiluminescent detection
558
. Thus it is a reasonable possibility that the detection 
and quantification method employed could not have been the reason for the low 
concentrations of DHA detected. 
Again, it is uncertain from the results of efavirenz steady concentrations whether the 
reductions in concentrations observed during the co-administration of artesunate were 
due to efavirenz ebbing towards its Cmin or were from pharmacokinetic effects of 
artesunate. The steady state kinetics of efavirenz among HIV-infected patients not on 
artesunate anti-malarial therapy for comparison could prove useful in providing some 
idea on whether the anti-malarial causes clinically relevant reductions in the 
concentrations of efavirenz. However, it should be noted that these reductions were 
within the therapeutic range of efavirenz and probably of minor clinical relevance given 
that that interassay variability of efavirenz quantification is within 10%. Indeed several 
valuable lessons have been learnt by the author from the challenges in this endeavour 
that should prepare him for these future studies aimed at answering these important 
scientific questions. 
In conclusion this study has shown that there are no significant changes in the steady 
state plasma concentration of efavirenz with co-administration of artesunate for the 
treatment of malaria. Overall, artesunate was well tolerated by patients on efavirenz and 
appeared clinically effective in relieving symptoms and parasitemia with no adverse 
 319 
toxicity events from efavirenz. This data is reassuring and future studies are needed to 
corroborate these findings.  
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CHAPTER EIGHT 
The impact of selected CYP2B6, CYP2A6, UGT2B7 and CAR single nucleotide 
polymorphisms on plasma steady state concentrations of efavirenz, risk for 
neuropsychiatric toxicity and immunological outcomes in Ghanaian HIV-infected 
patients. 
8.0 Introduction 
Following standard doses of antiretroviral drugs, huge inter-individual variability has 
been observed, up to (CV%) of 75->110% occurs for NNRTIs and PIs, from 
prospective clinical trials
289
. The causes of this variability are multifactorial and include 
poor adherence, body weight, gender and interacting medications
559, 560
. Host genetic 
polymorphisms may account for some of the variation in pharmacokinetics and 
responses to ART. Genetic variability in the drug metabolising enzymes (e.g. 
cytochrome P450, glucoronyl transferase) or drug transporters (e.g. MDR1, MRP1 & 
2), prevalent at differing frequencies across ethnic groups probably explain some of the 
differences between populations.   
Efavirenz is an essential component of the preferred non-nucleoside reverse 
transcriptase regimen for the initial treatment of HIV-1 infection in both the 
industrialised
111
 and developing
1
 countries. Despite the proven potency and favourable 
tolerability of efavirenz-based regimen, large inter-individual variability in plasma 
efavirenz concentrations predisposes to the development of treatment- limiting toxicity 
or failure to achieve durable viral load suppression
122, 561
. Efavirenz is administered 
orally as a single fixed dose of 600mg in adults and undergoes phase I oxidative 
metabolism primarily by the hepatic CYP2B6 enzyme
276
 with minor contributions from 
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CYP3A4 and the recently identified CYP2A6. Subsequent phase II metabolism 
involves glucuronidation of oxidised efavirenz metabolites by the UGT2B7 enzyme. 
Genetic variations in the enzymes responsible for the metabolism of efavirenz and 
nuclear factors such as the constitutive androstane receptor (CAR) involved in the 
induction of enzyme expression may partially explain the inter-individual variability in 
plasma efavirenz concentrations. 
It has become apparent that the profound inter-individual differences in hepatic 
CYP2B6 expression and enzymatic activities may result in variable systemic exposure 
and therapeutic response to the drugs metabolized by CYP2B6. Indeed considerable 
polymorphisms exist for cytochrome P450 2B6
280
, the major enzyme for detoxification 
of the NNRTIs EFV and NVP.   An allelic variant (G516T) which is more common in 
African Americans (TT 20%) than Hispanics (6.7%) or Caucasians (3.4%) was 
associated with slower clearance of EFV leading to a hierarchy of EFV exposure (and 
associated CNS toxicity) in the rank order: African Americans  > Hispanics  > 
Caucasians
209
. Whilst considerable work has been done showing the effect of the 
G516T mutation on efavirenz levels, the effect of the T983C mutation in the CYP2B6 
isoform on either efavirenz or nevirapine levels have emerged in recent times and the 
minor allele of this gene is relatively common among Ghanaians
35, 36
. In addition to 
polymorphisms in CYP2B6, this isoenzyme is highly inducible and chemically 
mediated induction is regulated at the transcriptional level through complex interactions 
of nuclear factors such as CAR and PXR. In-vitro evidence suggests that efavirenz is 
one of the selective agents for human CAR mediated CYP2B6 induction but to the best 
of my knowledge no in-vivo studies have been conducted to assess the contribution of 
polymorphisms in the CAR C>Trs2307424 receptors on efavirenz exposure in an HIV 
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population in sub-Saharan Africa. Furthermore it has been postulated that in the 
presence of aberrant 2B6 expression and/or function, CYP P450 2A6 may assume an 
essential role in hydroxylation of efavirenz via the 7-OH accessory pathway hence 
polymorphisms in isoforms of this enzyme in the populations where there is a high 
prevalence of variants of 2B6 assumes importance
281
. 
The aims of this study were first to investigate the frequencies of the 516G>T and 
983T>C Single Nucleotide Polymorphisms (SNPs) of the CYP2B6, the allelic variants 
of CYP2A6*9B, the 802C>T and 735A>G SNPs of the UGT2B7 and the C>T 
(rs2307424) SNP of CAR in a cohort of Ghanaian HIV patients. The second objective 
was to assess the impact of the genetic polymorphisms in the CYP2B6, CYP2A6, UGT 
and CAR on the plasma concentrations of efavirenz as well as possible gene-gene 
interactions. Finally, the pharmacodynamic impact of the selected SNPs and efavirenz 
exposure on the risks for CNS toxicity and long-term treatment outcomes such as 
immunological failure were retrospectively assessed in a subset of patients.  
8.1 Methods 
Please refer to chapter two from subsections 2.8.1.1 to 2.8.1.5.  
8.2 Results 
Demographic and anthropometric data: The median (range) age of study participants 
was 40 (17 – 68) years, with a female to male ratio of 2:1.  The age and gender 
distribution of patients involved in the study are shown in Figure 8.1. The median (IQR) 
body mass index of males of 22.7 (20.0 – 26.1 kg/m2) was not significantly higher than 
22.1 (20.1 – 26.1 kg/m2) in females, p=0.10. Five hundred and seventy-eight 578 
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(72.3%) patients were on cART while 222(27.7%) were naïve at time of sampling. Of 
those on cART, 521 were on efavirenz-based therapy, 56 were on nevirapine-based 
therapy while 1 was on nelfinavir-based therapy; 277 (47.8%) were on zidovudine plus 
lamivudine, 300 (52.2%) on stavudine plus lamivudine and 1 on didanosine plus 
lamivudine nucleoside backbone. 
 
 
 
Figure 8.1. Age and gender distribution of study participants who were involved in the 
pharmacogenomic study. 
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Frequencies of genetic polymorphisms in efavirenz metabolising enzymes: Of the 800 
samples from which genomic DNA were extracted, genotyping was successful for 705 
(88%) of CYP2B6 G516T, 701 (88%) of CYP2B6 T983C, 678 (85%) of CYP2A6*9B, 
704 (88%) of UGT2B7*1A, 697 (87%) of UGT2B7*2 and 695 (87%) of CAR 
C>Trs2307424 SNPs respectively (see Figure 8.2 for study profile). When a Chi-square 
test of observed versus predicted genotype frequencies was conducted, all 
polymorphisms were found to be in Hardy Weinberg equilibrium. Allele frequency and 
genotypes of the SNPs analysed in this study is shown in Table 8.1. Briefly, the minor 
allele frequencies for CYP2B6 G516T and T983C SNPs were 0.48 and 0.04 
respectively; that for UGT2B7 _735 and _802 were 0.15 and 0.23 respectively and for 
CYP2A6*9B and CAR C>T rs2307424 were 0.03 and 0.07 respectively. Overall, the 
genotype frequencies of CYP2B6 G516T were GG 208 (29.5%), GT 320 (45.4%), TT 
177(25.1%); CYP2B6 T983C were TT 639 (91.2%), CT 61 (8.7%), CC 1 (0.1%); 
UGT2B7_735 A>G were AA 507(72.0%), AG 172 (24.4%), GG 25 (3.6%); 
UGT2B7_802 were CC 391 (56.1%), CT 287 (41.2%), TT 19 (2.7%); CYP2A6*9B 
were CC 635 (93.7%), CA 42(6.2%), AA 1(0.1%) and CAR C>Trs2307424 were CC 
602(86.6%), CT 89(12.8%) and TT 4(0.6%). 
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Figure 8.2.The profile of the pharmacogenomic study. 
 
Table 8.1 The genotype and allele frequencies of selected SNPs of enzymes 
involved in metabolism of efavirenz.  
SNP Genotype Allele n (%) 
CYP2B6 
516G>T 
GG 
208 
GT 
320 
TT 
177 
G 
730(52) 
T 
674(48) 
CYP2B6 
983T>C 
TT 
639 
TC 
61 
CC 
1 
T 
1339 (96) 
C 
63 (4) 
CYP2A6*9b CC 
635 
CA 
42 
AA 
1 
C 
1312 (97) 
A 
44(3) 
UGT2B7*1A AA 
507 
AG 
172 
GG 
25 
A 
1186 (85) 
G 
222 (15) 
UGT2B7*2 CC 
391 
CT 
287 
TT 
19 
C 
1069 (77) 
T 
325 (23) 
CAR C>T 
(rs2307424) 
CC 
602 
CT 
89 
TT 
4 
C 
1293 (93) 
T 
97 (7) 
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Mid-dose plasma efavirenz concentrations: 521 patients on efavirenz containing cART 
had mid-dose plasma efavirenz determined. Median (IQR) concentration of plasma 
efavirenz was not significantly different in males 1090 (533.3 – 2173 ng/ml) compared 
with females 1083 (559.9 – 2102 ng/ml). 46% had sub-therapeutic mid-dose 
concentrations of plasma efavirenz (<1000ng/ml), 44% were within the therapeutic 
range (1000 – 4000 ng/ml) and 10% had supra-therapeutic concentrations of efavirenz.  
Selected SNPs and impact on plasma efavirenz concentrations: Concentration of 
efavirenz was significantly higher in individuals homozygous for the variant allele (TT) 
at position 516 of the CYP2B6 gene (TT [n=128]: 1800ng/ml vs 1073ng/ml and 929 
ng/ml for GT [n=226] and GG [n=120] individuals respectively; p<0.0001). Similarly, 
concentration of efavirenz was significantly higher in individuals homozygous or 
heterozygous for the variant allele (CC) at position 983 of the CYP2B6 gene [CC n=1 
and TC n=42]: 3235ng/ml vs 1053 ng/ml for TT [n=429] individuals; p<0.0001). Also 
the concentration of efavirenz was significantly higher in individuals homozygous or 
heterozygous for the variant allele (AA) at position 1836 of the CYP2A6 gene [AA n=1 
and CA n=27]: 2192 vs 1093 ng/ml for CC [n=425] individuals; p<0.001). However the 
concentration of efavirenz was not significantly different in individuals homozygous or 
heterozygous for the variant allele (GG) at position 735 of the UGT2B7 gene [GG n=13 
and AG n=112]: 802.9ng/ml vs 1160ng/ml and for normal AA [n=345] individuals of 
1107ng/ml (p=0.84). Also concentration of efavirenz was not significantly different in 
individuals homozygous or heterozygous for the variant allele (TT) at position 802 of 
the UGT2B7 gene [TT n=16 and CT n=192]: 823.3 ng/ml vs 1034ng/ml and for normal 
CC [n=258]- 1172ng/ml individuals, p=0.67. Finally the concentration of efavirenz of 
1001 ng/ml was not significantly different in individuals homozygous for the variant 
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allele (TT) n=1 or heterozygous variant allele [CT] n=66 and for normal CC [n=395] 
individuals 1130ng/ml, p=0.3 of the CAR C>T rs2307424 gene. The impact of each 
selected SNP on the mid-dose plasma concentration of efavirenz is depicted in Figures 
8.3A-F. 
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Figure 8. 3A-F: The impact of selected SNPs on mid-dose plasma efavirenz exposure. 
3A shows the impact of polymorphism of CYP2B6 516G>T; 3B shows the impact of 
polymorphisms of CYP2B6 983T>C; 3C shows the impact of polymorphisms of 
UGT2B7 735 A>G; 3D shows the impact of polymorphisms of UGT2B7 802 C>T; 3E 
shows the impact of polymorphisms of CYP2A6 1836 C>A; and 3F shows the impact 
of CAR C>Trs2307424 on the steady state concentrations of efavirenz. Each circle 
represents concentration of efavirenz for one study participant and each horizontal line 
represents a median.  
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Gene-gene interactions: It is well known that polymorphisms in CYP2B6 account for a 
significant proportion of genetically mediated inter-individual variation in efavirenz 
exposure. A 2-way ANOVA analysis was conducted to assess the impact of variants of 
CYP2A6*9B, CAR C>Trs2307424, UGT2B7*1A and UGT2B7*2 on efavirenz 
exposure by controlling for CYP2B6 516G>T and 983T>C individually, including 
evaluation for possible gene-gene interactions. This analysis was performed on 420 
patients who had a full set of genotypes successfully performed and efavirenz 
measurements. Significant interaction was observed between variants of CYP2B6 
516G>T and CYP2B6 983T>C with a p-value of 0.0006 for interaction between these 
two SNPs. Figure 8.4A shows that, as the number of mutants in the two CYP2B6 SNPs 
increases the plasma concentrations of efavirenz significantly increases accordingly 
with median (IQR) concentrations of 728 (311 – 1293 ng/ml), 1019 (613 – 1788 ng/ml), 
1973 (968 – 3534 ng/ml) and 5854 (2083 – 9289 ng/ml) with nil, 1, 2 and 3 mutations 
respectively corresponding to 1.4-fold, 2.7-fold and 8.0-fold increases compared with 
no mutations in the CYP2B6 516/983 composite variants.  
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Figure 8.4A. The influence of cumulative mutations in the CYP2B6 516G>T or 
983T>C polymorphisms on plasma efavirenz mid-dose concentrations. 
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Next, the impact of gene-gene interaction between CYP2A6*9B and the CYP2B6 
G516T and T983C SNPs were performed and as shown in Figure 8.4B, the slow 
metaboliser variant of the CYP2A6*9B was independently associated with higher 
efavirenz exposure after adjusting for CYP2B6 516G>T, p=0.0006 for CYP2A6*9B 
effect on efavirenz variance; p=0.45 for interaction. In a posthoc pairwise analysis using 
Mann-Whitney’s U-test, it emerged that heterozygotes of 516G>T with mutant variants 
of 2A6*9B compared with wild type variants had a significantly higher efavirenz 
exposure. However after adjusting for CYP2B6 983T>C variants, CYP2A6*9B variants 
did not exert a significant independent effect on efavirenz variance (Figure 8.4C), 
although no significant interactions were observed between the two genes. Overall, the 
CYP2A6*9B variants appear to exert an impact towards higher efavirenz exposure in 
the presence of increasing numbers of SNPs in the two CYP2B6 alleles (Figure 8.4D).  
Generally the selected SNPs in UGT2B7*1A, UGT2B7*2 and CAR rs2307424 did not 
interact significantly with either CYP2B6 516G>T or T983C SNPs individually or as a 
composite in explaining the impact exerted by these SNPs on the variance of plasma 
efavirenz exposure (Table 8.2). However, there was a trend towards lower exposure to 
efavirenz among patients with the CAR C>T rs2307424 mutant SNP in the absence of 
mutant SNPs in the CYP2B6 alleles as summarised in Figure 8.4E. Conversely among 
patients with CYP2A6*9B SNPs, there was a trend towards higher plasma efavirenz 
exposure in the presence of loss-of-function SNPs in the CYP2B6 alleles (Figure 8.4E). 
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Figure 8.4B. Influence of CYP2A6*9B slow metaboliser genotype and CYP2B6 516G>T 
on plasma efavirenz mid-dose concentrations. 
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Figure 8.4C. Influence of CYP2A6*9B slow metaboliser genotype and CYP2B6 983T>C 
on plasma efavirenz mid-dose concentrations. 
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Figure 8.4D. The influence of CYP2A6*9B slow metaboliser genotype on cumulative 
mutations in the CYP2B6 516G>T or 983T>C polymorphisms on plasma efavirenz 
mid-dose concentrations. There were significant interactions between the CYP2B6 
composite SNPs and the CYP2A6*9B SNP. 
 
   
Table 8.2 showing a post-hoc two-way analysis of variance testing for interactions between wild type and mutant type alleles for selected 
SNPs and a composite of CYP2B6 mutation status. 
 
Mean ± SEM of mid-dose 
plasma efavirenz 
concentration 
CYP 2B6  
no mutation 
CYP 2B6  
1 mutation 
CYP 2B6  
2 mutations 
% total variation due to 
2B6 variants  
(p-value) 
% total variation due 
to variants of SNPs 
on each row (p-
value) 
% total variation 
due to interaction  
(p-value) 
CYP 2A6*9B    7.23 (<0.0001) 1.91 (0.0030) 2.05 (0.0089) 
              No mutation 978 ± 98.3 (n=87) 1564 ± 126.7 
(n=197) 
2600 ± 212.7  
(n=113) 
            1 mutations 1486 ± 580.9 
(n=3) 
1809 ± 673.0 
(n =10) 
6049 ± 1353  
(n =10) 
UGT2B7_705    11.86 (<0.0001) 0.07 (0.6) 0.28 (0.5) 
              No mutation 1000 ± 124.9 
(n=64) 
1600 ± 138.3 
(n=149) 
2758 ± 269.8  
(n=93) 
            1 mutations 981 ± 137.0 
(n=26) 
1516 ± 268.9 
(n=58) 
3260 ± 500.8 
(n=30) 
UGT2B7_802    12.95 (<0.0001) 0.41 (0.2) 0.17 (0.7) 
                No mutation 1160 ± 137.6 
(n=57) 
1589 ± 151.3 
(n=117) 
3072 ± 361.4 (n=62) 
              1 mutations 709.3 ± 99.5 
(n=33) 
1559 ± 209.0 
(n=90) 
2686 ± 308.3 (n=61) 
CAR C>T rs2307424    5.51 (<0.0001) 0.25 (0.3) 0.27 (0.5) 
                  No mutation 975 ± 89.3 (n=78) 1663 ± 144.4 
(n=173) 
2957 ± 267.6 
(n=105) 
               1 mutations 1122 ± 452.9 
(n=12) 
1136 ± 169.2 
(n=34) 
2435 ± 444.1 
(n=18) 
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Figure 8.4E. The impact of SNPs in CARrs2307424 and CYP2A6 in relation to loss-of-function SNPs in CYP2B6 on efavirenz exposure.
   
Multivariate linear regression analyses: The median (range) plasma concentration of 
efavirenz was 1087 (110.0 – 12,146.0 ng/ml) and a mean ± standard deviation of 1792 ± 
2024ng/ml with a coefficient of variation of 113%. On univariate analyses 
polymorphisms in CYP2B6 G516T (p=2.5 x 10
-7
); T983C (p=4.5 x 10
-14
); CYP2A6*9b 
p=0.002), and body weight in kilograms (p=0.008) were all significantly correlated with 
log transformed plasma efavirenz concentration. On multivariate analysis 
CYP2B6*516G>T, *983T>C and body weight were identified as independent variables 
of efavirenz exposure as shown on Table 8.3. The G516T and T983C SNPs in the 
CYP2B6 gene explained 32% and 38% respectively of the variation in mid-dose 
concentrations of efavirenz among this Ghanaian cohort. CAR rs2307424 
polymorphism was marginally significant while increasing weight was inversely 
correlated with efavirenz exposure. 
Table 8.3. Univariate and multivariate analyses of independent variables on the log 
concentration of efavirenz as dependent variable. 
Covariate Univariate 
probability 
Multivariate 
probability 
Multivariate 
coefficient (b) 
CYP2B6 516G>T  2.5 x 10
-7
 1.4 x 10
-11
 0.32 
CYP2B6 983T>C 4.5 x 10
-14
 1.3 x 10
-15
 0.38 
CYP2A6*9B 0.002 0.60 - 
UGT2B7*1 0.84 - - 
UGT2B7*2 0.24 - - 
CAR rs2307424 0.12 0.07 0.08 
Age 0.23 - - 
Gender 0.84 - - 
Weight 0.008 0.016 -0.11 
Height 0.45 - - 
 
 
 
 
339 
 340 
The pharmacodynamic impact of SNPs and efavirenz exposure on clinically relevant 
outcomes of efavirenz-based cART: The analyses in this section are post hoc and 
retrospective in nature and are an attempt to evaluate associations between the 
pharmacogenomic and efavirenz exposure data above presented and clinically relevant 
outcomes presented in other chapters of this dissertation, namely Chapters 5 (toxicity of 
NNRTI-based cART) and 6 (effectiveness of efavirenz-based cART compared with 
nevirapine). In this respect, two main pharmacodynamic effects evaluated were the risks 
for central nervous system toxicity and immunological failure in relation to efavirenz 
exposure and SNPs in the CYP2B6 composite and CYP2A6.  
To begin with, Tables 8.4A and 8.4B show the risks for sub-therapeutic, therapeutic and 
supra-therapeutic exposure according to the selected SNPs in CYP2B6, CYP2A6, CAR 
and UGT2B7. It is evident that mutant SNPs in the CYP2B6 and CYP2A6 significantly 
increases the risk of exposure to supra-therapeutic levels of efavirenz and conversely 
lower risk for sub-therapeutic exposure in this cross-section of randomly selected 
plasma samples from patients on efavirenz-based cART. Therefore analysis was 
restricted to these 3 alleles.   
   
 
Table 8.4A. Chi-squared analysis for trend between selected SNPs and three clinically relevant therapeutic levels of plasma efavirenz 
concentrations among a random sample of patients on efavirenz-based cART. 
            Clinically relevant plasma efavirenz exposure   
SNP (no. of patients) Variant status Sub-therapeutic 
exposure 
EFV 
concentration 
<1000ng/ml  
Therapeutic 
exposure 
EFV 
concentration 
1000-4000ng/ml 
Supra-therapeutic 
exposure 
EFV concentration 
>4000ng/ml  
Chi-square 
test, df 
p-value 
CYP2B6 983T>C 
n=493 
wild type 219 200 30 77.73, 2 <0.0001 
mutant type 5 18 21   
CYP2B6 516G>T 
n= 496 
wild type 70 53 5 10.86, 2 0.0044 
mutant type 152 171 45   
CYP2A6*9B 
n=475 
wild type 208 201 38 16.96, 2 0.0002 
mutant type 8 11 9   
UGT2B7*1A 
n= 494 
wild type 161 161 40 0.83, 2 0.66 
mutant type 62 59 11   
UGT2B7*2 
n=488 
wild type 119 127 28 0.72, 2 0.70 
mutant type 100 91 23   
CAR C>T rs2307424 
n=484 
wild type 182 189 44 1.16, 2 0.57 
mutant type 35 28 6   
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Table 8.4B. The relative risk and odd’s ratios of sub-therapeutic and supra-therapeutic exposure to efavirenz according to 
variants of 6 selected SNPs involved in the metabolism of efavirenz. 
SNP (no. of patients) RR and OR (95% CI ) of sub-
therapeutic exposure to 
efavirenz 
Fisher’s exact test 
p-value 
RR and OR (95% CI) of supra-
therapeutic concentrations of 
efavirenz 
Fisher’s exact test 
p-value 
CYP2B6 983T>C 
n=493 
0.23 (0.10 – 0.53) 
0.13 (0.05 – 0.35) 
<0.0001 7.14 (4.49 – 11.36) 
12.75(6.34 – 25.63) 
<0.0001 
CYP2B6 516G>T 
n= 496 
0.76 (0.62 – 0.92) 
0.58 (0.39 – 0.87) 
0.0099 3.13 (1.27 – 7.72) 
3.43 (1.33 – 8.84) 
0.0059 
CYP2A6*9B 
n=475 
0.61 (0.34 – 1.11) 
0.46 (0.20 – 1.07) 
0.0783 3.78 (2.04 – 7.02) 
5.10 (2.16 – 12.05) 
0.0007 
UGT2B7*1A 
n= 494 
1.06 (0.85 – 1.31) 
1.11 (0.74 – 1.65) 
0.6829 0.75 (0.40 – 1.43) 
0.73 (0.36 – 1.47) 
0.5037 
UGT2B7*2 
n=488 
1.08 (0.88 – 1.31) 
1.14 (0.80 – 1.63) 
0.5209 1.05 (0.62 – 1.77) 
1.06 (0.59 – 1.90) 
0.8821 
CAR C>T rs2307424 
n=484 
1.16 (0.89 – 1.50) 
1.32 (0.79 – 2.20) 
0.2985 0.82 (0.36 – 1.85) 
0.80 (0.33 – 1.96) 
0.8308 
 
 
   
Risk of CNS toxicity according to CYP2B6 composite and CYP2A6 SNPs: 407 patients 
with data on CYP2B6 composite SNPs and 298 patients with data on efavirenz plasma 
concentrations were included in this sub-analysis. 37 (9.1%) patients with genomic and 
28 (9.4%) with plasma efavirenz data had documented CNS toxicity. Compared with 
patients without any SNPs in the CYP2B6 composite of G516T/T983C those with SNPs 
had a non-significant trend towards a higher risk for developing CNS toxicity as shown 
in Figure 8.5 with a hazards ratio of 1.72 (95%CI of 0.76 to 3.43), p=0.21. At 2 months 
where most of CNS events occurred, cumulative estimate of events in CYP2B6 mutants 
compared with wild types was 5.3% (95% CI of 2.8% to 7.8%) vs 3.9% (0.2% to 7.7%). 
Among this cohort only one event led to efavirenz discontinuation in a patient with 
heterozygosity for G516T, UGT2B7_802, UGT2B7_735 and wild type for T983C, 
CAR and CYP2A6*9B but undetectable plasma efavirenz concentration. No significant 
trends were observed for CYP2A6*9B or plasma efavirenz concentrations from random 
samples and risk for development of CNS toxicity (not shown). 
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Figure 8.5. Kaplan-Meier risk analysis for reported CNS toxicity due to efavirenz according to SNPs in the composite CYP2B6 
G516T/T983C.
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b. Risk of immunological failure according to efavirenz exposure and CYP2B6 SNPs: 
407 patients with data on CYP2B6 composite SNPs and 298 patients with data on 
efavirenz plasma concentrations were included in this sub-analysis. 56 patients with 
genomic data and 42 patients with pharmacokinetic data experienced immunological 
failure during follow-up on efavirenz-based cART. The median time to immunological 
failure was 66 months (IQR, of 48 to 78 months). There was a trend towards decreasing 
risk of immunological failure with increasing number of SNPs in the composite of 
G516T/T983C as shown in Figure 8.6, although conventional statistical significance 
level was not reached, p=0.11. Also the hazards ratio for immunological failure from 
mutant SNPs of CARrs2307424 was 1.42 (95% CI of 0.77-2.63), p=0.26 and that for 
SNPs of CYP2A6*9B was 1.02 (95%CI of 0.37 to 2.82), p=0.97. Figure 8.7 shows that 
among a random sample of patients with efavirenz measurements (n=298) in this 
cohort, there was a significant trend of lower efavirenz exposure predisposing patients 
towards a higher risk of immunological failure over the long-term and vice versa for 
supra-therapeutic exposure, log-rank test for trend, p=0.03.
345 
   
  
Figure 8.6. Kaplan-Meier risk of immunological failure on efavirenz according to number of SNPs in a composite of CYPB26 G516T 
and T983C in randomly selected patient samples. 
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Figure 8.7. Kaplan-Meier risk of immunological failure on efavirenz according to exposure of efavirenz in randomly selected patient 
samples.
   
8.4 Discussion 
This study has assessed the frequencies of selected polymorphisms in three enzymes 
involved in the phase I and II metabolism of efavirenz - CYP2B6, CYP2A6 and 
UGT2B7-and one nuclear factor (CAR) which modulates induction of CYP2B6 
expression, amongst HIV infected Ghanaian patients. In this study population of 800 
patients out of which between 85% and 88% of selected SNPs were successfully 
genotyped, the frequencies of mutant alleles in CYP2B6 516G>T, *983T>C; 
CYP2A6*9B, UGT2B7 *1A and *2 and CAR C>Trs2307424 were 0.48, 0.04, 0.03, 
0.15, 0.23 and 0.07 respectively. 521 patients were on efavirenz with an inter-individual 
coefficient of variance of 113% corroborating the well-established wide variance in the 
steady state plasma efavirenz concentrations
122, 561
. SNPs in the CYP2B6 G516T/T983C 
composite alleles were significant predictors of the efavirenz exposure explaining 32% 
and 38% of mid-dose efavirenz variance respectively. The impact of mutant SNPs in 
CYP2A6 becomes pronounced in the presence of loss-of-functions mutations in the 
CYP2B6 SNPs. Finally, in posthoc retrospective analysis there was a significant trend 
in the risk for long-term immunological failure on efavirenz-based cART according to 
plasma efavirenz exposure which was mirrored closely by the number of CYP2B6 
SNPs. 
Cytochrome P450 2B6 is the major enzyme isoform for the hydroxylation of efavirenz 
to the major metabolite 8-OH, 8,14-OH efavirenz and the minor 7-OH efavirenz. There 
are over 100 SNPs described so far with numerous complex haplotypes and different 
frequencies in different populations
562
. However evidence from several studies show 
that models inculcating the composite of SNPs in the 516G>T/983T>C predicts 
efavirenz pharmacokinetics best
335, 340
. In the present study involving only patients with 
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black ethnicity, the frequency of the poor CYP2B6*516G>T metaboliser TT frequency 
of 25% is comparable with the 23% found among a South African cohort
563
, 20% 
amongst an African-American cohort
276
 and 19% in another Ghanaian cohort
282
. 
Similarly the allelic frequency of CYP2B6 983T>C variants was 91% for homozygous 
wild type TT and 9% for heterozygous mutants CT which is similar to that observed in 
the Ghanaian cohort
283
. Only one patient was a homozygous mutant CC for the 983T>C 
SNP. Thus the minor allelic frequency of 0.04 in the 983T>C SNP in our study closely 
agrees with that found by Kwara et al
283
 among Ghanaians and the 0.045 among West 
Africans reported by Melhotra et al
35
.  
In-vitro evidence suggests that efavirenz is one of the selective agents for human CAR 
mediated CYP2B6 induction
318
. When efavirenz binds to CAR in the cytosol of 
hepatocytes, this triggers a heterodimer association between CAR and RXR (9-cis 
retinoic acid receptor), which migrates and binds to response elements in the promoter 
region of the CYP2B6 gene thus inducing its expression. Until recently, no in-vivo 
studies had been conducted to assess the contribution of CAR C>Trs2307424 receptor 
variants on efavirenz steady state exposure particularly among Africans. In a German 
cohort where 25.5% (n= 373) were of black ethnicity, the variant allele of CAR C>T 
rs2307424 was present at a frequency of 0.15 among blacks compared with 0.33 among 
whites
564
. Thus the minor allele frequency in the population of 0.07 in the present study 
shows that this is a fairly common SNP and certainly further studies are needed to 
estimate its frequency in other settings. The minor allelic frequency of the CYP2A6*9B 
gene of 0.03 is comparable with the 0.05 found in another study
283
. Hydroxylated 
metabolites of efavirenz are subsequently glucuronidated to form an N-glucuronide of 
hydroxy-efavirenz with the recently identified UGT2B7 playing a predominant role
278
. 
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Kwara et al. reported UGT2B7*1A and *2 minor allelic frequency of 0.26 and 0.46
283
 
among Ghanaians while 0.15 and 0.23 respectively was found in the present study.  
As expected polymorphisms in CYP2B6 516G>T and 983T>C individually (Figures 
8.3A and 8.3B) and in combination (Figure 8.4A) were associated with exposure to 
higher efavirenz mid-dose concentrations as has been noted in several other studies 
across several ethnicities
209, 335, 340, 565
. On univariate analysis, it was found that variant 
allele carriers (AC/AA) of the CYP2A6*9B had a 2-fold higher concentration of 
efavirenz compared to homozygous wild type CC, p=0.0064. A 2-way ANOVA testing 
for possible gene-gene interaction between the two CYP2B6 SNPs and CYP2A6*9B 
indicated an absence of significant interaction between the individual 2B6 SNPs and 
2A6*9B (Figures 8.4B and 8.4C). Indeed 2A6*9B mutant variants independently had 
higher levels of plasma efavirenz after adjusting for CYP2B6 516G>T, an effect which 
was significant among heterozygotes for 516G>T with 2A6*9B mutants compared with 
2A6*9B wild types as shown in Figure 8.4B. However this 2A6*9B effect was not 
observed on adjusting for 983T>C (Figure 8.4C) perhaps highlighting the dominant 
impact of the 983T>C null allele and the possible reason why 2A6*9B was not a 
significant independent variable in the multivariate model (Table 8.3). These findings 
are generally in agreement with those of previous reports 
281, 282
.  
This study is the first to examine the impact of variants of the nuclear factor CAR on 
efavirenz exposure among Ghanaians and shows overall (Figure 8.3F) the rs2307424 
variant of CAR did not significantly influence efavirenz exposure in our study 
population. The precise mechanistic role of this mutant of CAR remains to be 
elucidated: looking at Figure 8.4E it is tempting to speculate that it appears to probably 
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exert its effect by enhancing the induction of CYP2B6 in the absence of SNPs in the 
CYP2B6 G516T/T983C composite allele with a trend towards lower exposure to 
efavirenz. Kwara et al. were the first to report on the effect of UGT2B7 variants on 
plasma efavirenz exposure and noted that while carriers of *1A variant had higher 
efavirenz concentrations than wild type carriers, variant *2 carriers were exposed to 
lower concentrations of efavirenz compared with wild type
283
. We could not confirm 
their findings in our study population. Overall, given the large numbers in the present 
study compared to theirs and the large inter-individual variability in efavirenz exposure, 
it is likely that our data is better placed to capture the effect of UGT2B7 SNPs if such 
effects were present. Therefore more studies are required to resolve the impact of 
UGT2B7 variants on efavirenz exposure in other populations. 
Forty-six percent of our participants had sub-therapeutic levels of mid-dose plasma 
efavirenz concentrations. The finding that nearly half of our participants had sub-
therapeutic concentrations of efavirenz is worrying, because of the high risk of selecting 
resistant strains of HIV. Indeed a recent survey in Johannesburg showed that the 
frequency of the K103N mutant strains was 25% among patients established on 
cART
566
. Certainly in programmatic settings where viral loads are not routinely used to 
monitor treatment efficacy, where therapy options are constrained, where therapy is 
initiated with non-nucleoside based cART with an inherently low genetic barrier to 
resistance and where adherence to therapy is assessed by pill counts and patient 
reporting, this finding should be used by clinicians and peer educators to emphasise and 
re-enforce the message of adherence to cART. Direct evidence in support of this 
worrying trend is based on the finding that the risk of immunological failure (Figure 
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8.7) was associated with plasma efavirenz exposure with the highest risk identified 
among patients with sub-therapeutic exposure.  
It is certainly plausible that the majority of these participants with sub-therapeutic 
exposure could be non-adherent to their medications. Secondly, there is also the 
possibility that samples used for the analysis in this chapter most of which were 
collected in 2006 may have undergone some degradation under storage conditions over 
time. In support of this, the median (range) plasma concentration of efavirenz in the 
efavirenz / artesunate pharmacokinetic study (collected in 2010) in chapter seven of this 
thesis concentration was 2413 (312.9 – 13,060ng/ml) compared with 1087 (110.0 – 
12,146.0 ng/ml) for the samples in this chapter. Thirdly, the potential also exists for 
certain SNPs inducing the so-called “gain-of function” or ultra-rapid metaboliser 
phenotypic CYP2B6 expression leading to accelerated clearance of efavirenz could 
partly explain this high proportion of patients with low mid-dose range efavirenz 
concentration. For instance, a novel haplotype 2B6*22 which combines 4 promoter 
mutations -1848C>A, -801G>T, -750T>C and -82T>C has been identified among 
Caucasians DNA samples and demonstrated an enhanced transcriptional activation up 
to 9-fold compared with the reference CYP2B6 promoter
567
. Furthermore, Leger et al, 
identified among a Haitian HIV infected cohort who initiated cART with 
AZT/3TC/EFV and where intake of these medications were observed/supervised that 
there was a distinct SNP rs36118214 in CYP2B6 which was associated with reduced 
efavirenz plasma exposure
568
. The minor allele frequency of rs36118214 is thought to 
be as high as 0.42 among Sub-Saharan Africans
569
. The impact of rs36118214 was not 
investigated in the present study, but these findings suggest that some patients may be 
exposed to sub-therapeutic efavirenz concentrations on the basis of their genetic profile. 
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This could also account for the higher virologic failure rates on the predominantly 
efavirenz-containing regimens in the AIDS Clinical Trial Group protocol A5095 among 
blacks compared to whites after adjusting for self-reported non-adherence
580
. In this 
study we show that the highest risk group for immunological failure were the wild types 
for both G561T/T983C composite alleles of CYP2B6 followed by those with mutant 
alleles (Figure 8.6) buttressing the point that genetic profiling may impact treatment 
outcomes significantly.  
Above a steady-state plasma efavirenz concentration of 4ug/l, the risk of central nervous 
system toxicity increases significantly especially within the first few weeks at initiation 
of efavirenz-based cART but with continual use patients often develop tolerance to 
these side effects. In the present study 10% of participants had supra-therapeutic 
concentrations of efavirenz. The median (range) duration on therapy at pharmacokinetic 
sampling was 12 months (2 months to 24 months). At this median time point it is 
expected that majority of patients who were within the supra-therapeutic range would 
have developed tolerance for CNS toxicity although a formal assessment was not 
conducted at the time of collecting blood samples in the present study. The potential 
long- term implications of such sustained exposure to supra-therapeutic levels remains 
to be determined. However in a retrospective analysis of 407 patients with genomic 
data, a non-significant trend towards a higher risk for CNS toxicity was observed 
among mutant carriers of SNPs in the CYP2B6 G516T/T983C genotypes (Figure 8.5) 
compared with wild type. However only one patient discontinued therapy from 
efavirenz related toxicity in this subset retrospective analysis precluding any further 
analysis on associations between genotypic, pharmacokinetic data and risk to treatment-
limiting toxicity from efavirenz. As shown in Tables 8.4A and 8.4B, the relative risk of 
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exposure to supra-therapeutic concentrations of efavirenz was significant for mutant 
allele carriers of the CYP2B6 983T>C, CYP2B6 516G>T and CYP2A6*9B with RRs 
of 7.14, 3.13 and 3.78 respectively but not the UGT2B7 or the CAR variants. 
Conversely, the relative risks of sub-therapeutic exposure was significantly lower for 
mutant carriers of *983T>C and *516G>T but not *9B. It is noteworthy that Ribaudo et 
al. has reported that one of the pharmacodynamic effects of the composite 516/983 
genotypes among black patients is decreased virological failure rate
571
. Alternatively 
patients with variants of this composite polymorphism are at increased risk of selecting 
mutant virus on stopping cART because of the prolonged half-life of efavirenz.  
The findings in this study show that as a strategy for optimising antiretroviral therapy in 
Sub-Saharan Africa, therapeutic drug monitoring with dosing of according to genotypic 
profile may be useful should the technology become accessible in the future. Certainly 
in this population with a high prevalence of loss-of-function mutations in the metabolic 
axis of efavirenz, we may be able to achieve effective therapeutic levels with lower 
doses of efavirenz than is currently recommended for carefully selected patients. 
Gatananga and colleagues
572
 were able to show by using a reduced dose of either 
400mg or 200mg of efavirenz for patients with CYP2B6 516G>T SNP, that there was 
an improvement in CNS related toxicity without a loss of virological suppression. 
However in countries like Ghana where the goal of adequate access to antiretroviral 
therapy for all HIV-infected patients remains to be achieved, the added expense of 
pharmacogenomic genotyping and TDM may seem unrealistic. Furthermore evidence 
that genotyping and measurement of EFV plasma concentrations actually improve 
patient outcome is lacking and also most CNS toxicity from efavirenz resolves with 
continual usage of the medication. 
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This study had the following limitations worth noting. Samples for this study were 
collected from a repository without assessing patients for clinical events such as 
toxicity, treatment failure and adherence prospectively. Therefore adherence was 
assessed retrospectively by patient self reports and pill counts which has been shown to 
be reasonably reliable for predicting treatment response
573,574
. In view of the 
retrospective nature in which the two pharmacodynamic variables- CNS toxicity and 
immunological failure- were assessed, any associations herein presented should be 
interpreted with caution and should await confirmation from prospective studies to 
generalise the import of these observations. Between 12-15% of participants could not 
be successfully genotyped because there wasn’t sufficient genomic DNA in their serum 
samples. Ideally whole blood sample provide better yield for whole genomic DNA and 
this would be considered in future studies. These missing data may have biased 
observations to an extent.  
In conclusion, this study shows that there is a high frequency of loss-of-function 
polymorphisms in the CYP2B6 G516T/T983C composite alleles among Ghanaian HIV-
infected patients predicting high exposure to efavirenz. In the presence of mutant SNPs 
in the CYP2B6, mutant variants of CYP2A6 assume as important role as the sole 
alternative route for hydroxylation of efavirenz. SNPs in the UGT2B7 and CAR 
rs2307424 may be of minor relevance in efavirenz exposure among Ghanaians. 
Interesting trends were observed between CYP2B6 SNPs, random plasma efavirenz 
concentrations and the risks of CNS toxicity and immunological failure. These are 
promising findings highlighting the prospects of predictive links between 
pharmacogenomics and pharmocodynamics of efavirenz via its pharmacokinetic 
exposure among HIV-infected patients. When the technology becomes accessible in 
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Sub-Saharan Africa, it may be possible to dose patients on the basis of the genetics and 
kinetics of efavirenz to maintain patients within therapeutic range to achieve the fine 
balance between tolerability and efficacy of efavirenz. 
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CHAPTER NINE 
CONCLUSIONS AND RECOMMENDATIONS 
This chapter draws the emergent themes and findings of this investigation together, 
discusses how the research could have been improved and suggests where future 
research may fruitfully be undertaken. 
Purpose for this study 
Since 2004, combination antiretroviral therapy for the long-term management of 
patients living with HIV/AIDS has been available in Ghana where they are administered 
predominantly through national programmatic settings in ART clinics. Treatment is 
initiated using a limited repertoire of first line cART comprising of two nucleoside 
reverse transcriptase inhibitors of either stavudine or zidovudine with lamivudine 
together with a non-nucleoside reverse transcriptase inhibitor of either efavirenz or 
nevirapine. This study was conducted because there is a knowledge gap in the Ghanaian 
ART programme on the long-term effectiveness of cART. Specifically, this study was 
designed to compare the long-term clinical and immunological outcomes of an 
efavirenz-based cART compared with nevirapine-based cART within a busy out-patient 
HIV clinic in Kumasi, Ghana. This was primarily driven by two main observations, the 
first being that in many similar settings in Sub-Saharan Africa, the effectiveness of 
efavirenz has not been compared with nevirapine-based cART over the long-term to 
assess their durability. Secondly, in spite of the toxicity profile of nevirapine, several 
ART programmes use a predominantly nevirapine-based cART for first line due 
primarily to cost considerations. It is however anticipated over the coming years that 
efavirenz may become increasing accessible to many programmes as its cost decreases 
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and this study therefore assessed the tolerability and risk factors for efavirenz related 
toxicity from three main perspectives: first, from a retrospective analysis of documented 
events of central nervous system toxicity, hepatotoxicity and cutaneous reactions on 
efavirenz compared with nevirapine; second, from a pharmacogenomic perspective by 
assessing the frequencies of selected single nucleotide polymorphisms in the enzymes 
that are central to the metabolism of efavirenz namely the cytochrome P450 sub-family 
2B6, 2A6 and UGT2B7 as well as CAR which is a constitutively expressed androstane 
receptor required for the induction of the expression CYP2B6 and their impact on the 
mid-dose exposure of plasma efavirenz concentrations; and third, from a 
pharmacokinetic perspective by prospectively assessing the interactions and safety of a 
commonly administered antimalarial, artesunate, for the treatment of clinically 
suspected malaria among HIV-infected patients established on efavirenz-based cART 
compared with a control group whose HIV-sero-status was unknown.    
Final discussion of findings 
Combination antiretroviral therapy was commenced for 4,039 patients between January 
2004 to December 2010 and at closure of data for analysis on 31
st
 December 2011, 68% 
of patients were still alive and active in the clinic, 24% were lost to follow up and 8% 
mortality was documented over 11,236.8 person years of follow-up. The overwhelming 
majority of patients were started on cART at low CD4 counts and with various AIDS-
defining illnesses on a predominantly NNRTI-based cART (99%) of either efavirenz 
(59%) or nevirapine (40%) with a backbone of stavudine plus lamivudine (52%) and 
zidovudine plus lamivudine (48%). Overall first-line cART was effective in this cohort 
and was accompanied by robust CD4+ T-cell count recovery, reduction in the incidence 
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of AIDS-defining events and sustained increment in body mass index among those who 
remained on cART. With only 154 (3.8%) patients switching to second line cART due 
to immunological failure and the profound state of AIDS-associated morbidities of most 
patients at initiation, first line cART might be considered successful over the long-term 
in this cohort on the basis of the evidence available from this analysis. This 
notwithstanding, the lack of viral load data means that treatment success of first-line 
ART in this cohort may have been over-estimated. For instance, in a retrospective 
cohort of the first 237 Ghanaian HIV-infected patients initiating cART in Kumasi with 
follow up to 3 years, although CD4 responses were robust, 6 out of 40 patients with 
viral load data had virological failure
575
. Similarly, in the HEPIK cohort (Hepatitis B 
HIV Coinfection in Kumasi), up to 35% (n=300) of patients on first-line cART had 
evidence of virological failure (personal communications with Prof. Anna Maria 
Geretti, University of Liverpool, UK) without documented immunological failure. The 
poor correlation between virological and immunological responses to cART is well 
characterised
269-271
. In settings such as ours where CD4 counts are used to monitor 
treatment outcomes, the effectiveness of second line cART could be severely 
compromised as patients might fail virologically on first line cART for a prolonged 
time period, accumulate drug resistance mutations before immunological failure is 
detected.  
Efavirenz-based cART was comparable to nevirapine-based cART overall in a 
composite outcome measure of treatment failure that comprised deaths, disease 
progression and all-cause treatment discontinuations due either to toxicity, 
immunologically/clinically determined treatment failure or patient/physician preference 
with an adjusted HR and OR of 1.20 (95% CI of 0.97 to 1.49), p=0.10 and 1.09 (95% CI 
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of 0.79 to 1.49), p=0.61 in primary analysis. This combination of outcomes has been 
termed by some authors as the ‘durability’ of cART5, 576. There was a higher overall risk 
of treatment discontinuation on nevirapine compared with efavirenz due predominantly 
to treatment-limiting mucocutaneous drug reactions and severe hepatotoxicity. Indeed 
two deaths from severe muco-cutaneous reactions were associated with nevirapine.  
Overall, efavirenz was better tolerated with central nervous system toxicity such as 
insomnia, headaches and dizziness, which although were present at a documented 
frequency of 7.6% (n= 2,376) among patients on efavirenz led to only 17% (n=180) 
treatment discontinuations with resolution of these symptoms in the majority over long-
term use. 
Mutant single nucleotide polymorphisms in genes controlling the production of 
enzymes and proteins involved in the hepatic metabolism of efavirenz were commonly 
found in this Ghanaian population of 800 HIV-infected patients. Genotyping by allelic 
discrimination using real-time PCR was successful in approximately 85% of samples. 
As expected SNPs in the composite of CYP2B6 *G516T and *T983C were 
predominantly associated with higher exposure to plasma efavirenz and predicted 32% 
and 38% of inter-patient variation in plasma efavirenz exposure respectively. This study 
has shown that in settings where polymorphisms in the CYP2B6 oxidative pathway for 
efavirenz are common, the CYP2A6 pathway assumes importance as an alternative 
oxidative metabolic pathway with mutants in *9B predicting even higher efavirenz 
exposure in the presence of CYP2B6 mutants. It was retrospectively determined that 
loss-of-function mutants in the CYP2B6 composite of *G516T and *T983C were 
associated with a trend towards increased risk for CNS toxicity and reduced risk for 
long-term immunological failure on efavirenz in a subset analysis. Thus the data 
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presented in this study corroborates the important role of mutant SNPs in CYP2B6 in 
plasma efavirenz with the potential for predicting clinical outcomes such as toxicity and 
long-term treatment response such as risk for immunological failure while UGT2B7 and 
CAR may be less important in this regard.  
Patients on efavirenz tolerated co-administered artesunate well with no documented 
toxicity from either medications and clinical failures of malaria treatment assessed on 
day 5 after completing antimalarial treatment with artesunate therapy. The mid-dose 
plasma concentrations of efavirenz did not significantly change during the first 6-hours 
after the first dose of 200mg of oral artesunate and also on day 5 after 6-hours after the 
last dose.  
In essence the findings from this study suggests that efavirenz is effective clinically and 
immunologically and is well tolerated among this Ghanaian cohort a significant 
majority of whom started with advanced HIV disease. Polymorphisms in the enzymes 
responsible for metabolism of efavirenz are highly prevalent among this Ghanaian 
cohort and predicted efavirenz therapeutic exposure particularly the CYP2B6 G516T 
and T983C. The CYP2B6 516/983 composite was the most significant in predicting 
supra-therapeutic exposure to EFV, trends towards increased risk of CNS toxicity but 
lower risk of long-term immunological failure. Finally even though potential 
interactions and safety concerns have been proposed for co-administration of artesunate 
in patients on efavirenz, this study shows that the two medications can be safely 
administered and were well-tolerated with no significant changes in the mid-dose 
plasma concentrations of efavirenz.  
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Representativeness and generalisability of the conclusions 
The study has strengths worth noting. This study was conducted in a resource 
constrained country within a programme setting with the challenges of large patients 
numbers, limited variety of antiretroviral therapy options and laboratory monitoring as 
it pertains to many ART programmes in Sub-Saharan Africa and therefore the findings 
may be applicable to other such settings. Although it is noted that nevirapine is more 
frequently used in other settings within SSA, this cohort had nearly 60% of patients 
starting an efavirenz-based cART, thus provided the opportunity to conduct this study 
where the effectiveness of efavirenz could be assessed in comparison with nevirapine. 
The cohort in this study is one of the largest to be reported from a single treatment site 
in SSA with a median follow up of 30 months (range of 0 to 90 months) hence 
permitting long-term treatment outcomes of first line cART to be assessed. Again the 
demographic and clinical/laboratory characteristics of patients initiating cART in this 
cohort were consistently representative and similar to several other cohorts reported 
from similar settings. These qualities of the study make the data representative and the 
conclusions drawn on the long-term effectiveness of cART generalisable to many such 
ART programmes in SSA.  
Again the sample size for the pharmacogenomic study of 800 is among the largest to be 
conducted in SSA to date and was drawn from a clinic where the patients came from at 
least 8 out of the 10 regions of Ghana representing a significant ethnic diversity for this 
analysis. Pharmacogenomic data presented are comparable with those of other studies 
from Sub-Saharan Africa with a high prevalence of SNPs in the CYP2B6 516/983 
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composite with higher risk of supra-therapeutic exposure to efavirenz. This study 
highlights the potentials for use of genotyping to tailor the dosing efavirenz and 
therapeutic drug monitoring to assess adherence should the technology become 
available in the future. Although this is not in routine use in Ghana and certainly across 
most ART programmes in Africa, they may serve as useful adjuncts to enhancing 
adherence to cART in a setting where options are limited. 
The use of artesunate monotherapy although not encouraged is practised in some 
settings like ours. There has been considerable difficulty in coming out with 
recommendations for antimalarial use among HIV-infected patients on cART by 
institutions such as the WHO due to the complex predicted interactions and safety 
concerns between antimalarials and antiretrovirals. Although results of other trials 
evaluating these questions have been completed and awaiting publication, this study 
provides some reassuring data on the safety of artesunate when co-administered with 
efavirenz. 
Limitations of the research design 
There are important limitations to this study that are noteworthy. The long-term 
effectiveness of cART was assessed retrospectively in a cohort with important biases 
such as information and indication biases that are characteristic of such observational 
studies. Thus although adjusted analysis has been presented throughout this dissertation, 
there still could be unmeasured biases for which reason, the data presented on 
effectiveness should be interpreted with these limitations in mind. Data on HIV typing 
is conspicuously missing from this analysis because this testing was inconsistently 
performed routinely for patients. This is important because HIV-2 is inherently resistant 
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to NNRTIs and only 40 patients were started on a PI-based cART due to either HIV-2 
mono- or HIV1/2 dual-infections out of an estimated 200 or so patients given the 
prevalence of 4% in the Ghanaian population
577
. It therefore likely that a proportion of 
patients with HIV-2 infection were started inadvertently on an NNRTI-based cART. 
Furthermore, although 410 patients had immunological failure by WHO definition on 
independent analysis, only 154 patients were switched on account of immunologically 
determined treatment failure by clinicians treating these patients. Finally reported 
incidences of AIDS-defining events, IRIS, non-AIDS-defining events, toxicity were 
based on documented events in patient folders and were classified by the author 
together with the local supervisor. Because these classifications were conducted based 
on clinical descriptions in patient folders, there is the possibility of mis-classifications 
and diagnostic overlaps. 
The pharmacogenomic study was conducted in retrospectively stored samples from a 
sample repository hence adherence at the time of sampling was not assessed, thus the 
correlations between efavirenz plasma concentrations, genotypic data and the predicted 
associations between efavirenz exposure and SNPs with central nervous system toxicity 
and risk of immunologic failure should be interpreted within the context of this 
limitation. Again, this study cannot conclude on the impact of efavirenz on the 
pharmacokinetics of artesunate or its metabolite Dihydroartemisinin due to degradation 
of these compounds which is suspected to have occurred during the preparation of these 
samples for assaying drug levels of the anti-malarial.  
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Defence of methods 
Data for assessing long-term effectiveness was collected from patient folders by the 
author due to incompleteness of data that was stored in clinic database at the Public 
Health unit. Given the considerable number of folders that had to be examined, it was 
felt at the preparation stages to randomly select a sample folders and examine them but 
it was thought that the best way to have an accurate overview of treatment effect was to 
document the incidence rates of events such as toxicity, immunological failures, AIDS 
defining events and non-AIDS-defining events was by assessing all the patients who 
started therapy within the first 7 years of the ART programme in Kumasi. The 
advantage of this approach was that it allowed for sub-set analysis to be performed 
without losing statistical power to draw inferences and conclusions. Again, setting up 
this database will have potential future use for further follow-up prospective analysis of 
treatment effectiveness. 
In assessing treatment outcomes, loss-to-follow up was a major confounder in analysis 
since it represented an unmeasured treatment outcome. As much as 24% of patients 
were lost to follow up in this cohort. Therefore in analysing the composite outcome 
measure of treatment failure on either efavirenz-based or nevirapine-based cART, 
analyses were performed with right-sided censoring by considering missing=censored 
when patient had not experienced any of the co-primary outcome measures or missing= 
treatment failure (as sensitivity analysis). The former approach assumes that missing 
patients might not have experienced the composite outcome measure of interest while 
under follow up (best case scenario) while the latter assumes that missing patients may 
have experienced any of the components the composite treatment failure as a reason for 
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their ‘missingness’ (worst case scenario). The premise of the latter assumption was 
corroborated by direct evidence from a survey of contacts of patients who were lost to 
follow up which confirmed among respondents that those lost to follow up had died or 
were still not assessable because of inactivation of telephone numbers. Either way, the 
conclusions on the effectiveness of efavirenz or nevirapine-based cART were 
comparable using both assumptions. Methodologically, the potential bias that could 
have been introduced by censoring may have been approached by using an inverse 
probability weighting modelling which could be employed to account for missing data 
when subjects with missing data cannot be included in the primary analysis. 
Alternatively, a competing risk analysis where loss-to-follow up is considered as a 
competing risk for death could have been undertaken. But these statistical methods were 
beyond the authors’ scope. 
Future research and recommendations for improvement of clinical care. 
This cohort had a high pre-treatment attrition from the ART programme with only 38% 
of those registering for ART between 2004 and 2010 starting therapy. Although no 
analysis was performed on this subject matter, it is suspected from personal 
observations from patients folders that most of these patients may have died. From my 
experience at the clinic, most of these patients present with several AIDS-defining 
conditions for which treatment for opportunistic infections are initiated while 
preparations to initiate cART are made by taking patients through adherence 
counselling. This period could last between 3 to 8 weeks and constitutes a potential 
delay in initiating cART. Given the success of cART that was observed among those 
who initiated therapy even with advanced disease, early initiation of cART could serve 
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to reduce the pre-cART attrition. Future research should be directed towards identifying 
the characteristic differences if any between those who initiate cART and those who did 
not intiate cART and to formulate strategies for ameloriating this high pre-treatment 
attrition from the ART programme in Kumasi. Although there are no simple solutions, 
the author proposes the following: first, admitting the very sick HIV-infected patients 
who present for cART for supervised treatment of opportunistic infections and where 
necessary initiation of ART in order to identify toxicity and progression promptly; 
second, cART could be initiated while pre-treatment adherence counselling proceeds 
with education given principally to the adherence monitors of prospective patients; 
third, home visits by supporting network of allied health personnel of the clinic for 
those who register for ART to be monitored actively.  
It became evident from the analysis, that the use of stavudine was associated with a 
significantly higher risk of death, loss to follow-up and mitochondrial toxicity. Thus the 
strategy to replace stavudine with tenofovir as part of the first-line cART is possibly a 
step in the right direction given the high prevalence of hepatitis B co-infection among 
this cohort for which tenofovir has potent antiviral activity against. However this 
approach calls for careful and frequent monitoring of renal function using urine analysis 
and serum biochemistry to identify potential nephrotoxicity because of the high 
prevalence of baseline renal impairment in this population.  
There is also the need to assess the long-term virological outcomes of first line cART 
among Ghanaian HIV-infected patients. This is because there is a low genetic barrier 
for resistance to NNRTI and although this study shows robust and sustained CD4 
increases on cART, viral loads might help clarify treatment success better as discussed 
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earlier. Importantly there is an urgent need to identify the levels and profiles of drug 
resistance in patients failing virologically to assess potential treatment options for 
second line therapy. Previous studies in other African cohorts have identified high 
frequencies of M184V and Thymidine analogue mutations (TAMS) among patients 
with virological failure implying that patients may start second line with full resistance 
to 3TC (and FTC) and partial or full resistance to other NRTIs
578
. Because second-line 
cART in our ART programme is constructed around 2NRTIs plus a PI (boosted 
lopinavir the only available option), the PI should be very potent, tolerable and should 
have a high genetic barrier given that the NRTI base may have been compromised. 
Whether boosted lopinavir fulfils these criteria for second line PI for sub-saharan Africa 
remains to be determined. However an analysis of outcomes of second line therapy in 
our cohort in Kumasi (not presented as part of the main thesis) showed a less robust 
CD4 recovery, high frequency of clinical events (AIDS-defining events, loss to follow 
up and deaths) on the predominantly ritonavir-boosted lopinavir-based second line 
cART. Whilst the need for viral load monitoring can not be overemphasised, there is 
also the need to increase our repertoire of second line medications especially robust, 
affordable and novel strategies such as boosted-darunavir used on an optimised 
backbone or as a monotherapy as has been shown in the MONET
579
 study as well as 
other classes of antiretroviral medications as patients stay longer on first line.  
Prospective pharmacogenomic studies where viral loads, clinical events such as toxicity 
could be collected to substantiate these preliminary observations of the associations 
between efavirenz pharmacogenomics, pharmacokinetics and pharmacodynamics. In the 
present study no viral loads could be performed as part of the pharmacogenomics study 
principally because there wasn’t sufficient funding and also samples had been stored at -
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o
C under conditions were electrical power supply was not always assured thus the 
integrity of samples stored for viral loads could not be guaranteed. This study could not 
conclude on the impact of efavirenz on the pharmacokinetics of artesunate and this 
requires further studies particularly those that would involve artemisinin-combination 
therapies and the NNRTIs. A prospective evaluation of long-term neuro-psychiatry side 
effects of efavirenz on the basis of genotypic data would be useful in assessing the 
impact of polymorphisms in CYP2B6 *G516T and *T983C on the risk of persistent 
CNS toxicity on efavirenz. Alternatively, a study randomising patients with persisting 
CNS toxicity after 2-3 months of efavirenz to (‘genotypically- and therapeutic drug 
monitoring-determined’) reduced doses of EFV compared with ‘standard care’ to assess 
success in terms of achieving sustained viral load suppression with improved CNS 
toxicity profile. Such a study would provide useful proof-of-concept data on the 
potential of treating patients to target on lower doses of efavirenz on the basis of the 
high frequency of SNPs in the CYP2B6 in our population. 
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APPENDIX 1: ETHICAL APPROVALS 
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Appendix 2: Proforma for collection of data on HIV-infected patients who initiated cART in Kumasi. 
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Appendix 3: Clinic record forms for registration, initial patient assessment, follow-up 
clinical care on antiretroviral therapy and laboratory data. 
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